CINXE.COM

<!DOCTYPE html><html data-capo=""><head><meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1"> <script id="CookieBot" src="https://consent.cookiebot.com/uc.js?cbid=6b5b25c6-89f0-4619-834a-8af9d1157dc1" async type="text/javascript"></script> <link rel="preconnect" href="https://pub.mdpi-res.com" crossorigin> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/fonts/suisse/fonts.css" media="all"> <style>/*! tailwindcss v3.3.2 | MIT License | https://tailwindcss.com*/*,:after,:before{border:0 solid;box-sizing:border-box}:after,:before{--tw-content:""}html{line-height:1.5;-webkit-text-size-adjust:100%;font-family:Suisse Int\'l,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji;font-feature-settings:normal;font-variation-settings:normal;tab-size:4}body{line-height:inherit;margin:0}hr{border-top-width:1px;color:inherit;height:0}abbr:where([title]){-webkit-text-decoration:underline dotted;text-decoration:underline dotted}h1,h2,h3,h4,h5,h6{font-size:inherit;font-weight:inherit}a{color:inherit;text-decoration:inherit}b,strong{font-weight:bolder}code,kbd,pre,samp{font-family:ui-monospace,SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:initial}sub{bottom:-.25em}sup{top:-.5em}table{border-collapse:collapse;border-color:inherit;text-indent:0}button,input,optgroup,select,textarea{color:inherit;font-family:inherit;font-size:100%;font-weight:inherit;line-height:inherit;margin:0;padding:0}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button;background-color:initial;background-image:none}:-moz-focusring{outline:auto}:-moz-ui-invalid{box-shadow:none}progress{vertical-align:initial}::-webkit-inner-spin-button,::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}summary{display:list-item}blockquote,dd,dl,figure,h1,h2,h3,h4,h5,h6,hr,p,pre{margin:0}fieldset{margin:0}fieldset,legend{padding:0}menu,ol,ul{list-style:none;margin:0;padding:0}textarea{resize:vertical}input::placeholder,textarea::placeholder{color:#9ca3af;opacity:1}[role=button],button{cursor:pointer}:disabled{cursor:default}audio,canvas,embed,iframe,img,object,svg,video{display:block;vertical-align:middle}img,video{height:auto;max-width:100%}[hidden]{display:none}html{color:var(--color-text-default)}*,::backdrop,:after,:before{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }.container{width:100%}@media (min-width:576px){.container{max-width:576px}}@media (min-width:768px){.container{max-width:768px}}@media (min-width:1024px){.container{max-width:1024px}}@media (min-width:1280px){.container{max-width:1280px}}@media (min-width:1440px){.container{max-width:1440px}}@media (min-width:1920px){.container{max-width:1920px}}.prose{color:var(--tw-prose-body);max-width:65ch}.prose :where(p):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em;margin-top:1.25em}.prose :where([class~=lead]):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-lead);font-size:1.25em;line-height:1.6;margin-bottom:1.2em;margin-top:1.2em}.prose :where(a):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-links);font-weight:500;text-decoration:underline}.prose :where(strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-bold);font-weight:600}.prose :where(a strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(blockquote strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(thead th strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(ol):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:decimal;margin-bottom:1.25em;margin-top:1.25em;padding-inline-start:1.625em}.prose :where(ol[type=A]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-alpha}.prose :where(ol[type=a]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-alpha}.prose :where(ol[type=A s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-alpha}.prose :where(ol[type=a s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-alpha}.prose :where(ol[type=I]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-roman}.prose :where(ol[type=i]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-roman}.prose :where(ol[type=I s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-roman}.prose :where(ol[type=i s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-roman}.prose :where(ol[type="1"]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:decimal}.prose :where(ul):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:disc;margin-bottom:1.25em;margin-top:1.25em;padding-inline-start:1.625em}.prose :where(ol>li):not(:where([class~=not-prose],[class~=not-prose] *))::marker{color:var(--tw-prose-counters);font-weight:400}.prose :where(ul>li):not(:where([class~=not-prose],[class~=not-prose] *))::marker{color:var(--tw-prose-bullets)}.prose :where(dt):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;margin-top:1.25em}.prose :where(hr):not(:where([class~=not-prose],[class~=not-prose] *)){border-color:var(--tw-prose-hr);border-top-width:1px;margin-bottom:3em;margin-top:3em}.prose :where(blockquote):not(:where([class~=not-prose],[class~=not-prose] *)){border-inline-start-color:var(--tw-prose-quote-borders);border-inline-start-width:.25rem;color:var(--tw-prose-quotes);font-style:italic;font-weight:500;margin-bottom:1.6em;margin-top:1.6em;padding-inline-start:1em;quotes:"\201C""\201D""\2018""\2019"}.prose :where(blockquote p:first-of-type):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:open-quote}.prose :where(blockquote p:last-of-type):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:close-quote}.prose :where(h1):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:2.25em;font-weight:800;line-height:1.1111111;margin-bottom:.8888889em;margin-top:0}.prose :where(h1 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:900}.prose :where(h2):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:1.5em;font-weight:700;line-height:1.3333333;margin-bottom:1em;margin-top:2em}.prose :where(h2 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:800}.prose :where(h3):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:1.25em;font-weight:600;line-height:1.6;margin-bottom:.6em;margin-top:1.6em}.prose :where(h3 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:700}.prose :where(h4):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;line-height:1.5;margin-bottom:.5em;margin-top:1.5em}.prose :where(h4 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:700}.prose :where(img):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(picture):not(:where([class~=not-prose],[class~=not-prose] *)){display:block;margin-bottom:2em;margin-top:2em}.prose :where(video):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(kbd):not(:where([class~=not-prose],[class~=not-prose] *)){border-radius:.3125rem;box-shadow:0 0 0 1px rgb(var(--tw-prose-kbd-shadows)/10%),0 3px 0 rgb(var(--tw-prose-kbd-shadows)/10%);color:var(--tw-prose-kbd);font-family:inherit;font-size:.875em;font-weight:500;padding-inline-end:.375em;padding-bottom:.1875em;padding-top:.1875em;padding-inline-start:.375em}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-code);font-size:.875em;font-weight:600}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:"`"}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:"`"}.prose :where(a code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(h1 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(h2 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-size:.875em}.prose :where(h3 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-size:.9em}.prose :where(h4 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(blockquote code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(thead th code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(pre):not(:where([class~=not-prose],[class~=not-prose] *)){background-color:var(--tw-prose-pre-bg);border-radius:.375rem;color:var(--tw-prose-pre-code);font-size:.875em;font-weight:400;line-height:1.7142857;margin-bottom:1.7142857em;margin-top:1.7142857em;overflow-x:auto;padding-inline-end:1.1428571em;padding-bottom:.8571429em;padding-top:.8571429em;padding-inline-start:1.1428571em}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)){background-color:initial;border-radius:0;border-width:0;color:inherit;font-family:inherit;font-size:inherit;font-weight:inherit;line-height:inherit;padding:0}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:none}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:none}.prose :where(table):not(:where([class~=not-prose],[class~=not-prose] *)){font-size:.875em;line-height:1.7142857;margin-bottom:2em;margin-top:2em;table-layout:auto;width:100%}.prose :where(thead):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-color:var(--tw-prose-th-borders);border-bottom-width:1px}.prose :where(thead th):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;padding-inline-end:.5714286em;padding-bottom:.5714286em;padding-inline-start:.5714286em;vertical-align:bottom}.prose :where(tbody tr):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-color:var(--tw-prose-td-borders);border-bottom-width:1px}.prose :where(tbody tr:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-width:0}.prose :where(tbody td):not(:where([class~=not-prose],[class~=not-prose] *)){vertical-align:initial}.prose :where(tfoot):not(:where([class~=not-prose],[class~=not-prose] *)){border-top-color:var(--tw-prose-th-borders);border-top-width:1px}.prose :where(tfoot td):not(:where([class~=not-prose],[class~=not-prose] *)){vertical-align:top}.prose :where(th,td):not(:where([class~=not-prose],[class~=not-prose] *)){text-align:start}.prose :where(figure>*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0;margin-top:0}.prose :where(figcaption):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-captions);font-size:.875em;line-height:1.4285714;margin-top:.8571429em}.prose{--tw-prose-body:#374151;--tw-prose-headings:#111827;--tw-prose-lead:#4b5563;--tw-prose-links:#111827;--tw-prose-bold:#111827;--tw-prose-counters:#6b7280;--tw-prose-bullets:#d1d5db;--tw-prose-hr:#e5e7eb;--tw-prose-quotes:#111827;--tw-prose-quote-borders:#e5e7eb;--tw-prose-captions:#6b7280;--tw-prose-kbd:#111827;--tw-prose-kbd-shadows:17 24 39;--tw-prose-code:#111827;--tw-prose-pre-code:#e5e7eb;--tw-prose-pre-bg:#1f2937;--tw-prose-th-borders:#d1d5db;--tw-prose-td-borders:#e5e7eb;--tw-prose-invert-body:#d1d5db;--tw-prose-invert-headings:#fff;--tw-prose-invert-lead:#9ca3af;--tw-prose-invert-links:#fff;--tw-prose-invert-bold:#fff;--tw-prose-invert-counters:#9ca3af;--tw-prose-invert-bullets:#4b5563;--tw-prose-invert-hr:#374151;--tw-prose-invert-quotes:#f3f4f6;--tw-prose-invert-quote-borders:#374151;--tw-prose-invert-captions:#9ca3af;--tw-prose-invert-kbd:#fff;--tw-prose-invert-kbd-shadows:255 255 255;--tw-prose-invert-code:#fff;--tw-prose-invert-pre-code:#d1d5db;--tw-prose-invert-pre-bg:#00000080;--tw-prose-invert-th-borders:#4b5563;--tw-prose-invert-td-borders:#374151;font-size:1rem;line-height:1.75}.prose :where(picture>img):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0;margin-top:0}.prose :where(li):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.5em;margin-top:.5em}.prose :where(ol>li):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:.375em}.prose :where(ul>li):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:.375em}.prose :where(.prose>ul>li p):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.75em;margin-top:.75em}.prose :where(.prose>ul>li>p:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:1.25em}.prose :where(.prose>ul>li>p:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em}.prose :where(.prose>ol>li>p:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:1.25em}.prose :where(.prose>ol>li>p:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em}.prose :where(ul ul,ul ol,ol ul,ol ol):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.75em;margin-top:.75em}.prose :where(dl):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em;margin-top:1.25em}.prose :where(dd):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:.5em;padding-inline-start:1.625em}.prose :where(hr+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h2+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h3+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h4+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(thead th:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:0}.prose :where(thead th:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:0}.prose :where(tbody td,tfoot td):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:.5714286em;padding-bottom:.5714286em;padding-top:.5714286em;padding-inline-start:.5714286em}.prose :where(tbody td:first-child,tfoot td:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:0}.prose :where(tbody td:last-child,tfoot td:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:0}.prose :where(figure):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(.prose>:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(.prose>:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0}.sr-only{height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;clip:rect(0,0,0,0);border-width:0;white-space:nowrap}.pointer-events-none{pointer-events:none}.visible{visibility:visible}.invisible{visibility:hidden}.collapse{visibility:collapse}.static{position:static}.fixed{position:fixed}.\!absolute{position:absolute!important}.absolute{position:absolute}.relative{position:relative}.sticky{position:sticky}.inset-0{inset:0}.inset-y-0{bottom:0;top:0}.-top-px{top:-1px}.bottom-0{bottom:0}.bottom-1{bottom:.25rem}.bottom-1\.5{bottom:.375rem}.bottom-10{bottom:2.5rem}.bottom-24{bottom:6rem}.bottom-4{bottom:1rem}.bottom-6{bottom:1.5rem}.bottom-\[7\.5rem\]{bottom:7.5rem}.bottom-md{bottom:var(--spacing-md)}.left-0{left:0}.left-1\/2{left:50%}.left-12{left:3rem}.left-4{left:1rem}.left-6{left:1.5rem}.left-md{left:var(--spacing-md)}.right-0{right:0}.right-1{right:.25rem}.right-1\.5{right:.375rem}.right-12{right:3rem}.right-2{right:.5rem}.right-2\.5{right:.625rem}.right-4{right:1rem}.right-6{right:1.5rem}.right-8{right:2rem}.right-\[-10px\]{right:-10px}.right-\[-4px\]{right:-4px}.right-\[-8px\]{right:-8px}.right-\[1rem\]{right:1rem}.right-\[3\.125rem\]{right:3.125rem}.top-0{top:0}.top-1{top:.25rem}.top-1\/2{top:50%}.top-12{top:3rem}.top-14{top:3.5rem}.top-16{top:4rem}.top-20{top:5rem}.top-4{top:1rem}.top-6{top:1.5rem}.top-\[-4px\]{top:-4px}.top-\[-5\.875rem\]{top:-5.875rem}.top-\[4\.625rem\]{top:4.625rem}.top-\[48\%\]{top:48%}.top-\[calc$50vh\+15rem$\]{top:calc(50vh + 15rem)}.top-\[calc$50vh\+6\.25rem$\]{top:calc(50vh + 6.25rem)}.isolate{isolation:isolate}.-z-10{z-index:-10}.z-0{z-index:0}.z-1{z-index:1}.z-10{z-index:10}.z-20{z-index:20}.z-40{z-index:40}.z-50{z-index:50}.float-left{float:left}.clear-left{clear:left}.m-0{margin:0}.m-\[\.625rem\]{margin:.625rem}.m-auto{margin:auto}.m-md{margin:var(--spacing-md)}.mx-auto{margin-left:auto;margin-right:auto}.mx-lg{margin-left:var(--spacing-lg);margin-right:var(--spacing-lg)}.mx-md{margin-left:var(--spacing-md);margin-right:var(--spacing-md)}.mx-sm{margin-left:var(--spacing-sm);margin-right:var(--spacing-sm)}.my-0{margin-bottom:0;margin-top:0}.my-2xl{margin-bottom:var(--spacing-2xl);margin-top:var(--spacing-2xl)}.my-4{margin-bottom:1rem;margin-top:1rem}.my-5xl{margin-bottom:var(--spacing-5xl);margin-top:var(--spacing-5xl)}.my-lg{margin-bottom:var(--spacing-lg);margin-top:var(--spacing-lg)}.my-md{margin-bottom:var(--spacing-md);margin-top:var(--spacing-md)}.my-sm{margin-bottom:var(--spacing-sm);margin-top:var(--spacing-sm)}.my-xl{margin-bottom:var(--spacing-xl);margin-top:var(--spacing-xl)}.-mr-0{margin-right:0}.-mr-0\.5{margin-right:-.125rem}.-mr-1{margin-right:-.25rem}.-mr-2{margin-right:-.5rem}.-mr-2\.5{margin-right:-.625rem}.-mt-xs{margin-top:calc(var(--spacing-xs)*-1)}.mb-1{margin-bottom:.25rem}.mb-2{margin-bottom:.5rem}.mb-2xl{margin-bottom:var(--spacing-2xl)}.mb-3{margin-bottom:.75rem}.mb-4{margin-bottom:1rem}.mb-6{margin-bottom:1.5rem}.mb-7xl{margin-bottom:var(--spacing-7xl)}.mb-\[0\.25rem\]{margin-bottom:.25rem}.mb-lg{margin-bottom:var(--spacing-lg)}.mb-md{margin-bottom:var(--spacing-md)}.mb-sm{margin-bottom:var(--spacing-sm)}.mb-xl{margin-bottom:var(--spacing-xl)}.mb-xs{margin-bottom:var(--spacing-xs)}.ml-2{margin-left:.5rem}.ml-2xl{margin-left:var(--spacing-2xl)}.ml-\[-0\.0625rem\]{margin-left:-.0625rem}.ml-\[-0\.75rem\]{margin-left:-.75rem}.ml-\[0\.625rem\]{margin-left:.625rem}.ml-\[0\.75rem\]{margin-left:.75rem}.ml-auto{margin-left:auto}.ml-lg{margin-left:var(--spacing-lg)}.ml-md{margin-left:var(--spacing-md)}.ml-sm{margin-left:var(--spacing-sm)}.ml-xs{margin-left:var(--spacing-xs)}.mr-4{margin-right:1rem}.mr-5{margin-right:1.25rem}.mr-6{margin-right:1.5rem}.mr-\[\.125rem\]{margin-right:.125rem}.mr-\[\.625rem\]{margin-right:.625rem}.mr-\[0\.3125rem\]{margin-right:.3125rem}.mr-\[2\.3125rem\]{margin-right:2.3125rem}.mr-\[2\.375rem\]{margin-right:2.375rem}.mr-\[5\.625rem\]{margin-right:5.625rem}.mr-lg{margin-right:var(--spacing-lg)}.mr-md{margin-right:var(--spacing-md)}.mr-sm{margin-right:var(--spacing-sm)}.mr-xl{margin-right:var(--spacing-xl)}.mr-xs{margin-right:var(--spacing-xs)}.mt-1{margin-top:.25rem}.mt-2xl{margin-top:var(--spacing-2xl)}.mt-3xl{margin-top:var(--spacing-3xl)}.mt-6{margin-top:1.5rem}.mt-\[-3rem\]{margin-top:-3rem}.mt-\[\.625rem\]{margin-top:.625rem}.mt-\[1\.25rem\]{margin-top:1.25rem}.mt-\[1rem\]{margin-top:1rem}.mt-lg{margin-top:var(--spacing-lg)}.mt-md{margin-top:var(--spacing-md)}.mt-sm{margin-top:var(--spacing-sm)}.mt-xl{margin-top:var(--spacing-xl)}.mt-xs{margin-top:var(--spacing-xs)}.box-border{box-sizing:border-box}.line-clamp-1{-webkit-line-clamp:1}.line-clamp-1,.line-clamp-3{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical}.line-clamp-3{-webkit-line-clamp:3}.\!block{display:block!important}.block{display:block}.\!inline-block{display:inline-block!important}.inline-block{display:inline-block}.\!inline{display:inline!important}.inline{display:inline}.flex{display:flex}.\!inline-flex{display:inline-flex!important}.inline-flex{display:inline-flex}.table{display:table}.grid{display:grid}.contents{display:contents}.\!hidden{display:none!important}.hidden{display:none}.aspect-\[1\/1\.414\]{aspect-ratio:1/1.414}.aspect-\[1200\/630\]{aspect-ratio:1200/630}.aspect-\[381\/200\]{aspect-ratio:381/200}.aspect-\[4\/5\]{aspect-ratio:4/5}.aspect-square{aspect-ratio:1/1}.aspect-video{aspect-ratio:16/9}.\!h-6{height:1.5rem!important}.h-0{height:0}.h-0\.5{height:.125rem}.h-1{height:.25rem}.h-1\.5{height:.375rem}.h-10{height:2.5rem}.h-12{height:3rem}.h-14{height:3.5rem}.h-16{height:4rem}.h-2{height:.5rem}.h-20{height:5rem}.h-28{height:7rem}.h-3{height:.75rem}.h-32{height:8rem}.h-36{height:9rem}.h-4{height:1rem}.h-48{height:12rem}.h-5{height:1.25rem}.h-52{height:13rem}.h-6{height:1.5rem}.h-7{height:1.75rem}.h-8{height:2rem}.h-80{height:20rem}.h-9{height:2.25rem}.h-96{height:24rem}.h-\[\.25rem\]{height:.25rem}.h-\[0\.5rem\]{height:.5rem}.h-\[0\.9rem\]{height:.9rem}.h-\[1\.15em\]{height:1.15em}.h-\[1\.3rem\]{height:1.3rem}.h-\[1\.4rem\]{height:1.4rem}.h-\[1\.5rem\]{height:1.5rem}.h-\[1\.8125rem\]{height:1.8125rem}.h-\[1\.875rem\]{height:1.875rem}.h-\[100\%\]{height:100%}.h-\[100px\]{height:100px}.h-\[150px\]{height:150px}.h-\[160px\]{height:160px}.h-\[1rem\]{height:1rem}.h-\[2\.5rem\]{height:2.5rem}.h-\[24rem\]{height:24rem}.h-\[25\.25rem\]{height:25.25rem}.h-\[3\.625rem\]{height:3.625rem}.h-\[3\.75rem\]{height:3.75rem}.h-\[30rem\]{height:30rem}.h-\[35\.5rem\]{height:35.5rem}.h-\[38rem\]{height:38rem}.h-\[4\.5rem\]{height:4.5rem}.h-\[50rem\]{height:50rem}.h-\[5rem\]{height:5rem}.h-\[6\.5rem\]{height:6.5rem}.h-\[6px\]{height:6px}.h-\[auto\],.h-auto{height:auto}.h-fit{height:fit-content}.h-full{height:100%}.h-px{height:1px}.max-h-60{max-height:15rem}.max-h-80{max-height:20rem}.min-h-\[1\.5rem\]{min-height:1.5rem}.min-h-\[100px\]{min-height:100px}.min-h-\[15vh\]{min-height:15vh}.min-h-\[45rem\]{min-height:45rem}.min-h-\[70vh\]{min-height:70vh}.min-h-full{min-height:100%}.\!w-2xl{width:var(--spacing-2xl)!important}.\!w-40{width:10rem!important}.\!w-fit{width:fit-content!important}.\!w-full{width:100%!important}.w-1{width:.25rem}.w-1\.5{width:.375rem}.w-1\/2{width:50%}.w-1\/4{width:25%}.w-1\/5{width:20%}.w-10{width:2.5rem}.w-12{width:3rem}.w-14{width:3.5rem}.w-16{width:4rem}.w-2{width:.5rem}.w-20{width:5rem}.w-28{width:7rem}.w-3{width:.75rem}.w-3\/5{width:60%}.w-32{width:8rem}.w-36{width:9rem}.w-4{width:1rem}.w-4\/5{width:80%}.w-40{width:10rem}.w-4xl{width:var(--spacing-4xl)}.w-5{width:1.25rem}.w-6{width:1.5rem}.w-60{width:15rem}.w-7{width:1.75rem}.w-8{width:2rem}.w-80{width:20rem}.w-9{width:2.25rem}.w-96{width:24rem}.w-\[\.25rem\]{width:.25rem}.w-\[1\.15em\]{width:1.15em}.w-\[1\.4rem\]{width:1.4rem}.w-\[1\.5rem\]{width:1.5rem}.w-\[1\.6rem\]{width:1.6rem}.w-\[10\%\]{width:10%}.w-\[10\.25rem\]{width:10.25rem}.w-\[10\.625rem\]{width:10.625rem}.w-\[100\%\]{width:100%}.w-\[10rem\]{width:10rem}.w-\[13\.125rem\]{width:13.125rem}.w-\[13rem\]{width:13rem}.w-\[15\%\]{width:15%}.w-\[18rem\]{width:18rem}.w-\[1rem\]{width:1rem}.w-\[2\.5rem\]{width:2.5rem}.w-\[2\.75rem\]{width:2.75rem}.w-\[20\%\]{width:20%}.w-\[22px\]{width:22px}.w-\[25rem\]{width:25rem}.w-\[30\%\]{width:30%}.w-\[33\%\]{width:33%}.w-\[4\.5rem\]{width:4.5rem}.w-\[6\.5rem\]{width:6.5rem}.w-\[6\.75rem\]{width:6.75rem}.w-\[7\.5rem\]{width:7.5rem}.w-\[92\.5vw\]{width:92.5vw}.w-auto{width:auto}.w-fit{width:fit-content}.w-full{width:100%}.w-max{width:max-content}.w-min{width:min-content}.w-px{width:1px}.w-screen{width:100vw}.\!min-w-0{min-width:0!important}.min-w-10{min-width:2.5rem}.min-w-12{min-width:3rem}.min-w-14{min-width:3.5rem}.min-w-28{min-width:7rem}.min-w-5{min-width:1.25rem}.min-w-6{min-width:1.5rem}.min-w-7{min-width:1.75rem}.min-w-8{min-width:2rem}.min-w-\[0\.5rem\]{min-width:.5rem}.min-w-\[0\.9rem\]{min-width:.9rem}.min-w-\[1\.3rem\]{min-width:1.3rem}.min-w-\[12\.5rem\]{min-width:12.5rem}.min-w-\[146px\]{min-width:146px}.min-w-\[156px\]{min-width:156px}.min-w-\[21rem\]{min-width:21rem}.min-w-\[3\.75rem\]{min-width:3.75rem}.min-w-\[4\.5rem\]{min-width:4.5rem}.min-w-\[6\.5rem\]{min-width:6.5rem}.min-w-fit{min-width:fit-content}.max-w-\[100\%\]{max-width:100%}.max-w-\[20rem\]{max-width:20rem}.max-w-\[25rem\]{max-width:25rem}.max-w-\[28\.5rem\]{max-width:28.5rem}.max-w-\[30\%\]{max-width:30%}.max-w-\[5rem\]{max-width:5rem}.max-w-\[6px\]{max-width:6px}.max-w-\[80\%\]{max-width:80%}.max-w-\[90rem\]{max-width:90rem}.max-w-\[96\%\]{max-width:96%}.max-w-\[98vw\]{max-width:98vw}.max-w-full{max-width:100%}.max-w-prose{max-width:65ch}.max-w-sm{max-width:24rem}.max-w-xs{max-width:20rem}.\!flex-none{flex:none!important}.flex-1{flex:1 1 0%}.flex-\[1\]{flex:1}.flex-\[2\]{flex:2}.flex-\[3\]{flex:3}.flex-auto{flex:1 1 auto}.flex-none{flex:none}.flex-shrink-0,.shrink-0{flex-shrink:0}.shrink-\[14\]{flex-shrink:14}.grow{flex-grow:1}.grow-\[2\]{flex-grow:2}.basis-6{flex-basis:1.5rem}.origin-bottom{transform-origin:bottom}.origin-bottom-left{transform-origin:bottom left}.origin-bottom-right{transform-origin:bottom right}.origin-center{transform-origin:center}.origin-left{transform-origin:left}.origin-right{transform-origin:right}.origin-top{transform-origin:top}.origin-top-left{transform-origin:top left}.origin-top-right{transform-origin:top right}.-translate-x-1\/2{--tw-translate-x:-50%;transform:translate(-50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-x-full{--tw-translate-x:-100%;transform:translate(-100%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-1\/2{--tw-translate-y:-50%;transform:translate(var(--tw-translate-x),-50%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-2{--tw-translate-y:-0.5rem;transform:translate(var(--tw-translate-x),-.5rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-4{--tw-translate-y:-1rem;transform:translate(var(--tw-translate-x),-1rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-\[calc$100\%\+0\.25rem$\]{--tw-translate-y:calc(-100% + -0.25rem);transform:translate(var(--tw-translate-x),calc(-100% + -.25rem)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-full{--tw-translate-y:-100%;transform:translate(var(--tw-translate-x),-100%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-0{--tw-translate-x:0px;transform:translateY(var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-0\.5{--tw-translate-x:0.125rem;transform:translate(.125rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-\[1\.375rem\]{--tw-translate-x:1.375rem;transform:translate(1.375rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-full{--tw-translate-x:100%;transform:translate(100%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-0{--tw-translate-y:0px;transform:translate(var(--tw-translate-x)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-4{--tw-translate-y:1rem;transform:translate(var(--tw-translate-x),1rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-full{--tw-translate-y:100%;transform:translate(var(--tw-translate-x),100%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-180{--tw-rotate:180deg;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(180deg) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-45{--tw-rotate:45deg;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(45deg) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-100{--tw-scale-x:1;--tw-scale-y:1;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(1) scaleY(1);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-95{--tw-scale-x:.95;--tw-scale-y:.95;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(.95) scaleY(.95);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-\[101\.5\%\]{--tw-scale-x:101.5%;--tw-scale-y:101.5%;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(101.5%) scaleY(101.5%)}.scale-\[101\.5\%\],.transform{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}@keyframes spin{to{transform:rotate(1turn)}}.animate-spin{animation:spin 1s linear infinite}.cursor-default{cursor:default}.cursor-move{cursor:move}.cursor-not-allowed{cursor:not-allowed}.cursor-pointer{cursor:pointer}.select-none{-webkit-user-select:none;user-select:none}.resize-none{resize:none}.resize{resize:both}.\!list-inside{list-style-position:inside!important}.list-inside{list-style-position:inside}.list-decimal{list-style-type:decimal}.list-disc{list-style-type:disc}.appearance-none{appearance:none}.grid-cols-3{grid-template-columns:repeat(3,minmax(0,1fr))}.flex-row{flex-direction:row}.flex-row-reverse{flex-direction:row-reverse}.flex-col{flex-direction:column}.flex-col-reverse{flex-direction:column-reverse}.flex-wrap{flex-wrap:wrap}.place-content-center{place-content:center}.content-center{align-content:center}.items-start{align-items:flex-start}.items-end{align-items:flex-end}.items-center{align-items:center}.items-baseline{align-items:baseline}.\!justify-start{justify-content:flex-start!important}.justify-start{justify-content:flex-start}.justify-end{justify-content:flex-end}.justify-center{justify-content:center}.\!justify-between{justify-content:space-between!important}.justify-between{justify-content:space-between}.justify-around{justify-content:space-around}.\!gap-md{gap:var(--spacing-md)!important}.gap-1{gap:.25rem}.gap-2{gap:.5rem}.gap-2\.5{gap:.625rem}.gap-3{gap:.75rem}.gap-4{gap:1rem}.gap-5{gap:1.25rem}.gap-6{gap:1.5rem}.gap-8{gap:2rem}.gap-\[0\.65em\]{gap:.65em}.gap-lg{gap:var(--spacing-lg)}.gap-md{gap:var(--spacing-md)}.gap-sm{gap:var(--spacing-sm)}.gap-xl{gap:var(--spacing-xl)}.gap-xs{gap:var(--spacing-xs)}.gap-x-1{column-gap:.25rem}.gap-x-4{column-gap:1rem}.gap-x-lg{column-gap:var(--spacing-lg)}.gap-x-sm{column-gap:var(--spacing-sm)}.gap-x-xs{column-gap:var(--spacing-xs)}.gap-y-5{row-gap:1.25rem}.gap-y-lg{row-gap:var(--spacing-lg)}.gap-y-md{row-gap:var(--spacing-md)}.gap-y-sm{row-gap:var(--spacing-sm)}.gap-y-xl{row-gap:var(--spacing-xl)}.gap-y-xs{row-gap:var(--spacing-xs)}.space-x-1>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:.25rem;margin-left:calc(.25rem*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(.25rem*var(--tw-space-x-reverse))}.space-x-5>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:1.25rem;margin-left:calc(1.25rem*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(1.25rem*var(--tw-space-x-reverse))}.space-y-1>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(.25rem*var(--tw-space-y-reverse));margin-top:.25rem;margin-top:calc(.25rem*(1 - var(--tw-space-y-reverse)))}.space-y-2>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(.5rem*var(--tw-space-y-reverse));margin-top:.5rem;margin-top:calc(.5rem*(1 - var(--tw-space-y-reverse)))}.space-y-2xl>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-2xl)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-2xl)*(1 - var(--tw-space-y-reverse)))}.space-y-4>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(1rem*var(--tw-space-y-reverse));margin-top:1rem;margin-top:calc(1rem*(1 - var(--tw-space-y-reverse)))}.space-y-lg>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-lg)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-lg)*(1 - var(--tw-space-y-reverse)))}.space-y-md>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-md)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-md)*(1 - var(--tw-space-y-reverse)))}.space-y-sm>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-sm)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-sm)*(1 - var(--tw-space-y-reverse)))}.space-y-xs>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-xs)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-xs)*(1 - var(--tw-space-y-reverse)))}.divide-y>:not([hidden])~:not([hidden]){--tw-divide-y-reverse:0;border-bottom-width:0;border-bottom-width:calc(1px*var(--tw-divide-y-reverse));border-top-width:1px;border-top-width:calc(1px*(1 - var(--tw-divide-y-reverse)))}.divide-color-default>:not([hidden])~:not([hidden]){--tw-divide-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-divide-opacity))}.self-center{align-self:center}.overflow-auto{overflow:auto}.\!overflow-hidden{overflow:hidden!important}.overflow-hidden{overflow:hidden}.\!overflow-visible{overflow:visible!important}.overflow-scroll{overflow:scroll}.overflow-x-auto{overflow-x:auto}.overflow-y-auto{overflow-y:auto}.overflow-y-hidden{overflow-y:hidden}.overflow-y-scroll{overflow-y:scroll}.overscroll-none{overscroll-behavior:none}.truncate{overflow:hidden;white-space:nowrap}.text-ellipsis,.truncate{text-overflow:ellipsis}.whitespace-nowrap{white-space:nowrap}.whitespace-pre{white-space:pre}.whitespace-pre-line{white-space:pre-line}.\!break-words{overflow-wrap:break-word!important}.break-words{overflow-wrap:break-word}.\!break-all{word-break:break-all!important}.break-all{word-break:break-all}.rounded{border-radius:.25rem}.rounded-2xl{border-radius:1rem}.rounded-3xl{border-radius:1.5rem}.rounded-\[0\.15em\]{border-radius:.15em}.rounded-\[100\%\]{border-radius:100%}.rounded-\[4px\]{border-radius:4px}.rounded-\[50\%\]{border-radius:50%}.rounded-full{border-radius:9999px}.rounded-lg{border-radius:.5rem}.rounded-md{border-radius:.375rem}.rounded-none{border-radius:0}.rounded-sm{border-radius:.125rem}.rounded-xl{border-radius:.75rem}.border{border-width:1px}.border-2{border-width:2px}.border-\[\.0625rem\]{border-width:.0625rem}.border-\[0\.15em\]{border-width:.15em}.border-x-0{border-left-width:0;border-right-width:0}.border-b{border-bottom-width:1px}.border-b-2{border-bottom-width:2px}.border-l{border-left-width:1px}.border-l-2{border-left-width:2px}.border-l-\[0\.0625rem\]{border-left-width:.0625rem}.border-l-\[0\.125rem\]{border-left-width:.125rem}.border-l-\[3px\]{border-left-width:3px}.border-r{border-right-width:1px}.border-t{border-top-width:1px}.border-t-0{border-top-width:0}.border-t-2{border-top-width:2px}.border-t-\[\.0625rem\]{border-top-width:.0625rem}.border-solid{border-style:solid}.border-dashed{border-style:dashed}.border-none{border-style:none}.\!border-color-bold{--tw-border-opacity:1!important;border-color:rgba(var(--color-border-bold),var(--tw-border-opacity))!important}.\!border-color-brand{--tw-border-opacity:1!important;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))!important}.border-\[\#000\]{--tw-border-opacity:1;border-color:#000;border-color:rgb(0 0 0/var(--tw-border-opacity))}.border-\[\#DCDFE4\]{--tw-border-opacity:1;border-color:#dcdfe4;border-color:rgb(220 223 228/var(--tw-border-opacity))}.border-\[\#F8F9FD\]{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.border-\[\#FACC15\]{--tw-border-opacity:1;border-color:#facc15;border-color:rgb(250 204 21/var(--tw-border-opacity))}.border-\[\#FEF9C3\]{--tw-border-opacity:1;border-color:#fef9c3;border-color:rgb(254 249 195/var(--tw-border-opacity))}.border-\[\#b3b9c4\]{--tw-border-opacity:1;border-color:#b3b9c4;border-color:rgb(179 185 196/var(--tw-border-opacity))}.border-\[\#dcdfe6\]{--tw-border-opacity:1;border-color:#dcdfe6;border-color:rgb(220 223 230/var(--tw-border-opacity))}.border-\[\#f8f9fd\]{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.border-\[white\]{--tw-border-opacity:1;border-color:#fff;border-color:rgb(255 255 255/var(--tw-border-opacity))}.border-color-bold{--tw-border-opacity:1;border-color:rgba(var(--color-border-bold),var(--tw-border-opacity))}.border-color-brand{--tw-border-opacity:1;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))}.border-color-default{--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.border-color-error{--tw-border-opacity:1;border-color:rgba(var(--color-border-error),var(--tw-border-opacity))}.border-color-info{--tw-border-opacity:1;border-color:rgba(var(--color-border-info),var(--tw-border-opacity))}.border-color-inherit{border-color:inherit}.border-color-success{--tw-border-opacity:1;border-color:rgba(var(--color-border-success),var(--tw-border-opacity))}.border-color-transparent{border-color:#0000}.border-color-warning{--tw-border-opacity:1;border-color:rgba(var(--color-border-warning),var(--tw-border-opacity))}.border-t-color-default{--tw-border-opacity:1;border-top-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.\!bg-black{--tw-bg-opacity:1!important;background-color:rgba(var(--color-black),1)!important;background-color:rgba(var(--color-black),var(--tw-bg-opacity))!important}.\!bg-brand-bold{--tw-bg-opacity:1!important;background-color:rgba(var(--color-brand-bold),1)!important;background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))!important}.\!bg-brand-default{--tw-bg-opacity:1!important;background-color:rgba(var(--color-brand-default),1)!important;background-color:rgba(var(--color-brand-default),var(--tw-bg-opacity))!important}.\!bg-brand-subtler{--tw-bg-opacity:1!important;background-color:rgba(var(--color-brand-subtler),1)!important;background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))!important}.\!bg-brand-sunken{--tw-bg-opacity:1!important;background-color:rgba(var(--color-brand-sunken),1)!important;background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))!important}.\!bg-success-subtlest{--tw-bg-opacity:1!important;background-color:rgba(var(--color-bg-success-subtlest),1)!important;background-color:rgba(var(--color-bg-success-subtlest),var(--tw-bg-opacity))!important}.\!bg-surface-disabled{--tw-bg-opacity:1!important;background-color:rgba(var(--color-surface-disabled),1)!important;background-color:rgba(var(--color-surface-disabled),var(--tw-bg-opacity))!important}.\!bg-surface-subtle{--tw-bg-opacity:1!important;background-color:rgba(var(--color-surface-subtle),1)!important;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))!important}.\!bg-warning-bold{--tw-bg-opacity:1!important;background-color:rgba(var(--color-bg-warning-bold),1)!important;background-color:rgba(var(--color-bg-warning-bold),var(--tw-bg-opacity))!important}.bg-\[\#000000\],.bg-\[\#000\]{--tw-bg-opacity:1;background-color:#000;background-color:rgb(0 0 0/var(--tw-bg-opacity))}.bg-\[\#2867B2\]{--tw-bg-opacity:1;background-color:#2867b2;background-color:rgb(40 103 178/var(--tw-bg-opacity))}.bg-\[\#409eff\]{--tw-bg-opacity:1;background-color:#409eff;background-color:rgb(64 158 255/var(--tw-bg-opacity))}.bg-\[\#66b1ff\]{--tw-bg-opacity:1;background-color:#66b1ff;background-color:rgb(102 177 255/var(--tw-bg-opacity))}.bg-\[\#EAB308\]{--tw-bg-opacity:1;background-color:#eab308;background-color:rgb(234 179 8/var(--tw-bg-opacity))}.bg-\[\#F8F9FD\]{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgb(248 249 253/var(--tw-bg-opacity))}.bg-\[\#b3b9c4\]{--tw-bg-opacity:1;background-color:#b3b9c4;background-color:rgb(179 185 196/var(--tw-bg-opacity))}.bg-\[\#eaeaee\]{--tw-bg-opacity:1;background-color:#eaeaee;background-color:rgb(234 234 238/var(--tw-bg-opacity))}.bg-\[\#facc15\]{--tw-bg-opacity:1;background-color:#facc15;background-color:rgb(250 204 21/var(--tw-bg-opacity))}.bg-\[\#fff\]{--tw-bg-opacity:1;background-color:#fff;background-color:rgb(255 255 255/var(--tw-bg-opacity))}.bg-black{--tw-bg-opacity:1;background-color:rgba(var(--color-black),1);background-color:rgba(var(--color-black),var(--tw-bg-opacity))}.bg-black\/50{background-color:rgba(var(--color-black),.5)}.bg-black\/60{background-color:rgba(var(--color-black),.6)}.bg-black\/\[0\.12\]{background-color:rgba(var(--color-black),.12)}.bg-brand-bold{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.bg-brand-boldest{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-boldest),1);background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.bg-brand-default{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-default),1);background-color:rgba(var(--color-brand-default),var(--tw-bg-opacity))}.bg-brand-subtler{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-subtler),1);background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))}.bg-brand-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-subtlest),1);background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.bg-brand-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-sunken),1);background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))}.bg-content-bolder{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-bolder),1);background-color:rgba(var(--color-bg-content-bolder),var(--tw-bg-opacity))}.bg-content-default{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-default),1);background-color:rgba(var(--color-bg-content-default),var(--tw-bg-opacity))}.bg-content-inverse-subtler{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-inverse-subtler),1);background-color:rgba(var(--color-bg-content-inverse-subtler),var(--tw-bg-opacity))}.bg-content-subtle{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtle),1);background-color:rgba(var(--color-bg-content-subtle),var(--tw-bg-opacity))}.bg-content-subtler{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtler),1);background-color:rgba(var(--color-bg-content-subtler),var(--tw-bg-opacity))}.bg-content-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtlest),1);background-color:rgba(var(--color-bg-content-subtlest),var(--tw-bg-opacity))}.bg-content-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-sunken),1);background-color:rgba(var(--color-bg-content-sunken),var(--tw-bg-opacity))}.bg-error-bold{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-error-bold),1);background-color:rgba(var(--color-bg-error-bold),var(--tw-bg-opacity))}.bg-error-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-error-subtlest),1);background-color:rgba(var(--color-bg-error-subtlest),var(--tw-bg-opacity))}.bg-error-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-error-sunken),1);background-color:rgba(var(--color-bg-error-sunken),var(--tw-bg-opacity))}.bg-info-bold{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-info-bold),1);background-color:rgba(var(--color-bg-info-bold),var(--tw-bg-opacity))}.bg-info-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-info-subtlest),1);background-color:rgba(var(--color-bg-info-subtlest),var(--tw-bg-opacity))}.bg-info-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-info-sunken),1);background-color:rgba(var(--color-bg-info-sunken),var(--tw-bg-opacity))}.bg-inherit{background-color:inherit}.bg-success-bold{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-success-bold),1);background-color:rgba(var(--color-bg-success-bold),var(--tw-bg-opacity))}.bg-success-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-success-subtlest),1);background-color:rgba(var(--color-bg-success-subtlest),var(--tw-bg-opacity))}.bg-success-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-success-sunken),1);background-color:rgba(var(--color-bg-success-sunken),var(--tw-bg-opacity))}.bg-surface-default{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.bg-surface-disabled{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-disabled),1);background-color:rgba(var(--color-surface-disabled),var(--tw-bg-opacity))}.bg-surface-inverse{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-inverse),1);background-color:rgba(var(--color-surface-inverse),var(--tw-bg-opacity))}.bg-surface-selected{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-selected),1);background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.bg-surface-subtle{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.bg-transparent{background-color:initial}.bg-warning-bold{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-warning-bold),1);background-color:rgba(var(--color-bg-warning-bold),var(--tw-bg-opacity))}.bg-warning-subtlest{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-warning-subtlest),1);background-color:rgba(var(--color-bg-warning-subtlest),var(--tw-bg-opacity))}.bg-warning-sunken{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-warning-sunken),1);background-color:rgba(var(--color-bg-warning-sunken),var(--tw-bg-opacity))}.bg-white{--tw-bg-opacity:1;background-color:rgba(var(--color-white),1);background-color:rgba(var(--color-white),var(--tw-bg-opacity))}.bg-opacity-25{--tw-bg-opacity:0.25}.bg-opacity-75{--tw-bg-opacity:0.75}.bg-\[url$\'\/img\/homepage\.png\'$\]{background-image:url(/img/homepage.png)}.bg-gradient-to-r{background-image:linear-gradient(to right,var(--tw-gradient-stops))}.bg-none{background-image:none}.from-black\/70{--tw-gradient-from:rgba(var(--color-black),0.7) var(--tw-gradient-from-position);--tw-gradient-to:rgba(var(--color-black),0) var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.from-transparent{--tw-gradient-from:#0000 var(--tw-gradient-from-position);--tw-gradient-to:#0000 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.to-black\/5{--tw-gradient-to:rgba(var(--color-black),0.05) var(--tw-gradient-to-position)}.to-white{--tw-gradient-to:rgba(var(--color-white),1) var(--tw-gradient-to-position)}.bg-cover{background-size:cover}.bg-fixed{background-attachment:fixed}.bg-center{background-position:50%}.bg-no-repeat{background-repeat:no-repeat}.fill-brand-bold{fill:rgba(var(--color-brand-bold),1)}.fill-brand-sunken{fill:rgba(var(--color-brand-sunken),1)}.object-cover{object-fit:cover}.\!p-0{padding:0!important}.\!p-sm{padding:var(--spacing-sm)!important}.\!p-xs{padding:var(--spacing-xs)!important}.p-0{padding:0}.p-0\.5{padding:.125rem}.p-4{padding:1rem}.p-5{padding:1.25rem}.p-8{padding:2rem}.p-\[\.75rem\]{padding:.75rem}.p-lg{padding:var(--spacing-lg)}.p-md{padding:var(--spacing-md)}.p-px{padding:1px}.p-sm{padding:var(--spacing-sm)}.p-xl{padding:var(--spacing-xl)}.\!px-0{padding-left:0!important;padding-right:0!important}.\!px-sm{padding-left:var(--spacing-sm)!important;padding-right:var(--spacing-sm)!important}.px-0{padding-left:0;padding-right:0}.px-10{padding-left:2.5rem;padding-right:2.5rem}.px-2{padding-left:.5rem;padding-right:.5rem}.px-4{padding-left:1rem;padding-right:1rem}.px-5{padding-left:1.25rem;padding-right:1.25rem}.px-8{padding-left:2rem;padding-right:2rem}.px-\[\.625rem\]{padding-left:.625rem;padding-right:.625rem}.px-\[\.9375rem\]{padding-left:.9375rem;padding-right:.9375rem}.px-\[0\.2rem\]{padding-left:.2rem;padding-right:.2rem}.px-\[0\.625rem\]{padding-left:.625rem;padding-right:.625rem}.px-lg{padding-left:var(--spacing-lg);padding-right:var(--spacing-lg)}.px-md{padding-left:var(--spacing-md);padding-right:var(--spacing-md)}.px-sm{padding-left:var(--spacing-sm);padding-right:var(--spacing-sm)}.px-xl{padding-left:var(--spacing-xl);padding-right:var(--spacing-xl)}.px-xs{padding-left:var(--spacing-xs);padding-right:var(--spacing-xs)}.py-0{padding-bottom:0;padding-top:0}.py-0\.5{padding-bottom:.125rem;padding-top:.125rem}.py-10{padding-bottom:2.5rem;padding-top:2.5rem}.py-2{padding-bottom:.5rem;padding-top:.5rem}.py-2xl{padding-bottom:var(--spacing-2xl);padding-top:var(--spacing-2xl)}.py-3{padding-bottom:.75rem;padding-top:.75rem}.py-3xl{padding-bottom:var(--spacing-3xl);padding-top:var(--spacing-3xl)}.py-4{padding-bottom:1rem;padding-top:1rem}.py-5xl{padding-bottom:var(--spacing-5xl);padding-top:var(--spacing-5xl)}.py-6{padding-bottom:1.5rem;padding-top:1.5rem}.py-7xl{padding-bottom:var(--spacing-7xl);padding-top:var(--spacing-7xl)}.py-\[\.3125rem\]{padding-bottom:.3125rem;padding-top:.3125rem}.py-\[0\.625rem\],.py-\[\.625rem\]{padding-bottom:.625rem;padding-top:.625rem}.py-\[1\.5rem\]{padding-bottom:1.5rem;padding-top:1.5rem}.py-lg{padding-bottom:var(--spacing-lg);padding-top:var(--spacing-lg)}.py-md{padding-bottom:var(--spacing-md);padding-top:var(--spacing-md)}.py-sm{padding-bottom:var(--spacing-sm);padding-top:var(--spacing-sm)}.py-xl{padding-bottom:var(--spacing-xl);padding-top:var(--spacing-xl)}.py-xs{padding-bottom:var(--spacing-xs);padding-top:var(--spacing-xs)}.\!pl-0{padding-left:0!important}.\!pl-sm{padding-left:var(--spacing-sm)!important}.\!pr-sm{padding-right:var(--spacing-sm)!important}.pb-0{padding-bottom:0}.pb-2xl{padding-bottom:var(--spacing-2xl)}.pb-3{padding-bottom:.75rem}.pb-6{padding-bottom:1.5rem}.pb-7xl{padding-bottom:var(--spacing-7xl)}.pb-\[\.5rem\]{padding-bottom:.5rem}.pb-\[1\.875rem\]{padding-bottom:1.875rem}.pb-lg{padding-bottom:var(--spacing-lg)}.pb-md{padding-bottom:var(--spacing-md)}.pb-sm{padding-bottom:var(--spacing-sm)}.pb-xl{padding-bottom:var(--spacing-xl)}.pb-xs{padding-bottom:var(--spacing-xs)}.pl-0{padding-left:0}.pl-10{padding-left:2.5rem}.pl-2xl{padding-left:var(--spacing-2xl)}.pl-3{padding-left:.75rem}.pl-5{padding-left:1.25rem}.pl-8{padding-left:2rem}.pl-lg{padding-left:var(--spacing-lg)}.pl-md{padding-left:var(--spacing-md)}.pl-sm{padding-left:var(--spacing-sm)}.pl-xl{padding-left:var(--spacing-xl)}.pl-xs{padding-left:var(--spacing-xs)}.pr-0{padding-right:0}.pr-2xl{padding-right:var(--spacing-2xl)}.pr-3{padding-right:.75rem}.pr-lg{padding-right:var(--spacing-lg)}.pr-md{padding-right:var(--spacing-md)}.pr-sm{padding-right:var(--spacing-sm)}.pr-xl{padding-right:var(--spacing-xl)}.pr-xs{padding-right:var(--spacing-xs)}.pt-12{padding-top:3rem}.pt-14{padding-top:3.5rem}.pt-2xl{padding-top:var(--spacing-2xl)}.pt-3xl{padding-top:var(--spacing-3xl)}.pt-5xl{padding-top:var(--spacing-5xl)}.pt-6{padding-top:1.5rem}.pt-7xl{padding-top:var(--spacing-7xl)}.pt-\[\.625rem\]{padding-top:.625rem}.pt-\[\.75rem\]{padding-top:.75rem}.pt-\[0\.125rem\]{padding-top:.125rem}.pt-\[1\.25rem\]{padding-top:1.25rem}.pt-\[1\.875rem\]{padding-top:1.875rem}.pt-\[1rem\]{padding-top:1rem}.pt-\[2rem\]{padding-top:2rem}.pt-\[5rem\]{padding-top:5rem}.pt-lg{padding-top:var(--spacing-lg)}.pt-md{padding-top:var(--spacing-md)}.pt-sm{padding-top:var(--spacing-sm)}.pt-xl{padding-top:var(--spacing-xl)}.pt-xs{padding-top:var(--spacing-xs)}.text-left{text-align:left}.text-center{text-align:center}.text-right{text-align:right}.\!align-middle{vertical-align:middle!important}.align-middle{vertical-align:middle}.\!align-text-bottom{vertical-align:text-bottom!important}.\!text-base{font-size:1rem!important;line-height:1.5rem!important}.\!text-lg{font-size:1.125rem!important;line-height:1.75rem!important}.\!text-xs{font-size:.75rem!important;line-height:1rem!important}.text-2xl{font-size:1.5rem;line-height:2rem}.text-3xl{font-size:1.875rem;line-height:2.25rem}.text-4xl{font-size:2.25rem;line-height:2.5rem}.text-5xl{font-size:3rem;line-height:1}.text-\[\.4rem\]{font-size:.4rem}.text-\[\.75rem\]{font-size:.75rem}.text-\[\.875rem\]{font-size:.875rem}.text-\[0\.4rem\]{font-size:.4rem}.text-\[0\.575rem\]{font-size:.575rem}.text-\[1\.875rem\]{font-size:1.875rem}.text-\[2\.5rem\]{font-size:2.5rem}.text-base{font-size:1rem;line-height:1.5rem}.text-lg{font-size:1.125rem;line-height:1.75rem}.text-sm{font-size:.875rem;line-height:1.25rem}.text-xl{font-size:1.25rem;line-height:1.75rem}.text-xs{font-size:.75rem;line-height:1rem}.font-bold{font-weight:700}.font-light{font-weight:300}.font-medium{font-weight:500}.font-normal{font-weight:400}.font-semibold{font-weight:600}.uppercase{text-transform:uppercase}.lowercase{text-transform:lowercase}.italic{font-style:italic}.\!leading-\[0\]{line-height:0!important}.leading-10{line-height:2.5rem}.leading-6{line-height:1.5rem}.leading-\[0\]{line-height:0}.leading-\[1\.125rem\]{line-height:1.125rem}.leading-\[1\.1\]{line-height:1.1}.leading-\[1\.875rem\]{line-height:1.875rem}.leading-\[140\%\]{line-height:140%}.leading-none{line-height:1}.leading-normal{line-height:1.5}.\!text-color-black{--tw-text-opacity:1!important;color:rgba(var(--color-black),1)!important;color:rgba(var(--color-black),var(--tw-text-opacity))!important}.\!text-color-brand-bold{--tw-text-opacity:1!important;color:rgba(var(--color-text-brand-bold),1)!important;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))!important}.\!text-color-default{--tw-text-opacity:1!important;color:rgba(var(--color-text-default),1)!important;color:rgba(var(--color-text-default),var(--tw-text-opacity))!important}.\!text-color-disabled{--tw-text-opacity:1!important;color:rgba(var(--color-text-disabled),1)!important;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))!important}.\!text-color-link-bold{--tw-text-opacity:1!important;color:rgba(var(--color-text-link-bold),1)!important;color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))!important}.\!text-color-subtle{--tw-text-opacity:1!important;color:rgba(var(--color-text-subtle),1)!important;color:rgba(var(--color-text-subtle),var(--tw-text-opacity))!important}.\!text-color-white{--tw-text-opacity:1!important;color:rgba(var(--color-white),1)!important;color:rgba(var(--color-white),var(--tw-text-opacity))!important}.text-\[\#000\]{--tw-text-opacity:1;color:#000;color:rgb(0 0 0/var(--tw-text-opacity))}.text-\[\#0156CE\]{--tw-text-opacity:1;color:#0156ce;color:rgb(1 86 206/var(--tw-text-opacity))}.text-\[\#172B4D\]{--tw-text-opacity:1;color:#172b4d;color:rgb(23 43 77/var(--tw-text-opacity))}.text-\[\#626F86\]{--tw-text-opacity:1;color:#626f86;color:rgb(98 111 134/var(--tw-text-opacity))}.text-\[\#758195\]{--tw-text-opacity:1;color:#758195;color:rgb(117 129 149/var(--tw-text-opacity))}.text-\[\#EAB308\]{--tw-text-opacity:1;color:#eab308;color:rgb(234 179 8/var(--tw-text-opacity))}.text-\[\#F1F2F4\]{--tw-text-opacity:1;color:#f1f2f4;color:rgb(241 242 244/var(--tw-text-opacity))}.text-\[\#FACC15\]{--tw-text-opacity:1;color:#facc15;color:rgb(250 204 21/var(--tw-text-opacity))}.text-\[\#FFFFFF\]{--tw-text-opacity:1;color:#fff;color:rgb(255 255 255/var(--tw-text-opacity))}.text-\[\#b3b9c4\]{--tw-text-opacity:1;color:#b3b9c4;color:rgb(179 185 196/var(--tw-text-opacity))}.text-\[\#f00\]{--tw-text-opacity:1;color:red;color:rgb(255 0 0/var(--tw-text-opacity))}.text-\[\#fff\]{--tw-text-opacity:1;color:#fff;color:rgb(255 255 255/var(--tw-text-opacity))}.text-color-black{--tw-text-opacity:1;color:rgba(var(--color-black),1);color:rgba(var(--color-black),var(--tw-text-opacity))}.text-color-border-bold{--tw-text-opacity:1;color:rgba(var(--color-border-bold),1);color:rgba(var(--color-border-bold),var(--tw-text-opacity))}.text-color-brand-bold{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.text-color-brand-bolder{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bolder),1);color:rgba(var(--color-text-brand-bolder),var(--tw-text-opacity))}.text-color-current{color:currentColor}.text-color-default{--tw-text-opacity:1;color:rgba(var(--color-text-default),1);color:rgba(var(--color-text-default),var(--tw-text-opacity))}.text-color-disabled{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.text-color-error{--tw-text-opacity:1;color:rgba(var(--color-text-error),1);color:rgba(var(--color-text-error),var(--tw-text-opacity))}.text-color-info{--tw-text-opacity:1;color:rgba(var(--color-text-info),1);color:rgba(var(--color-text-info),var(--tw-text-opacity))}.text-color-inherit{color:inherit}.text-color-inverse{--tw-text-opacity:1;color:rgba(var(--color-white),1);color:rgba(var(--color-white),var(--tw-text-opacity))}.text-color-link-bold{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.text-color-link-bolder{--tw-text-opacity:1;color:rgba(var(--color-text-link-bolder),1);color:rgba(var(--color-text-link-bolder),var(--tw-text-opacity))}.text-color-link-subtle{--tw-text-opacity:1;color:rgba(var(--color-text-link-subtle),1);color:rgba(var(--color-text-link-subtle),var(--tw-text-opacity))}.text-color-on-brand{--tw-text-opacity:1;color:rgba(var(--color-text-on-brand),1);color:rgba(var(--color-text-on-brand),var(--tw-text-opacity))}.text-color-subtle{--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.text-color-subtlest{--tw-text-opacity:1;color:rgba(var(--color-text-subtlest),1);color:rgba(var(--color-text-subtlest),var(--tw-text-opacity))}.text-color-success{--tw-text-opacity:1;color:rgba(var(--color-text-success),1);color:rgba(var(--color-text-success),var(--tw-text-opacity))}.text-color-warning{--tw-text-opacity:1;color:rgba(var(--color-text-warning),1);color:rgba(var(--color-text-warning),var(--tw-text-opacity))}.text-color-white{--tw-text-opacity:1;color:rgba(var(--color-white),1);color:rgba(var(--color-white),var(--tw-text-opacity))}.underline{text-decoration-line:underline}.\!no-underline{text-decoration-line:none!important}.no-underline{text-decoration-line:none}.antialiased{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.placeholder-text-color-subtle::placeholder{--tw-placeholder-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-placeholder-opacity))}.opacity-0{opacity:0}.opacity-100{opacity:1}.opacity-25{opacity:.25}.opacity-40{opacity:.4}.shadow{--tw-shadow:0 1px 3px 0 #0000001a,0 1px 2px -1px #0000001a;--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 1px 3px 0 #0000001a,0 1px 2px -1px #0000001a;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-\[4px_8px_10px_rgba$214\2c 217\2c 222\2c 0\.8$\]{--tw-shadow:4px 8px 10px #d6d9decc;--tw-shadow-colored:4px 8px 10px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,4px 8px 10px #d6d9decc;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-lg{--tw-shadow:0 10px 15px -3px #0000001a,0 4px 6px -4px #0000001a;--tw-shadow-colored:0 10px 15px -3px var(--tw-shadow-color),0 4px 6px -4px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 10px 15px -3px #0000001a,0 4px 6px -4px #0000001a;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-md{--tw-shadow:0 4px 6px -1px #0000001a,0 2px 4px -2px #0000001a;--tw-shadow-colored:0 4px 6px -1px var(--tw-shadow-color),0 2px 4px -2px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 4px 6px -1px #0000001a,0 2px 4px -2px #0000001a;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-slider{--tw-shadow:0.5px 0.5px 2px 1px #00000052;--tw-shadow-colored:0.5px 0.5px 2px 1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,.5px .5px 2px 1px #00000052;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-slider-active{--tw-shadow:0.5px 0.5px 2px 1px #0000006b;--tw-shadow-colored:0.5px 0.5px 2px 1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,.5px .5px 2px 1px #0000006b;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-sm{--tw-shadow:0 1px 2px 0 #0000000d;--tw-shadow-colored:0 1px 2px 0 var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 1px 2px 0 #0000000d;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-xl{--tw-shadow:0 20px 25px -5px #0000001a,0 8px 10px -6px #0000001a;--tw-shadow-colored:0 20px 25px -5px var(--tw-shadow-color),0 8px 10px -6px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 20px 25px -5px #0000001a,0 8px 10px -6px #0000001a;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.outline-none{outline:2px solid #0000;outline-offset:2px}.outline{outline-style:solid}.outline-2{outline-width:2px}.outline-offset-2{outline-offset:2px}.outline-\[\#EAB308\]{outline-color:#eab308}.outline-color-bold{outline-color:rgba(var(--color-border-bold),1)}.outline-color-brand{outline-color:rgba(var(--color-border-brand),1)}.ring-0{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.blur{--tw-blur:blur(8px);filter:blur(8px) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.grayscale{--tw-grayscale:grayscale(100%);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) grayscale(100%) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.filter,.grayscale{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.transition{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,-webkit-backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter,-webkit-backdrop-filter;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-all{transition-duration:.15s;transition-property:all;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-colors{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-height{transition-duration:.15s;transition-property:height;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-opacity{transition-duration:.15s;transition-property:opacity;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-transform{transition-duration:.15s;transition-property:transform;transition-timing-function:cubic-bezier(.4,0,.2,1)}.duration-100{transition-duration:.1s}.duration-150{transition-duration:.15s}.duration-200{transition-duration:.2s}.duration-300{transition-duration:.3s}.duration-75{transition-duration:75ms}.duration-\[350ms\]{transition-duration:.35s}.ease-in{transition-timing-function:cubic-bezier(.4,0,1,1)}.ease-in-out{transition-timing-function:cubic-bezier(.4,0,.2,1)}.ease-out{transition-timing-function:cubic-bezier(0,0,.2,1)}.content-\[\'\'\]{--tw-content:"";content:"";content:var(--tw-content)}.cursor-grab{cursor:grab}.cursor-grabbing{cursor:grabbing}.touch-none{touch-action:none}.tap-highlight-transparent{-webkit-tap-highlight-color:rgba(0,0,0,0)}.touch-callout-none{-webkit-touch-callout:none}.transform-origin-0{transform-origin:0 0}.transform-style-flat{transform-style:flat}.cursor-ew-resize{cursor:ew-resize}.arrow-left:before{border:5px solid #0000;border-right-color:inherit;left:-10px}.arrow-left:before,.arrow-right:before{content:"";height:0;position:absolute;top:50%;transform:translateY(-50%);width:0}.arrow-right:before{border:5px solid #0000;border-left-color:inherit;right:-10px}.text-body{font-size:.875rem;line-height:1.25rem}@media (min-width:768px){.text-body{font-size:1rem;line-height:1.5rem}}.\[appearance\:textfield\]{appearance:textfield}.before\:absolute:before{content:var(--tw-content);position:absolute}.before\:-inset-2:before{content:var(--tw-content);inset:-.5rem}.after\:absolute:after{content:var(--tw-content);position:absolute}.after\:hidden:after{content:var(--tw-content);display:none}.after\:h-1\/2:after{content:var(--tw-content);height:50%}.after\:w-1\/2:after{content:var(--tw-content);width:50%}.after\:rounded-full:after{border-radius:9999px;content:var(--tw-content)}.after\:bg-brand-bold:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.after\:bg-content-default:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-default),1);background-color:rgba(var(--color-bg-content-default),var(--tw-bg-opacity))}.first\:pt-0:first-child{padding-top:0}.focus-within\:outline-none:focus-within{outline:2px solid #0000;outline-offset:2px}.focus-within\:outline:focus-within{outline-style:solid}.hover\:rounded-2xl:hover{border-radius:1rem}.hover\:border-2:hover{border-width:2px}.hover\:border-\[\#0156CE\]:hover{--tw-border-opacity:1;border-color:#0156ce;border-color:rgb(1 86 206/var(--tw-border-opacity))}.hover\:border-\[\#F8F9FD\]:hover{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.hover\:border-color-brand:hover{--tw-border-opacity:1;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))}.hover\:\!bg-surface-selected:hover{--tw-bg-opacity:1!important;background-color:rgba(var(--color-surface-selected),1)!important;background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))!important}.hover\:\!bg-transparent:hover{background-color:initial!important}.hover\:bg-brand-bolder:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bolder),1);background-color:rgba(var(--color-brand-bolder),var(--tw-bg-opacity))}.hover\:bg-brand-subtlest:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-subtlest),1);background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.hover\:bg-brand-sunken:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-sunken),1);background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))}.hover\:bg-content-bold:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-bold),1);background-color:rgba(var(--color-bg-content-bold),var(--tw-bg-opacity))}.hover\:bg-content-sunken:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-sunken),1);background-color:rgba(var(--color-bg-content-sunken),var(--tw-bg-opacity))}.hover\:bg-surface-default:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.hover\:bg-surface-selected:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-selected),1);background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.hover\:pl-sm:hover{padding-left:var(--spacing-sm)}.hover\:font-semibold:hover{font-weight:600}.hover\:\!text-color-black:hover{--tw-text-opacity:1!important;color:rgba(var(--color-black),1)!important;color:rgba(var(--color-black),var(--tw-text-opacity))!important}.hover\:text-color-black:hover{--tw-text-opacity:1;color:rgba(var(--color-black),1);color:rgba(var(--color-black),var(--tw-text-opacity))}.hover\:text-color-brand-bold:hover{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.hover\:text-color-link-bold:hover{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.hover\:text-color-link-bolder:hover{--tw-text-opacity:1;color:rgba(var(--color-text-link-bolder),1);color:rgba(var(--color-text-link-bolder),var(--tw-text-opacity))}.hover\:text-color-subtle:hover{--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.hover\:underline:hover{text-decoration-line:underline}.hover\:grayscale-0:hover{--tw-grayscale:grayscale(0);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) grayscale(0) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.focus\:bg-brand-strong:focus{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-strong),1);background-color:rgba(var(--color-brand-strong),var(--tw-bg-opacity))}.focus\:outline-none:focus{outline:2px solid #0000;outline-offset:2px}.focus\:outline-color-brand:focus{outline-color:rgba(var(--color-border-brand),1)}.focus\:ring-2:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.focus\:ring-text-color-border-selected:focus{--tw-ring-opacity:1;--tw-ring-color:rgba(var(--color-border-selected),var(--tw-ring-opacity))}.focus-visible\:bg-brand-bold:focus-visible{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.focus-visible\:bg-brand-boldest:focus-visible{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-boldest),1);background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.focus-visible\:bg-error-bold:focus-visible{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-error-bold),1);background-color:rgba(var(--color-bg-error-bold),var(--tw-bg-opacity))}.focus-visible\:bg-surface-default:focus-visible{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.focus-visible\:bg-surface-selected:focus-visible{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-selected),1);background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.focus-visible\:outline-none:focus-visible{outline:2px solid #0000;outline-offset:2px}.focus-visible\:outline:focus-visible{outline-style:solid}.focus-visible\:outline-2:focus-visible{outline-width:2px}.focus-visible\:outline-color-selected:focus-visible{outline-color:rgba(var(--color-border-selected),1)}.focus-visible\:ring-2:focus-visible{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.focus-visible\:ring-offset-2:focus-visible{--tw-ring-offset-width:2px}.focus-visible\:ring-offset-brand-bold:focus-visible{--tw-ring-offset-color:rgba(var(--color-brand-bold),1)}.focus-visible\:ring-offset-white:focus-visible{--tw-ring-offset-color:rgba(var(--color-white),1)}.active\:\!bg-brand-subtlest:active{--tw-bg-opacity:1!important;background-color:rgba(var(--color-brand-subtlest),1)!important;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))!important}.active\:\!bg-inherit:active{background-color:inherit!important}.active\:\!bg-transparent:active{background-color:initial!important}.active\:bg-brand-boldest:active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-boldest),1);background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.active\:bg-brand-strong:active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-strong),1);background-color:rgba(var(--color-brand-strong),var(--tw-bg-opacity))}.active\:bg-brand-subtler:active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-subtler),1);background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))}.active\:bg-brand-subtlest:active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-subtlest),1);background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.active\:bg-content-bolder:active{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-bolder),1);background-color:rgba(var(--color-bg-content-bolder),var(--tw-bg-opacity))}.active\:bg-content-subtlest:active{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtlest),1);background-color:rgba(var(--color-bg-content-subtlest),var(--tw-bg-opacity))}.active\:text-color-brand-boldest:active{--tw-text-opacity:1;color:rgba(var(--color-text-brand-boldest),1);color:rgba(var(--color-text-brand-boldest),var(--tw-text-opacity))}.disabled\:border-color-default:disabled{--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.disabled\:bg-surface-subtle:disabled{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.disabled\:text-color-disabled:disabled{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.group:hover .group-hover\:after\:bg-brand-bolder:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bolder),1);background-color:rgba(var(--color-brand-bolder),var(--tw-bg-opacity))}.group:active .group-active\:after\:bg-brand-boldest:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:rgba(var(--color-brand-boldest),1);background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.aria-disabled\:pointer-events-none[aria-disabled=true]{pointer-events:none}.aria-disabled\:cursor-default[aria-disabled=true]{cursor:default}.aria-disabled\:text-color-disabled[aria-disabled=true]{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.ui-open\:text-color-brand-bold[data-headlessui-state~=open]{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}:where([data-headlessui-state~=open]) .ui-open\:text-color-brand-bold{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.ui-disabled\:pointer-events-none[data-headlessui-state~=disabled]{pointer-events:none}.ui-disabled\:cursor-default[data-headlessui-state~=disabled]{cursor:default}.ui-disabled\:text-color-disabled[data-headlessui-state~=disabled]{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}:where([data-headlessui-state~=disabled]) .ui-disabled\:pointer-events-none{pointer-events:none}:where([data-headlessui-state~=disabled]) .ui-disabled\:cursor-default{cursor:default}:where([data-headlessui-state~=disabled]) .ui-disabled\:text-color-disabled{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}:where([data-headlessui-focus-visible]) .ui-focus-visible\:outline-color-brand:focus{outline-color:rgba(var(--color-border-brand),1)}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-2:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-brand-bold:focus{--tw-ring-opacity:1;--tw-ring-color:rgba(var(--color-brand-bold),var(--tw-ring-opacity))}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-opacity-75:focus{--tw-ring-opacity:0.75}.slider-horizontal .h\:-right-2{right:-.5rem}.slider-horizontal .h\:-top-1{top:-.25rem}.slider-horizontal .h\:-top-1\.5{top:-.375rem}.slider-horizontal .h\:left-1\/2{left:50%}.slider-horizontal .h\:h-0{height:0}.slider-horizontal .h\:h-4{height:1rem}.slider-horizontal .h\:w-4{width:1rem}.slider-horizontal .h\:-translate-x-1\/2{--tw-translate-x:-50%;transform:translate(-50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-horizontal .h\:arrow-bottom:before{border:5px solid #0000;border-top-color:inherit;bottom:-10px}.slider-horizontal .h\:arrow-bottom:before,.slider-horizontal .h\:arrow-top:before{content:"";height:0;left:50%;position:absolute;transform:translate(-50%);width:0}.slider-horizontal .h\:arrow-top:before{border:5px solid #0000;border-bottom-color:inherit;top:-10px}.slider-vertical .v\:-right-1{right:-.25rem}.slider-vertical .v\:-right-1\.25{right:-.3125rem}.slider-vertical .v\:-top-2{top:-.5rem}.slider-vertical .v\:-top-full{top:-100%}.slider-vertical .v\:top-1\/2{top:50%}.slider-vertical .v\:h-4{height:1rem}.slider-vertical .v\:w-0{width:0}.slider-vertical .v\:w-4{width:1rem}.slider-vertical .v\:-translate-y-1\/2{--tw-translate-y:-50%;transform:translate(var(--tw-translate-x),-50%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-vertical .v\:cursor-ns-resize{cursor:ns-resize}.slider-vertical .v\:arrow-left:before{border:5px solid #0000;border-right-color:inherit;left:-10px}.slider-vertical .v\:arrow-left:before,.slider-vertical .v\:arrow-right:before{content:"";height:0;position:absolute;top:50%;transform:translateY(-50%);width:0}.slider-vertical .v\:arrow-right:before{border:5px solid #0000;border-left-color:inherit;right:-10px}.slider-horizontal .slider-origin>.merge-h\:bottom-3{bottom:.75rem}.slider-horizontal .slider-origin>.merge-h\:bottom-3\.5{bottom:.875rem}.slider-horizontal .slider-origin>.merge-h\:left-auto{left:auto}.slider-horizontal .slider-origin>.merge-h\:top-5{top:1.25rem}.slider-horizontal .slider-origin>.merge-h\:translate-x-1\/2{--tw-translate-x:50%;transform:translate(50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-vertical .slider-origin>.merge-v\:left-7{left:1.75rem}.slider-vertical .slider-origin>.merge-v\:right-1{right:.25rem}.slider-vertical .slider-origin>.merge-v\:top-auto{top:auto}.slider-vertical .slider-origin>.merge-v\:-translate-x-4{--tw-translate-x:-1rem;transform:translate(-1rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:-left-2{left:-.5rem}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:left-0{left:0}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:right-auto{right:auto}.slider-tap .tap\:transition-transform{transition-duration:.15s;transition-property:transform;transition-timing-function:cubic-bezier(.4,0,.2,1)}.slider-tap .tap\:duration-300{transition-duration:.3s}.slider-tooltip-focus:not(.slider-focused) .tt-focus\:hidden{display:none!important}.slider-tooltip-focus.slider-focused:not(.slider-tooltip-hidden) .tt-focused\:block{display:block!important}.slider-tooltip-drag:not(.slider-state-drag) .tt-drag\:hidden{display:none!important}.slider-tooltip-drag.slider-state-drag .tt-dragging\:block\:not$\.slider-tooltip-hidden${display:block!important}@media not all and (min-width:1280px){.max-xl\:w-full{width:100%}}@media not all and (min-width:1024px){.max-lg\:items-center{align-items:center}.max-lg\:gap-x-6{column-gap:1.5rem}.max-lg\:pt-lg{padding-top:var(--spacing-lg)}}@media (min-width:576px){.sm\:sticky{position:sticky}.sm\:top-20{top:5rem}.sm\:w-20{width:5rem}.sm\:w-2xl{width:var(--spacing-2xl)}.sm\:w-\[100\%\]{width:100%}.sm\:w-\[50\%\]{width:50%}.sm\:\!max-w-\[20\%\]{max-width:20%!important}.sm\:max-w-\[33\%\]{max-width:33%}.sm\:grid-cols-2{grid-template-columns:repeat(2,minmax(0,1fr))}.sm\:border-0{border-width:0}.sm\:border-t{border-top-width:1px}.sm\:border-\[\#000\]{--tw-border-opacity:1;border-color:#000;border-color:rgb(0 0 0/var(--tw-border-opacity))}.sm\:pr-md{padding-right:var(--spacing-md)}.sm\:pt-0{padding-top:0}.sm\:pt-\[\.625rem\]{padding-top:.625rem}}@media (min-width:768px){.md\:h-9{height:2.25rem}.md\:w-9{width:2.25rem}.md\:w-\[100\%\]{width:100%}.md\:w-\[50\%\]{width:50%}.md\:flex-row{flex-direction:row}.md\:flex-row-reverse{flex-direction:row-reverse}}@media (min-width:1024px){.lg\:absolute{position:absolute}.lg\:sticky{position:sticky}.lg\:\!bottom-\[50vh\]{bottom:50vh!important}.lg\:bottom-xl{bottom:var(--spacing-xl)}.lg\:left-xl{left:var(--spacing-xl)}.lg\:top-7xl{top:var(--spacing-7xl)}.lg\:top-\[10\%\]{top:10%}.lg\:top-\[20\%\]{top:20%}.lg\:top-\[30\%\]{top:30%}.lg\:top-\[4\.5rem\]{top:4.5rem}.lg\:top-\[40\%\]{top:40%}.lg\:top-\[50\%\]{top:50%}.lg\:top-\[60\%\]{top:60%}.lg\:top-\[70\%\]{top:70%}.lg\:order-first{order:-9999}.lg\:m-0{margin:0}.lg\:m-lg{margin:var(--spacing-lg)}.lg\:mx-auto{margin-left:auto;margin-right:auto}.lg\:my-0{margin-bottom:0;margin-top:0}.lg\:my-12{margin-bottom:3rem;margin-top:3rem}.lg\:my-7xl{margin-bottom:var(--spacing-7xl);margin-top:var(--spacing-7xl)}.lg\:my-\[18\.75rem\]{margin-bottom:18.75rem;margin-top:18.75rem}.lg\:-mt-4xl{margin-top:calc(var(--spacing-4xl)*-1)}.lg\:mb-0{margin-bottom:0}.lg\:mb-10xl{margin-bottom:var(--spacing-10xl)}.lg\:mb-lg{margin-bottom:var(--spacing-lg)}.lg\:ml-3xl{margin-left:var(--spacing-3xl)}.lg\:ml-lg{margin-left:var(--spacing-lg)}.lg\:ml-sm{margin-left:var(--spacing-sm)}.lg\:mr-8xl{margin-right:var(--spacing-8xl)}.lg\:mr-\[4\.6875rem\]{margin-right:4.6875rem}.lg\:mr-lg{margin-right:var(--spacing-lg)}.lg\:mr-xl{margin-right:var(--spacing-xl)}.lg\:mt-0{margin-top:0}.lg\:mt-\[-3rem\]{margin-top:-3rem}.lg\:mt-lg{margin-top:var(--spacing-lg)}.lg\:mt-md{margin-top:var(--spacing-md)}.lg\:\!block{display:block!important}.lg\:block{display:block}.lg\:flex{display:flex}.lg\:\!inline-flex{display:inline-flex!important}.lg\:grid{display:grid}.lg\:\!hidden{display:none!important}.lg\:hidden{display:none}.lg\:aspect-\[1\/1\.414\]{aspect-ratio:1/1.414}.lg\:aspect-square{aspect-ratio:1/1}.lg\:h-12{height:3rem}.lg\:h-\[296px\]{height:296px}.lg\:h-\[7\.5rem\]{height:7.5rem}.lg\:max-h-\[100\%\]{max-height:100%}.lg\:max-h-\[30\%\]{max-height:30%}.lg\:max-h-\[40\%\]{max-height:40%}.lg\:max-h-\[50\%\]{max-height:50%}.lg\:max-h-\[60\%\]{max-height:60%}.lg\:max-h-\[70\%\]{max-height:70%}.lg\:max-h-\[80\%\]{max-height:80%}.lg\:max-h-\[90\%\]{max-height:90%}.lg\:min-h-screen{min-height:100vh}.lg\:\!w-\[20\%\]{width:20%!important}.lg\:\!w-\[75\%\]{width:75%!important}.lg\:\!w-fit{width:fit-content!important}.lg\:w-1\/2{width:50%}.lg\:w-1\/4{width:25%}.lg\:w-1\/5{width:20%}.lg\:w-12{width:3rem}.lg\:w-2\/3{width:66.666667%}.lg\:w-4\/5{width:80%}.lg\:w-\[100\%\]{width:100%}.lg\:w-\[19\.0625rem\]{width:19.0625rem}.lg\:w-\[22\.5rem\]{width:22.5rem}.lg\:w-\[25\%\]{width:25%}.lg\:w-\[31\.25rem\]{width:31.25rem}.lg\:w-\[315px\]{width:315px}.lg\:w-\[32rem\]{width:32rem}.lg\:w-\[33\%\]{width:33%}.lg\:w-\[333px\]{width:333px}.lg\:w-\[360px\]{width:360px}.lg\:w-\[50\%\]{width:50%}.lg\:w-fit{width:fit-content}.lg\:w-full{width:100%}.lg\:w-max{width:max-content}.lg\:\!min-w-\[40\%\]{min-width:40%!important}.lg\:max-w-2xl{max-width:42rem}.lg\:max-w-3xl{max-width:48rem}.lg\:max-w-4xl{max-width:56rem}.lg\:max-w-5xl{max-width:64rem}.lg\:max-w-6xl{max-width:72rem}.lg\:max-w-7xl{max-width:80rem}.lg\:max-w-\[28\.5rem\]{max-width:28.5rem}.lg\:max-w-\[30\%\]{max-width:30%}.lg\:max-w-\[32\%\]{max-width:32%}.lg\:max-w-\[80\%\]{max-width:80%}.lg\:max-w-lg{max-width:32rem}.lg\:max-w-md{max-width:28rem}.lg\:max-w-sm{max-width:24rem}.lg\:max-w-xl{max-width:36rem}.lg\:max-w-xs{max-width:20rem}.lg\:flex-1{flex:1 1 0%}.lg\:flex-auto{flex:1 1 auto}.lg\:flex-none{flex:none}.lg\:basis-1\/2{flex-basis:50%}.lg\:basis-1\/4{flex-basis:25%}.lg\:basis-\[15\.625rem\]{flex-basis:15.625rem}.lg\:list-disc{list-style-type:disc}.lg\:grid-cols-3{grid-template-columns:repeat(3,minmax(0,1fr))}.lg\:flex-row{flex-direction:row}.lg\:flex-row-reverse{flex-direction:row-reverse}.lg\:flex-col{flex-direction:column}.lg\:flex-wrap{flex-wrap:wrap}.lg\:flex-nowrap{flex-wrap:nowrap}.lg\:items-center{align-items:center}.lg\:justify-end{justify-content:flex-end}.lg\:justify-between{justify-content:space-between}.lg\:gap-0{gap:0}.lg\:gap-2xl{gap:var(--spacing-2xl)}.lg\:gap-lg{gap:var(--spacing-lg)}.lg\:gap-xl{gap:var(--spacing-xl)}.lg\:gap-x-lg{column-gap:var(--spacing-lg)}.lg\:gap-y-lg{row-gap:var(--spacing-lg)}.lg\:\!space-y-0>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0!important;margin-bottom:0!important;margin-bottom:calc(0px*var(--tw-space-y-reverse))!important;margin-top:0!important;margin-top:calc(0px*(1 - var(--tw-space-y-reverse)))!important}.lg\:space-x-lg>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:calc(var(--spacing-lg)*(1 - var(--tw-space-x-reverse)));margin-right:calc(var(--spacing-lg)*var(--tw-space-x-reverse))}.lg\:space-x-xl>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:calc(var(--spacing-xl)*(1 - var(--tw-space-x-reverse)));margin-right:calc(var(--spacing-xl)*var(--tw-space-x-reverse))}.lg\:space-y-0>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(0px*var(--tw-space-y-reverse));margin-top:0;margin-top:calc(0px*(1 - var(--tw-space-y-reverse)))}.lg\:space-y-2xl>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:calc(var(--spacing-2xl)*var(--tw-space-y-reverse));margin-top:calc(var(--spacing-2xl)*(1 - var(--tw-space-y-reverse)))}.lg\:rounded-2xl{border-radius:1rem}.lg\:rounded-3xl{border-radius:1.5rem}.lg\:border{border-width:1px}.lg\:border-0{border-width:0}.lg\:border-b{border-bottom-width:1px}.lg\:border-l{border-left-width:1px}.lg\:border-t-0{border-top-width:0}.lg\:border-none{border-style:none}.lg\:bg-surface-subtle{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.lg\:p-0{padding:0}.lg\:p-2xl{padding:var(--spacing-2xl)}.lg\:p-lg{padding:var(--spacing-lg)}.lg\:px-0{padding-left:0;padding-right:0}.lg\:px-10{padding-left:2.5rem;padding-right:2.5rem}.lg\:px-4{padding-left:1rem;padding-right:1rem}.lg\:px-4xl{padding-left:var(--spacing-4xl);padding-right:var(--spacing-4xl)}.lg\:px-\[\.9375rem\]{padding-left:.9375rem;padding-right:.9375rem}.lg\:px-lg{padding-left:var(--spacing-lg);padding-right:var(--spacing-lg)}.lg\:py-0{padding-bottom:0;padding-top:0}.lg\:py-10xl{padding-bottom:var(--spacing-10xl);padding-top:var(--spacing-10xl)}.lg\:py-12{padding-bottom:3rem;padding-top:3rem}.lg\:py-2xl{padding-bottom:var(--spacing-2xl);padding-top:var(--spacing-2xl)}.lg\:py-32{padding-bottom:8rem;padding-top:8rem}.lg\:py-3xl{padding-bottom:var(--spacing-3xl);padding-top:var(--spacing-3xl)}.lg\:py-4xl{padding-bottom:var(--spacing-4xl);padding-top:var(--spacing-4xl)}.lg\:py-5xl{padding-bottom:var(--spacing-5xl);padding-top:var(--spacing-5xl)}.lg\:py-7xl{padding-bottom:var(--spacing-7xl);padding-top:var(--spacing-7xl)}.lg\:py-lg{padding-bottom:var(--spacing-lg);padding-top:var(--spacing-lg)}.lg\:py-xl{padding-bottom:var(--spacing-xl);padding-top:var(--spacing-xl)}.lg\:pb-0{padding-bottom:0}.lg\:pb-2xl{padding-bottom:var(--spacing-2xl)}.lg\:pb-3xl{padding-bottom:var(--spacing-3xl)}.lg\:pb-5xl{padding-bottom:var(--spacing-5xl)}.lg\:pb-7xl{padding-bottom:var(--spacing-7xl)}.lg\:pb-\[12\.5rem\]{padding-bottom:12.5rem}.lg\:pb-\[6\.3125rem\]{padding-bottom:6.3125rem}.lg\:pb-lg{padding-bottom:var(--spacing-lg)}.lg\:pb-md{padding-bottom:var(--spacing-md)}.lg\:pb-sm{padding-bottom:var(--spacing-sm)}.lg\:pl-10{padding-left:2.5rem}.lg\:pl-2xl{padding-left:var(--spacing-2xl)}.lg\:pl-lg{padding-left:var(--spacing-lg)}.lg\:pl-sm{padding-left:var(--spacing-sm)}.lg\:pl-xl{padding-left:var(--spacing-xl)}.lg\:pr-0{padding-right:0}.lg\:pr-lg{padding-right:var(--spacing-lg)}.lg\:pr-xl{padding-right:var(--spacing-xl)}.lg\:pt-0{padding-top:0}.lg\:pt-2xl{padding-top:var(--spacing-2xl)}.lg\:pt-3xl{padding-top:var(--spacing-3xl)}.lg\:pt-5xl{padding-top:var(--spacing-5xl)}.lg\:pt-7xl{padding-top:var(--spacing-7xl)}.lg\:pt-\[5rem\]{padding-top:5rem}.lg\:pt-\[7\.5rem\]{padding-top:7.5rem}.lg\:pt-\[8\.125rem\]{padding-top:8.125rem}.lg\:pt-lg{padding-top:var(--spacing-lg)}.lg\:pt-md{padding-top:var(--spacing-md)}.lg\:pt-xl{padding-top:var(--spacing-xl)}.lg\:text-center{text-align:center}.lg\:\!text-3xl{font-size:1.875rem!important;line-height:2.25rem!important}}@media (min-width:1280px){.xl\:mr-7xl{margin-right:var(--spacing-7xl)}.xl\:mr-lg{margin-right:var(--spacing-lg)}.xl\:h-16{height:4rem}.xl\:w-16{width:4rem}.xl\:w-4{width:1rem}.xl\:w-\[100\%\]{width:100%}.xl\:w-\[25\%\]{width:25%}.xl\:w-\[27\.6875rem\]{width:27.6875rem}.xl\:w-\[33\%\]{width:33%}.xl\:w-\[50\%\]{width:50%}.xl\:space-x-3xl>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:calc(var(--spacing-3xl)*(1 - var(--tw-space-x-reverse)));margin-right:calc(var(--spacing-3xl)*var(--tw-space-x-reverse))}}@media (min-width:1440px){.xxl\:w-\[33\%\]{width:33%}}.\[\&\:\:-webkit-inner-spin-button\]\:appearance-none::-webkit-inner-spin-button,.\[\&\:\:-webkit-outer-spin-button\]\:appearance-none::-webkit-outer-spin-button{appearance:none}.\[\&\>a\]\:block>a{display:block}.\[\&\>a\]\:w-full>a{width:100%}.\[\&\>a\]\:px-2>a{padding-left:.5rem;padding-right:.5rem}.\[\&\>a\]\:px-4>a{padding-left:1rem;padding-right:1rem}.\[\&\>a\]\:py-md>a{padding-bottom:var(--spacing-md);padding-top:var(--spacing-md)}.\[\&\>div\]\:z-1>div{z-index:1}.\[\&\>div\]\:z-10>div{z-index:10}.\[\&\>div\]\:w-fit>div{width:fit-content}.\[\&\>ol\>li\]\:truncate>ol>li{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.\[\&\>span\]\:overflow-hidden>span{overflow:hidden}.\[\&\>span\]\:truncate>span{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.\[\&_input\]\:\!w-\[1\.15em\] input{width:1.15em!important}.\[\&_input\]\:text-center input{text-align:center}.\[\&_span\]\:hover\:text-color-brand-bold:hover span,.\[\&_span\]\:text-color-brand-bold span{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}</style> <style>@charset "UTF-8"; /*! tailwindcss v3.3.2 | MIT License | https://tailwindcss.com*/*,:after,:before{border:0 solid;box-sizing:border-box}:after,:before{--tw-content:""}html{line-height:1.5;-webkit-text-size-adjust:100%;font-family:Suisse Int\'l,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji;font-feature-settings:normal;font-variation-settings:normal;-moz-tab-size:4;-o-tab-size:4;tab-size:4}body{line-height:inherit;margin:0}hr{border-top-width:1px;color:inherit;height:0}abbr:where([title]){-webkit-text-decoration:underline dotted;text-decoration:underline dotted}h1,h2,h3,h4,h5,h6{font-size:inherit;font-weight:inherit}a{color:inherit;text-decoration:inherit}b,strong{font-weight:bolder}code,kbd,pre,samp{font-family:ui-monospace,SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}table{border-collapse:collapse;border-color:inherit;text-indent:0}button,input,optgroup,select,textarea{color:inherit;font-family:inherit;font-size:100%;font-weight:inherit;line-height:inherit;margin:0;padding:0}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button;background-color:transparent;background-image:none}:-moz-focusring{outline:auto}:-moz-ui-invalid{box-shadow:none}progress{vertical-align:baseline}::-webkit-inner-spin-button,::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}summary{display:list-item}blockquote,dd,dl,figure,h1,h2,h3,h4,h5,h6,hr,p,pre{margin:0}fieldset{margin:0}fieldset,legend{padding:0}menu,ol,ul{list-style:none;margin:0;padding:0}textarea{resize:vertical}input::-moz-placeholder,textarea::-moz-placeholder{color:#9ca3af;opacity:1}input::placeholder,textarea::placeholder{color:#9ca3af;opacity:1}[role=button],button{cursor:pointer}:disabled{cursor:default}audio,canvas,embed,iframe,img,object,svg,video{display:block;vertical-align:middle}img,video{height:auto;max-width:100%}[hidden]{display:none}html{color:0,0,0;color:var(--color-text-default)}:root{--color-blue-000:233,241,255;--color-blue-100:208,228,255;--color-blue-200:155,203,255;--color-blue-300:105,176,245;--color-blue-400:76,149,216;--color-blue-500:51,122,183;--color-blue-600:0,98,159;--color-blue-700:0,88,144;--color-blue-800:0,74,121;--color-blue-900:0,50,86;--color-blue-1000:0,29,52;--color-red-000:255,251,255;--color-red-100:255,218,212;--color-red-200:255,180,166;--color-red-300:255,138,117;--color-red-400:255,85,59;--color-red-500:225,25,0;--color-red-600:211,28,4;--color-red-700:189,19,0;--color-red-800:144,12,0;--color-red-900:103,6,0;--color-red-1000:64,2,0;--color-yellow-000:254,252,232;--color-yellow-100:254,249,195;--color-yellow-200:254,240,138;--color-yellow-300:253,224,71;--color-yellow-400:250,204,21;--color-yellow-500:234,179,8;--color-yellow-600:209,149,7;--color-yellow-700:196,132,4;--color-yellow-800:168,106,7;--color-yellow-900:143,87,13;--color-yellow-1000:125,75,17;--color-green-000:241,254,248;--color-green-100:191,238,215;--color-green-200:101,214,160;--color-green-300:60,194,129;--color-green-400:34,173,106;--color-green-500:5,148,79;--color-green-600:9,133,73;--color-green-700:0,109,56;--color-green-800:0,82,41;--color-green-900:0,57,26;--color-green-1000:0,33,13;--color-cyan-000:245,251,255;--color-cyan-100:220,243,255;--color-cyan-200:195,234,254;--color-cyan-300:170,224,253;--color-cyan-400:145,214,251;--color-cyan-500:89,186,240;--color-cyan-600:44,154,207;--color-cyan-700:0,127,176;--color-cyan-800:0,101,141;--color-cyan-900:0,76,107;--color-cyan-1000:0,52,75;--color-neutral-000:248,249,253;--color-neutral-100:247,248,249;--color-neutral-200:241,242,244;--color-neutral-300:220,223,228;--color-neutral-400:179,185,196;--color-neutral-500:133,144,162;--color-neutral-600:117,129,149;--color-neutral-700:98,111,134;--color-neutral-800:68,84,111;--color-neutral-900:44,62,93;--color-neutral-1000:23,43,77;--color-white:255,255,255;--color-black:0,0,0;--color-brand-sunken:var(--color-yellow-000);--color-brand-subtlest:var(--color-yellow-100);--color-brand-subtler:var(--color-yellow-200);--color-brand-subtle:var(--color-yellow-300);--color-brand-default:var(--color-yellow-400);--color-brand-bold:var(--color-yellow-500);--color-brand-bolder:var(--color-yellow-600);--color-brand-boldest:var(--color-yellow-700);--color-brand-strong:var(--color-yellow-800);--color-brand-stronger:var(--color-yellow-900);--color-brand-strongest:var(--color-yellow-1000);--color-accent-sunken:var(--color-black);--color-accent-subtlest:var(--color-black);--color-accent-subtler:var(--color-black);--color-accent-subtle:var(--color-black);--color-accent-default:var(--color-black);--color-accent-bold:var(--color-black);--color-accent-bolder:var(--color-black);--color-accent-boldest:var(--color-black);--color-accent-strong:var(--color-black);--color-accent-stronger:var(--color-black);--color-accent-strongest:var(--color-black);--color-error-sunken:var(--color-red-000);--color-error-subtlest:var(--color-red-100);--color-error-bold:var(--color-red-500);--color-warning-sunken:var(--color-yellow-000);--color-warning-subtlest:var(--color-yellow-100);--color-warning-bold:var(--color-yellow-500);--color-success-sunken:var(--color-green-000);--color-success-subtlest:var(--color-green-100);--color-success-bold:var(--color-green-500);--color-info-sunken:var(--color-cyan-000);--color-info-subtlest:var(--color-cyan-100);--color-info-bold:var(--color-cyan-500);--color-link-bold:1,86,206;--color-link-bolder:1,75,181;--color-link-boldest:1,65,155;--color-text-default:var(--color-black);--color-text-subtle:var(--color-neutral-700);--color-text-subtlest:var(--color-neutral-600);--color-text-disabled:var(--color-neutral-400);--color-text-inverse:var(--color-white);--color-text-onbrand:var(--color-white);--color-text-onaccent:var(--color-white);--color-text-brand-bold:var(--color-brand-bold);--color-text-brand-bolder:var(--color-brand-bolder);--color-text-brand-boldest:var(--color-brand-boldest);--color-text-accent-bold:var(--color-white);--color-text-accent-bolder:var(--color-white);--color-text-accent-boldest:var(--color-white);--color-text-link-bold:var(--color-link-bold);--color-text-link-bolder:var(--color-link-bolder);--color-text-link-boldest:var(--color-link-boldest);--color-text-link-subtle:var(--color-neutral-700);--color-text-error:var(--color-red-600);--color-text-warning:var(--color-yellow-600);--color-text-success:var(--color-green-600);--color-text-info:var(--color-cyan-600);--color-surface-subtle:var(--color-neutral-000);--color-surface-default:var(--color-white);--color-surface-inverse:var(--color-black);--color-surface-selected:var(--color-neutral-000);--color-surface-disabled:var(--color-neutral-200);--color-bg-brand-sunken:var(--color-brand-sunken);--color-bg-brand-subtlest:var(--color-brand-subtlest);--color-bg-brand-subtler:var(--color-brand-subtler);--color-bg-brand-subtle:var(--color-brand-subtle);--color-bg-brand-default:var(--color-brand-default);--color-bg-brand-bold:var(--color-brand-bold);--color-bg-brand-bolder:var(--color-brand-bolder);--color-bg-brand-boldest:var(--color-brand-boldest);--color-bg-brand-strong:var(--color-brand-strong);--color-bg-brand-stronger:var(--color-brand-stronger);--color-bg-brand-strongest:var(--color-brand-strongest);--color-bg-accent-sunken:var(--color-accent-sunken);--color-bg-accent-subtlest:var(--color-accent-subtlest);--color-bg-accent-subtler:var(--color-accent-subtler);--color-bg-accent-subtle:var(--color-accent-subtle);--color-bg-accent-default:var(--color-accent-default);--color-bg-accent-bold:var(--color-accent-bold);--color-bg-accent-bolder:var(--color-accent-bolder);--color-bg-accent-boldest:var(--color-accent-boldest);--color-bg-accent-strong:var(--color-accent-strong);--color-bg-accent-stronger:var(--color-accent-stronger);--color-bg-accent-strongest:var(--color-accent-strongest);--color-bg-content-sunken:var(--color-brand-sunken);--color-bg-content-subtlest:var(--color-brand-subtlest);--color-bg-content-subtler:var(--color-brand-subtler);--color-bg-content-subtle:var(--color-brand-subtle);--color-bg-content-default:var(--color-brand-default);--color-bg-content-bold:var(--color-brand-bold);--color-bg-content-bolder:var(--color-brand-bolder);--color-bg-content-boldest:var(--color-brand-boldest);--color-bg-content-inverse-subtler:var(--color-brand-strong);--color-bg-content-inverse-subtle:var(--color-brand-stronger);--color-bg-content-inverse:var(--color-brand-strongest);--color-bg-error-sunken:var(--color-error-sunken);--color-bg-error-subtlest:var(--color-error-subtlest);--color-bg-error-bold:var(--color-error-bold);--color-bg-warning-sunken:var(--color-warning-sunken);--color-bg-warning-subtlest:var(--color-warning-subtlest);--color-bg-warning-bold:var(--color-warning-bold);--color-bg-success-sunken:var(--color-success-sunken);--color-bg-success-subtlest:var(--color-success-subtlest);--color-bg-success-bold:var(--color-success-bold);--color-bg-info-sunken:var(--color-info-sunken);--color-bg-info-subtlest:var(--color-info-subtlest);--color-bg-info-bold:var(--color-info-bold);--color-border-default:var(--color-neutral-300);--color-border-bold:var(--color-neutral-400);--color-border-brand:var(--color-brand-bold);--color-border-selected:var(--color-brand-bold);--color-border-error:var(--color-error-bold);--color-border-warning:var(--color-warning-bold);--color-border-success:var(--color-success-bold);--color-border-info:var(--color-info-bold);--spacing-xs:0.25rem;--spacing-sm:0.5rem;--spacing-md:1rem;--spacing-lg:1.5rem;--spacing-xl:2rem;--spacing-2xl:2.5rem;--spacing-3xl:3rem;--spacing-4xl:3.5rem;--spacing-5xl:4rem;--spacing-6xl:4.5rem;--spacing-7xl:5rem;--spacing-8xl:5.5rem;--spacing-9xl:6rem;--spacing-10xl:6.5rem;--h1-lg-size:3.75rem;--h1-md-size:3rem;--h1-sm-size:2.25rem;--h2-lg-size:3rem;--h2-md-size:2.25rem;--h2-sm-size:1.875rem;--h3-lg-size:2.375rem;--h3-md-size:1.875rem;--h3-sm-size:1.5rem;--h4-lg-size:1.875rem;--h4-md-size:1.5rem;--h4-sm-size:1.25rem;--h5-lg-size:1.25rem;--h5-md-size:1.125rem;--h5-sm-size:1rem;--h6-lg-size:1.125rem;--h6-md-size:1rem;--h6-sm-size:0.875rem;--h1-lg-line-height:1;--h1-md-line-height:1;--h1-sm-line-height:1.11;--h2-lg-line-height:1.2;--h2-md-line-height:1.11;--h2-sm-line-height:1.2;--h3-lg-line-height:1.3;--h3-md-line-height:1.2;--h3-sm-line-height:1.33;--h4-lg-line-height:1.3;--h4-md-line-height:1.33;--h4-sm-line-height:1.4;--h5-lg-line-height:1.5;--h5-md-line-height:1.55;--h5-sm-line-height:1.5;--h6-lg-line-height:1.55;--h6-md-line-height:1.5;--h6-sm-line-height:1.5}.m-switch{--color-brand-default:35,35,35;--color-bg-content-default:var(--color-neutral-400);--color-bg-content-bold:var(--color-neutral-500);--color-bg-content-bolder:var(--color-neutral-600);--color-brand-bold:var(--color-black);--color-brand-bolder:var(--color-black)}.m-checkbox{--color-brand-bold:0,0,0;--color-border-brand:0,0,0;--color-brand-default:0,0,0}.m-autocomplete,.m-select{--color-text-brand-bold:0,0,0;--color-text-brand-bolder:0,0,0}.m-range-slider{--color-brand-bold:0,0,0;--color-brand-bolder:0,0,0;--color-brand-strong:0,0,0;--color-bg-content-default:var(--color-border-default)}.m-tag{--color-text-brand-bold:0,0,0}.m-chip{--color-text-brand-bolder:0,0,0}.m-dropdown,.m-list,.m-notification,.m-tabs{--color-text-brand-bold:0,0,0}.m-tabs__header{--color-bg-content-subtle:var(--color-border-default)}.m-loader{--color-brand-bold:0,0,0;--color-brand-sunken:var(--color-neutral-100)}.m-search-select{--color-surface-selected:var(--color-brand-default);--color-surface-subtle:var(--color-white);--color-text-brand-bold:var(--color-black)}.m-button-group>.m-button--active{--color-brand-strong:var(--color-black);--color-text-on-brand:var(--color-white)}.m-radio-group{--color-border-brand:0,0,0;--color-brand-bold:0,0,0;--color-brand-bolder:0,0,0;--color-brand-boldest:0,0,0}.m-stepper{--color-surface-selected:var(--color-bg-brand-boldest);--color-text-brand-bold:var(--color-black);--color-brand-bold:var(--color-bg-brand-subtler);--color-white:var(--color-text-subtle);--color-brand-default:var(--color-bg-brand-subtlest);--color-text-default:var(--color-text-subtle)}.m-stepper__line{--color-brand-bold:var(--color-black);--color-bg-content-default:var(--color-border-bold)}.m-feature{--color-text-brand-bolder:var(--color-brand-default)}*,:after,:before{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:rgba(59,130,246,.5);--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }::backdrop{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:rgba(59,130,246,.5);--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }.container{width:100%}@media (min-width:576px){.container{max-width:576px}}@media (min-width:768px){.container{max-width:768px}}@media (min-width:1024px){.container{max-width:1024px}}@media (min-width:1280px){.container{max-width:1280px}}@media (min-width:1440px){.container{max-width:1440px}}@media (min-width:1920px){.container{max-width:1920px}}.prose{color:var(--tw-prose-body);max-width:65ch}.prose :where(p):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em;margin-top:1.25em}.prose :where([class~=lead]):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-lead);font-size:1.25em;line-height:1.6;margin-bottom:1.2em;margin-top:1.2em}.prose :where(a):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-links);font-weight:500;text-decoration:underline}.prose :where(strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-bold);font-weight:600}.prose :where(a strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(blockquote strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(thead th strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(ol):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:decimal;margin-bottom:1.25em;margin-top:1.25em;padding-inline-start:1.625em}.prose :where(ol[type=A]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-alpha}.prose :where(ol[type=a]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-alpha}.prose :where(ol[type=A s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-alpha}.prose :where(ol[type=a s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-alpha}.prose :where(ol[type=I]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-roman}.prose :where(ol[type=i]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-roman}.prose :where(ol[type=I s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:upper-roman}.prose :where(ol[type=i s]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:lower-roman}.prose :where(ol[type="1"]):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:decimal}.prose :where(ul):not(:where([class~=not-prose],[class~=not-prose] *)){list-style-type:disc;margin-bottom:1.25em;margin-top:1.25em;padding-inline-start:1.625em}.prose :where(ol>li):not(:where([class~=not-prose],[class~=not-prose] *))::marker{color:var(--tw-prose-counters);font-weight:400}.prose :where(ul>li):not(:where([class~=not-prose],[class~=not-prose] *))::marker{color:var(--tw-prose-bullets)}.prose :where(dt):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;margin-top:1.25em}.prose :where(hr):not(:where([class~=not-prose],[class~=not-prose] *)){border-color:var(--tw-prose-hr);border-top-width:1px;margin-bottom:3em;margin-top:3em}.prose :where(blockquote):not(:where([class~=not-prose],[class~=not-prose] *)){border-inline-start-color:var(--tw-prose-quote-borders);border-inline-start-width:.25rem;color:var(--tw-prose-quotes);font-style:italic;font-weight:500;margin-bottom:1.6em;margin-top:1.6em;padding-inline-start:1em;quotes:"\201C""\201D""\2018""\2019"}.prose :where(blockquote p:first-of-type):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:open-quote}.prose :where(blockquote p:last-of-type):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:close-quote}.prose :where(h1):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:2.25em;font-weight:800;line-height:1.1111111;margin-bottom:.8888889em;margin-top:0}.prose :where(h1 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:900}.prose :where(h2):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:1.5em;font-weight:700;line-height:1.3333333;margin-bottom:1em;margin-top:2em}.prose :where(h2 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:800}.prose :where(h3):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-size:1.25em;font-weight:600;line-height:1.6;margin-bottom:.6em;margin-top:1.6em}.prose :where(h3 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:700}.prose :where(h4):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;line-height:1.5;margin-bottom:.5em;margin-top:1.5em}.prose :where(h4 strong):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-weight:700}.prose :where(img):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(picture):not(:where([class~=not-prose],[class~=not-prose] *)){display:block;margin-bottom:2em;margin-top:2em}.prose :where(video):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(kbd):not(:where([class~=not-prose],[class~=not-prose] *)){border-radius:.3125rem;box-shadow:0 0 0 1px rgb(var(--tw-prose-kbd-shadows)/10%),0 3px 0 rgb(var(--tw-prose-kbd-shadows)/10%);color:var(--tw-prose-kbd);font-family:inherit;font-size:.875em;font-weight:500;padding-inline-end:.375em;padding-bottom:.1875em;padding-top:.1875em;padding-inline-start:.375em}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-code);font-size:.875em;font-weight:600}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:"`"}.prose :where(code):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:"`"}.prose :where(a code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(h1 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(h2 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-size:.875em}.prose :where(h3 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit;font-size:.9em}.prose :where(h4 code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(blockquote code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(thead th code):not(:where([class~=not-prose],[class~=not-prose] *)){color:inherit}.prose :where(pre):not(:where([class~=not-prose],[class~=not-prose] *)){background-color:var(--tw-prose-pre-bg);border-radius:.375rem;color:var(--tw-prose-pre-code);font-size:.875em;font-weight:400;line-height:1.7142857;margin-bottom:1.7142857em;margin-top:1.7142857em;overflow-x:auto;padding-inline-end:1.1428571em;padding-bottom:.8571429em;padding-top:.8571429em;padding-inline-start:1.1428571em}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)){background-color:transparent;border-radius:0;border-width:0;color:inherit;font-family:inherit;font-size:inherit;font-weight:inherit;line-height:inherit;padding:0}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)):before{content:none}.prose :where(pre code):not(:where([class~=not-prose],[class~=not-prose] *)):after{content:none}.prose :where(table):not(:where([class~=not-prose],[class~=not-prose] *)){font-size:.875em;line-height:1.7142857;margin-bottom:2em;margin-top:2em;table-layout:auto;width:100%}.prose :where(thead):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-color:var(--tw-prose-th-borders);border-bottom-width:1px}.prose :where(thead th):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-headings);font-weight:600;padding-inline-end:.5714286em;padding-bottom:.5714286em;padding-inline-start:.5714286em;vertical-align:bottom}.prose :where(tbody tr):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-color:var(--tw-prose-td-borders);border-bottom-width:1px}.prose :where(tbody tr:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){border-bottom-width:0}.prose :where(tbody td):not(:where([class~=not-prose],[class~=not-prose] *)){vertical-align:baseline}.prose :where(tfoot):not(:where([class~=not-prose],[class~=not-prose] *)){border-top-color:var(--tw-prose-th-borders);border-top-width:1px}.prose :where(tfoot td):not(:where([class~=not-prose],[class~=not-prose] *)){vertical-align:top}.prose :where(th,td):not(:where([class~=not-prose],[class~=not-prose] *)){text-align:start}.prose :where(figure>*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0;margin-top:0}.prose :where(figcaption):not(:where([class~=not-prose],[class~=not-prose] *)){color:var(--tw-prose-captions);font-size:.875em;line-height:1.4285714;margin-top:.8571429em}.prose{--tw-prose-body:#374151;--tw-prose-headings:#111827;--tw-prose-lead:#4b5563;--tw-prose-links:#111827;--tw-prose-bold:#111827;--tw-prose-counters:#6b7280;--tw-prose-bullets:#d1d5db;--tw-prose-hr:#e5e7eb;--tw-prose-quotes:#111827;--tw-prose-quote-borders:#e5e7eb;--tw-prose-captions:#6b7280;--tw-prose-kbd:#111827;--tw-prose-kbd-shadows:17 24 39;--tw-prose-code:#111827;--tw-prose-pre-code:#e5e7eb;--tw-prose-pre-bg:#1f2937;--tw-prose-th-borders:#d1d5db;--tw-prose-td-borders:#e5e7eb;--tw-prose-invert-body:#d1d5db;--tw-prose-invert-headings:#fff;--tw-prose-invert-lead:#9ca3af;--tw-prose-invert-links:#fff;--tw-prose-invert-bold:#fff;--tw-prose-invert-counters:#9ca3af;--tw-prose-invert-bullets:#4b5563;--tw-prose-invert-hr:#374151;--tw-prose-invert-quotes:#f3f4f6;--tw-prose-invert-quote-borders:#374151;--tw-prose-invert-captions:#9ca3af;--tw-prose-invert-kbd:#fff;--tw-prose-invert-kbd-shadows:255 255 255;--tw-prose-invert-code:#fff;--tw-prose-invert-pre-code:#d1d5db;--tw-prose-invert-pre-bg:rgba(0,0,0,.5);--tw-prose-invert-th-borders:#4b5563;--tw-prose-invert-td-borders:#374151;font-size:1rem;line-height:1.75}.prose :where(picture>img):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0;margin-top:0}.prose :where(li):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.5em;margin-top:.5em}.prose :where(ol>li):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:.375em}.prose :where(ul>li):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:.375em}.prose :where(.prose>ul>li p):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.75em;margin-top:.75em}.prose :where(.prose>ul>li>p:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:1.25em}.prose :where(.prose>ul>li>p:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em}.prose :where(.prose>ol>li>p:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:1.25em}.prose :where(.prose>ol>li>p:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em}.prose :where(ul ul,ul ol,ol ul,ol ol):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:.75em;margin-top:.75em}.prose :where(dl):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:1.25em;margin-top:1.25em}.prose :where(dd):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:.5em;padding-inline-start:1.625em}.prose :where(hr+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h2+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h3+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(h4+*):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(thead th:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:0}.prose :where(thead th:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:0}.prose :where(tbody td,tfoot td):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:.5714286em;padding-bottom:.5714286em;padding-top:.5714286em;padding-inline-start:.5714286em}.prose :where(tbody td:first-child,tfoot td:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-start:0}.prose :where(tbody td:last-child,tfoot td:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){padding-inline-end:0}.prose :where(figure):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:2em;margin-top:2em}.prose :where(.prose>:first-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-top:0}.prose :where(.prose>:last-child):not(:where([class~=not-prose],[class~=not-prose] *)){margin-bottom:0}.sr-only{height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;clip:rect(0,0,0,0);border-width:0;white-space:nowrap}.pointer-events-none{pointer-events:none}.visible{visibility:visible}.invisible{visibility:hidden}.collapse{visibility:collapse}.static{position:static}.fixed{position:fixed}.\!absolute{position:absolute!important}.absolute{position:absolute}.relative{position:relative}.sticky{position:sticky}.inset-0{inset:0}.inset-y-0{bottom:0;top:0}.-top-px{top:-1px}.bottom-0{bottom:0}.bottom-1{bottom:.25rem}.bottom-1\.5{bottom:.375rem}.bottom-10{bottom:2.5rem}.bottom-24{bottom:6rem}.bottom-4{bottom:1rem}.bottom-6{bottom:1.5rem}.bottom-\[7\.5rem\]{bottom:7.5rem}.bottom-md{bottom:1rem;bottom:var(--spacing-md)}.left-0{left:0}.left-1\/2{left:50%}.left-12{left:3rem}.left-4{left:1rem}.left-6{left:1.5rem}.left-md{left:1rem;left:var(--spacing-md)}.right-0{right:0}.right-1{right:.25rem}.right-1\.5{right:.375rem}.right-12{right:3rem}.right-2{right:.5rem}.right-2\.5{right:.625rem}.right-4{right:1rem}.right-6{right:1.5rem}.right-8{right:2rem}.right-\[-10px\]{right:-10px}.right-\[-4px\]{right:-4px}.right-\[-8px\]{right:-8px}.right-\[1rem\]{right:1rem}.right-\[3\.125rem\]{right:3.125rem}.top-0{top:0}.top-1{top:.25rem}.top-1\/2{top:50%}.top-12{top:3rem}.top-14{top:3.5rem}.top-16{top:4rem}.top-20{top:5rem}.top-4{top:1rem}.top-6{top:1.5rem}.top-\[-4px\]{top:-4px}.top-\[-5\.875rem\]{top:-5.875rem}.top-\[4\.625rem\]{top:4.625rem}.top-\[48\%\]{top:48%}.top-\[calc$50vh\+15rem$\]{top:calc(50vh + 15rem)}.top-\[calc$50vh\+6\.25rem$\]{top:calc(50vh + 6.25rem)}.isolate{isolation:isolate}.-z-10{z-index:-10}.z-0{z-index:0}.z-1{z-index:1}.z-10{z-index:10}.z-20{z-index:20}.z-40{z-index:40}.z-50{z-index:50}.float-left{float:left}.clear-left{clear:left}.m-0{margin:0}.m-\[\.625rem\]{margin:.625rem}.m-auto{margin:auto}.m-md{margin:1rem;margin:var(--spacing-md)}.mx-auto{margin-left:auto;margin-right:auto}.mx-lg{margin-left:1.5rem;margin-left:var(--spacing-lg);margin-right:1.5rem;margin-right:var(--spacing-lg)}.mx-md{margin-left:1rem;margin-left:var(--spacing-md);margin-right:1rem;margin-right:var(--spacing-md)}.mx-sm{margin-left:.5rem;margin-left:var(--spacing-sm);margin-right:.5rem;margin-right:var(--spacing-sm)}.my-0{margin-bottom:0;margin-top:0}.my-2xl{margin-bottom:2.5rem;margin-bottom:var(--spacing-2xl);margin-top:2.5rem;margin-top:var(--spacing-2xl)}.my-4{margin-bottom:1rem;margin-top:1rem}.my-5xl{margin-bottom:4rem;margin-bottom:var(--spacing-5xl);margin-top:4rem;margin-top:var(--spacing-5xl)}.my-lg{margin-bottom:1.5rem;margin-bottom:var(--spacing-lg);margin-top:1.5rem;margin-top:var(--spacing-lg)}.my-md{margin-bottom:1rem;margin-bottom:var(--spacing-md);margin-top:1rem;margin-top:var(--spacing-md)}.my-sm{margin-bottom:.5rem;margin-bottom:var(--spacing-sm);margin-top:.5rem;margin-top:var(--spacing-sm)}.my-xl{margin-bottom:2rem;margin-bottom:var(--spacing-xl);margin-top:2rem;margin-top:var(--spacing-xl)}.-mr-0{margin-right:0}.-mr-0\.5{margin-right:-.125rem}.-mr-1{margin-right:-.25rem}.-mr-2{margin-right:-.5rem}.-mr-2\.5{margin-right:-.625rem}.-mt-xs{margin-top:-.25rem;margin-top:calc(var(--spacing-xs)*-1)}.mb-1{margin-bottom:.25rem}.mb-2{margin-bottom:.5rem}.mb-2xl{margin-bottom:2.5rem;margin-bottom:var(--spacing-2xl)}.mb-3{margin-bottom:.75rem}.mb-4{margin-bottom:1rem}.mb-6{margin-bottom:1.5rem}.mb-7xl{margin-bottom:5rem;margin-bottom:var(--spacing-7xl)}.mb-\[0\.25rem\]{margin-bottom:.25rem}.mb-lg{margin-bottom:1.5rem;margin-bottom:var(--spacing-lg)}.mb-md{margin-bottom:1rem;margin-bottom:var(--spacing-md)}.mb-sm{margin-bottom:.5rem;margin-bottom:var(--spacing-sm)}.mb-xl{margin-bottom:2rem;margin-bottom:var(--spacing-xl)}.mb-xs{margin-bottom:.25rem;margin-bottom:var(--spacing-xs)}.ml-2{margin-left:.5rem}.ml-2xl{margin-left:2.5rem;margin-left:var(--spacing-2xl)}.ml-\[-0\.0625rem\]{margin-left:-.0625rem}.ml-\[-0\.75rem\]{margin-left:-.75rem}.ml-\[0\.625rem\]{margin-left:.625rem}.ml-\[0\.75rem\]{margin-left:.75rem}.ml-auto{margin-left:auto}.ml-lg{margin-left:1.5rem;margin-left:var(--spacing-lg)}.ml-md{margin-left:1rem;margin-left:var(--spacing-md)}.ml-sm{margin-left:.5rem;margin-left:var(--spacing-sm)}.ml-xs{margin-left:.25rem;margin-left:var(--spacing-xs)}.mr-4{margin-right:1rem}.mr-5{margin-right:1.25rem}.mr-6{margin-right:1.5rem}.mr-\[\.125rem\]{margin-right:.125rem}.mr-\[\.625rem\]{margin-right:.625rem}.mr-\[0\.3125rem\]{margin-right:.3125rem}.mr-\[2\.3125rem\]{margin-right:2.3125rem}.mr-\[2\.375rem\]{margin-right:2.375rem}.mr-\[5\.625rem\]{margin-right:5.625rem}.mr-lg{margin-right:1.5rem;margin-right:var(--spacing-lg)}.mr-md{margin-right:1rem;margin-right:var(--spacing-md)}.mr-sm{margin-right:.5rem;margin-right:var(--spacing-sm)}.mr-xl{margin-right:2rem;margin-right:var(--spacing-xl)}.mr-xs{margin-right:.25rem;margin-right:var(--spacing-xs)}.mt-1{margin-top:.25rem}.mt-2xl{margin-top:2.5rem;margin-top:var(--spacing-2xl)}.mt-3xl{margin-top:3rem;margin-top:var(--spacing-3xl)}.mt-6{margin-top:1.5rem}.mt-\[-3rem\]{margin-top:-3rem}.mt-\[\.625rem\]{margin-top:.625rem}.mt-\[1\.25rem\]{margin-top:1.25rem}.mt-\[1rem\]{margin-top:1rem}.mt-lg{margin-top:1.5rem;margin-top:var(--spacing-lg)}.mt-md{margin-top:1rem;margin-top:var(--spacing-md)}.mt-sm{margin-top:.5rem;margin-top:var(--spacing-sm)}.mt-xl{margin-top:2rem;margin-top:var(--spacing-xl)}.mt-xs{margin-top:.25rem;margin-top:var(--spacing-xs)}.box-border{box-sizing:border-box}.line-clamp-1{-webkit-line-clamp:1}.line-clamp-1,.line-clamp-3{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical}.line-clamp-3{-webkit-line-clamp:3}.\!block{display:block!important}.block{display:block}.\!inline-block{display:inline-block!important}.inline-block{display:inline-block}.\!inline{display:inline!important}.inline{display:inline}.flex{display:flex}.\!inline-flex{display:inline-flex!important}.inline-flex{display:inline-flex}.table{display:table}.grid{display:grid}.contents{display:contents}.\!hidden{display:none!important}.hidden{display:none}.aspect-\[1\/1\.414\]{aspect-ratio:1/1.414}.aspect-\[1200\/630\]{aspect-ratio:1200/630}.aspect-\[381\/200\]{aspect-ratio:381/200}.aspect-\[4\/5\]{aspect-ratio:4/5}.aspect-square{aspect-ratio:1/1}.aspect-video{aspect-ratio:16/9}.\!h-6{height:1.5rem!important}.h-0{height:0}.h-0\.5{height:.125rem}.h-1{height:.25rem}.h-1\.5{height:.375rem}.h-10{height:2.5rem}.h-12{height:3rem}.h-14{height:3.5rem}.h-16{height:4rem}.h-2{height:.5rem}.h-20{height:5rem}.h-28{height:7rem}.h-3{height:.75rem}.h-32{height:8rem}.h-36{height:9rem}.h-4{height:1rem}.h-48{height:12rem}.h-5{height:1.25rem}.h-52{height:13rem}.h-6{height:1.5rem}.h-7{height:1.75rem}.h-8{height:2rem}.h-80{height:20rem}.h-9{height:2.25rem}.h-96{height:24rem}.h-\[\.25rem\]{height:.25rem}.h-\[0\.5rem\]{height:.5rem}.h-\[0\.9rem\]{height:.9rem}.h-\[1\.15em\]{height:1.15em}.h-\[1\.3rem\]{height:1.3rem}.h-\[1\.4rem\]{height:1.4rem}.h-\[1\.5rem\]{height:1.5rem}.h-\[1\.8125rem\]{height:1.8125rem}.h-\[1\.875rem\]{height:1.875rem}.h-\[100\%\]{height:100%}.h-\[100px\]{height:100px}.h-\[150px\]{height:150px}.h-\[160px\]{height:160px}.h-\[1rem\]{height:1rem}.h-\[2\.5rem\]{height:2.5rem}.h-\[24rem\]{height:24rem}.h-\[25\.25rem\]{height:25.25rem}.h-\[3\.625rem\]{height:3.625rem}.h-\[3\.75rem\]{height:3.75rem}.h-\[30rem\]{height:30rem}.h-\[35\.5rem\]{height:35.5rem}.h-\[38rem\]{height:38rem}.h-\[4\.5rem\]{height:4.5rem}.h-\[50rem\]{height:50rem}.h-\[5rem\]{height:5rem}.h-\[6\.5rem\]{height:6.5rem}.h-\[6px\]{height:6px}.h-\[auto\],.h-auto{height:auto}.h-fit{height:-moz-fit-content;height:fit-content}.h-full{height:100%}.h-px{height:1px}.max-h-60{max-height:15rem}.max-h-80{max-height:20rem}.min-h-\[1\.5rem\]{min-height:1.5rem}.min-h-\[100px\]{min-height:100px}.min-h-\[15vh\]{min-height:15vh}.min-h-\[45rem\]{min-height:45rem}.min-h-\[70vh\]{min-height:70vh}.min-h-full{min-height:100%}.\!w-2xl{width:2.5rem!important;width:var(--spacing-2xl)!important}.\!w-40{width:10rem!important}.\!w-fit{width:-moz-fit-content!important;width:fit-content!important}.\!w-full{width:100%!important}.w-1{width:.25rem}.w-1\.5{width:.375rem}.w-1\/2{width:50%}.w-1\/4{width:25%}.w-1\/5{width:20%}.w-10{width:2.5rem}.w-12{width:3rem}.w-14{width:3.5rem}.w-16{width:4rem}.w-2{width:.5rem}.w-20{width:5rem}.w-28{width:7rem}.w-3{width:.75rem}.w-3\/5{width:60%}.w-32{width:8rem}.w-36{width:9rem}.w-4{width:1rem}.w-4\/5{width:80%}.w-40{width:10rem}.w-4xl{width:3.5rem;width:var(--spacing-4xl)}.w-5{width:1.25rem}.w-6{width:1.5rem}.w-60{width:15rem}.w-7{width:1.75rem}.w-8{width:2rem}.w-80{width:20rem}.w-9{width:2.25rem}.w-96{width:24rem}.w-\[\.25rem\]{width:.25rem}.w-\[1\.15em\]{width:1.15em}.w-\[1\.4rem\]{width:1.4rem}.w-\[1\.5rem\]{width:1.5rem}.w-\[1\.6rem\]{width:1.6rem}.w-\[10\%\]{width:10%}.w-\[10\.25rem\]{width:10.25rem}.w-\[10\.625rem\]{width:10.625rem}.w-\[100\%\]{width:100%}.w-\[10rem\]{width:10rem}.w-\[13\.125rem\]{width:13.125rem}.w-\[13rem\]{width:13rem}.w-\[15\%\]{width:15%}.w-\[18rem\]{width:18rem}.w-\[1rem\]{width:1rem}.w-\[2\.5rem\]{width:2.5rem}.w-\[2\.75rem\]{width:2.75rem}.w-\[20\%\]{width:20%}.w-\[22px\]{width:22px}.w-\[25rem\]{width:25rem}.w-\[30\%\]{width:30%}.w-\[33\%\]{width:33%}.w-\[4\.5rem\]{width:4.5rem}.w-\[6\.5rem\]{width:6.5rem}.w-\[6\.75rem\]{width:6.75rem}.w-\[7\.5rem\]{width:7.5rem}.w-\[92\.5vw\]{width:92.5vw}.w-auto{width:auto}.w-fit{width:-moz-fit-content;width:fit-content}.w-full{width:100%}.w-max{width:-moz-max-content;width:max-content}.w-min{width:-moz-min-content;width:min-content}.w-px{width:1px}.w-screen{width:100vw}.\!min-w-0{min-width:0!important}.min-w-10{min-width:2.5rem}.min-w-12{min-width:3rem}.min-w-14{min-width:3.5rem}.min-w-28{min-width:7rem}.min-w-5{min-width:1.25rem}.min-w-6{min-width:1.5rem}.min-w-7{min-width:1.75rem}.min-w-8{min-width:2rem}.min-w-\[0\.5rem\]{min-width:.5rem}.min-w-\[0\.9rem\]{min-width:.9rem}.min-w-\[1\.3rem\]{min-width:1.3rem}.min-w-\[12\.5rem\]{min-width:12.5rem}.min-w-\[146px\]{min-width:146px}.min-w-\[156px\]{min-width:156px}.min-w-\[21rem\]{min-width:21rem}.min-w-\[3\.75rem\]{min-width:3.75rem}.min-w-\[4\.5rem\]{min-width:4.5rem}.min-w-\[6\.5rem\]{min-width:6.5rem}.min-w-fit{min-width:-moz-fit-content;min-width:fit-content}.max-w-\[100\%\]{max-width:100%}.max-w-\[20rem\]{max-width:20rem}.max-w-\[25rem\]{max-width:25rem}.max-w-\[28\.5rem\]{max-width:28.5rem}.max-w-\[30\%\]{max-width:30%}.max-w-\[5rem\]{max-width:5rem}.max-w-\[6px\]{max-width:6px}.max-w-\[80\%\]{max-width:80%}.max-w-\[90rem\]{max-width:90rem}.max-w-\[96\%\]{max-width:96%}.max-w-\[98vw\]{max-width:98vw}.max-w-full{max-width:100%}.max-w-prose{max-width:65ch}.max-w-sm{max-width:24rem}.max-w-xs{max-width:20rem}.\!flex-none{flex:none!important}.flex-1{flex:1 1 0%}.flex-\[1\]{flex:1}.flex-\[2\]{flex:2}.flex-\[3\]{flex:3}.flex-auto{flex:1 1 auto}.flex-none{flex:none}.flex-shrink-0,.shrink-0{flex-shrink:0}.shrink-\[14\]{flex-shrink:14}.grow{flex-grow:1}.grow-\[2\]{flex-grow:2}.basis-6{flex-basis:1.5rem}.origin-bottom{transform-origin:bottom}.origin-bottom-left{transform-origin:bottom left}.origin-bottom-right{transform-origin:bottom right}.origin-center{transform-origin:center}.origin-left{transform-origin:left}.origin-right{transform-origin:right}.origin-top{transform-origin:top}.origin-top-left{transform-origin:top left}.origin-top-right{transform-origin:top right}.-translate-x-1\/2{--tw-translate-x:-50%;transform:translate(-50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-x-full{--tw-translate-x:-100%;transform:translate(-100%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-1\/2{--tw-translate-y:-50%;transform:translate(var(--tw-translate-x),-50%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-2{--tw-translate-y:-0.5rem;transform:translate(var(--tw-translate-x),-.5rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-4{--tw-translate-y:-1rem;transform:translate(var(--tw-translate-x),-1rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-\[calc$100\%\+0\.25rem$\]{--tw-translate-y:calc(-100% + -0.25rem);transform:translate(var(--tw-translate-x),calc(-100% + -.25rem)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-full{--tw-translate-y:-100%;transform:translate(var(--tw-translate-x),-100%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-0{--tw-translate-x:0px;transform:translateY(var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-0\.5{--tw-translate-x:0.125rem;transform:translate(.125rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-\[1\.375rem\]{--tw-translate-x:1.375rem;transform:translate(1.375rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-full{--tw-translate-x:100%;transform:translate(100%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-0{--tw-translate-y:0px;transform:translate(var(--tw-translate-x)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-4{--tw-translate-y:1rem;transform:translate(var(--tw-translate-x),1rem) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-y-full{--tw-translate-y:100%;transform:translate(var(--tw-translate-x),100%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-180{--tw-rotate:180deg;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(180deg) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-45{--tw-rotate:45deg;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(45deg) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-100{--tw-scale-x:1;--tw-scale-y:1;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(1) scaleY(1);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-95{--tw-scale-x:.95;--tw-scale-y:.95;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(.95) scaleY(.95);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.scale-\[101\.5\%\]{--tw-scale-x:101.5%;--tw-scale-y:101.5%;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(101.5%) scaleY(101.5%)}.scale-\[101\.5\%\],.transform{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}@keyframes spin{to{transform:rotate(1turn)}}.animate-spin{animation:spin 1s linear infinite}.cursor-default{cursor:default}.cursor-move{cursor:move}.cursor-not-allowed{cursor:not-allowed}.cursor-pointer{cursor:pointer}.select-none{-webkit-user-select:none;-moz-user-select:none;user-select:none}.resize-none{resize:none}.resize{resize:both}.\!list-inside{list-style-position:inside!important}.list-inside{list-style-position:inside}.list-decimal{list-style-type:decimal}.list-disc{list-style-type:disc}.appearance-none{-webkit-appearance:none;-moz-appearance:none;appearance:none}.grid-cols-3{grid-template-columns:repeat(3,minmax(0,1fr))}.flex-row{flex-direction:row}.flex-row-reverse{flex-direction:row-reverse}.flex-col{flex-direction:column}.flex-col-reverse{flex-direction:column-reverse}.flex-wrap{flex-wrap:wrap}.place-content-center{place-content:center}.content-center{align-content:center}.items-start{align-items:flex-start}.items-end{align-items:flex-end}.items-center{align-items:center}.items-baseline{align-items:baseline}.\!justify-start{justify-content:flex-start!important}.justify-start{justify-content:flex-start}.justify-end{justify-content:flex-end}.justify-center{justify-content:center}.\!justify-between{justify-content:space-between!important}.justify-between{justify-content:space-between}.justify-around{justify-content:space-around}.\!gap-md{gap:1rem!important;gap:var(--spacing-md)!important}.gap-1{gap:.25rem}.gap-2{gap:.5rem}.gap-2\.5{gap:.625rem}.gap-3{gap:.75rem}.gap-4{gap:1rem}.gap-5{gap:1.25rem}.gap-6{gap:1.5rem}.gap-8{gap:2rem}.gap-\[0\.65em\]{gap:.65em}.gap-lg{gap:1.5rem;gap:var(--spacing-lg)}.gap-md{gap:1rem;gap:var(--spacing-md)}.gap-sm{gap:.5rem;gap:var(--spacing-sm)}.gap-xl{gap:2rem;gap:var(--spacing-xl)}.gap-xs{gap:.25rem;gap:var(--spacing-xs)}.gap-x-1{-moz-column-gap:.25rem;column-gap:.25rem}.gap-x-4{-moz-column-gap:1rem;column-gap:1rem}.gap-x-lg{-moz-column-gap:1.5rem;column-gap:1.5rem;-moz-column-gap:var(--spacing-lg);column-gap:var(--spacing-lg)}.gap-x-sm{-moz-column-gap:.5rem;column-gap:.5rem;-moz-column-gap:var(--spacing-sm);column-gap:var(--spacing-sm)}.gap-x-xs{-moz-column-gap:.25rem;column-gap:.25rem;-moz-column-gap:var(--spacing-xs);column-gap:var(--spacing-xs)}.gap-y-5{row-gap:1.25rem}.gap-y-lg{row-gap:1.5rem;row-gap:var(--spacing-lg)}.gap-y-md{row-gap:1rem;row-gap:var(--spacing-md)}.gap-y-sm{row-gap:.5rem;row-gap:var(--spacing-sm)}.gap-y-xl{row-gap:2rem;row-gap:var(--spacing-xl)}.gap-y-xs{row-gap:.25rem;row-gap:var(--spacing-xs)}.space-x-1>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:.25rem;margin-left:calc(.25rem*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(.25rem*var(--tw-space-x-reverse))}.space-x-5>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:1.25rem;margin-left:calc(1.25rem*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(1.25rem*var(--tw-space-x-reverse))}.space-y-1>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(.25rem*var(--tw-space-y-reverse));margin-top:.25rem;margin-top:calc(.25rem*(1 - var(--tw-space-y-reverse)))}.space-y-2>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(.5rem*var(--tw-space-y-reverse));margin-top:.5rem;margin-top:calc(.5rem*(1 - var(--tw-space-y-reverse)))}.space-y-2xl>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-2xl)*var(--tw-space-y-reverse));margin-top:2.5rem;margin-top:calc(var(--spacing-2xl)*(1 - var(--tw-space-y-reverse)))}.space-y-4>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(1rem*var(--tw-space-y-reverse));margin-top:1rem;margin-top:calc(1rem*(1 - var(--tw-space-y-reverse)))}.space-y-lg>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-lg)*var(--tw-space-y-reverse));margin-top:1.5rem;margin-top:calc(var(--spacing-lg)*(1 - var(--tw-space-y-reverse)))}.space-y-md>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-md)*var(--tw-space-y-reverse));margin-top:1rem;margin-top:calc(var(--spacing-md)*(1 - var(--tw-space-y-reverse)))}.space-y-sm>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-sm)*var(--tw-space-y-reverse));margin-top:.5rem;margin-top:calc(var(--spacing-sm)*(1 - var(--tw-space-y-reverse)))}.space-y-xs>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-xs)*var(--tw-space-y-reverse));margin-top:.25rem;margin-top:calc(var(--spacing-xs)*(1 - var(--tw-space-y-reverse)))}.divide-y>:not([hidden])~:not([hidden]){--tw-divide-y-reverse:0;border-bottom-width:0;border-bottom-width:calc(1px*var(--tw-divide-y-reverse));border-top-width:1px;border-top-width:calc(1px*(1 - var(--tw-divide-y-reverse)))}.divide-color-default>:not([hidden])~:not([hidden]){--tw-divide-opacity:1;border-color:#dcdfe4;border-color:rgba(var(--color-border-default),var(--tw-divide-opacity))}.self-center{align-self:center}.overflow-auto{overflow:auto}.\!overflow-hidden{overflow:hidden!important}.overflow-hidden{overflow:hidden}.\!overflow-visible{overflow:visible!important}.overflow-scroll{overflow:scroll}.overflow-x-auto{overflow-x:auto}.overflow-y-auto{overflow-y:auto}.overflow-y-hidden{overflow-y:hidden}.overflow-y-scroll{overflow-y:scroll}.overscroll-none{overscroll-behavior:none}.truncate{overflow:hidden;white-space:nowrap}.text-ellipsis,.truncate{text-overflow:ellipsis}.whitespace-nowrap{white-space:nowrap}.whitespace-pre{white-space:pre}.whitespace-pre-line{white-space:pre-line}.\!break-words{overflow-wrap:break-word!important}.break-words{overflow-wrap:break-word}.\!break-all{word-break:break-all!important}.break-all{word-break:break-all}.rounded{border-radius:.25rem}.rounded-2xl{border-radius:1rem}.rounded-3xl{border-radius:1.5rem}.rounded-\[0\.15em\]{border-radius:.15em}.rounded-\[100\%\]{border-radius:100%}.rounded-\[4px\]{border-radius:4px}.rounded-\[50\%\]{border-radius:50%}.rounded-full{border-radius:9999px}.rounded-lg{border-radius:.5rem}.rounded-md{border-radius:.375rem}.rounded-none{border-radius:0}.rounded-sm{border-radius:.125rem}.rounded-xl{border-radius:.75rem}.border{border-width:1px}.border-2{border-width:2px}.border-\[\.0625rem\]{border-width:.0625rem}.border-\[0\.15em\]{border-width:.15em}.border-x-0{border-left-width:0;border-right-width:0}.border-b{border-bottom-width:1px}.border-b-2{border-bottom-width:2px}.border-l{border-left-width:1px}.border-l-2{border-left-width:2px}.border-l-\[0\.0625rem\]{border-left-width:.0625rem}.border-l-\[0\.125rem\]{border-left-width:.125rem}.border-l-\[3px\]{border-left-width:3px}.border-r{border-right-width:1px}.border-t{border-top-width:1px}.border-t-0{border-top-width:0}.border-t-2{border-top-width:2px}.border-t-\[\.0625rem\]{border-top-width:.0625rem}.border-solid{border-style:solid}.border-dashed{border-style:dashed}.border-none{border-style:none}.\!border-color-bold{--tw-border-opacity:1!important;border-color:#b3b9c4!important;border-color:rgba(var(--color-border-bold),var(--tw-border-opacity))!important}.\!border-color-brand{--tw-border-opacity:1!important;border-color:#eab308!important;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))!important}.border-\[\#000\]{--tw-border-opacity:1;border-color:#000;border-color:rgb(0 0 0/var(--tw-border-opacity))}.border-\[\#DCDFE4\]{--tw-border-opacity:1;border-color:#dcdfe4;border-color:rgb(220 223 228/var(--tw-border-opacity))}.border-\[\#F8F9FD\]{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.border-\[\#FACC15\]{--tw-border-opacity:1;border-color:#facc15;border-color:rgb(250 204 21/var(--tw-border-opacity))}.border-\[\#FEF9C3\]{--tw-border-opacity:1;border-color:#fef9c3;border-color:rgb(254 249 195/var(--tw-border-opacity))}.border-\[\#b3b9c4\]{--tw-border-opacity:1;border-color:#b3b9c4;border-color:rgb(179 185 196/var(--tw-border-opacity))}.border-\[\#dcdfe6\]{--tw-border-opacity:1;border-color:#dcdfe6;border-color:rgb(220 223 230/var(--tw-border-opacity))}.border-\[\#f8f9fd\]{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.border-\[white\]{--tw-border-opacity:1;border-color:#fff;border-color:rgb(255 255 255/var(--tw-border-opacity))}.border-color-bold{--tw-border-opacity:1;border-color:#b3b9c4;border-color:rgba(var(--color-border-bold),var(--tw-border-opacity))}.border-color-brand{--tw-border-opacity:1;border-color:#eab308;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))}.border-color-default{--tw-border-opacity:1;border-color:#dcdfe4;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.border-color-error{--tw-border-opacity:1;border-color:#e11900;border-color:rgba(var(--color-border-error),var(--tw-border-opacity))}.border-color-info{--tw-border-opacity:1;border-color:#59baf0;border-color:rgba(var(--color-border-info),var(--tw-border-opacity))}.border-color-inherit{border-color:inherit}.border-color-success{--tw-border-opacity:1;border-color:#05944f;border-color:rgba(var(--color-border-success),var(--tw-border-opacity))}.border-color-transparent{border-color:transparent}.border-color-warning{--tw-border-opacity:1;border-color:#eab308;border-color:rgba(var(--color-border-warning),var(--tw-border-opacity))}.border-t-color-default{--tw-border-opacity:1;border-top-color:#dcdfe4;border-top-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.\!bg-black{--tw-bg-opacity:1!important;background-color:#000!important;background-color:rgba(var(--color-black),var(--tw-bg-opacity))!important}.\!bg-brand-bold{--tw-bg-opacity:1!important;background-color:#eab308!important;background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))!important}.\!bg-brand-default{--tw-bg-opacity:1!important;background-color:#facc15!important;background-color:rgba(var(--color-brand-default),var(--tw-bg-opacity))!important}.\!bg-brand-subtler{--tw-bg-opacity:1!important;background-color:#fef08a!important;background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))!important}.\!bg-brand-sunken{--tw-bg-opacity:1!important;background-color:#fefce8!important;background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))!important}.\!bg-success-subtlest{--tw-bg-opacity:1!important;background-color:#bfeed7!important;background-color:rgba(var(--color-bg-success-subtlest),var(--tw-bg-opacity))!important}.\!bg-surface-disabled{--tw-bg-opacity:1!important;background-color:#f1f2f4!important;background-color:rgba(var(--color-surface-disabled),var(--tw-bg-opacity))!important}.\!bg-surface-subtle{--tw-bg-opacity:1!important;background-color:#f8f9fd!important;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))!important}.\!bg-warning-bold{--tw-bg-opacity:1!important;background-color:#eab308!important;background-color:rgba(var(--color-bg-warning-bold),var(--tw-bg-opacity))!important}.bg-\[\#000000\],.bg-\[\#000\]{--tw-bg-opacity:1;background-color:#000;background-color:rgb(0 0 0/var(--tw-bg-opacity))}.bg-\[\#2867B2\]{--tw-bg-opacity:1;background-color:#2867b2;background-color:rgb(40 103 178/var(--tw-bg-opacity))}.bg-\[\#409eff\]{--tw-bg-opacity:1;background-color:#409eff;background-color:rgb(64 158 255/var(--tw-bg-opacity))}.bg-\[\#66b1ff\]{--tw-bg-opacity:1;background-color:#66b1ff;background-color:rgb(102 177 255/var(--tw-bg-opacity))}.bg-\[\#EAB308\]{--tw-bg-opacity:1;background-color:#eab308;background-color:rgb(234 179 8/var(--tw-bg-opacity))}.bg-\[\#F8F9FD\]{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgb(248 249 253/var(--tw-bg-opacity))}.bg-\[\#b3b9c4\]{--tw-bg-opacity:1;background-color:#b3b9c4;background-color:rgb(179 185 196/var(--tw-bg-opacity))}.bg-\[\#eaeaee\]{--tw-bg-opacity:1;background-color:#eaeaee;background-color:rgb(234 234 238/var(--tw-bg-opacity))}.bg-\[\#facc15\]{--tw-bg-opacity:1;background-color:#facc15;background-color:rgb(250 204 21/var(--tw-bg-opacity))}.bg-\[\#fff\]{--tw-bg-opacity:1;background-color:#fff;background-color:rgb(255 255 255/var(--tw-bg-opacity))}.bg-black{--tw-bg-opacity:1;background-color:#000;background-color:rgba(var(--color-black),var(--tw-bg-opacity))}.bg-black\/50{background-color:rgba(0,0,0,.5);background-color:rgba(var(--color-black),.5)}.bg-black\/60{background-color:rgba(0,0,0,.6);background-color:rgba(var(--color-black),.6)}.bg-black\/\[0\.12\]{background-color:rgba(0,0,0,.12);background-color:rgba(var(--color-black),.12)}.bg-brand-bold{--tw-bg-opacity:1;background-color:#eab308;background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.bg-brand-boldest{--tw-bg-opacity:1;background-color:#c48404;background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.bg-brand-default{--tw-bg-opacity:1;background-color:#facc15;background-color:rgba(var(--color-brand-default),var(--tw-bg-opacity))}.bg-brand-subtler{--tw-bg-opacity:1;background-color:#fef08a;background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))}.bg-brand-subtlest{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.bg-brand-sunken{--tw-bg-opacity:1;background-color:#fefce8;background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))}.bg-content-bolder{--tw-bg-opacity:1;background-color:#d19507;background-color:rgba(var(--color-bg-content-bolder),var(--tw-bg-opacity))}.bg-content-default{--tw-bg-opacity:1;background-color:#facc15;background-color:rgba(var(--color-bg-content-default),var(--tw-bg-opacity))}.bg-content-inverse-subtler{--tw-bg-opacity:1;background-color:#a86a07;background-color:rgba(var(--color-bg-content-inverse-subtler),var(--tw-bg-opacity))}.bg-content-subtle{--tw-bg-opacity:1;background-color:#fde047;background-color:rgba(var(--color-bg-content-subtle),var(--tw-bg-opacity))}.bg-content-subtler{--tw-bg-opacity:1;background-color:#fef08a;background-color:rgba(var(--color-bg-content-subtler),var(--tw-bg-opacity))}.bg-content-subtlest{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-bg-content-subtlest),var(--tw-bg-opacity))}.bg-content-sunken{--tw-bg-opacity:1;background-color:#fefce8;background-color:rgba(var(--color-bg-content-sunken),var(--tw-bg-opacity))}.bg-error-bold{--tw-bg-opacity:1;background-color:#e11900;background-color:rgba(var(--color-bg-error-bold),var(--tw-bg-opacity))}.bg-error-subtlest{--tw-bg-opacity:1;background-color:#ffdad4;background-color:rgba(var(--color-bg-error-subtlest),var(--tw-bg-opacity))}.bg-error-sunken{--tw-bg-opacity:1;background-color:#fffbff;background-color:rgba(var(--color-bg-error-sunken),var(--tw-bg-opacity))}.bg-info-bold{--tw-bg-opacity:1;background-color:#59baf0;background-color:rgba(var(--color-bg-info-bold),var(--tw-bg-opacity))}.bg-info-subtlest{--tw-bg-opacity:1;background-color:#dcf3ff;background-color:rgba(var(--color-bg-info-subtlest),var(--tw-bg-opacity))}.bg-info-sunken{--tw-bg-opacity:1;background-color:#f5fbff;background-color:rgba(var(--color-bg-info-sunken),var(--tw-bg-opacity))}.bg-inherit{background-color:inherit}.bg-success-bold{--tw-bg-opacity:1;background-color:#05944f;background-color:rgba(var(--color-bg-success-bold),var(--tw-bg-opacity))}.bg-success-subtlest{--tw-bg-opacity:1;background-color:#bfeed7;background-color:rgba(var(--color-bg-success-subtlest),var(--tw-bg-opacity))}.bg-success-sunken{--tw-bg-opacity:1;background-color:#f1fef8;background-color:rgba(var(--color-bg-success-sunken),var(--tw-bg-opacity))}.bg-surface-default{--tw-bg-opacity:1;background-color:#fff;background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.bg-surface-disabled{--tw-bg-opacity:1;background-color:#f1f2f4;background-color:rgba(var(--color-surface-disabled),var(--tw-bg-opacity))}.bg-surface-inverse{--tw-bg-opacity:1;background-color:#000;background-color:rgba(var(--color-surface-inverse),var(--tw-bg-opacity))}.bg-surface-selected{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.bg-surface-subtle{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.bg-transparent{background-color:transparent}.bg-warning-bold{--tw-bg-opacity:1;background-color:#eab308;background-color:rgba(var(--color-bg-warning-bold),var(--tw-bg-opacity))}.bg-warning-subtlest{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-bg-warning-subtlest),var(--tw-bg-opacity))}.bg-warning-sunken{--tw-bg-opacity:1;background-color:#fefce8;background-color:rgba(var(--color-bg-warning-sunken),var(--tw-bg-opacity))}.bg-white{--tw-bg-opacity:1;background-color:#fff;background-color:rgba(var(--color-white),var(--tw-bg-opacity))}.bg-opacity-25{--tw-bg-opacity:0.25}.bg-opacity-75{--tw-bg-opacity:0.75}.bg-\[url$\'\/img\/homepage\.png\'$\]{background-image:url(/img/homepage.png)}.bg-gradient-to-r{background-image:linear-gradient(to right,var(--tw-gradient-stops))}.bg-none{background-image:none}.from-black\/70{--tw-gradient-from:rgba(var(--color-black),0.7) var(--tw-gradient-from-position);--tw-gradient-to:rgba(var(--color-black),0) var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.from-transparent{--tw-gradient-from:transparent var(--tw-gradient-from-position);--tw-gradient-to:transparent var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.to-black\/5{--tw-gradient-to:rgba(var(--color-black),0.05) var(--tw-gradient-to-position)}.to-white{--tw-gradient-to:rgba(var(--color-white),1) var(--tw-gradient-to-position)}.bg-cover{background-size:cover}.bg-fixed{background-attachment:fixed}.bg-center{background-position:50%}.bg-no-repeat{background-repeat:no-repeat}.fill-brand-bold{fill:#eab308;fill:rgba(var(--color-brand-bold),1)}.fill-brand-sunken{fill:#fefce8;fill:rgba(var(--color-brand-sunken),1)}.object-cover{-o-object-fit:cover;object-fit:cover}.\!p-0{padding:0!important}.\!p-sm{padding:.5rem!important;padding:var(--spacing-sm)!important}.\!p-xs{padding:.25rem!important;padding:var(--spacing-xs)!important}.p-0{padding:0}.p-0\.5{padding:.125rem}.p-4{padding:1rem}.p-5{padding:1.25rem}.p-8{padding:2rem}.p-\[\.75rem\]{padding:.75rem}.p-lg{padding:1.5rem;padding:var(--spacing-lg)}.p-md{padding:1rem;padding:var(--spacing-md)}.p-px{padding:1px}.p-sm{padding:.5rem;padding:var(--spacing-sm)}.p-xl{padding:2rem;padding:var(--spacing-xl)}.\!px-0{padding-left:0!important;padding-right:0!important}.\!px-sm{padding-left:.5rem!important;padding-left:var(--spacing-sm)!important;padding-right:.5rem!important;padding-right:var(--spacing-sm)!important}.px-0{padding-left:0;padding-right:0}.px-10{padding-left:2.5rem;padding-right:2.5rem}.px-2{padding-left:.5rem;padding-right:.5rem}.px-4{padding-left:1rem;padding-right:1rem}.px-5{padding-left:1.25rem;padding-right:1.25rem}.px-8{padding-left:2rem;padding-right:2rem}.px-\[\.625rem\]{padding-left:.625rem;padding-right:.625rem}.px-\[\.9375rem\]{padding-left:.9375rem;padding-right:.9375rem}.px-\[0\.2rem\]{padding-left:.2rem;padding-right:.2rem}.px-\[0\.625rem\]{padding-left:.625rem;padding-right:.625rem}.px-lg{padding-left:1.5rem;padding-left:var(--spacing-lg);padding-right:1.5rem;padding-right:var(--spacing-lg)}.px-md{padding-left:1rem;padding-left:var(--spacing-md);padding-right:1rem;padding-right:var(--spacing-md)}.px-sm{padding-left:.5rem;padding-left:var(--spacing-sm);padding-right:.5rem;padding-right:var(--spacing-sm)}.px-xl{padding-left:2rem;padding-left:var(--spacing-xl);padding-right:2rem;padding-right:var(--spacing-xl)}.px-xs{padding-left:.25rem;padding-left:var(--spacing-xs);padding-right:.25rem;padding-right:var(--spacing-xs)}.py-0{padding-bottom:0;padding-top:0}.py-0\.5{padding-bottom:.125rem;padding-top:.125rem}.py-10{padding-bottom:2.5rem;padding-top:2.5rem}.py-2{padding-bottom:.5rem;padding-top:.5rem}.py-2xl{padding-bottom:2.5rem;padding-bottom:var(--spacing-2xl);padding-top:2.5rem;padding-top:var(--spacing-2xl)}.py-3{padding-bottom:.75rem;padding-top:.75rem}.py-3xl{padding-bottom:3rem;padding-bottom:var(--spacing-3xl);padding-top:3rem;padding-top:var(--spacing-3xl)}.py-4{padding-bottom:1rem;padding-top:1rem}.py-5xl{padding-bottom:4rem;padding-bottom:var(--spacing-5xl);padding-top:4rem;padding-top:var(--spacing-5xl)}.py-6{padding-bottom:1.5rem;padding-top:1.5rem}.py-7xl{padding-bottom:5rem;padding-bottom:var(--spacing-7xl);padding-top:5rem;padding-top:var(--spacing-7xl)}.py-\[\.3125rem\]{padding-bottom:.3125rem;padding-top:.3125rem}.py-\[0\.625rem\],.py-\[\.625rem\]{padding-bottom:.625rem;padding-top:.625rem}.py-\[1\.5rem\],.py-lg{padding-bottom:1.5rem;padding-top:1.5rem}.py-lg{padding-bottom:var(--spacing-lg);padding-top:var(--spacing-lg)}.py-md{padding-bottom:1rem;padding-bottom:var(--spacing-md);padding-top:1rem;padding-top:var(--spacing-md)}.py-sm{padding-bottom:.5rem;padding-bottom:var(--spacing-sm);padding-top:.5rem;padding-top:var(--spacing-sm)}.py-xl{padding-bottom:2rem;padding-bottom:var(--spacing-xl);padding-top:2rem;padding-top:var(--spacing-xl)}.py-xs{padding-bottom:.25rem;padding-bottom:var(--spacing-xs);padding-top:.25rem;padding-top:var(--spacing-xs)}.\!pl-0{padding-left:0!important}.\!pl-sm{padding-left:.5rem!important;padding-left:var(--spacing-sm)!important}.\!pr-sm{padding-right:.5rem!important;padding-right:var(--spacing-sm)!important}.pb-0{padding-bottom:0}.pb-2xl{padding-bottom:2.5rem;padding-bottom:var(--spacing-2xl)}.pb-3{padding-bottom:.75rem}.pb-6{padding-bottom:1.5rem}.pb-7xl{padding-bottom:5rem;padding-bottom:var(--spacing-7xl)}.pb-\[\.5rem\]{padding-bottom:.5rem}.pb-\[1\.875rem\]{padding-bottom:1.875rem}.pb-lg{padding-bottom:1.5rem;padding-bottom:var(--spacing-lg)}.pb-md{padding-bottom:1rem;padding-bottom:var(--spacing-md)}.pb-sm{padding-bottom:.5rem;padding-bottom:var(--spacing-sm)}.pb-xl{padding-bottom:2rem;padding-bottom:var(--spacing-xl)}.pb-xs{padding-bottom:.25rem;padding-bottom:var(--spacing-xs)}.pl-0{padding-left:0}.pl-10,.pl-2xl{padding-left:2.5rem}.pl-2xl{padding-left:var(--spacing-2xl)}.pl-3{padding-left:.75rem}.pl-5{padding-left:1.25rem}.pl-8{padding-left:2rem}.pl-lg{padding-left:1.5rem;padding-left:var(--spacing-lg)}.pl-md{padding-left:1rem;padding-left:var(--spacing-md)}.pl-sm{padding-left:.5rem;padding-left:var(--spacing-sm)}.pl-xl{padding-left:2rem;padding-left:var(--spacing-xl)}.pl-xs{padding-left:.25rem;padding-left:var(--spacing-xs)}.pr-0{padding-right:0}.pr-2xl{padding-right:2.5rem;padding-right:var(--spacing-2xl)}.pr-3{padding-right:.75rem}.pr-lg{padding-right:1.5rem;padding-right:var(--spacing-lg)}.pr-md{padding-right:1rem;padding-right:var(--spacing-md)}.pr-sm{padding-right:.5rem;padding-right:var(--spacing-sm)}.pr-xl{padding-right:2rem;padding-right:var(--spacing-xl)}.pr-xs{padding-right:.25rem;padding-right:var(--spacing-xs)}.pt-12{padding-top:3rem}.pt-14{padding-top:3.5rem}.pt-2xl{padding-top:2.5rem;padding-top:var(--spacing-2xl)}.pt-3xl{padding-top:3rem;padding-top:var(--spacing-3xl)}.pt-5xl{padding-top:4rem;padding-top:var(--spacing-5xl)}.pt-6{padding-top:1.5rem}.pt-7xl{padding-top:5rem;padding-top:var(--spacing-7xl)}.pt-\[\.625rem\]{padding-top:.625rem}.pt-\[\.75rem\]{padding-top:.75rem}.pt-\[0\.125rem\]{padding-top:.125rem}.pt-\[1\.25rem\]{padding-top:1.25rem}.pt-\[1\.875rem\]{padding-top:1.875rem}.pt-\[1rem\]{padding-top:1rem}.pt-\[2rem\]{padding-top:2rem}.pt-\[5rem\]{padding-top:5rem}.pt-lg{padding-top:1.5rem;padding-top:var(--spacing-lg)}.pt-md{padding-top:1rem;padding-top:var(--spacing-md)}.pt-sm{padding-top:.5rem;padding-top:var(--spacing-sm)}.pt-xl{padding-top:2rem;padding-top:var(--spacing-xl)}.pt-xs{padding-top:.25rem;padding-top:var(--spacing-xs)}.text-left{text-align:left}.text-center{text-align:center}.text-right{text-align:right}.\!align-middle{vertical-align:middle!important}.align-middle{vertical-align:middle}.\!align-text-bottom{vertical-align:text-bottom!important}.\!text-base{font-size:1rem!important;line-height:1.5rem!important}.\!text-lg{font-size:1.125rem!important;line-height:1.75rem!important}.\!text-xs{font-size:.75rem!important;line-height:1rem!important}.text-2xl{font-size:1.5rem;line-height:2rem}.text-3xl{font-size:1.875rem;line-height:2.25rem}.text-4xl{font-size:2.25rem;line-height:2.5rem}.text-5xl{font-size:3rem;line-height:1}.text-\[\.4rem\]{font-size:.4rem}.text-\[\.75rem\]{font-size:.75rem}.text-\[\.875rem\]{font-size:.875rem}.text-\[0\.4rem\]{font-size:.4rem}.text-\[0\.575rem\]{font-size:.575rem}.text-\[1\.875rem\]{font-size:1.875rem}.text-\[2\.5rem\]{font-size:2.5rem}.text-base{font-size:1rem;line-height:1.5rem}.text-lg{font-size:1.125rem;line-height:1.75rem}.text-sm{font-size:.875rem;line-height:1.25rem}.text-xl{font-size:1.25rem;line-height:1.75rem}.text-xs{font-size:.75rem;line-height:1rem}.font-bold{font-weight:700}.font-light{font-weight:300}.font-medium{font-weight:500}.font-normal{font-weight:400}.font-semibold{font-weight:600}.uppercase{text-transform:uppercase}.lowercase{text-transform:lowercase}.italic{font-style:italic}.\!leading-\[0\]{line-height:0!important}.leading-10{line-height:2.5rem}.leading-6{line-height:1.5rem}.leading-\[0\]{line-height:0}.leading-\[1\.125rem\]{line-height:1.125rem}.leading-\[1\.1\]{line-height:1.1}.leading-\[1\.875rem\]{line-height:1.875rem}.leading-\[140\%\]{line-height:140%}.leading-none{line-height:1}.leading-normal{line-height:1.5}.\!text-color-black{--tw-text-opacity:1!important;color:#000!important;color:rgba(var(--color-black),var(--tw-text-opacity))!important}.\!text-color-brand-bold{--tw-text-opacity:1!important;color:#eab308!important;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))!important}.\!text-color-default{--tw-text-opacity:1!important;color:#000!important;color:rgba(var(--color-text-default),var(--tw-text-opacity))!important}.\!text-color-disabled{--tw-text-opacity:1!important;color:#b3b9c4!important;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))!important}.\!text-color-link-bold{--tw-text-opacity:1!important;color:#0156ce!important;color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))!important}.\!text-color-subtle{--tw-text-opacity:1!important;color:#626f86!important;color:rgba(var(--color-text-subtle),var(--tw-text-opacity))!important}.\!text-color-white{--tw-text-opacity:1!important;color:#fff!important;color:rgba(var(--color-white),var(--tw-text-opacity))!important}.text-\[\#000\]{--tw-text-opacity:1;color:#000;color:rgb(0 0 0/var(--tw-text-opacity))}.text-\[\#0156CE\]{--tw-text-opacity:1;color:#0156ce;color:rgb(1 86 206/var(--tw-text-opacity))}.text-\[\#172B4D\]{--tw-text-opacity:1;color:#172b4d;color:rgb(23 43 77/var(--tw-text-opacity))}.text-\[\#626F86\]{--tw-text-opacity:1;color:#626f86;color:rgb(98 111 134/var(--tw-text-opacity))}.text-\[\#758195\]{--tw-text-opacity:1;color:#758195;color:rgb(117 129 149/var(--tw-text-opacity))}.text-\[\#EAB308\]{--tw-text-opacity:1;color:#eab308;color:rgb(234 179 8/var(--tw-text-opacity))}.text-\[\#F1F2F4\]{--tw-text-opacity:1;color:#f1f2f4;color:rgb(241 242 244/var(--tw-text-opacity))}.text-\[\#FACC15\]{--tw-text-opacity:1;color:#facc15;color:rgb(250 204 21/var(--tw-text-opacity))}.text-\[\#FFFFFF\]{--tw-text-opacity:1;color:#fff;color:rgb(255 255 255/var(--tw-text-opacity))}.text-\[\#b3b9c4\]{--tw-text-opacity:1;color:#b3b9c4;color:rgb(179 185 196/var(--tw-text-opacity))}.text-\[\#f00\]{--tw-text-opacity:1;color:red;color:rgb(255 0 0/var(--tw-text-opacity))}.text-\[\#fff\]{--tw-text-opacity:1;color:#fff;color:rgb(255 255 255/var(--tw-text-opacity))}.text-color-black{--tw-text-opacity:1;color:#000;color:rgba(var(--color-black),var(--tw-text-opacity))}.text-color-border-bold{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-border-bold),var(--tw-text-opacity))}.text-color-brand-bold{--tw-text-opacity:1;color:#eab308;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.text-color-brand-bolder{--tw-text-opacity:1;color:#d19507;color:rgba(var(--color-text-brand-bolder),var(--tw-text-opacity))}.text-color-current{color:currentColor}.text-color-default{--tw-text-opacity:1;color:#000;color:rgba(var(--color-text-default),var(--tw-text-opacity))}.text-color-disabled{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.text-color-error{--tw-text-opacity:1;color:#d31c04;color:rgba(var(--color-text-error),var(--tw-text-opacity))}.text-color-info{--tw-text-opacity:1;color:#2c9acf;color:rgba(var(--color-text-info),var(--tw-text-opacity))}.text-color-inherit{color:inherit}.text-color-inverse{--tw-text-opacity:1;color:#fff;color:rgba(var(--color-white),var(--tw-text-opacity))}.text-color-link-bold{--tw-text-opacity:1;color:#0156ce;color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.text-color-link-bolder{--tw-text-opacity:1;color:#014bb5;color:rgba(var(--color-text-link-bolder),var(--tw-text-opacity))}.text-color-link-subtle{--tw-text-opacity:1;color:#626f86;color:rgba(var(--color-text-link-subtle),var(--tw-text-opacity))}.text-color-on-brand{--tw-text-opacity:1;color:rgba(var(--color-text-on-brand),1);color:rgba(var(--color-text-on-brand),var(--tw-text-opacity))}.text-color-subtle{--tw-text-opacity:1;color:#626f86;color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.text-color-subtlest{--tw-text-opacity:1;color:#758195;color:rgba(var(--color-text-subtlest),var(--tw-text-opacity))}.text-color-success{--tw-text-opacity:1;color:#098549;color:rgba(var(--color-text-success),var(--tw-text-opacity))}.text-color-warning{--tw-text-opacity:1;color:#d19507;color:rgba(var(--color-text-warning),var(--tw-text-opacity))}.text-color-white{--tw-text-opacity:1;color:#fff;color:rgba(var(--color-white),var(--tw-text-opacity))}.underline{text-decoration-line:underline}.\!no-underline{text-decoration-line:none!important}.no-underline{text-decoration-line:none}.antialiased{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.placeholder-text-color-subtle::-moz-placeholder{--tw-placeholder-opacity:1;color:#626f86;color:rgba(var(--color-text-subtle),var(--tw-placeholder-opacity))}.placeholder-text-color-subtle::placeholder{--tw-placeholder-opacity:1;color:#626f86;color:rgba(var(--color-text-subtle),var(--tw-placeholder-opacity))}.opacity-0{opacity:0}.opacity-100{opacity:1}.opacity-25{opacity:.25}.opacity-40{opacity:.4}.shadow{--tw-shadow:0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px -1px rgba(0,0,0,.1);--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px -1px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-\[4px_8px_10px_rgba$214\2c 217\2c 222\2c 0\.8$\]{--tw-shadow:4px 8px 10px rgba(214,217,222,.8);--tw-shadow-colored:4px 8px 10px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,4px 8px 10px rgba(214,217,222,.8);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-lg{--tw-shadow:0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -4px rgba(0,0,0,.1);--tw-shadow-colored:0 10px 15px -3px var(--tw-shadow-color),0 4px 6px -4px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -4px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-md{--tw-shadow:0 4px 6px -1px rgba(0,0,0,.1),0 2px 4px -2px rgba(0,0,0,.1);--tw-shadow-colored:0 4px 6px -1px var(--tw-shadow-color),0 2px 4px -2px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 4px 6px -1px rgba(0,0,0,.1),0 2px 4px -2px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-slider{--tw-shadow:0.5px 0.5px 2px 1px rgba(0,0,0,.32);--tw-shadow-colored:0.5px 0.5px 2px 1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,.5px .5px 2px 1px rgba(0,0,0,.32);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-slider-active{--tw-shadow:0.5px 0.5px 2px 1px rgba(0,0,0,.42);--tw-shadow-colored:0.5px 0.5px 2px 1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,.5px .5px 2px 1px rgba(0,0,0,.42);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-sm{--tw-shadow:0 1px 2px 0 rgba(0,0,0,.05);--tw-shadow-colored:0 1px 2px 0 var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 1px 2px 0 rgba(0,0,0,.05);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-xl{--tw-shadow:0 20px 25px -5px rgba(0,0,0,.1),0 8px 10px -6px rgba(0,0,0,.1);--tw-shadow-colored:0 20px 25px -5px var(--tw-shadow-color),0 8px 10px -6px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 20px 25px -5px rgba(0,0,0,.1),0 8px 10px -6px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.outline-none{outline:2px solid transparent;outline-offset:2px}.outline{outline-style:solid}.outline-2{outline-width:2px}.outline-offset-2{outline-offset:2px}.outline-\[\#EAB308\]{outline-color:#eab308}.outline-color-bold{outline-color:#b3b9c4;outline-color:rgba(var(--color-border-bold),1)}.outline-color-brand{outline-color:#eab308;outline-color:rgba(var(--color-border-brand),1)}.ring-0{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.blur{--tw-blur:blur(8px);filter:blur(8px) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.grayscale{--tw-grayscale:grayscale(100%);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) grayscale(100%) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.filter,.grayscale{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.transition{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,-webkit-backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter,-webkit-backdrop-filter;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-all{transition-duration:.15s;transition-property:all;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-colors{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-height{transition-duration:.15s;transition-property:height;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-opacity{transition-duration:.15s;transition-property:opacity;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-transform{transition-duration:.15s;transition-property:transform;transition-timing-function:cubic-bezier(.4,0,.2,1)}.duration-100{transition-duration:.1s}.duration-150{transition-duration:.15s}.duration-200{transition-duration:.2s}.duration-300{transition-duration:.3s}.duration-75{transition-duration:75ms}.duration-\[350ms\]{transition-duration:.35s}.ease-in{transition-timing-function:cubic-bezier(.4,0,1,1)}.ease-in-out{transition-timing-function:cubic-bezier(.4,0,.2,1)}.ease-out{transition-timing-function:cubic-bezier(0,0,.2,1)}.content-\[\'\'\]{--tw-content:"";content:"";content:var(--tw-content)}.cursor-grab{cursor:grab}.cursor-grabbing{cursor:grabbing}.touch-none{touch-action:none}.tap-highlight-transparent{-webkit-tap-highlight-color:rgba(0,0,0,0)}.touch-callout-none{-webkit-touch-callout:none}.transform-origin-0{transform-origin:0 0}.transform-style-flat{transform-style:flat}.cursor-ew-resize{cursor:ew-resize}.arrow-left:before{border:5px solid transparent;border-right-color:inherit;left:-10px}.arrow-left:before,.arrow-right:before{content:"";height:0;position:absolute;top:50%;transform:translateY(-50%);width:0}.arrow-right:before{border:5px solid transparent;border-left-color:inherit;right:-10px}.text-body{font-size:.875rem;line-height:1.25rem}@media (min-width:768px){.text-body{font-size:1rem;line-height:1.5rem}}.\[appearance\:textfield\]{-webkit-appearance:textfield;-moz-appearance:textfield;appearance:textfield}@media (max-width:64rem){.phone-drawer{z-index:20}.phone-drawer .w-screen{padding:0;width:75vw}.phone-drawer .user-info-nav li{line-height:1.5rem;margin-bottom:.9375rem;padding:.5rem 0 .5rem 2.375rem}.phone-drawer .user-info-nav li:hover{cursor:pointer}.phone-drawer .user-info-nav .active-nav{background-color:#f7f8f9}}.comment-drawer .m-drawer__panel{padding:1rem;padding:var(--spacing-md)}@media (min-width:1024px){.comment-drawer .m-drawer__panel{max-width:none;padding:1.5rem;padding:var(--spacing-lg);width:50.25rem}}.m-checkbox:active,.m-checkbox:target{--tw-text-opacity:1;color:#eab308;color:rgb(234 179 8/var(--tw-text-opacity))}body,html{scroll-behavior:auto!important}.mfp-mask{-webkit-backface-visibility:hidden;background-color:rgba(0,0,0,.85);display:none;outline:0!important;overflow:hidden auto;position:fixed;z-index:99}.mfp-mask,.mfp-mask .mfp-dialog{height:100%;left:0;top:0;width:100%}.mfp-mask .mfp-dialog{box-sizing:border-box;padding:0 8px;position:absolute;text-align:center}.mfp-mask .mfp-dialog .mfp-dialog-content{align-items:center;display:inline-block;display:flex;justify-content:center;margin:0 auto;min-height:100vh;position:relative;text-align:left;vertical-align:middle;z-index:100}.mfp-mask .mfp-dialog .mfp-dialog-content .html-fig_show{background:#fff;max-width:600px;overflow:auto;padding:20px;position:relative;width:auto}.mfp-mask .mfp-dialog .mfp-dialog-content .html-table_show{background:#fff;margin-bottom:40px;margin-top:40px;overflow:auto;padding:20px;position:relative;width:auto}@media (max-width:64rem){.mfp-mask .mfp-dialog .mfp-dialog-content .html-table_show{background:#fff;margin-bottom:40px;margin-top:40px;overflow:auto;padding:20px;position:relative;width:100%}}.mfp-mask .mfp-dialog .mfp-dialog-content .html-table_foot{max-width:650px}.mfp-mask .mfp-close{background:none;border:none;color:#000;cursor:pointer;font-size:16px;overflow:hidden;padding:10px 20px;position:absolute;right:10px;top:10px;z-index:999}.mfp-mask .mfp-close:before{bottom:0;content:"✖";height:20px;left:0;margin:auto;position:absolute;right:0;top:0;width:20px}.heading-with-anchor{scroll-margin-top:4rem}.global-search .m-drawer__panel{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.global-search .m-drawer__body,.global-search .m-drawer__header{margin-left:auto;margin-right:auto;width:90%}.MJX-TEX{font-family:Suisse Int\'l,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji!important}mark{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.before\:absolute:before{content:var(--tw-content);position:absolute}.before\:-inset-2:before{content:var(--tw-content);inset:-.5rem}.after\:absolute:after{content:var(--tw-content);position:absolute}.after\:hidden:after{content:var(--tw-content);display:none}.after\:h-1\/2:after{content:var(--tw-content);height:50%}.after\:w-1\/2:after{content:var(--tw-content);width:50%}.after\:rounded-full:after{border-radius:9999px;content:var(--tw-content)}.after\:bg-brand-bold:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:#eab308;background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.after\:bg-content-default:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:#facc15;background-color:rgba(var(--color-bg-content-default),var(--tw-bg-opacity))}.first\:pt-0:first-child{padding-top:0}.focus-within\:outline-none:focus-within{outline:2px solid transparent;outline-offset:2px}.focus-within\:outline:focus-within{outline-style:solid}.hover\:rounded-2xl:hover{border-radius:1rem}.hover\:border-2:hover{border-width:2px}.hover\:border-\[\#0156CE\]:hover{--tw-border-opacity:1;border-color:#0156ce;border-color:rgb(1 86 206/var(--tw-border-opacity))}.hover\:border-\[\#F8F9FD\]:hover{--tw-border-opacity:1;border-color:#f8f9fd;border-color:rgb(248 249 253/var(--tw-border-opacity))}.hover\:border-color-brand:hover{--tw-border-opacity:1;border-color:#eab308;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity))}.hover\:\!bg-surface-selected:hover{--tw-bg-opacity:1!important;background-color:#f8f9fd!important;background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))!important}.hover\:\!bg-transparent:hover{background-color:transparent!important}.hover\:bg-brand-bolder:hover{--tw-bg-opacity:1;background-color:#d19507;background-color:rgba(var(--color-brand-bolder),var(--tw-bg-opacity))}.hover\:bg-brand-subtlest:hover{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.hover\:bg-brand-sunken:hover{--tw-bg-opacity:1;background-color:#fefce8;background-color:rgba(var(--color-brand-sunken),var(--tw-bg-opacity))}.hover\:bg-content-bold:hover{--tw-bg-opacity:1;background-color:#eab308;background-color:rgba(var(--color-bg-content-bold),var(--tw-bg-opacity))}.hover\:bg-content-sunken:hover{--tw-bg-opacity:1;background-color:#fefce8;background-color:rgba(var(--color-bg-content-sunken),var(--tw-bg-opacity))}.hover\:bg-surface-default:hover{--tw-bg-opacity:1;background-color:#fff;background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.hover\:bg-surface-selected:hover{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.hover\:pl-sm:hover{padding-left:.5rem;padding-left:var(--spacing-sm)}.hover\:font-semibold:hover{font-weight:600}.hover\:\!text-color-black:hover{--tw-text-opacity:1!important;color:#000!important;color:rgba(var(--color-black),var(--tw-text-opacity))!important}.hover\:text-color-black:hover{--tw-text-opacity:1;color:#000;color:rgba(var(--color-black),var(--tw-text-opacity))}.hover\:text-color-brand-bold:hover{--tw-text-opacity:1;color:#eab308;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.hover\:text-color-link-bold:hover{--tw-text-opacity:1;color:#0156ce;color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.hover\:text-color-link-bolder:hover{--tw-text-opacity:1;color:#014bb5;color:rgba(var(--color-text-link-bolder),var(--tw-text-opacity))}.hover\:text-color-subtle:hover{--tw-text-opacity:1;color:#626f86;color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.hover\:underline:hover{text-decoration-line:underline}.hover\:grayscale-0:hover{--tw-grayscale:grayscale(0);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) grayscale(0) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow);filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.focus\:bg-brand-strong:focus{--tw-bg-opacity:1;background-color:#a86a07;background-color:rgba(var(--color-brand-strong),var(--tw-bg-opacity))}.focus\:outline-none:focus{outline:2px solid transparent;outline-offset:2px}.focus\:outline-color-brand:focus{outline-color:#eab308;outline-color:rgba(var(--color-border-brand),1)}.focus\:ring-2:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.focus\:ring-text-color-border-selected:focus{--tw-ring-opacity:1;--tw-ring-color:rgba(var(--color-border-selected),var(--tw-ring-opacity))}.focus-visible\:bg-brand-bold:focus-visible{--tw-bg-opacity:1;background-color:#eab308;background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.focus-visible\:bg-brand-boldest:focus-visible{--tw-bg-opacity:1;background-color:#c48404;background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.focus-visible\:bg-error-bold:focus-visible{--tw-bg-opacity:1;background-color:#e11900;background-color:rgba(var(--color-bg-error-bold),var(--tw-bg-opacity))}.focus-visible\:bg-surface-default:focus-visible{--tw-bg-opacity:1;background-color:#fff;background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.focus-visible\:bg-surface-selected:focus-visible{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity))}.focus-visible\:outline-none:focus-visible{outline:2px solid transparent;outline-offset:2px}.focus-visible\:outline:focus-visible{outline-style:solid}.focus-visible\:outline-2:focus-visible{outline-width:2px}.focus-visible\:outline-color-selected:focus-visible{outline-color:#eab308;outline-color:rgba(var(--color-border-selected),1)}.focus-visible\:ring-2:focus-visible{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.focus-visible\:ring-offset-2:focus-visible{--tw-ring-offset-width:2px}.focus-visible\:ring-offset-brand-bold:focus-visible{--tw-ring-offset-color:rgba(var(--color-brand-bold),1)}.focus-visible\:ring-offset-white:focus-visible{--tw-ring-offset-color:rgba(var(--color-white),1)}.active\:\!bg-brand-subtlest:active{--tw-bg-opacity:1!important;background-color:#fef9c3!important;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))!important}.active\:\!bg-inherit:active{background-color:inherit!important}.active\:\!bg-transparent:active{background-color:transparent!important}.active\:bg-brand-boldest:active{--tw-bg-opacity:1;background-color:#c48404;background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.active\:bg-brand-strong:active{--tw-bg-opacity:1;background-color:#a86a07;background-color:rgba(var(--color-brand-strong),var(--tw-bg-opacity))}.active\:bg-brand-subtler:active{--tw-bg-opacity:1;background-color:#fef08a;background-color:rgba(var(--color-brand-subtler),var(--tw-bg-opacity))}.active\:bg-brand-subtlest:active{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-brand-subtlest),var(--tw-bg-opacity))}.active\:bg-content-bolder:active{--tw-bg-opacity:1;background-color:#d19507;background-color:rgba(var(--color-bg-content-bolder),var(--tw-bg-opacity))}.active\:bg-content-subtlest:active{--tw-bg-opacity:1;background-color:#fef9c3;background-color:rgba(var(--color-bg-content-subtlest),var(--tw-bg-opacity))}.active\:text-color-brand-boldest:active{--tw-text-opacity:1;color:#c48404;color:rgba(var(--color-text-brand-boldest),var(--tw-text-opacity))}.disabled\:border-color-default:disabled{--tw-border-opacity:1;border-color:#dcdfe4;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.disabled\:bg-surface-subtle:disabled{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.disabled\:text-color-disabled:disabled{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.group:hover .group-hover\:after\:bg-brand-bolder:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:#d19507;background-color:rgba(var(--color-brand-bolder),var(--tw-bg-opacity))}.group:active .group-active\:after\:bg-brand-boldest:after{content:var(--tw-content);--tw-bg-opacity:1;background-color:#c48404;background-color:rgba(var(--color-brand-boldest),var(--tw-bg-opacity))}.aria-disabled\:pointer-events-none[aria-disabled=true]{pointer-events:none}.aria-disabled\:cursor-default[aria-disabled=true]{cursor:default}.aria-disabled\:text-color-disabled[aria-disabled=true]{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.ui-open\:text-color-brand-bold[data-headlessui-state~=open]{--tw-text-opacity:1;color:#eab308;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}:where([data-headlessui-state~=open]) .ui-open\:text-color-brand-bold{--tw-text-opacity:1;color:#eab308;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.ui-disabled\:pointer-events-none[data-headlessui-state~=disabled]{pointer-events:none}.ui-disabled\:cursor-default[data-headlessui-state~=disabled]{cursor:default}.ui-disabled\:text-color-disabled[data-headlessui-state~=disabled]{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}:where([data-headlessui-state~=disabled]) .ui-disabled\:pointer-events-none{pointer-events:none}:where([data-headlessui-state~=disabled]) .ui-disabled\:cursor-default{cursor:default}:where([data-headlessui-state~=disabled]) .ui-disabled\:text-color-disabled{--tw-text-opacity:1;color:#b3b9c4;color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}:where([data-headlessui-focus-visible]) .ui-focus-visible\:outline-color-brand:focus{outline-color:#eab308;outline-color:rgba(var(--color-border-brand),1)}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-2:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-brand-bold:focus{--tw-ring-opacity:1;--tw-ring-color:rgba(var(--color-brand-bold),var(--tw-ring-opacity))}:where([data-headlessui-focus-visible]) .ui-focus-visible\:ring-opacity-75:focus{--tw-ring-opacity:0.75}.slider-horizontal .h\:-right-2{right:-.5rem}.slider-horizontal .h\:-top-1{top:-.25rem}.slider-horizontal .h\:-top-1\.5{top:-.375rem}.slider-horizontal .h\:left-1\/2{left:50%}.slider-horizontal .h\:h-0{height:0}.slider-horizontal .h\:h-4{height:1rem}.slider-horizontal .h\:w-4{width:1rem}.slider-horizontal .h\:-translate-x-1\/2{--tw-translate-x:-50%;transform:translate(-50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-horizontal .h\:arrow-bottom:before{border:5px solid transparent;border-top-color:inherit;bottom:-10px}.slider-horizontal .h\:arrow-bottom:before,.slider-horizontal .h\:arrow-top:before{content:"";height:0;left:50%;position:absolute;transform:translate(-50%);width:0}.slider-horizontal .h\:arrow-top:before{border:5px solid transparent;border-bottom-color:inherit;top:-10px}.slider-vertical .v\:-right-1{right:-.25rem}.slider-vertical .v\:-right-1\.25{right:-.3125rem}.slider-vertical .v\:-top-2{top:-.5rem}.slider-vertical .v\:-top-full{top:-100%}.slider-vertical .v\:top-1\/2{top:50%}.slider-vertical .v\:h-4{height:1rem}.slider-vertical .v\:w-0{width:0}.slider-vertical .v\:w-4{width:1rem}.slider-vertical .v\:-translate-y-1\/2{--tw-translate-y:-50%;transform:translate(var(--tw-translate-x),-50%) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-vertical .v\:cursor-ns-resize{cursor:ns-resize}.slider-vertical .v\:arrow-left:before{border:5px solid transparent;border-right-color:inherit;left:-10px}.slider-vertical .v\:arrow-left:before,.slider-vertical .v\:arrow-right:before{content:"";height:0;position:absolute;top:50%;transform:translateY(-50%);width:0}.slider-vertical .v\:arrow-right:before{border:5px solid transparent;border-left-color:inherit;right:-10px}.slider-horizontal .slider-origin>.merge-h\:bottom-3{bottom:.75rem}.slider-horizontal .slider-origin>.merge-h\:bottom-3\.5{bottom:.875rem}.slider-horizontal .slider-origin>.merge-h\:left-auto{left:auto}.slider-horizontal .slider-origin>.merge-h\:top-5{top:1.25rem}.slider-horizontal .slider-origin>.merge-h\:translate-x-1\/2{--tw-translate-x:50%;transform:translate(50%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-vertical .slider-origin>.merge-v\:left-7{left:1.75rem}.slider-vertical .slider-origin>.merge-v\:right-1{right:.25rem}.slider-vertical .slider-origin>.merge-v\:top-auto{top:auto}.slider-vertical .slider-origin>.merge-v\:-translate-x-4{--tw-translate-x:-1rem;transform:translate(-1rem,var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:-left-2{left:-.5rem}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:left-0{left:0}.slider-horizontal.slider-txt-rtl .txt-rtl-h\:right-auto{right:auto}.slider-tap .tap\:transition-transform{transition-duration:.15s;transition-property:transform;transition-timing-function:cubic-bezier(.4,0,.2,1)}.slider-tap .tap\:duration-300{transition-duration:.3s}.slider-tooltip-focus:not(.slider-focused) .tt-focus\:hidden{display:none!important}.slider-tooltip-focus.slider-focused:not(.slider-tooltip-hidden) .tt-focused\:block{display:block!important}.slider-tooltip-drag:not(.slider-state-drag) .tt-drag\:hidden{display:none!important}.slider-tooltip-drag.slider-state-drag .tt-dragging\:block\:not$\.slider-tooltip-hidden${display:block!important}@media not all and (min-width:1280px){.max-xl\:w-full{width:100%}}@media not all and (min-width:1024px){.max-lg\:items-center{align-items:center}.max-lg\:gap-x-6{-moz-column-gap:1.5rem;column-gap:1.5rem}.max-lg\:pt-lg{padding-top:1.5rem;padding-top:var(--spacing-lg)}}@media (min-width:576px){.sm\:sticky{position:sticky}.sm\:top-20{top:5rem}.sm\:w-20{width:5rem}.sm\:w-2xl{width:2.5rem;width:var(--spacing-2xl)}.sm\:w-\[100\%\]{width:100%}.sm\:w-\[50\%\]{width:50%}.sm\:\!max-w-\[20\%\]{max-width:20%!important}.sm\:max-w-\[33\%\]{max-width:33%}.sm\:grid-cols-2{grid-template-columns:repeat(2,minmax(0,1fr))}.sm\:border-0{border-width:0}.sm\:border-t{border-top-width:1px}.sm\:border-\[\#000\]{--tw-border-opacity:1;border-color:#000;border-color:rgb(0 0 0/var(--tw-border-opacity))}.sm\:pr-md{padding-right:1rem;padding-right:var(--spacing-md)}.sm\:pt-0{padding-top:0}.sm\:pt-\[\.625rem\]{padding-top:.625rem}}@media (min-width:768px){.md\:h-9{height:2.25rem}.md\:w-9{width:2.25rem}.md\:w-\[100\%\]{width:100%}.md\:w-\[50\%\]{width:50%}.md\:flex-row{flex-direction:row}.md\:flex-row-reverse{flex-direction:row-reverse}}@media (min-width:1024px){.lg\:absolute{position:absolute}.lg\:sticky{position:sticky}.lg\:\!bottom-\[50vh\]{bottom:50vh!important}.lg\:bottom-xl{bottom:2rem;bottom:var(--spacing-xl)}.lg\:left-xl{left:2rem;left:var(--spacing-xl)}.lg\:top-7xl{top:5rem;top:var(--spacing-7xl)}.lg\:top-\[10\%\]{top:10%}.lg\:top-\[20\%\]{top:20%}.lg\:top-\[30\%\]{top:30%}.lg\:top-\[4\.5rem\]{top:4.5rem}.lg\:top-\[40\%\]{top:40%}.lg\:top-\[50\%\]{top:50%}.lg\:top-\[60\%\]{top:60%}.lg\:top-\[70\%\]{top:70%}.lg\:order-first{order:-9999}.lg\:m-0{margin:0}.lg\:m-lg{margin:1.5rem;margin:var(--spacing-lg)}.lg\:mx-auto{margin-left:auto;margin-right:auto}.lg\:my-0{margin-bottom:0;margin-top:0}.lg\:my-12{margin-bottom:3rem;margin-top:3rem}.lg\:my-7xl{margin-bottom:5rem;margin-bottom:var(--spacing-7xl);margin-top:5rem;margin-top:var(--spacing-7xl)}.lg\:my-\[18\.75rem\]{margin-bottom:18.75rem;margin-top:18.75rem}.lg\:-mt-4xl{margin-top:-3.5rem;margin-top:calc(var(--spacing-4xl)*-1)}.lg\:mb-0{margin-bottom:0}.lg\:mb-10xl{margin-bottom:6.5rem;margin-bottom:var(--spacing-10xl)}.lg\:mb-lg{margin-bottom:1.5rem;margin-bottom:var(--spacing-lg)}.lg\:ml-3xl{margin-left:3rem;margin-left:var(--spacing-3xl)}.lg\:ml-lg{margin-left:1.5rem;margin-left:var(--spacing-lg)}.lg\:ml-sm{margin-left:.5rem;margin-left:var(--spacing-sm)}.lg\:mr-8xl{margin-right:5.5rem;margin-right:var(--spacing-8xl)}.lg\:mr-\[4\.6875rem\]{margin-right:4.6875rem}.lg\:mr-lg{margin-right:1.5rem;margin-right:var(--spacing-lg)}.lg\:mr-xl{margin-right:2rem;margin-right:var(--spacing-xl)}.lg\:mt-0{margin-top:0}.lg\:mt-\[-3rem\]{margin-top:-3rem}.lg\:mt-lg{margin-top:1.5rem;margin-top:var(--spacing-lg)}.lg\:mt-md{margin-top:1rem;margin-top:var(--spacing-md)}.lg\:\!block{display:block!important}.lg\:block{display:block}.lg\:flex{display:flex}.lg\:\!inline-flex{display:inline-flex!important}.lg\:grid{display:grid}.lg\:\!hidden{display:none!important}.lg\:hidden{display:none}.lg\:aspect-\[1\/1\.414\]{aspect-ratio:1/1.414}.lg\:aspect-square{aspect-ratio:1/1}.lg\:h-12{height:3rem}.lg\:h-\[296px\]{height:296px}.lg\:h-\[7\.5rem\]{height:7.5rem}.lg\:max-h-\[100\%\]{max-height:100%}.lg\:max-h-\[30\%\]{max-height:30%}.lg\:max-h-\[40\%\]{max-height:40%}.lg\:max-h-\[50\%\]{max-height:50%}.lg\:max-h-\[60\%\]{max-height:60%}.lg\:max-h-\[70\%\]{max-height:70%}.lg\:max-h-\[80\%\]{max-height:80%}.lg\:max-h-\[90\%\]{max-height:90%}.lg\:min-h-screen{min-height:100vh}.lg\:\!w-\[20\%\]{width:20%!important}.lg\:\!w-\[75\%\]{width:75%!important}.lg\:\!w-fit{width:-moz-fit-content!important;width:fit-content!important}.lg\:w-1\/2{width:50%}.lg\:w-1\/4{width:25%}.lg\:w-1\/5{width:20%}.lg\:w-12{width:3rem}.lg\:w-2\/3{width:66.666667%}.lg\:w-4\/5{width:80%}.lg\:w-\[100\%\]{width:100%}.lg\:w-\[19\.0625rem\]{width:19.0625rem}.lg\:w-\[22\.5rem\]{width:22.5rem}.lg\:w-\[25\%\]{width:25%}.lg\:w-\[31\.25rem\]{width:31.25rem}.lg\:w-\[315px\]{width:315px}.lg\:w-\[32rem\]{width:32rem}.lg\:w-\[33\%\]{width:33%}.lg\:w-\[333px\]{width:333px}.lg\:w-\[360px\]{width:360px}.lg\:w-\[50\%\]{width:50%}.lg\:w-fit{width:-moz-fit-content;width:fit-content}.lg\:w-full{width:100%}.lg\:w-max{width:-moz-max-content;width:max-content}.lg\:\!min-w-\[40\%\]{min-width:40%!important}.lg\:max-w-2xl{max-width:42rem}.lg\:max-w-3xl{max-width:48rem}.lg\:max-w-4xl{max-width:56rem}.lg\:max-w-5xl{max-width:64rem}.lg\:max-w-6xl{max-width:72rem}.lg\:max-w-7xl{max-width:80rem}.lg\:max-w-\[28\.5rem\]{max-width:28.5rem}.lg\:max-w-\[30\%\]{max-width:30%}.lg\:max-w-\[32\%\]{max-width:32%}.lg\:max-w-\[80\%\]{max-width:80%}.lg\:max-w-lg{max-width:32rem}.lg\:max-w-md{max-width:28rem}.lg\:max-w-sm{max-width:24rem}.lg\:max-w-xl{max-width:36rem}.lg\:max-w-xs{max-width:20rem}.lg\:flex-1{flex:1 1 0%}.lg\:flex-auto{flex:1 1 auto}.lg\:flex-none{flex:none}.lg\:basis-1\/2{flex-basis:50%}.lg\:basis-1\/4{flex-basis:25%}.lg\:basis-\[15\.625rem\]{flex-basis:15.625rem}.lg\:list-disc{list-style-type:disc}.lg\:grid-cols-3{grid-template-columns:repeat(3,minmax(0,1fr))}.lg\:flex-row{flex-direction:row}.lg\:flex-row-reverse{flex-direction:row-reverse}.lg\:flex-col{flex-direction:column}.lg\:flex-wrap{flex-wrap:wrap}.lg\:flex-nowrap{flex-wrap:nowrap}.lg\:items-center{align-items:center}.lg\:justify-end{justify-content:flex-end}.lg\:justify-between{justify-content:space-between}.lg\:gap-0{gap:0}.lg\:gap-2xl{gap:2.5rem;gap:var(--spacing-2xl)}.lg\:gap-lg{gap:1.5rem;gap:var(--spacing-lg)}.lg\:gap-xl{gap:2rem;gap:var(--spacing-xl)}.lg\:gap-x-lg{-moz-column-gap:1.5rem;column-gap:1.5rem;-moz-column-gap:var(--spacing-lg);column-gap:var(--spacing-lg)}.lg\:gap-y-lg{row-gap:1.5rem;row-gap:var(--spacing-lg)}.lg\:\!space-y-0>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0!important;margin-bottom:0!important;margin-bottom:calc(0px*var(--tw-space-y-reverse))!important;margin-top:0!important;margin-top:calc(0px*(1 - var(--tw-space-y-reverse)))!important}.lg\:space-x-lg>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:1.5rem;margin-left:calc(var(--spacing-lg)*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(var(--spacing-lg)*var(--tw-space-x-reverse))}.lg\:space-x-xl>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:2rem;margin-left:calc(var(--spacing-xl)*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(var(--spacing-xl)*var(--tw-space-x-reverse))}.lg\:space-y-0>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(0px*var(--tw-space-y-reverse));margin-top:0;margin-top:calc(0px*(1 - var(--tw-space-y-reverse)))}.lg\:space-y-2xl>:not([hidden])~:not([hidden]){--tw-space-y-reverse:0;margin-bottom:0;margin-bottom:calc(var(--spacing-2xl)*var(--tw-space-y-reverse));margin-top:2.5rem;margin-top:calc(var(--spacing-2xl)*(1 - var(--tw-space-y-reverse)))}.lg\:rounded-2xl{border-radius:1rem}.lg\:rounded-3xl{border-radius:1.5rem}.lg\:border{border-width:1px}.lg\:border-0{border-width:0}.lg\:border-b{border-bottom-width:1px}.lg\:border-l{border-left-width:1px}.lg\:border-t-0{border-top-width:0}.lg\:border-none{border-style:none}.lg\:bg-surface-subtle{--tw-bg-opacity:1;background-color:#f8f9fd;background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.lg\:p-0{padding:0}.lg\:p-2xl{padding:2.5rem;padding:var(--spacing-2xl)}.lg\:p-lg{padding:1.5rem;padding:var(--spacing-lg)}.lg\:px-0{padding-left:0;padding-right:0}.lg\:px-10{padding-left:2.5rem;padding-right:2.5rem}.lg\:px-4{padding-left:1rem;padding-right:1rem}.lg\:px-4xl{padding-left:3.5rem;padding-left:var(--spacing-4xl);padding-right:3.5rem;padding-right:var(--spacing-4xl)}.lg\:px-\[\.9375rem\]{padding-left:.9375rem;padding-right:.9375rem}.lg\:px-lg{padding-left:1.5rem;padding-left:var(--spacing-lg);padding-right:1.5rem;padding-right:var(--spacing-lg)}.lg\:py-0{padding-bottom:0;padding-top:0}.lg\:py-10xl{padding-bottom:6.5rem;padding-bottom:var(--spacing-10xl);padding-top:6.5rem;padding-top:var(--spacing-10xl)}.lg\:py-12{padding-bottom:3rem;padding-top:3rem}.lg\:py-2xl{padding-bottom:2.5rem;padding-bottom:var(--spacing-2xl);padding-top:2.5rem;padding-top:var(--spacing-2xl)}.lg\:py-32{padding-bottom:8rem;padding-top:8rem}.lg\:py-3xl{padding-bottom:3rem;padding-bottom:var(--spacing-3xl);padding-top:3rem;padding-top:var(--spacing-3xl)}.lg\:py-4xl{padding-bottom:3.5rem;padding-bottom:var(--spacing-4xl);padding-top:3.5rem;padding-top:var(--spacing-4xl)}.lg\:py-5xl{padding-bottom:4rem;padding-bottom:var(--spacing-5xl);padding-top:4rem;padding-top:var(--spacing-5xl)}.lg\:py-7xl{padding-bottom:5rem;padding-bottom:var(--spacing-7xl);padding-top:5rem;padding-top:var(--spacing-7xl)}.lg\:py-lg{padding-bottom:1.5rem;padding-bottom:var(--spacing-lg);padding-top:1.5rem;padding-top:var(--spacing-lg)}.lg\:py-xl{padding-bottom:2rem;padding-bottom:var(--spacing-xl);padding-top:2rem;padding-top:var(--spacing-xl)}.lg\:pb-0{padding-bottom:0}.lg\:pb-2xl{padding-bottom:2.5rem;padding-bottom:var(--spacing-2xl)}.lg\:pb-3xl{padding-bottom:3rem;padding-bottom:var(--spacing-3xl)}.lg\:pb-5xl{padding-bottom:4rem;padding-bottom:var(--spacing-5xl)}.lg\:pb-7xl{padding-bottom:5rem;padding-bottom:var(--spacing-7xl)}.lg\:pb-\[12\.5rem\]{padding-bottom:12.5rem}.lg\:pb-\[6\.3125rem\]{padding-bottom:6.3125rem}.lg\:pb-lg{padding-bottom:1.5rem;padding-bottom:var(--spacing-lg)}.lg\:pb-md{padding-bottom:1rem;padding-bottom:var(--spacing-md)}.lg\:pb-sm{padding-bottom:.5rem;padding-bottom:var(--spacing-sm)}.lg\:pl-10,.lg\:pl-2xl{padding-left:2.5rem}.lg\:pl-2xl{padding-left:var(--spacing-2xl)}.lg\:pl-lg{padding-left:1.5rem;padding-left:var(--spacing-lg)}.lg\:pl-sm{padding-left:.5rem;padding-left:var(--spacing-sm)}.lg\:pl-xl{padding-left:2rem;padding-left:var(--spacing-xl)}.lg\:pr-0{padding-right:0}.lg\:pr-lg{padding-right:1.5rem;padding-right:var(--spacing-lg)}.lg\:pr-xl{padding-right:2rem;padding-right:var(--spacing-xl)}.lg\:pt-0{padding-top:0}.lg\:pt-2xl{padding-top:2.5rem;padding-top:var(--spacing-2xl)}.lg\:pt-3xl{padding-top:3rem;padding-top:var(--spacing-3xl)}.lg\:pt-5xl{padding-top:4rem;padding-top:var(--spacing-5xl)}.lg\:pt-7xl{padding-top:5rem;padding-top:var(--spacing-7xl)}.lg\:pt-\[5rem\]{padding-top:5rem}.lg\:pt-\[7\.5rem\]{padding-top:7.5rem}.lg\:pt-\[8\.125rem\]{padding-top:8.125rem}.lg\:pt-lg{padding-top:1.5rem;padding-top:var(--spacing-lg)}.lg\:pt-md{padding-top:1rem;padding-top:var(--spacing-md)}.lg\:pt-xl{padding-top:2rem;padding-top:var(--spacing-xl)}.lg\:text-center{text-align:center}.lg\:\!text-3xl{font-size:1.875rem!important;line-height:2.25rem!important}}@media (min-width:1280px){.xl\:mr-7xl{margin-right:5rem;margin-right:var(--spacing-7xl)}.xl\:mr-lg{margin-right:1.5rem;margin-right:var(--spacing-lg)}.xl\:h-16{height:4rem}.xl\:w-16{width:4rem}.xl\:w-4{width:1rem}.xl\:w-\[100\%\]{width:100%}.xl\:w-\[25\%\]{width:25%}.xl\:w-\[27\.6875rem\]{width:27.6875rem}.xl\:w-\[33\%\]{width:33%}.xl\:w-\[50\%\]{width:50%}.xl\:space-x-3xl>:not([hidden])~:not([hidden]){--tw-space-x-reverse:0;margin-left:3rem;margin-left:calc(var(--spacing-3xl)*(1 - var(--tw-space-x-reverse)));margin-right:0;margin-right:calc(var(--spacing-3xl)*var(--tw-space-x-reverse))}}@media (min-width:1440px){.xxl\:w-\[33\%\]{width:33%}}.\[\&\:\:-webkit-inner-spin-button\]\:appearance-none::-webkit-inner-spin-button,.\[\&\:\:-webkit-outer-spin-button\]\:appearance-none::-webkit-outer-spin-button{-webkit-appearance:none;appearance:none}.\[\&\>a\]\:block>a{display:block}.\[\&\>a\]\:w-full>a{width:100%}.\[\&\>a\]\:px-2>a{padding-left:.5rem;padding-right:.5rem}.\[\&\>a\]\:px-4>a{padding-left:1rem;padding-right:1rem}.\[\&\>a\]\:py-md>a{padding-bottom:1rem;padding-bottom:var(--spacing-md);padding-top:1rem;padding-top:var(--spacing-md)}.\[\&\>div\]\:z-1>div{z-index:1}.\[\&\>div\]\:z-10>div{z-index:10}.\[\&\>div\]\:w-fit>div{width:-moz-fit-content;width:fit-content}.\[\&\>ol\>li\]\:truncate>ol>li{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.\[\&\>span\]\:overflow-hidden>span{overflow:hidden}.\[\&\>span\]\:truncate>span{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.\[\&_input\]\:\!w-\[1\.15em\] input{width:1.15em!important}.\[\&_input\]\:text-center input{text-align:center}.\[\&_span\]\:hover\:text-color-brand-bold:hover span,.\[\&_span\]\:text-color-brand-bold span{--tw-text-opacity:1;color:#eab308;color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}</style> <style>html{scroll-behavior:smooth}.common-field{display:flex;flex-direction:column;font-size:.875rem;gap:.25rem;line-height:1.25rem;position:relative;width:100%}.common-field--success .common-field__dropdown-input,.common-field--success .common-field__input,.common-field--success .common-field__textarea{--tw-text-opacity:1;color:rgba(var(--color-text-success),1);color:rgba(var(--color-text-success),var(--tw-text-opacity));outline-color:rgba(var(--color-border-success),1);outline-style:solid}.common-field--success>.common-field__hint{--tw-text-opacity:1;color:rgba(var(--color-text-success),1);color:rgba(var(--color-text-success),var(--tw-text-opacity))}.common-field--error .common-field__dropdown-input,.common-field--error .common-field__input,.common-field--error .common-field__textarea{--tw-text-opacity:1;color:rgba(var(--color-text-error),1);color:rgba(var(--color-text-error),var(--tw-text-opacity));outline-color:rgba(var(--color-border-error),1);outline-style:solid}.common-field--error>.common-field__hint{--tw-text-opacity:1;color:rgba(var(--color-text-error),1);color:rgba(var(--color-text-error),var(--tw-text-opacity))}.common-field.common-field--readonly .common-field__dropdown-input,.common-field.common-field--readonly .common-field__input,.common-field.common-field--readonly .common-field__textarea,.common-field.common-field--readonly input,.common-field.common-field--readonly textarea{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.common-field input::-moz-placeholder,.common-field textarea::-moz-placeholder{--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.common-field input::placeholder,.common-field textarea::placeholder{--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.common-field__wrapper{width:100%}.common-field__label{display:block;font-size:.75rem;line-height:1rem;margin-bottom:var(--spacing-xs);white-space:nowrap}.common-field__hint{font-size:.75rem;line-height:1rem;--tw-text-opacity:1;color:rgba(var(--color-text-subtlest),1);color:rgba(var(--color-text-subtlest),var(--tw-text-opacity));margin-top:var(--spacing-xs)}.common-field__options{border-radius:.25rem;border-width:1px;max-height:15rem;min-width:-moz-fit-content;min-width:fit-content;overflow:auto;position:absolute;width:100%;z-index:20;--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity));--tw-bg-opacity:1;background-color:rgba(var(--color-white),1);background-color:rgba(var(--color-white),var(--tw-bg-opacity));font-size:.875rem;line-height:1.25rem;padding:.25rem;--tw-shadow:0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -4px rgba(0,0,0,.1);--tw-shadow-colored:0 10px 15px -3px var(--tw-shadow-color),0 4px 6px -4px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -4px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.common-field__options:focus{outline:2px solid transparent;outline-offset:2px}.common-field__input{width:100%;--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));outline-color:rgba(var(--color-border-brand),1);outline-offset:-1px;outline-width:2px}.common-field__dropdown-input{align-items:center;border-radius:.25rem;display:flex;gap:.5rem;justify-content:space-between;margin-bottom:2px;padding-right:var(--spacing-sm);white-space:nowrap}.common-field__dropdown-input,.common-field__textarea{width:100%;--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));outline-color:rgba(var(--color-border-brand),1);outline-offset:-1px;outline-width:2px;padding-left:var(--spacing-md)}.common-field__textarea{padding-right:var(--spacing-md)}.common-field input,.common-field textarea{width:100%;--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.common-field--outlined .common-field__dropdown-input,.common-field--outlined .common-field__input,.common-field--outlined .common-field__textarea{border-width:1px;--tw-border-opacity:1;background-color:transparent;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.common-field--outlined input,.common-field--outlined textarea{background-color:transparent}.common-field--fit-content{max-width:-moz-fit-content;max-width:fit-content}.common-field--inline .common-field__wrapper{align-items:center;display:flex;flex-direction:row;gap:.5rem}.common-field--inline .common-field__wrapper .common-field__label{margin-bottom:0}.common-field--disabled,.common-field--disabled .common-field__dropdown-input,.common-field--disabled .common-field__hint,.common-field--disabled .common-field__placeholder,.common-field--disabled input,.common-field--disabled textarea{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.common-field--disabled input::-moz-placeholder,.common-field--disabled textarea::-moz-placeholder{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.common-field--disabled input::placeholder,.common-field--disabled textarea::placeholder{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.m-button-group .m-button.m-button--primary:not(.m-button--active){--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));--tw-text-opacity:1;color:rgba(var(--color-text-default),1);color:rgba(var(--color-text-default),var(--tw-text-opacity))}.m-button-group .m-button.m-button--primary:not(.m-button--active):hover{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.m-button-group .m-button.m-button--active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity))}.m-button{align-items:center;display:flex;font-size:.875rem;font-weight:400;line-height:1.25rem;outline-color:rgba(var(--color-border-brand),1);position:relative;transition-duration:.1s;transition-timing-function:cubic-bezier(0,0,.2,1);width:-moz-fit-content;width:fit-content}.m-button--sm{height:var(--spacing-lg)}.m-button--md,.m-button--sm{padding-left:var(--spacing-md);padding-right:var(--spacing-md)}.m-button--md{height:var(--spacing-xl)}.m-button--lg{height:var(--spacing-2xl);padding-left:var(--spacing-md);padding-right:var(--spacing-md)}.m-button--disabled{pointer-events:none;--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.m-button--tonal{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-sunken),1);background-color:rgba(var(--color-bg-content-sunken),var(--tw-bg-opacity))}.m-button--tonal:not(.m-button--disabled):hover{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtler),1);background-color:rgba(var(--color-bg-content-subtler),var(--tw-bg-opacity))}.m-button--tonal:not(.m-button--disabled).m-button--active,.m-button--tonal:not(.m-button--disabled):active{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtle),1);background-color:rgba(var(--color-bg-content-subtle),var(--tw-bg-opacity))}.m-button--tonal.m-button--disabled,.m-button--tonal:disabled{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-disabled),1);background-color:rgba(var(--color-surface-disabled),var(--tw-bg-opacity))}.m-button--primary{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity));--tw-text-opacity:1;color:rgba(var(--color-text-on-brand),1);color:rgba(var(--color-text-on-brand),var(--tw-text-opacity))}.m-button--primary:not(.m-button--disabled):hover{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bolder),1);background-color:rgba(var(--color-brand-bolder),var(--tw-bg-opacity))}.m-button--primary:not(.m-button--disabled).m-button--active,.m-button--primary:not(.m-button--disabled):active{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-strong),1);background-color:rgba(var(--color-brand-strong),var(--tw-bg-opacity))}.m-button--primary.m-button--disabled,.m-button--primary:disabled{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.m-button--accent{--tw-bg-opacity:1;background-color:rgba(var(--color-accent-bold),1);background-color:rgba(var(--color-accent-bold),var(--tw-bg-opacity));--tw-text-opacity:1;color:rgba(var(--color-text-on-accent),1);color:rgba(var(--color-text-on-accent),var(--tw-text-opacity));outline-color:rgba(var(--color-border-accent),1)}.m-button--accent:not(.m-button--disabled):hover{--tw-bg-opacity:1;background-color:rgba(var(--color-accent-bolder),1);background-color:rgba(var(--color-accent-bolder),var(--tw-bg-opacity))}.m-button--accent:not(.m-button--disabled).m-button--active,.m-button--accent:not(.m-button--disabled):active{--tw-bg-opacity:1;background-color:rgba(var(--color-accent-strong),1);background-color:rgba(var(--color-accent-strong),var(--tw-bg-opacity))}.m-button--accent.m-button--disabled,.m-button--accent:disabled{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.m-button--secondary{border-width:1px;--tw-border-opacity:1;border-color:rgba(var(--color-border-bold),var(--tw-border-opacity))}.m-button--secondary:not(.m-button--disabled):hover{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.m-button--secondary:not(.m-button--disabled).m-button--active,.m-button--secondary:not(.m-button--disabled):active{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity))}.m-button--secondary.m-button--disabled,.m-button--secondary:disabled{--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.m-button--tertiary{position:relative;--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity));height:var(--spacing-lg);outline-offset:2px;padding:0}.m-button--tertiary:after{background-image:linear-gradient(to right,rgba(var(--color-text-link-bold),1) var(--tw-gradient-from-position),rgba(var(--color-text-link-bold),1) var(--tw-gradient-to-position));background-image:linear-gradient(to right,var(--tw-gradient-stops));bottom:-.125rem;content:"";height:.125rem;left:0;position:absolute;right:0;--tw-gradient-from:rgba(var(--color-text-link-bold),1) var(--tw-gradient-from-position);--tw-gradient-to:rgba(var(--color-text-link-bold),0) var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to);--tw-gradient-to:rgba(var(--color-text-link-bold),1) var(--tw-gradient-to-position);opacity:0;transition-duration:.15s;transition-timing-function:cubic-bezier(0,0,.2,1)}.m-button--tertiary:not(.m-button--disabled):hover:after{content:var(--tw-content);opacity:1}.m-button--tertiary:not(.m-button--disabled):active{--tw-text-opacity:1;color:rgba(var(--color-text-link-boldest),1);color:rgba(var(--color-text-link-boldest),var(--tw-text-opacity))}.m-button--tertiary:not(.m-button--disabled).m-button--active{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.m-button--tertiary:not(.m-button--disabled).m-button--active:after{--tw-gradient-from:rgba(var(--color-text-link-bold),1) var(--tw-gradient-from-position);--tw-gradient-to:rgba(var(--color-text-link-bold),0) var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to);--tw-gradient-to:rgba(var(--color-text-link-bold),1) var(--tw-gradient-to-position);opacity:1}.m-button--tertiary.m-button--disabled,.m-button--tertiary:disabled{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity));opacity:.6}.m-button--tertiary-subtle{position:relative;--tw-text-opacity:1;color:rgba(var(--color-text-link-subtle),1);color:rgba(var(--color-text-link-subtle),var(--tw-text-opacity));height:var(--spacing-lg);outline-offset:2px;padding:0}.m-button--tertiary-subtle:not(.m-button--disabled):active,.m-button--tertiary-subtle:not(.m-button--disabled):hover{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.m-button--tertiary-subtle:not(.m-button--disabled).m-button--active{--tw-text-opacity:1;color:rgba(var(--color-text-link-boldest),1);color:rgba(var(--color-text-link-boldest),var(--tw-text-opacity))}.m-button--tertiary-subtle.m-button--disabled,.m-button--tertiary-subtle:disabled{--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity));opacity:.6}.m-button--full-width{width:100%}.m-button--full-width.m-button--link a{text-align:center;width:100%}.m-button--link{padding:0}.m-button--link a{align-items:center;color:inherit;display:flex;font-size:.875rem;gap:.5rem;height:100%;justify-content:center;line-height:1.25rem;width:100%}.m-button--link.m-button--lg a,.m-button--link.m-button--md a,.m-button--link.m-button--sm a{padding-left:var(--spacing-md);padding-right:var(--spacing-md)}.m-button--link.m-button--is-icon a{font-size:.875rem;line-height:1.25rem;padding-left:var(--spacing-sm);padding-right:var(--spacing-sm)}.m-button--link.m-button--tertiary a,.m-button--link.m-button--tertiary-subtle a{padding:0}.m-button--link.m-button--is-link-icon a{padding-left:var(--spacing-sm);padding-right:var(--spacing-sm)}.m-button--link.m-button--disabled a{pointer-events:none;--tw-text-opacity:1;color:rgba(var(--color-text-disabled),1);color:rgba(var(--color-text-disabled),var(--tw-text-opacity))}.m-button--is-icon{padding-left:var(--spacing-sm);padding-right:var(--spacing-sm)}.m-rich-text a{text-decoration-line:underline;transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.m-rich-text a:hover{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}.m-rich-text ul{list-style-position:inside;list-style-type:disc;text-align:left}.m-rich-text ul li{margin-left:1.6em;text-indent:-1.35em}.m-rich-text ol{list-style-position:inside;list-style-type:decimal;text-align:left}@media screen and (max-width:768px){.m-rich-text ol li{margin-left:1.25em;text-indent:-1.22em}}.m-h1{font-size:var(--h1-sm-size);line-height:var(--h1-sm-line-height)}@media (min-width:768px){.m-h1{font-size:var(--h1-md-size);line-height:var(--h1-md-line-height)}}@media (min-width:1024px){.m-h1{font-size:var(--h1-lg-size);line-height:var(--h1-lg-line-height)}}.m-h2{font-size:var(--h2-sm-size);line-height:var(--h2-sm-line-height)}@media (min-width:768px){.m-h2{font-size:var(--h2-md-size);line-height:var(--h2-md-line-height)}}@media (min-width:1024px){.m-h2{font-size:var(--h2-lg-size);line-height:var(--h2-lg-line-height)}}.m-h3{font-size:var(--h3-sm-size);line-height:var(--h3-sm-line-height)}@media (min-width:768px){.m-h3{font-size:var(--h3-md-size);line-height:var(--h3-md-line-height)}}@media (min-width:1024px){.m-h3{font-size:var(--h3-lg-size);line-height:var(--h3-lg-line-height)}}.m-h4{font-size:var(--h4-sm-size);line-height:var(--h4-sm-line-height)}@media (min-width:768px){.m-h4{font-size:var(--h4-md-size);line-height:var(--h4-md-line-height)}}@media (min-width:1024px){.m-h4{font-size:var(--h4-lg-size);line-height:var(--h4-lg-line-height)}}.m-h5{font-size:var(--h5-sm-size);line-height:var(--h5-sm-line-height)}@media (min-width:768px){.m-h5{font-size:var(--h5-md-size);line-height:var(--h5-md-line-height)}}@media (min-width:1024px){.m-h5{font-size:var(--h5-lg-size);line-height:var(--h5-lg-line-height)}}.m-h6{font-size:var(--h6-sm-size);line-height:var(--h6-sm-line-height)}@media (min-width:768px){.m-h6{font-size:var(--h6-md-size);line-height:var(--h6-md-line-height)}}@media (min-width:1024px){.m-h6{font-size:var(--h6-lg-size);line-height:var(--h6-lg-line-height)}}.m-tabs__header:after{bottom:-.125rem;content:"";height:.125rem;left:0;position:absolute;right:0;z-index:-1;--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtle),1);background-color:rgba(var(--color-bg-content-subtle),var(--tw-bg-opacity))}.m-icon-button{align-items:center;display:inline-flex;font-size:1rem;font-weight:400;gap:.5rem;justify-content:center;line-height:1.5rem;padding:.5rem;transition-duration:.1s;transition-timing-function:cubic-bezier(0,0,.2,1);white-space:nowrap;width:-moz-fit-content;width:fit-content}.m-icon-button:hover{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.m-icon-button:active{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.m-icon-button--disabled{color:rgba(var(--color-black),.5);pointer-events:none}.m-icon-button.m-icon-button--link{padding:0}.m-icon-button a{align-items:center;display:flex;justify-content:center;padding:.5rem}.m-card:hover .image-container{--tw-scale-x:1.1;--tw-scale-y:1.1;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(1.1) scaleY(1.1);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.m-card .image-container{transition-duration:.2s;transition-property:all;transition-timing-function:cubic-bezier(.4,0,.2,1)}.m-tabs__tab.m-button{align-items:center;display:flex;font-size:.875rem;font-weight:400;line-height:1.25rem;outline:2px solid transparent;outline-offset:2px;position:relative;transition-duration:.1s;transition-timing-function:cubic-bezier(0,0,.2,1);width:-moz-fit-content;width:fit-content}:where([data-headlessui-focus-visible]) .m-tabs__tab.m-button:focus{outline-color:rgba(var(--color-border-brand),1)}.m-tabs__tab.m-button:after{bottom:-.125rem;content:"";height:.125rem;left:0;position:absolute;right:0;--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity));opacity:0;transition-duration:.15s;transition-timing-function:cubic-bezier(0,0,.2,1)}.m-tabs__tab.m-button.m-button--active{--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}.m-tabs__tab.m-button.m-button--active:after{--tw-bg-opacity:1;background-color:rgba(var(--color-brand-bold),1);background-color:rgba(var(--color-brand-bold),var(--tw-bg-opacity));opacity:1}.m-checkbox__control:focus-visible{outline:max(1px,.1em) solid rgba(var(--color-brand-default));outline-offset:max(2px,.15em)}.m-checkbox__control:checked:before{--tw-scale-x:1;--tw-scale-y:1;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(1) scaleY(1);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.m-checkbox__control:before{background-color:CanvasText;clip-path:polygon(16% 55%,24% 47%,38% 60%,73% 25%,81% 33%,38% 75%);content:"";height:1.2em;width:1.2em;--tw-scale-x:0;--tw-scale-y:0;background-color:currentColor;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(0) scaleY(0);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.m-search-select__select[data-v-8ebcb524]{border-bottom-left-radius:.25rem;border-top-left-radius:.25rem}.m-search-select__select[data-v-8ebcb524] button{margin-bottom:0;--tw-bg-opacity:1;background-color:rgba(var(--color-surface-selected),1);background-color:rgba(var(--color-surface-selected),var(--tw-bg-opacity));--tw-text-opacity:1;color:rgba(var(--color-text-brand-bold),1);color:rgba(var(--color-text-brand-bold),var(--tw-text-opacity))}@media (min-width:1024px){.m-search-select__select[data-v-8ebcb524] button{border-bottom-right-radius:0;border-top-right-radius:0}.m-search-select__input[data-v-8ebcb524] .common-field__input{border-bottom-left-radius:0;border-left-width:0;border-top-left-radius:0}}.m-range-slider--disabled .m-range-slider__base{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-subtle),1);background-color:rgba(var(--color-bg-content-subtle),var(--tw-bg-opacity))}.m-range-slider--disabled .m-range-slider__connect,.m-range-slider--disabled .m-range-slider__handle{--tw-bg-opacity:1;background-color:rgba(var(--color-bg-content-default),1);background-color:rgba(var(--color-bg-content-default),var(--tw-bg-opacity))}.m-input__done-icon,.m-input__reset-button{display:none}.m-input__left-icon,.m-input__right-icon{--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}.m-input--filled:not(.m-input--filled.common-field--error):not(:focus-within) .m-input__done-icon{display:flex}.m-input--filled:focus-within .m-input__reset-button{display:flex}.m-input--filled .m-input__left-icon,.m-input--filled .m-input__right-icon{--tw-text-opacity:1;color:rgba(var(--color-text-default),1);color:rgba(var(--color-text-default),var(--tw-text-opacity))}.m-skeleton-item:after{height:100%;left:0;position:absolute;top:0;width:100%;--tw-translate-x:-100%;animation:shimmer 1.5s infinite;background-image:linear-gradient(90deg,hsla(0,0%,100%,0),hsla(0,0%,100%,.3),rgba(37,22,22,0));content:"";transform:translate(-100%,var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skew(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}@keyframes shimmer{to{transform:translate(100%)}}.vc-mui-brand{--vc-accent-50:rgba(var(--color-brand-sunken));--vc-accent-100:rgba(var(--color-brand-sunken));--vc-accent-200:rgba(var(--color-brand-subtlest));--vc-accent-300:rgba(var(--color-brand-subtle));--vc-accent-400:rgba(var(--color-brand-default));--vc-accent-500:rgba(var(--color-brand-bold));--vc-accent-600:rgba(var(--color-brand-bolder));--vc-accent-700:rgba(var(--color-brand-boldest));--vc-accent-800:rgba(var(--color-brand-strong));--vc-accent-900:rgba(var(--color-brand-stronger))}.m-date-picker-input-wrapper{display:flex;flex-direction:column;gap:.5rem;justify-content:space-between}.m-date-picker-input-wrapper__inline{align-items:center;flex-direction:row}.m-date-picker-input-wrapper__label{font-size:.75rem;line-height:1rem}.m-date-picker .vc-header{flex-grow:1;margin-bottom:.75rem;margin-top:.75rem}.m-date-picker .vc-title:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.m-date-picker .vc-title:focus-visible{--tw-ring-offset-width:2px;--tw-ring-offset-color:rgba(var(--color-brand-bold),1)}.m-date-picker .vc-arrow{border-style:solid;border-width:1px;--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity))}.m-date-picker .vc-pane{min-width:21.875rem}.m-date-picker .vc-popover-content{border-width:0}.m-date-picker .vc-popover-content .vc-nav-popover-container{min-width:13rem}.m-table--fixed-header th{position:sticky;top:0}.m-table--striped tr:nth-child(2n){--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.m-table--border-bottom tr{border-bottom-width:1px;--tw-border-opacity:1;border-bottom-color:rgba(var(--color-border-bold),var(--tw-border-opacity))}.m-table--hover-bg tr:hover{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity))}.m-table th{--tw-bg-opacity:1;background-color:rgba(var(--color-surface-default),1);background-color:rgba(var(--color-surface-default),var(--tw-bg-opacity));font-size:.75rem;font-weight:400;line-height:1rem;--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity));padding:.75rem 1rem}.m-table td{padding:.5rem 1rem}@media (min-width:1280px){.m-table td{padding-bottom:1rem;padding-top:1rem}}.m-container{--container-max-width:90rem;--container-ideal-width:94vw;max-width:90rem;max-width:var(--container-max-width);min-width:16rem;width:94vw;width:var(--container-ideal-width);width:clamp(16rem,94vw,90rem);width:clamp(16rem,var(--container-ideal-width),var(--container-max-width))}@media screen and (min-width:768px){.m-container{--container-ideal-width:92.5vw}}.m-container--percentages{--container-ideal-width:94%;min-width:10rem;width:clamp(10rem,94%,var(--container-max-width));width:clamp(10rem,var(--container-ideal-width),var(--container-max-width))}@media screen and (min-width:768px){.m-container--percentages{--container-ideal-width:92.5%}}.m-calendar{border-style:none}.m-calendar .vc-header{flex-grow:1;margin-bottom:.75rem;margin-top:.75rem}.m-calendar .vc-title:focus{--tw-ring-offset-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color);--tw-ring-shadow:var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color);box-shadow:var(--tw-ring-inset) 0 0 0 var(--tw-ring-offset-width) var(--tw-ring-offset-color),var(--tw-ring-inset) 0 0 0 calc(2px + var(--tw-ring-offset-width)) var(--tw-ring-color),0 0 #0000;box-shadow:var(--tw-ring-offset-shadow),var(--tw-ring-shadow),var(--tw-shadow,0 0 #0000)}.m-calendar .vc-title:focus-visible{--tw-ring-offset-width:2px;--tw-ring-offset-color:rgba(var(--color-brand-bold),1)}.m-calendar .vc-arrow{border-style:solid;border-width:1px;--tw-border-opacity:1;border-color:rgba(var(--color-border-default),var(--tw-border-opacity));padding:.75rem}.m-calendar .vc-arrows-container{padding-left:0;padding-right:0}.m-calendar .vc-pane,.m-calendar .vc-popover-content{min-width:350px}.vc-base-icon{display:inline-block;stroke:currentColor;stroke-width:2;fill:none}.vc-header{display:grid;grid-gap:4px;align-items:center;height:30px;margin-top:10px;padding-left:10px;padding-right:10px}.vc-header.is-lg{font-size:18px;font-size:var(--vc-text-lg)}.vc-header.is-xl{font-size:20px;font-size:var(--vc-text-xl)}.vc-header.is-2xl{font-size:24px;font-size:var(--vc-text-2xl)}.vc-header .vc-next,.vc-header .vc-prev,.vc-header .vc-title{align-items:center;border:0;border-radius:.25rem;border-radius:var(--vc-rounded);cursor:pointer;display:flex;grid-row:1;pointer-events:auto;-webkit-user-select:none;-moz-user-select:none;user-select:none}.vc-header .vc-title{color:var(--vc-header-title-color);font-weight:600;font-weight:var(--vc-font-semibold);grid-column:title;line-height:30px;margin:0;padding:0 8px;white-space:nowrap}.vc-header .vc-title:hover{opacity:.75}.vc-header .vc-arrow{align-items:center;color:var(--vc-header-arrow-color);display:flex;height:30px;justify-content:center;margin:0;padding:0;width:28px}.vc-header .vc-arrow:hover{background:var(--vc-header-arrow-hover-bg)}.vc-header .vc-arrow:disabled{opacity:.25;pointer-events:none}.vc-header .vc-prev{grid-column:prev}.vc-header .vc-next{grid-column:next}.vc-day{min-height:32px;position:relative;z-index:1}.vc-monthly .is-not-in-month *{opacity:0;pointer-events:none}.vc-day-layer{bottom:0;left:0;pointer-events:none;position:absolute;right:0;top:0}.vc-day-box-center-center{align-items:center;display:flex;justify-content:center;transform-origin:50% 50%}.vc-day-box-left-center{align-items:center;display:flex;justify-content:flex-start;transform-origin:0 50%}.vc-day-box-right-center{align-items:center;display:flex;justify-content:flex-end;transform-origin:100% 50%}.vc-day-box-center-bottom{align-items:flex-end;display:flex;justify-content:center}.vc-day-content{align-items:center;border-radius:9999px;border-radius:var(--vc-rounded-full);cursor:pointer;display:flex;font-size:14px;font-size:var(--vc-text-sm);font-weight:500;font-weight:var(--vc-font-medium);height:28px;justify-content:center;line-height:28px;-webkit-user-select:none;-moz-user-select:none;user-select:none;width:28px}.vc-day-content:hover{background-color:var(--vc-day-content-hover-bg)}.vc-day-content.vc-disabled{color:var(--vc-day-content-disabled-color)}.vc-content:not(.vc-base){color:var(--vc-content-color);font-weight:700;font-weight:var(--vc-font-bold)}.vc-highlights{overflow:hidden;pointer-events:none;z-index:-1}.vc-highlight{height:28px;width:28px}.vc-highlight.vc-highlight-base-start{border-radius:0!important;border-right-width:0!important;width:50%!important}.vc-highlight.vc-highlight-base-end{border-left-width:0!important;border-radius:0!important;width:50%!important}.vc-highlight.vc-highlight-base-middle{border-left-width:0!important;border-radius:0!important;border-right-width:0!important;margin:0 -1px;width:100%}.vc-highlight-bg-none,.vc-highlight-bg-outline{background-color:var(--vc-highlight-outline-bg);border:2px solid;border-color:var(--vc-highlight-outline-border);border-radius:9999px;border-radius:var(--vc-rounded-full)}.vc-highlight-bg-light{background-color:var(--vc-highlight-light-bg)}.vc-highlight-bg-light,.vc-highlight-bg-solid{border-radius:9999px;border-radius:var(--vc-rounded-full)}.vc-highlight-bg-solid{background-color:var(--vc-highlight-solid-bg)}.vc-highlight-content-none,.vc-highlight-content-outline{color:var(--vc-highlight-outline-content-color);font-weight:700;font-weight:var(--vc-font-bold)}.vc-highlight-content-light{color:var(--vc-highlight-light-content-color);font-weight:700;font-weight:var(--vc-font-bold)}.vc-highlight-content-solid{color:var(--vc-highlight-solid-content-color);font-weight:700;font-weight:var(--vc-font-bold)}.vc-dots{align-items:center;display:flex;justify-content:center}.vc-dot{border-radius:9999px;height:5px;transition:all .13s ease-in;transition:var(--vc-day-content-transition);width:5px}.vc-dot:not(:last-child){margin-right:3px}.vc-bars{align-items:center;display:flex;justify-content:flex-start;width:75%}.vc-bar{flex-grow:1;height:3px;transition:all .13s ease-in;transition:var(--vc-day-content-transition)}.vc-dot{background-color:var(--vc-dot-bg)}.vc-bar{background-color:var(--vc-bar-bg)}.vc-pane{min-width:250px}.vc-weeknumber{align-items:center;display:flex;justify-content:center;position:absolute}.vc-weeknumber.is-left{left:-26px;left:calc(var(--vc-weeknumber-offset-inside)*-1)}.vc-weeknumber.is-right{right:-26px;right:calc(var(--vc-weeknumber-offset-inside)*-1)}.vc-weeknumber.is-left-outside{left:-34px;left:calc(var(--vc-weeknumber-offset-outside)*-1)}.vc-weeknumber.is-right-outside{right:-34px;right:calc(var(--vc-weeknumber-offset-outside)*-1)}.vc-weeknumber-content{align-items:center;color:var(--vc-weeknumber-color);display:flex;font-size:12px;font-size:var(--vc-text-xs);font-style:italic;font-weight:500;font-weight:var(--vc-font-medium);height:28px;justify-content:center;margin-top:2px;-webkit-user-select:none;-moz-user-select:none;user-select:none;width:28px}.vc-weeks{position:relative;-webkit-overflow-scrolling:touch;min-width:232px;padding:6px}.vc-weeks.vc-show-weeknumbers-left{margin-left:26px;margin-left:var(--vc-weeknumber-offset-inside)}.vc-weeks.vc-show-weeknumbers-right{margin-right:26px;margin-right:var(--vc-weeknumber-offset-inside)}.vc-weekday{color:var(--vc-weekday-color);cursor:default;font-size:14px;font-size:var(--vc-text-sm);font-weight:700;font-weight:var(--vc-font-bold);line-height:14px;padding-bottom:8px;padding-top:4px;text-align:center;-webkit-user-select:none;-moz-user-select:none;user-select:none}.vc-week,.vc-weekdays{display:grid;grid-template-columns:repeat(7,1fr);position:relative}.vc-popover-content-wrapper{--popover-horizontal-content-offset:8px;--popover-vertical-content-offset:10px;--popover-caret-horizontal-offset:18px;--popover-caret-vertical-offset:8px;display:block;outline:none;position:absolute;z-index:10}.vc-popover-content-wrapper:not(.is-interactive){pointer-events:none}.vc-popover-content{background-color:var(--vc-popover-content-bg);border:1px solid;border-color:var(--vc-popover-content-border);border-radius:.5rem;border-radius:var(--vc-rounded-lg);box-shadow:0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -2px rgba(0,0,0,.05);box-shadow:var(--vc-shadow-lg);color:var(--vc-popover-content-color);font-weight:500;font-weight:var(--vc-font-medium);outline:none;padding:4px;position:relative;z-index:10}.vc-popover-content.direction-bottom{margin-top:var(--popover-vertical-content-offset)}.vc-popover-content.direction-top{margin-bottom:var(--popover-vertical-content-offset)}.vc-popover-content.direction-left{margin-right:var(--popover-horizontal-content-offset)}.vc-popover-content.direction-right{margin-left:var(--popover-horizontal-content-offset)}.vc-popover-caret{background-color:inherit;border-left:inherit;border-top:inherit;content:"";display:block;height:12px;position:absolute;width:12px;z-index:-1}.vc-popover-caret.direction-bottom{top:0}.vc-popover-caret.direction-bottom.align-left{transform:translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-bottom.align-center{transform:translate(-50%) translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-bottom.align-right{transform:translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-top{top:100%}.vc-popover-caret.direction-top.align-left{transform:translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-top.align-center{transform:translate(-50%) translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-top.align-right{transform:translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-left{left:100%}.vc-popover-caret.direction-left.align-top{transform:translate(-50%) rotate(135deg)}.vc-popover-caret.direction-left.align-middle{transform:translateY(-50%) translate(-50%) rotate(135deg)}.vc-popover-caret.direction-left.align-bottom{transform:translate(-50%) rotate(135deg)}.vc-popover-caret.direction-right{left:0}.vc-popover-caret.direction-right.align-top{transform:translate(-50%) rotate(-45deg)}.vc-popover-caret.direction-right.align-middle{transform:translateY(-50%) translate(-50%) rotate(-45deg)}.vc-popover-caret.direction-right.align-bottom{transform:translate(-50%) rotate(-45deg)}.vc-popover-caret.align-left{left:var(--popover-caret-horizontal-offset)}.vc-popover-caret.align-center{left:50%}.vc-popover-caret.align-right{right:var(--popover-caret-horizontal-offset)}.vc-popover-caret.align-top{top:var(--popover-caret-vertical-offset)}.vc-popover-caret.align-middle{top:50%}.vc-popover-caret.align-bottom{bottom:var(--popover-caret-vertical-offset)}.vc-nav-header{display:flex;justify-content:space-between}.vc-nav-arrow,.vc-nav-item,.vc-nav-title{border:0;border-radius:.25rem;border-radius:var(--vc-rounded);cursor:pointer;font-size:14px;font-size:var(--vc-text-sm);margin:0;-webkit-user-select:none;-moz-user-select:none;user-select:none;white-space:nowrap}.vc-nav-arrow:hover,.vc-nav-item:hover,.vc-nav-title:hover{background-color:var(--vc-nav-hover-bg)}.vc-nav-arrow:disabled,.vc-nav-item:disabled,.vc-nav-title:disabled{opacity:.25;pointer-events:none}.vc-nav-title{color:var(--vc-nav-title-color);font-weight:700;font-weight:var(--vc-font-bold);height:30px;line-height:1.375;line-height:var(--vc-leading-snug);padding:0 6px}.vc-nav-arrow{align-items:center;color:var(--vc-header-arrow-color);display:flex;height:30px;justify-content:center;padding:0;width:26px}.vc-nav-items{display:grid;grid-template-columns:repeat(3,1fr);grid-row-gap:2px;grid-column-gap:5px;margin-top:2px}.vc-nav-item{font-weight:600;font-weight:var(--vc-font-semibold);line-height:1.375;line-height:var(--vc-leading-snug);padding:6px 0;text-align:center;width:48px}.vc-nav-item.is-active{background-color:var(--vc-nav-item-active-bg);color:var(--vc-nav-item-active-color);font-weight:700;font-weight:var(--vc-font-bold)}.vc-nav-item.is-active:not(:focus){box-shadow:var(--vc-nav-item-active-box-shadow)}.vc-nav-item.is-current{color:var(--vc-nav-item-current-color)}.vc-day-popover-row{align-items:center;display:flex;transition:all .13s ease-in;transition:var(--vc-day-content-transition)}.vc-day-popover-row-indicator{align-items:center;display:flex;flex-grow:0;justify-content:center;width:15px}.vc-day-popover-row-indicator span{transition:all .13s ease-in;transition:var(--vc-day-content-transition)}.vc-day-popover-row-label{align-items:center;display:flex;flex-grow:1;flex-wrap:none;font-size:12px;font-size:var(--vc-text-xs);line-height:1.5;line-height:var(--vc-leading-normal);margin-left:4px;margin-right:4px;width:-moz-max-content;width:max-content}.vc-day-popover-row-highlight{border-radius:3px;height:5px;width:8px}.vc-day-popover-row-bar{height:3px;width:10px}.vc-pane-container{position:relative;width:100%}.vc-pane-container.in-transition{overflow:hidden}.vc-pane-layout{display:grid}.vc-pane-header-wrapper{pointer-events:none;position:absolute;top:0;width:100%}.vc-day-popover-container{font-size:12px;font-size:var(--vc-text-xs);font-weight:500;font-weight:var(--vc-font-medium)}.vc-day-popover-header{color:var(--vc-day-popover-header-color);font-size:12px;font-size:var(--vc-text-xs);font-weight:600;font-weight:var(--vc-font-semibold);text-align:center}.vc-base-select{position:relative}.vc-base-select select{-webkit-appearance:none;-moz-appearance:none;appearance:none;background-color:transparent;background-image:none;border-radius:.25rem;border-radius:var(--vc-rounded);color:var(--vc-select-color);cursor:pointer;display:block;font-size:16px;font-size:var(--vc-text-base);font-weight:500;font-weight:var(--vc-font-medium);height:30px;line-height:var(--leading-none);margin:0;padding:0 4px;text-align:center;text-indent:0;width:-moz-max-content;width:max-content}.vc-base-select select:hover{background-color:var(--vc-select-hover-bg)}.vc-base-select select.vc-has-icon{padding:0 24px 0 10px}.vc-base-select select.vc-small{font-size:14px;font-size:var(--vc-text-sm)}.vc-base-select select.vc-small.vc-has-icon{padding:0 20px 0 8}.vc-base-select select.vc-align-left{text-align:left}.vc-base-select select.vc-align-right{text-align:right}.vc-base-select .vc-base-icon{opacity:.6;pointer-events:none;position:absolute;right:4px;top:6px}.vc-time-picker{align-items:center;display:flex;flex-direction:column;padding:8px 4px}.vc-time-picker.vc-invalid{opacity:.5;pointer-events:none}.vc-time-picker.vc-attached{border-top:1px solid var(--vc-time-picker-border)}.vc-time-picker>*+*{margin-top:4px}.vc-time-header{align-items:center;display:flex;font-size:14px;font-size:var(--vc-text-sm);font-weight:600;font-weight:var(--vc-font-semibold);line-height:21px;margin-top:-4px;padding-left:4px;padding-right:4px;text-transform:uppercase}.vc-time-select-group{align-items:center;background:var(--vc-time-select-group-bg);border:1px solid var(--vc-time-select-group-border);border-radius:.375rem;border-radius:var(--vc-rounded-md);display:inline-flex;padding:0 4px}.vc-time-select-group .vc-base-icon{color:var(--vc-time-select-group-icon-color);margin-right:4px}.vc-time-weekday{color:var(--vc-time-weekday-color);letter-spacing:var(--tracking-wide)}.vc-time-month{color:var(--vc-time-month-color);margin-left:8px}.vc-time-day{color:var(--vc-time-day-color);margin-left:4px}.vc-time-year{color:var(--vc-time-year-color);margin-left:8px}.vc-time-colon{margin:0 1px 2px 2px}.vc-time-decimal{margin:0 0 0 1px}.vc-none-enter-active,.vc-none-leave-active{transition-duration:0s}.vc-fade-enter-active,.vc-fade-leave-active,.vc-slide-down-enter-active,.vc-slide-down-leave-active,.vc-slide-fade-enter-active,.vc-slide-fade-leave-active,.vc-slide-left-enter-active,.vc-slide-left-leave-active,.vc-slide-right-enter-active,.vc-slide-right-leave-active,.vc-slide-up-enter-active,.vc-slide-up-leave-active{backface-visibility:hidden;pointer-events:none;transition:transform .15s ease,opacity .15s ease;transition:transform var(--vc-slide-duration) var(--vc-slide-timing),opacity var(--vc-slide-duration) var(--vc-slide-timing)}.vc-fade-leave-active,.vc-none-leave-active,.vc-slide-down-leave-active,.vc-slide-left-leave-active,.vc-slide-right-leave-active,.vc-slide-up-leave-active{position:absolute!important;width:100%}.vc-fade-enter-from,.vc-fade-leave-to,.vc-none-enter-from,.vc-none-leave-to,.vc-slide-down-enter-from,.vc-slide-down-leave-to,.vc-slide-fade-enter-from,.vc-slide-fade-leave-to,.vc-slide-left-enter-from,.vc-slide-left-leave-to,.vc-slide-right-enter-from,.vc-slide-right-leave-to,.vc-slide-up-enter-from,.vc-slide-up-leave-to{opacity:0}.vc-slide-fade-enter-from.direction-left,.vc-slide-fade-leave-to.direction-left,.vc-slide-left-enter-from,.vc-slide-right-leave-to{transform:translate(22px);transform:translate(var(--vc-slide-translate))}.vc-slide-fade-enter-from.direction-right,.vc-slide-fade-leave-to.direction-right,.vc-slide-left-leave-to,.vc-slide-right-enter-from{transform:translate(-22px);transform:translate(calc(var(--vc-slide-translate)*-1))}.vc-slide-down-leave-to,.vc-slide-fade-enter-from.direction-top,.vc-slide-fade-leave-to.direction-top,.vc-slide-up-enter-from{transform:translateY(22px);transform:translateY(var(--vc-slide-translate))}.vc-slide-down-enter-from,.vc-slide-fade-enter-from.direction-bottom,.vc-slide-fade-leave-to.direction-bottom,.vc-slide-up-leave-to{transform:translateY(-22px);transform:translateY(calc(var(--vc-slide-translate)*-1))}:root{--vc-white:#fff;--vc-black:#000;--vc-gray-50:#f8fafc;--vc-gray-100:#f1f5f9;--vc-gray-200:#e2e8f0;--vc-gray-300:#cbd5e1;--vc-gray-400:#94a3b8;--vc-gray-500:#64748b;--vc-gray-600:#475569;--vc-gray-700:#334155;--vc-gray-800:#1e293b;--vc-gray-900:#0f172a;--vc-font-family:BlinkMacSystemFont,-apple-system,"Segoe UI","Roboto","Oxygen","Ubuntu","Cantarell","Fira Sans","Droid Sans","Helvetica Neue","Helvetica","Arial",sans-serif;--vc-font-normal:400;--vc-font-medium:500;--vc-font-semibold:600;--vc-font-bold:700;--vc-text-2xs:10px;--vc-text-xs:12px;--vc-text-sm:14px;--vc-text-base:16px;--vc-text-lg:18px;--vc-text-xl:20px;--vc-text-2xl:24px;--vc-leading-none:1;--vc-leading-tight:1.25;--vc-leading-snug:1.375;--vc-leading-normal:1.5;--vc-rounded:.25rem;--vc-rounded-md:.375rem;--vc-rounded-lg:.5rem;--vc-rounded-full:9999px;--vc-shadow:0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px 0 rgba(0,0,0,.06);--vc-shadow-lg:0 10px 15px -3px rgba(0,0,0,.1),0 4px 6px -2px rgba(0,0,0,.05);--vc-shadow-inner:inset 0 2px 4px 0 rgba(0,0,0,.06);--vc-slide-translate:22px;--vc-slide-duration:.15s;--vc-slide-timing:ease;--vc-day-content-transition:all .13s ease-in;--vc-weeknumber-offset-inside:26px;--vc-weeknumber-offset-outside:34px}.vc-gray{--vc-accent-50:var(--vc-gray-50);--vc-accent-100:var(--vc-gray-100);--vc-accent-200:var(--vc-gray-200);--vc-accent-300:var(--vc-gray-300);--vc-accent-400:var(--vc-gray-400);--vc-accent-500:var(--vc-gray-500);--vc-accent-600:var(--vc-gray-600);--vc-accent-700:var(--vc-gray-700);--vc-accent-800:var(--vc-gray-800);--vc-accent-900:var(--vc-gray-900)}.vc-red{--vc-accent-50:#fef2f2;--vc-accent-100:#fee2e2;--vc-accent-200:#fecaca;--vc-accent-300:#fca5a5;--vc-accent-400:#f87171;--vc-accent-500:#ef4444;--vc-accent-600:#dc2626;--vc-accent-700:#b91c1c;--vc-accent-800:#991b1b;--vc-accent-900:#7f1d1d}.vc-orange{--vc-accent-50:#fff7ed;--vc-accent-100:#ffedd5;--vc-accent-200:#fed7aa;--vc-accent-300:#fdba74;--vc-accent-400:#fb923c;--vc-accent-500:#f97316;--vc-accent-600:#ea580c;--vc-accent-700:#c2410c;--vc-accent-800:#9a3412;--vc-accent-900:#7c2d12}.vc-yellow{--vc-accent-50:#fefce8;--vc-accent-100:#fef9c3;--vc-accent-200:#fef08a;--vc-accent-300:#fde047;--vc-accent-400:#facc15;--vc-accent-500:#eab308;--vc-accent-600:#ca8a04;--vc-accent-700:#a16207;--vc-accent-800:#854d0e;--vc-accent-900:#713f12}.vc-green{--vc-accent-50:#f0fdf4;--vc-accent-100:#dcfce7;--vc-accent-200:#bbf7d0;--vc-accent-300:#86efac;--vc-accent-400:#4ade80;--vc-accent-500:#22c55e;--vc-accent-600:#16a34a;--vc-accent-700:#15803d;--vc-accent-800:#166534;--vc-accent-900:#14532d}.vc-teal{--vc-accent-50:#f0fdfa;--vc-accent-100:#ccfbf1;--vc-accent-200:#99f6e4;--vc-accent-300:#5eead4;--vc-accent-400:#2dd4bf;--vc-accent-500:#14b8a6;--vc-accent-600:#0d9488;--vc-accent-700:#0f766e;--vc-accent-800:#115e59;--vc-accent-900:#134e4a}.vc-blue{--vc-accent-50:#eff6ff;--vc-accent-100:#dbeafe;--vc-accent-200:#bfdbfe;--vc-accent-300:#93c5fd;--vc-accent-400:#60a5fa;--vc-accent-500:#3b82f6;--vc-accent-600:#2563eb;--vc-accent-700:#1d4ed8;--vc-accent-800:#1e40af;--vc-accent-900:#1e3a8a}.vc-indigo{--vc-accent-50:#eef2ff;--vc-accent-100:#e0e7ff;--vc-accent-200:#c7d2fe;--vc-accent-300:#a5b4fc;--vc-accent-400:#818cf8;--vc-accent-500:#6366f1;--vc-accent-600:#4f46e5;--vc-accent-700:#4338ca;--vc-accent-800:#3730a3;--vc-accent-900:#312e81}.vc-purple{--vc-accent-50:#faf5ff;--vc-accent-100:#f3e8ff;--vc-accent-200:#e9d5ff;--vc-accent-300:#d8b4fe;--vc-accent-400:#c084fc;--vc-accent-500:#a855f7;--vc-accent-600:#9333ea;--vc-accent-700:#7e22ce;--vc-accent-800:#6b21a8;--vc-accent-900:#581c87}.vc-pink{--vc-accent-50:#fdf2f8;--vc-accent-100:#fce7f3;--vc-accent-200:#fbcfe8;--vc-accent-300:#f9a8d4;--vc-accent-400:#f472b6;--vc-accent-500:#ec4899;--vc-accent-600:#db2777;--vc-accent-700:#be185d;--vc-accent-800:#9d174d;--vc-accent-900:#831843}.vc-focus:focus-within{box-shadow:var(--vc-focus-ring);outline:0}.vc-light{--vc-color:var(--vc-gray-900);--vc-bg:var(--vc-white);--vc-border:var(--vc-gray-300);--vc-hover-bg:rgba(204,214,224,.3);--vc-focus-ring:0 0 0 2px rgba(59,131,246,.4);--vc-header-arrow-color:var(--vc-gray-500);--vc-header-arrow-hover-bg:var(--vc-gray-200);--vc-header-title-color:var(--vc-gray-900);--vc-weekday-color:var(--vc-gray-500);--vc-weeknumber-color:var(--vc-gray-400);--vc-nav-hover-bg:var(--vc-gray-200);--vc-nav-title-color:var(--vc-gray-900);--vc-nav-item-hover-box-shadow:none;--vc-nav-item-active-color:var(--vc-white);--vc-nav-item-active-bg:var(--vc-accent-500);--vc-nav-item-active-box-shadow:var(--vc-shadow);--vc-nav-item-current-color:var(--vc-accent-600);--vc-day-popover-container-color:var(--vc-white);--vc-day-popover-container-bg:var(--vc-gray-800);--vc-day-popover-container-border:var(--vc-gray-700);--vc-day-popover-header-color:var(--vc-gray-700);--vc-popover-content-color:var(--vc-gray-900);--vc-popover-content-bg:var(--vc-gray-50);--vc-popover-content-border:var(--vc-gray-300);--vc-time-picker-border:var(--vc-gray-300);--vc-time-weekday-color:var(--vc-gray-700);--vc-time-month-color:var(--vc-accent-600);--vc-time-day-color:var(--vc-accent-600);--vc-time-year-color:var(--vc-gray-500);--vc-time-select-group-bg:var(--vc-gray-50);--vc-time-select-group-border:var(--vc-gray-300);--vc-time-select-group-icon-color:var(--vc-accent-500);--vc-select-color:var(--vc-gray-900);--vc-select-bg:var(--vg-gray-50);--vc-select-hover-bg:var(--vc-gray-100);--vc-select-border:var(--vc-gray-300);--vc-day-content-hover-bg:var(--vc-hover-bg);--vc-day-content-disabled-color:var(--vc-gray-400)}.vc-light .vc-attr,.vc-light.vc-attr{--vc-content-color:var(--vc-accent-600);--vc-highlight-outline-bg:var(--vc-white);--vc-highlight-outline-border:var(--vc-accent-600);--vc-highlight-outline-content-color:var(--vc-accent-700);--vc-highlight-light-bg:var(--vc-accent-200);--vc-highlight-light-content-color:var(--vc-accent-900);--vc-highlight-solid-bg:var(--vc-accent-600);--vc-highlight-solid-content-color:var(--vc-white);--vc-dot-bg:var(--vc-accent-600);--vc-bar-bg:var(--vc-accent-600)}.vc-dark{--vc-color:var(--vc-white);--vc-bg:var(--vc-gray-900);--vc-border:var(--vc-gray-700);--vc-hover-bg:rgba(114,129,151,.3);--vc-focus-ring:0 0 0 2px rgba(59,130,246,.7);--vc-header-arrow-color:var(--vc-gray-300);--vc-header-arrow-hover-bg:var(--vc-gray-800);--vc-header-title-color:var(--vc-gray-100);--vc-weekday-color:var(--vc-accent-200);--vc-weeknumber-color:var(--vc-gray-500);--vc-nav-hover-bg:var(--vc-gray-700);--vc-nav-title-color:var(--vc-gray-100);--vc-nav-item-hover-box-shadow:none;--vc-nav-item-active-color:var(--vc-white);--vc-nav-item-active-bg:var(--vc-accent-500);--vc-nav-item-active-box-shadow:none;--vc-nav-item-current-color:var(--vc-accent-400);--vc-day-popover-container-color:var(--vc-gray-800);--vc-day-popover-container-bg:var(--vc-white);--vc-day-popover-container-border:var(--vc-gray-100);--vc-day-popover-header-color:var(--vc-gray-300);--vc-popover-content-color:var(--vc-white);--vc-popover-content-bg:var(--vc-gray-800);--vc-popover-content-border:var(--vc-gray-700);--vc-time-picker-border:var(--vc-gray-700);--vc-time-weekday-color:var(--vc-gray-400);--vc-time-month-color:var(--vc-accent-400);--vc-time-day-color:var(--vc-accent-400);--vc-time-year-color:var(--vc-gray-500);--vc-time-select-group-bg:var(--vc-gray-700);--vc-time-select-group-border:var(--vc-gray-500);--vc-time-select-group-icon-color:var(--vc-accent-400);--vc-select-color:var(--vc-gray-200);--vc-select-bg:var(--vc-gray-700);--vc-select-hover-bg:var(--vc-gray-600);--vc-select-border:var(--vc-gray-500);--vc-day-content-hover-bg:var(--vc-hover-bg);--vc-day-content-disabled-color:var(--vc-gray-600)}.vc-dark .vc-attr,.vc-dark.vc-attr{--vc-content-color:var(--vc-accent-500);--vc-highlight-outline-bg:var(--vc-gray-900);--vc-highlight-outline-border:var(--vc-accent-300);--vc-highlight-outline-content-color:var(--vc-accent-200);--vc-highlight-light-bg:var(--vc-accent-800);--vc-highlight-light-content-color:var(--vc-accent-100);--vc-highlight-solid-bg:var(--vc-accent-500);--vc-highlight-solid-content-color:var(--vc-white);--vc-dot-bg:var(--vc-accent-500);--vc-bar-bg:var(--vc-accent-500)}.vc-container{background-color:var(--vc-bg);color:var(--vc-color);display:inline-flex;font-family:BlinkMacSystemFont,-apple-system,Segoe UI,Roboto,Oxygen,Ubuntu,Cantarell,Fira Sans,Droid Sans,Helvetica Neue,Helvetica,Arial,sans-serif;font-family:var(--vc-font-family);height:-moz-max-content;height:max-content;position:relative;width:-moz-max-content;width:max-content;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;-webkit-tap-highlight-color:transparent}.vc-container,.vc-container *{box-sizing:border-box}.vc-container :focus,.vc-container:focus{outline:none}.vc-container .vc-container{border:none}.vc-bordered{border:1px solid;border-color:var(--vc-border);border-radius:.5rem;border-radius:var(--vc-rounded-lg)}.vc-expanded{min-width:100%}.vc-transparent{background-color:transparent}.vc-date-picker-content{background-color:var(--vc-bg);padding:0}.vc-date-picker-content .vc-container{border:0}</style> <style>@font-face{font-family:swiper-icons;font-style:normal;font-weight:400;src:url("data:application/font-woff;charset=utf-8;base64, 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")}:root{--swiper-theme-color:#007aff}:host{display:block;margin-left:auto;margin-right:auto;position:relative;z-index:1}.swiper{display:block;list-style:none;margin-left:auto;margin-right:auto;overflow:hidden;overflow:clip;padding:0;position:relative;z-index:1}.swiper-vertical>.swiper-wrapper{flex-direction:column}.swiper-wrapper{box-sizing:content-box;display:flex;height:100%;position:relative;transition-property:transform;transition-timing-function:ease;transition-timing-function:var(--swiper-wrapper-transition-timing-function,initial);width:100%;z-index:1}.swiper-android .swiper-slide,.swiper-ios .swiper-slide,.swiper-wrapper{transform:translateZ(0)}.swiper-horizontal{touch-action:pan-y}.swiper-vertical{touch-action:pan-x}.swiper-slide{display:block;flex-shrink:0;height:100%;position:relative;transition-property:transform;width:100%}.swiper-slide-invisible-blank{visibility:hidden}.swiper-autoheight,.swiper-autoheight .swiper-slide{height:auto}.swiper-autoheight .swiper-wrapper{align-items:flex-start;transition-property:transform,height}.swiper-backface-hidden .swiper-slide{backface-visibility:hidden;transform:translateZ(0)}.swiper-3d.swiper-css-mode .swiper-wrapper{perspective:1200px}.swiper-3d .swiper-wrapper{transform-style:preserve-3d}.swiper-3d{perspective:1200px}.swiper-3d .swiper-cube-shadow,.swiper-3d .swiper-slide{transform-style:preserve-3d}.swiper-css-mode>.swiper-wrapper{overflow:auto;scrollbar-width:none;-ms-overflow-style:none}.swiper-css-mode>.swiper-wrapper::-webkit-scrollbar{display:none}.swiper-css-mode>.swiper-wrapper>.swiper-slide{scroll-snap-align:start start}.swiper-css-mode.swiper-horizontal>.swiper-wrapper{scroll-snap-type:x mandatory}.swiper-css-mode.swiper-vertical>.swiper-wrapper{scroll-snap-type:y mandatory}.swiper-css-mode.swiper-free-mode>.swiper-wrapper{scroll-snap-type:none}.swiper-css-mode.swiper-free-mode>.swiper-wrapper>.swiper-slide{scroll-snap-align:none}.swiper-css-mode.swiper-centered>.swiper-wrapper:before{content:"";flex-shrink:0;order:9999}.swiper-css-mode.swiper-centered>.swiper-wrapper>.swiper-slide{scroll-snap-align:center center;scroll-snap-stop:always}.swiper-css-mode.swiper-centered.swiper-horizontal>.swiper-wrapper>.swiper-slide:first-child{margin-inline-start:var(--swiper-centered-offset-before)}.swiper-css-mode.swiper-centered.swiper-horizontal>.swiper-wrapper:before{height:100%;min-height:1px;width:var(--swiper-centered-offset-after)}.swiper-css-mode.swiper-centered.swiper-vertical>.swiper-wrapper>.swiper-slide:first-child{margin-block-start:var(--swiper-centered-offset-before)}.swiper-css-mode.swiper-centered.swiper-vertical>.swiper-wrapper:before{height:var(--swiper-centered-offset-after);min-width:1px;width:100%}.swiper-3d .swiper-slide-shadow,.swiper-3d .swiper-slide-shadow-bottom,.swiper-3d .swiper-slide-shadow-left,.swiper-3d .swiper-slide-shadow-right,.swiper-3d .swiper-slide-shadow-top{height:100%;left:0;pointer-events:none;position:absolute;top:0;width:100%;z-index:10}.swiper-3d .swiper-slide-shadow{background:rgba(0,0,0,.15)}.swiper-3d .swiper-slide-shadow-left{background-image:linear-gradient(270deg,rgba(0,0,0,.5),transparent)}.swiper-3d .swiper-slide-shadow-right{background-image:linear-gradient(90deg,rgba(0,0,0,.5),transparent)}.swiper-3d .swiper-slide-shadow-top{background-image:linear-gradient(0deg,rgba(0,0,0,.5),transparent)}.swiper-3d .swiper-slide-shadow-bottom{background-image:linear-gradient(180deg,rgba(0,0,0,.5),transparent)}.swiper-lazy-preloader{border:4px solid #007aff;border:4px solid var(--swiper-preloader-color,var(--swiper-theme-color));border-radius:50%;border-top:4px solid transparent;box-sizing:border-box;height:42px;left:50%;margin-left:-21px;margin-top:-21px;position:absolute;top:50%;transform-origin:50%;width:42px;z-index:10}.swiper-watch-progress .swiper-slide-visible .swiper-lazy-preloader,.swiper:not(.swiper-watch-progress) .swiper-lazy-preloader{animation:swiper-preloader-spin 1s linear infinite}.swiper-lazy-preloader-white{--swiper-preloader-color:#fff}.swiper-lazy-preloader-black{--swiper-preloader-color:#000}@keyframes swiper-preloader-spin{0%{transform:rotate(0deg)}to{transform:rotate(1turn)}}</style> <style>.swiper .swiper-notification{left:0;opacity:0;pointer-events:none;position:absolute;top:0;z-index:-1000}</style> <style>.swiper-cards{overflow:visible}.swiper-cards .swiper-slide{backface-visibility:hidden;overflow:hidden;transform-origin:center bottom}</style> <style>.swiper-creative .swiper-slide{backface-visibility:hidden;overflow:hidden;transition-property:transform,opacity,height}</style> <style>.swiper-cube{overflow:visible}.swiper-cube .swiper-slide{backface-visibility:hidden;height:100%;pointer-events:none;transform-origin:0 0;visibility:hidden;width:100%;z-index:1}.swiper-cube .swiper-slide .swiper-slide{pointer-events:none}.swiper-cube.swiper-rtl .swiper-slide{transform-origin:100% 0}.swiper-cube .swiper-slide-active,.swiper-cube .swiper-slide-active .swiper-slide-active{pointer-events:auto}.swiper-cube .swiper-slide-active,.swiper-cube .swiper-slide-next,.swiper-cube .swiper-slide-prev{pointer-events:auto;visibility:visible}.swiper-cube .swiper-cube-shadow{bottom:0;height:100%;left:0;opacity:.6;position:absolute;width:100%;z-index:0}.swiper-cube .swiper-cube-shadow:before{background:#000;bottom:0;content:"";filter:blur(50px);left:0;position:absolute;right:0;top:0}.swiper-cube .swiper-slide-next+.swiper-slide{pointer-events:auto;visibility:visible}.swiper-cube .swiper-slide-shadow-cube.swiper-slide-shadow-bottom,.swiper-cube .swiper-slide-shadow-cube.swiper-slide-shadow-left,.swiper-cube .swiper-slide-shadow-cube.swiper-slide-shadow-right,.swiper-cube .swiper-slide-shadow-cube.swiper-slide-shadow-top{backface-visibility:hidden;z-index:0}</style> <style>.swiper-fade.swiper-free-mode .swiper-slide{transition-timing-function:ease-out}.swiper-fade .swiper-slide{pointer-events:none;transition-property:opacity}.swiper-fade .swiper-slide .swiper-slide{pointer-events:none}.swiper-fade .swiper-slide-active,.swiper-fade .swiper-slide-active .swiper-slide-active{pointer-events:auto}</style> <style>.swiper-flip{overflow:visible}.swiper-flip .swiper-slide{backface-visibility:hidden;pointer-events:none;z-index:1}.swiper-flip .swiper-slide .swiper-slide{pointer-events:none}.swiper-flip .swiper-slide-active,.swiper-flip .swiper-slide-active .swiper-slide-active{pointer-events:auto}.swiper-flip .swiper-slide-shadow-flip.swiper-slide-shadow-bottom,.swiper-flip .swiper-slide-shadow-flip.swiper-slide-shadow-left,.swiper-flip .swiper-slide-shadow-flip.swiper-slide-shadow-right,.swiper-flip .swiper-slide-shadow-flip.swiper-slide-shadow-top{backface-visibility:hidden;z-index:0}</style> <style>.swiper-free-mode>.swiper-wrapper{margin:0 auto;transition-timing-function:ease-out}</style> <style>.swiper-grid>.swiper-wrapper{flex-wrap:wrap}.swiper-grid-column>.swiper-wrapper{flex-direction:column;flex-wrap:wrap}</style> <style>:root{--swiper-navigation-size:44px}.swiper-button-next,.swiper-button-prev{align-items:center;color:var(--swiper-navigation-color,var(--swiper-theme-color));cursor:pointer;display:flex;height:44px;height:var(--swiper-navigation-size);justify-content:center;margin-top:-22px;margin-top:calc(0px - var(--swiper-navigation-size)/2);position:absolute;top:50%;top:var(--swiper-navigation-top-offset,50%);width:27px;width:calc(var(--swiper-navigation-size)/44*27);z-index:10}.swiper-button-next.swiper-button-disabled,.swiper-button-prev.swiper-button-disabled{cursor:auto;opacity:.35;pointer-events:none}.swiper-button-next.swiper-button-hidden,.swiper-button-prev.swiper-button-hidden{cursor:auto;opacity:0;pointer-events:none}.swiper-navigation-disabled .swiper-button-next,.swiper-navigation-disabled .swiper-button-prev{display:none!important}.swiper-button-next svg,.swiper-button-prev svg{height:100%;-o-object-fit:contain;object-fit:contain;transform-origin:center;width:100%}.swiper-rtl .swiper-button-next svg,.swiper-rtl .swiper-button-prev svg{transform:rotate(180deg)}.swiper-button-prev,.swiper-rtl .swiper-button-next{left:10px;left:var(--swiper-navigation-sides-offset,10px);right:auto}.swiper-button-lock{display:none}.swiper-button-next:after,.swiper-button-prev:after{font-family:swiper-icons;font-size:44px;font-size:var(--swiper-navigation-size);font-variant:normal;letter-spacing:0;line-height:1;text-transform:none!important}.swiper-button-prev:after,.swiper-rtl .swiper-button-next:after{content:"prev"}.swiper-button-next,.swiper-rtl .swiper-button-prev{left:auto;right:10px;right:var(--swiper-navigation-sides-offset,10px)}.swiper-button-next:after,.swiper-rtl .swiper-button-prev:after{content:"next"}</style> <style>.swiper-pagination{position:absolute;text-align:center;transform:translateZ(0);transition:opacity .3s;z-index:10}.swiper-pagination.swiper-pagination-hidden{opacity:0}.swiper-pagination-disabled>.swiper-pagination,.swiper-pagination.swiper-pagination-disabled{display:none!important}.swiper-horizontal>.swiper-pagination-bullets,.swiper-pagination-bullets.swiper-pagination-horizontal,.swiper-pagination-custom,.swiper-pagination-fraction{bottom:8px;bottom:var(--swiper-pagination-bottom,8px);left:0;top:auto;top:var(--swiper-pagination-top,auto);width:100%}.swiper-pagination-bullets-dynamic{font-size:0;overflow:hidden}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{position:relative;transform:scale(.33)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active,.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-main{transform:scale(1)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-prev{transform:scale(.66)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-prev-prev{transform:scale(.33)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-next{transform:scale(.66)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-next-next{transform:scale(.33)}.swiper-pagination-bullet{background:#000;background:var(--swiper-pagination-bullet-inactive-color,#000);border-radius:50%;border-radius:var(--swiper-pagination-bullet-border-radius,50%);display:inline-block;height:8px;height:var(--swiper-pagination-bullet-height,var(--swiper-pagination-bullet-size,8px));opacity:.2;opacity:var(--swiper-pagination-bullet-inactive-opacity,.2);width:8px;width:var(--swiper-pagination-bullet-width,var(--swiper-pagination-bullet-size,8px))}button.swiper-pagination-bullet{-webkit-appearance:none;-moz-appearance:none;appearance:none;border:none;box-shadow:none;margin:0;padding:0}.swiper-pagination-clickable .swiper-pagination-bullet{cursor:pointer}.swiper-pagination-bullet:only-child{display:none!important}.swiper-pagination-bullet-active{background:var(--swiper-pagination-color,var(--swiper-theme-color));opacity:1;opacity:var(--swiper-pagination-bullet-opacity,1)}.swiper-pagination-vertical.swiper-pagination-bullets,.swiper-vertical>.swiper-pagination-bullets{left:auto;left:var(--swiper-pagination-left,auto);right:8px;right:var(--swiper-pagination-right,8px);top:50%;transform:translate3d(0,-50%,0)}.swiper-pagination-vertical.swiper-pagination-bullets .swiper-pagination-bullet,.swiper-vertical>.swiper-pagination-bullets .swiper-pagination-bullet{display:block;margin:6px 0;margin:var(--swiper-pagination-bullet-vertical-gap,6px) 0}.swiper-pagination-vertical.swiper-pagination-bullets.swiper-pagination-bullets-dynamic,.swiper-vertical>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic{top:50%;transform:translateY(-50%);width:8px}.swiper-pagination-vertical.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet,.swiper-vertical>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{display:inline-block;transition:transform .2s,top .2s}.swiper-horizontal>.swiper-pagination-bullets .swiper-pagination-bullet,.swiper-pagination-horizontal.swiper-pagination-bullets .swiper-pagination-bullet{margin:0 4px;margin:0 var(--swiper-pagination-bullet-horizontal-gap,4px)}.swiper-horizontal>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic,.swiper-pagination-horizontal.swiper-pagination-bullets.swiper-pagination-bullets-dynamic{left:50%;transform:translateX(-50%);white-space:nowrap}.swiper-horizontal>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet,.swiper-pagination-horizontal.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{transition:transform .2s,left .2s}.swiper-horizontal.swiper-rtl>.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{transition:transform .2s,right .2s}.swiper-pagination-fraction{color:inherit;color:var(--swiper-pagination-fraction-color,inherit)}.swiper-pagination-progressbar{background:rgba(0,0,0,.25);background:var(--swiper-pagination-progressbar-bg-color,rgba(0,0,0,.25));position:absolute}.swiper-pagination-progressbar .swiper-pagination-progressbar-fill{background:var(--swiper-pagination-color,var(--swiper-theme-color));height:100%;left:0;position:absolute;top:0;transform:scale(0);transform-origin:left top;width:100%}.swiper-rtl .swiper-pagination-progressbar .swiper-pagination-progressbar-fill{transform-origin:right top}.swiper-horizontal>.swiper-pagination-progressbar,.swiper-pagination-progressbar.swiper-pagination-horizontal,.swiper-pagination-progressbar.swiper-pagination-vertical.swiper-pagination-progressbar-opposite,.swiper-vertical>.swiper-pagination-progressbar.swiper-pagination-progressbar-opposite{height:4px;height:var(--swiper-pagination-progressbar-size,4px);left:0;top:0;width:100%}.swiper-horizontal>.swiper-pagination-progressbar.swiper-pagination-progressbar-opposite,.swiper-pagination-progressbar.swiper-pagination-horizontal.swiper-pagination-progressbar-opposite,.swiper-pagination-progressbar.swiper-pagination-vertical,.swiper-vertical>.swiper-pagination-progressbar{height:100%;left:0;top:0;width:4px;width:var(--swiper-pagination-progressbar-size,4px)}.swiper-pagination-lock{display:none}</style> <style>.swiper-scrollbar{background:rgba(0,0,0,.1);background:var(--swiper-scrollbar-bg-color,rgba(0,0,0,.1));border-radius:10px;border-radius:var(--swiper-scrollbar-border-radius,10px);position:relative;touch-action:none}.swiper-scrollbar-disabled>.swiper-scrollbar,.swiper-scrollbar.swiper-scrollbar-disabled{display:none!important}.swiper-horizontal>.swiper-scrollbar,.swiper-scrollbar.swiper-scrollbar-horizontal{bottom:4px;bottom:var(--swiper-scrollbar-bottom,4px);height:4px;height:var(--swiper-scrollbar-size,4px);left:1%;left:var(--swiper-scrollbar-sides-offset,1%);position:absolute;top:auto;top:var(--swiper-scrollbar-top,auto);width:98%;width:calc(100% - var(--swiper-scrollbar-sides-offset, 1%)*2);z-index:50}.swiper-scrollbar.swiper-scrollbar-vertical,.swiper-vertical>.swiper-scrollbar{height:98%;height:calc(100% - var(--swiper-scrollbar-sides-offset, 1%)*2);left:auto;left:var(--swiper-scrollbar-left,auto);position:absolute;right:4px;right:var(--swiper-scrollbar-right,4px);top:1%;top:var(--swiper-scrollbar-sides-offset,1%);width:4px;width:var(--swiper-scrollbar-size,4px);z-index:50}.swiper-scrollbar-drag{background:rgba(0,0,0,.5);background:var(--swiper-scrollbar-drag-bg-color,rgba(0,0,0,.5));border-radius:10px;border-radius:var(--swiper-scrollbar-border-radius,10px);height:100%;left:0;position:relative;top:0;width:100%}.swiper-scrollbar-cursor-drag{cursor:move}.swiper-scrollbar-lock{display:none}</style> <style>.swiper-virtual .swiper-slide{-webkit-backface-visibility:hidden;transform:translateZ(0)}.swiper-virtual.swiper-css-mode .swiper-wrapper:after{content:"";left:0;pointer-events:none;position:absolute;top:0}.swiper-virtual.swiper-css-mode.swiper-horizontal .swiper-wrapper:after{height:1px;width:var(--swiper-virtual-size)}.swiper-virtual.swiper-css-mode.swiper-vertical .swiper-wrapper:after{height:var(--swiper-virtual-size);width:1px}</style> <style>.swiper-zoom-container{align-items:center;display:flex;height:100%;justify-content:center;text-align:center;width:100%}.swiper-zoom-container>canvas,.swiper-zoom-container>img,.swiper-zoom-container>svg{max-height:100%;max-width:100%;-o-object-fit:contain;object-fit:contain}.swiper-slide-zoomed{cursor:move;touch-action:none}</style> <style>.router-link-exact-active[data-v-ae15e636]{border-bottom-width:2px;--tw-border-opacity:1;border-color:rgba(var(--color-border-brand),var(--tw-border-opacity));--tw-text-opacity:1;color:rgba(var(--color-text-default),1);color:rgba(var(--color-text-default),var(--tw-text-opacity))}</style> <style>.download-btn[data-v-ffd1b8fd]{gap:var(--spacing-lg);width:100%}@media (min-width:1024px){.download-btn[data-v-ffd1b8fd]{width:-moz-fit-content;width:fit-content}}</style> <style>[data-v-4f3fc9a4] h2{font-size:revert;font-weight:600}[data-v-4f3fc9a4] h1{font-size:revert;font-weight:600}[data-v-4f3fc9a4] .publication-text ol{list-style-type:decimal;padding-left:var(--spacing-lg)}[data-v-4f3fc9a4] .publication-text ul{list-style-type:disc;padding-left:var(--spacing-lg)}</style> <style>[data-v-0016287f] .m-accordion__item span{font-size:.875rem;font-weight:600;line-height:1.25rem}</style> <style>.clamp-1{-webkit-line-clamp:1}.clamp-1,.clamp-2{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical}.clamp-2{-webkit-line-clamp:2}.clamp-3{-webkit-line-clamp:3}.clamp-3,.clamp-4{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical}.clamp-4{-webkit-line-clamp:4}.clamp-5{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical;-webkit-line-clamp:5}</style> <style>.m-tooltip[data-v-d8c082ee] .text-color-white{font-size:.75rem;font-weight:400;line-height:1rem;width:10rem;--tw-text-opacity:1;color:rgba(var(--color-text-subtle),1);color:rgba(var(--color-text-subtle),var(--tw-text-opacity))}</style> <style>.m-input[data-v-03f1a75d]{height:2.5rem;width:100%;--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));font-size:.875rem;line-height:1.25rem;padding-left:var(--spacing-md);padding-right:var(--spacing-md)}</style> <style>.m-tag[data-v-3ce94018]{border-radius:.25rem;height:1.5rem;margin-right:var(--spacing-xs);--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));font-size:.75rem;padding-left:var(--spacing-sm);--tw-text-opacity:1;color:rgba(var(--color-black),1);color:rgba(var(--color-black),var(--tw-text-opacity))}</style> <style>[data-v-da90062a] h2{font-size:1.125rem;font-weight:600;line-height:1.75rem;margin-top:-3rem;padding-bottom:var(--spacing-sm);padding-top:var(--spacing-7xl)}[data-v-da90062a] h4{font-size:1rem;font-weight:600;line-height:1.5rem;padding-bottom:var(--spacing-sm)}[data-v-da90062a] .html-p{font-size:1rem;line-height:1.5rem;padding-bottom:var(--spacing-lg)}[data-v-da90062a] .html-fig_img img,[data-v-da90062a] .html-table_wrap_td img{cursor:pointer;height:auto;margin:0 auto;width:100%}@media (min-width:1024px){[data-v-da90062a] .html-fig_img img,[data-v-da90062a] .html-table_wrap_td img{max-width:28.5rem}}[data-v-da90062a] .html-fig-wrap{padding-bottom:var(--spacing-lg);padding-top:var(--spacing-sm)}[data-v-da90062a] .html-fig_description,[data-v-da90062a] .html-table_wrap_discription{text-align:center}[data-v-da90062a] .html-disp-formula-info{display:flex;padding-bottom:var(--spacing-md);padding-top:var(--spacing-sm);width:100%}[data-v-da90062a] .html-disp-formula-info .f{width:80%}[data-v-da90062a] .html-disp-formula-info .l{text-align:right;width:20%}[data-v-da90062a] menu,[data-v-da90062a] ol,[data-v-da90062a] ul{list-style-type:decimal;padding-left:var(--spacing-md)}[data-v-da90062a] .mfp-content{display:none}[data-v-da90062a] .html-figpopup{margin:0 auto;max-width:28.5rem;position:relative}[data-v-da90062a] .html-bibr{position:relative}[data-v-da90062a] .mfp-popover{border-radius:1rem;height:auto;overflow-wrap:break-word;position:absolute;top:-5.875rem;width:24rem;z-index:10;--tw-bg-opacity:1;background-color:rgba(var(--color-white),1);background-color:rgba(var(--color-white),var(--tw-bg-opacity));font-size:.875rem;font-weight:400;line-height:1.25rem;padding:var(--spacing-md);--tw-shadow:0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px -1px rgba(0,0,0,.1);--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color);box-shadow:0 0 #0000,0 0 #0000,0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px -1px rgba(0,0,0,.1);box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}[data-v-da90062a] .html-p dt{clear:left;float:left;padding-right:var(--spacing-md);text-align:right}[data-v-da90062a] .html-bullet .html-p{padding-bottom:0}.m-tag[data-v-da90062a]{border-radius:.25rem;height:1.5rem;margin-right:var(--spacing-xs);--tw-bg-opacity:1;background-color:rgba(var(--color-surface-subtle),1);background-color:rgba(var(--color-surface-subtle),var(--tw-bg-opacity));font-size:.75rem;padding-left:var(--spacing-sm);--tw-text-opacity:1;color:rgba(var(--color-black),1);color:rgba(var(--color-black),var(--tw-text-opacity))}.container[data-v-da90062a]{margin-top:var(--spacing-lg)!important;--tw-bg-opacity:1!important;background-color:rgba(var(--color-white),1)!important;background-color:rgba(var(--color-white),var(--tw-bg-opacity))!important;padding-bottom:var(--spacing-sm)!important;padding-top:var(--spacing-sm)!important}.container[data-v-da90062a] svg{display:none!important}.container[data-v-da90062a] .m-button{height:1.8125rem}[data-v-da90062a] .html-fig_show{display:none}[data-v-da90062a] .html-table_show{display:none}.cite-container[data-v-da90062a]{--tw-bg-opacity:1!important;background-color:rgba(var(--color-white),1)!important;background-color:rgba(var(--color-white),var(--tw-bg-opacity))!important;padding-bottom:var(--spacing-sm)!important;padding-top:var(--spacing-sm)!important}.cite-container[data-v-da90062a] svg{display:none!important}[data-v-da90062a] .m-accordion__item span{font-size:.875rem;font-weight:600;line-height:1.25rem}[data-v-da90062a] .heading-with-anchor{word-break:break-all}[data-v-da90062a] #html-copyright{display:none}[data-v-da90062a] .cross-ref,[data-v-da90062a] .google-scholar,[data-v-da90062a] .html-fig,[data-v-da90062a] .html-table{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}[data-v-da90062a] .cross-ref:hover,[data-v-da90062a] .google-scholar:hover,[data-v-da90062a] .html-fig:hover,[data-v-da90062a] .html-table:hover{text-decoration-line:underline}[data-v-da90062a] a.html-bibr{--tw-text-opacity:1;color:rgba(var(--color-text-link-bold),1);color:rgba(var(--color-text-link-bold),var(--tw-text-opacity))}[data-v-da90062a] a.html-bibr:hover{text-decoration-line:underline}</style> <style>[data-v-694159ae] .m-accordion__item span{font-size:.875rem;font-weight:600;line-height:1.25rem}</style> <link rel="stylesheet" href="/_nuxt/swiper-vue.B8Qtp0_B.css"> <link rel="stylesheet" href="/_nuxt/page.ChZXZrEc.css"> <link rel="stylesheet" href="/_nuxt/CommonReadmore.Cfzbs3YM.css"> <link rel="stylesheet" href="/_nuxt/imagePreview.BhKeW-wZ.css"> <link rel="stylesheet" href="/_nuxt/ScrollLoading.CtBH3zbC.css"> <link rel="stylesheet" href="/_nuxt/AppTurnstileWidget.BrwyvPaT.css"> <link rel="stylesheet" href="/_nuxt/ScrollTop.B6N0Xde5.css"> <link rel="preload" as="style" href="https://pub.mdpi-res.com/assets/fonts/suisse/fonts.css"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/C27HaHQc.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/4rkk1glR.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/OU_lvVvo.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/MELp_9y7.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DJ_2xEbf.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DlAUqK2U.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BzbGl42-.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/bRFCaPyp.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/Bq-k6d50.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BaC8YmpO.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CsnXxeeo.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/Sr7NgQmL.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CJtxWM-4.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D15uM1gO.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D3XMzgcc.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/Bp32iicF.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BVnInYB2.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CT_MnTdM.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/C2t5_0WB.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BenGTscT.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/YuxR3Pu0.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/Dnb9tpsV.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/B3frQi_Q.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DvALqv7A.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/vv2Rmwly.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BACJKBe0.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D3_cLRFw.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D4jAlUYG.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/C88fzhO7.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D3jZIeS7.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CO7npeQl.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BtWxVOE2.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CPniVYxA.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BrnKO0a8.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CXj84r_J.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BjFvKq7p.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BfP5Yj9h.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BCHjbcVH.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DF1xWhrB.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CSftCEdt.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BUG3EtXz.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/VRsIP4ye.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DWlQ7dfc.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/h5QvUJzN.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D9M9y3zY.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DBJwQKo_.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/DJGN3rr3.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/Dg_sg7_-.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BTCqNyt1.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BlIUE5gg.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D64oYWtW.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BkYV1aS-.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/B79UeM0F.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CgwdhZu1.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/BHDep5Fd.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/B1WVniK0.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/UIFFOgeC.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/D2qdJ5wO.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/vRa2jP_-.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/CVOIiGAr.js"> <link rel="modulepreload" as="script" crossorigin href="/_nuxt/YbQyBXQk.js"> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" id="shenembed" defer></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" defer></script> <link rel="prefetch" as="image" type="image/png" href="/_nuxt/error.BAMwz5-m.png"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BICt5lEk.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/C_7JoYtI.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BQ8VW0UK.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Ccci8845.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CkuUyBkI.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Cuo3bhE5.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BDkYyAbu.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D0OoxKuM.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DcrixLdV.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BhBO-Kc3.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DnPbqzsC.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Dy33lEfh.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/w6QCel6Y.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DPpMCftk.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DDd-OE0i.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CSqnbcsA.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CaOeis0O.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/COF9GGY2.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/K08Ei7DG.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/EctWdbgJ.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BI-xnQ7w.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BTzD6Mkk.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/300XsdT0.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CJjj_ExW.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/C4Aq_-0L.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DgIKUgP-.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BHnT5fTp.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DG3nBRT1.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Cc08nYod.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/C1MSWdJj.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D3Q2qhlM.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DE7mHYmK.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BFguvHUo.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DCTbMpoV.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BYolaAY_.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Rw14-rL_.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CgOid6gM.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DpzONys6.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DPOWjGPB.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DfhgFNlI.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Di81R11W.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BU8JUNi1.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/humBfqf4.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BvXbeU5U.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/cO8boWAA.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/4wO3PQLb.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CDOCVby7.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DFPnb23O.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CBfN9KOs.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DjwPEAHj.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BlnoRm-J.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D3TjGg_5.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DbuP4Er7.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Btm5aAIe.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CNt80UN-.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CnYjD6y0.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Lhw1vk9W.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/C_UTzjh5.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Bg_lpcMp.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/IlH6o1Jh.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/AzIJCIsq.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/kXd3pXrK.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/DMuDThNb.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/Drgz-R_C.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/COsaROqB.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/jKG2QKjb.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D_AqDHVt.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BSsPjorf.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D6pyfHxW.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BtlE8llv.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/CsZfyd4s.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BG3hnnwA.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D3Pg72e7.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/I2gzi7nk.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/7FoSU0FK.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/_nBJwZwe.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/piZhExQU.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/BmanIOt3.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/D1165OEy.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/eMP0HJlR.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/n5xr6Ozy.js"> <link rel="prefetch" as="script" crossorigin href="/_nuxt/A7zJygdy.js"> <link rel="prefetch" as="image" type="image/png" href="/_nuxt/preprints.C_f_-Qxj.png"> <link rel="prefetch" as="image" type="image/png" href="/_nuxt/publicAccount.3LRUWsx7.png"> <meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"> <script>window.loadTurnstile = new Promise(resolve => { window.onloadTurnstileCallback = function () { resolve(); delete window.onloadTurnstileCallback; delete window.loadTurnstile; } })</script> <script type="module" src="/_nuxt/C27HaHQc.js" crossorigin></script></head><body class="antialiased duration-300 transition-colors text-gray-800 dark:text-gray-200 bg-white dark:bg-gray-900"><div id="__nuxt"><div class="nuxt-loading-indicator" style="position:fixed;top:0;right:0;left:0;pointer-events:none;width:auto;height:3px;opacity:0;background:rgb(var(--color-brand-default));background-size:Infinity% auto;transform:scaleX(0%);transform-origin:left;transition:transform 0.1s, height 0.4s, opacity 0.4s;z-index:999999;"></div><div class="page-warpper"><header class="sticky top-0 w-full bg-[#fff] border-b border-color-default" style="z-index:10;"><div class="mx-auto flex max-w-mobile-fluid items-center justify-between lg:max-w-desktop-fluid max-w-[96%] py-sm lg:py-0"><div class="flex items-center"><a href="/" class="font-bold text-lg text-primary-500 py-2 lg:mr-xl xl:mr-7xl"><div class="w-36 h-auto"><img src="/_nuxt/preprints.C_f_-Qxj.png" alt="Prerpints.org logo" class="w-36 h-auto"></div></a><nav class="hidden lg:flex" data-v-ae15e636><ul class="flex flex-row lg:space-x-xl xl:space-x-3xl text-sm" data-v-ae15e636><li class="flex h-full items-center" data-v-ae15e636><a href="/instructions-for-authors" class="py-lg" data-v-ae15e636>Instructions for Authors</a></li><li class="flex h-full items-center" data-v-ae15e636><a href="/about" class="py-lg" data-v-ae15e636>About</a></li><li class="flex h-full items-center" data-v-ae15e636><a href="/faq" class="py-lg" data-v-ae15e636>FAQ</a></li><li class="flex h-full items-center" data-v-ae15e636><a href="/blog" class="py-lg" data-v-ae15e636>Blog and News</a></li></ul></nav></div><div class="flex"><span></span></div></div></header><div class="w-full" style="min-height:var(--layout-page-content-min-height);"><div data-v-ffd1b8fd><div data-v-ffd1b8fd><div data-v-ffd1b8fd><div class="bg-surface-subtle" data-v-ffd1b8fd><div class="m-container mx-auto w-full pb-xl lg:pb-3xl" style="--container-ideal-width:92.5vw;" data-v-ffd1b8fd><nav aria-label="Breadcrumbs" class="m-breadcrumb py-sm my-md lg:my-0 lg:py-xl lg:pt-3xl lg:pb-2xl overflow-x-auto" data-v-ffd1b8fd><ol class="m-breadcrumb__items flex items-center space-x-1 whitespace-pre text-xs text-color-subtle"><li class="flex items-center gap-1"><a href="/" class="m-breadcrumb__item hover:text-color-link-bolder flex text-color-black lg:hidden" data-v-ffd1b8fd><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="home" class="lg:hidden" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a><a href="/" class="m-breadcrumb__item hover:text-color-link-bolder hidden lg:block" data-v-ffd1b8fd>Home</a><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="chevron_right" style="" width="16" height="16" viewBox="0 0 16 16"></svg></li><li class="flex items-center gap-1"><a href="/subject" class="m-breadcrumb__item hover:text-color-link-bolder" data-v-ffd1b8fd>Medicine and Pharmacology</a><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="chevron_right" style="" width="16" height="16" viewBox="0 0 16 16"></svg></li><li class="flex items-center gap-1"><a href="/subject/browse/Transplantation?name=Medicine+and+Pharmacology&id=130" class="m-breadcrumb__item hover:text-color-link-bolder" data-v-ffd1b8fd>Transplantation</a><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="chevron_right" style="" width="16" height="16" viewBox="0 0 16 16"></svg></li><li class="flex items-center gap-1"><a aria-current="page" href="/manuscript/202401.1027/v1" class="router-link-active router-link-exact-active m-breadcrumb__item text-color-link-bold hover:text-color-link-bolder" data-v-ffd1b8fd>DOI:10.20944/preprints202401.1027.v1 </a></li></ol></nav><div class="lg:flex justify-between pt-sm" data-v-ffd1b8fd><div data-v-ffd1b8fd><div class="flex items-center" data-v-ffd1b8fd><div class="m-tag flex items-center gap-2 rounded py-0.5 h-6 bg-content-inverse-subtler text-color-inverse px-2 mr-sm px-md !bg-surface-disabled !text-xs !text-color-default" data-v-ffd1b8fd><span class="flex items-center whitespace-nowrap text-xs leading-normal">Preprint</span></div><div class="m-tag flex items-center gap-2 rounded py-0.5 h-6 bg-content-inverse-subtler text-color-inverse px-2 mr-sm px-md !bg-surface-disabled !text-xs !text-color-default" data-v-ffd1b8fd>Article</div></div><div class="flex items-center pt-sm" data-v-ffd1b8fd><h4 class="m-heading text-inherit m-h4 font-normal" data-v-ffd1b8fd>Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation</h4></div></div><div class="w-full max-w-xs lg:ml-3xl flex-none" data-v-ffd1b8fd><div class="flex justify-between items-end border-b border-color-default" data-v-ffd1b8fd><p class="m-text text-sm py-sm" data-v-ffd1b8fd>Altmetrics</p><div class="altmetric-embed" data-badge-type="donut" data-badge-popover="left" data-link-target="_blank" data-doi="10.20944/preprints202401.1027.v1" data-v-ffd1b8fd></div></div><div class="flex justify-between py-sm border-b border-color-default" data-v-ffd1b8fd><p class="m-text text-sm" data-v-ffd1b8fd>Downloads</p><p class="m-text text-sm" data-v-ffd1b8fd>107</p></div><div class="flex justify-between py-sm border-b border-color-default" data-v-ffd1b8fd><p class="m-text text-sm" data-v-ffd1b8fd>Views</p><p class="m-text text-sm" data-v-ffd1b8fd>46</p></div><div class="flex justify-between py-sm border-b border-color-default" data-v-ffd1b8fd><p class="m-text text-sm" data-v-ffd1b8fd>Comments</p><p class="m-text text-sm" data-v-ffd1b8fd>0</p></div></div></div></div></div><div class="m-container mx-auto w-full py-section-mobile pb-7xl max-w-mobile-fluid lg:max-w-desktop-fluid" style="--container-ideal-width:92.5vw;" data-v-ffd1b8fd><div class="lg:hidden" data-v-ffd1b8fd><div class="w-full lg:ml-lg flex-none lg:hidden" data-v-ffd1b8fd><div class="pt-md"><div class="flex justify-end mb-md"><button class="m-button m-button--md m-button--tonal rounded mr-sm !bg-surface-subtle !text-color-default" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="format_quote" style="" width="16" height="16" viewBox="0 0 16 16"></svg><span class="hidden lg:block">Cite</span></span></button><button class="m-button m-button--md m-button--tonal rounded mr-sm !bg-surface-subtle !text-color-default" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="mode_comment" style="" width="16" height="16" viewBox="0 0 16 16"></svg> <span class="hidden lg:block">Comments</span></span></button><button class="m-button m-button--md m-button--tonal rounded !bg-surface-subtle !text-color-default" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="share" style="" width="16" height="16" viewBox="0 0 16 16"></svg><span class="hidden lg:block">Share</span></span></button></div><div data-v-4f3fc9a4></div><div></div></div><div role="status" class="m-notification relative isolate flex w-full items-center border-l-[3px] py-md pl-md pr-sm border-color-success bg-success-sunken text-color-success mb-sm"><div class="flex w-full items-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="info" class="mr-4 h-6 w-6" style="" width="24" height="24" viewBox="0 0 16 16"></svg><div class="flex w-full flex-wrap justify-between gap-x-4"><p class="text-sm text-color-default">A <a href="https://www.mdpi.com/2072-6694/16/7/1243"><span class="text-color-link-bold cursor-pointer hover:underline">peer-reviewed</span></a> article of this preprint also exists.</p></div></div></div><div class="w-ull"><button class="m-button m-button--lg m-button--primary m-button--full-width rounded" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="download" style="" width="24" height="24" viewBox="0 0 16 16"></svg>Download PDF</span></button></div><div><div class="pb-md border-b border-color-default pt-sm"><div class="w-full relative overflow-hidden"><div><div class="clamp-3"><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/3425892" target="_blank" rel="noopener noreferrer">Paolo De Simone</a></span><sup> *</sup><div class="m-icon-custom text-color-inherit pl-xs inline-block"><a href="https://orcid.org/0000-0001-6713-6170" rel="noopener noreferrer" target="_blank"><img src="/_ipx/_/img/articleorcid.webp" onerror="this.setAttribute('data-error', 1)" data-nuxt-img srcset="/_ipx/_/img/articleorcid.webp 1x, /_ipx/_/img/articleorcid.webp 2x" class="w-4"></a></div><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><span><a href="https://sciprofiles.com/profile/author/ekVRV2NoVzg0amp3TGRGUkc4SVd4Zjl0dkM0U3JFclVZcDJKWFJkQkY1OD0=" target="_blank" rel="noopener noreferrer">Arianna Precisi</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/974088" target="_blank" rel="noopener noreferrer">Quirino Lai</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/3407044" target="_blank" rel="noopener noreferrer">Juri Ducci</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/2123246" target="_blank" rel="noopener noreferrer">Daniela Campani</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/1944586" target="_blank" rel="noopener noreferrer">Piero Marchetti</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><span><a href="https://sciprofiles.com/profile/author/VzBWRXlRbXpVZUxKNU1PYjBtY2dRSnJpbXRBektGVWFqb1VwdVNrR0Fhbz0=" target="_blank" rel="noopener noreferrer">Stefano Gitto</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/img/user_image/1658005/laura_crocetti.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/1658005" target="_blank" rel="noopener noreferrer">Laura Crocetti</a></span><div class="m-icon-custom text-color-inherit pl-xs inline-block"><a href="https://orcid.org/0000-0002-8160-0483" rel="noopener noreferrer" target="_blank"><img src="/_ipx/_/img/articleorcid.webp" onerror="this.setAttribute('data-error', 1)" data-nuxt-img srcset="/_ipx/_/img/articleorcid.webp 1x, /_ipx/_/img/articleorcid.webp 2x" class="w-4"></a></div></span></span></div><div class="invisible absolute"><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/3425892" target="_blank" rel="noopener noreferrer">Paolo De Simone</a></span><sup> *</sup><div class="m-icon-custom text-color-inherit pl-xs inline-block"><a href="https://orcid.org/0000-0001-6713-6170" rel="noopener noreferrer" target="_blank"><img src="/_ipx/_/img/articleorcid.webp" onerror="this.setAttribute('data-error', 1)" data-nuxt-img srcset="/_ipx/_/img/articleorcid.webp 1x, /_ipx/_/img/articleorcid.webp 2x" class="w-4"></a></div><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><span><a href="https://sciprofiles.com/profile/author/ekVRV2NoVzg0amp3TGRGUkc4SVd4Zjl0dkM0U3JFclVZcDJKWFJkQkY1OD0=" target="_blank" rel="noopener noreferrer">Arianna Precisi</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/974088" target="_blank" rel="noopener noreferrer">Quirino Lai</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/3407044" target="_blank" rel="noopener noreferrer">Juri Ducci</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/2123246" target="_blank" rel="noopener noreferrer">Daniela Campani</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/statics/img/design/default-user.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/1944586" target="_blank" rel="noopener noreferrer">Piero Marchetti</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><span><a href="https://sciprofiles.com/profile/author/VzBWRXlRbXpVZUxKNU1PYjBtY2dRSnJpbXRBektGVWFqb1VwdVNrR0Fhbz0=" target="_blank" rel="noopener noreferrer">Stefano Gitto</a></span><span>,</span></span></span><span class="pr-sm"><span class="m-text text-sm"><div class="m-avatar flex items-center justify-center overflow-hidden rounded-full bg-brand-bold font-medium text-color-on-brand h-5 w-5 min-w-5 text-[0.575rem] !inline-block align-middle mr-xs" data-testid="m-avatar"><img src="/img/user_image/1658005/laura_crocetti.png"><span class="sr-only"></span></div><span><a href="https://sciprofiles.com/profile/1658005" target="_blank" rel="noopener noreferrer">Laura Crocetti</a></span><div class="m-icon-custom text-color-inherit pl-xs inline-block"><a href="https://orcid.org/0000-0002-8160-0483" rel="noopener noreferrer" target="_blank"><img src="/_ipx/_/img/articleorcid.webp" onerror="this.setAttribute('data-error', 1)" data-nuxt-img srcset="/_ipx/_/img/articleorcid.webp 1x, /_ipx/_/img/articleorcid.webp 2x" class="w-4"></a></div></span></span></div></div><div style="display:none;" class="mt-sm"><button class="m-button m-button--sm m-button--tertiary rounded !inline-flex after:hidden bg-white" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center">Show more <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="keyboard_arrow_down" style="" width="16" height="16" viewBox="0 0 16 16"></svg></span></button></div></div><p class="m-text text-sm text-color-error pt-sm">This version is not peer-reviewed</p></div></div><div class="py-md border-b border-color-default"><div class="m-select common-field bg-white"><div class="common-field__wrapper" data-headlessui-state><div class="relative w-full cursor-default"><div class="flex items-center"><button id="headlessui-listbox-button-mui-8240" type="button" aria-haspopup="listbox" aria-expanded="false" data-headlessui-state data-testid="select-activator" class="common-field__dropdown-input [&>span]:overflow-hidden h-10"><span class="flex w-full items-center gap-1 [&>span]:truncate"><span>Version 1</span></span><div class="flex"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="keyboard_arrow_down" class="duration-400 transition-transform" style="" width="24" height="24" viewBox="0 0 16 16"></svg></div></button></div></div></div></div><div class="pt-sm"><div class="flex"><p class="m-text text-xs">Submitted:</p><p class="m-text text-xs pl-xs">12 January 2024</p></div><div class="flex pt-sm"><p class="m-text text-xs">Posted: </p><p class="m-text text-xs pl-xs">15 January 2024</p></div></div><div class="pt-sm"><div><p class="m-text text-xs">You are already at the latest version </p></div></div><div></div></div><div class="py-md border-b border-color-default flex items-center justify-between" data-v-d8c082ee><div class="flex-none flex items-center" data-v-d8c082ee><span class="m-text text-xs pr-xs font-semibold flex-none" data-v-d8c082ee>Alerts</span><span data-v-d8c082ee></span></div><div class="m-switch flex items-center gap-2" data-v-d8c082ee><button class="relative inline-flex h-[1.4rem] w-[2.75rem] shrink-0 cursor-pointer items-center rounded-full border-2 border-color-transparent transition-colors duration-150 ease-out ui-focus-visible:ring-2 ui-focus-visible:ring-brand-bold ui-focus-visible:ring-opacity-75 bg-content-default hover:bg-content-bold active:bg-content-bolder" aria-label="Switch on" id="headlessui-switch-mui-8241" role="switch" type="button" tabindex="0" aria-checked="false" data-headlessui-state><span aria-hidden="true" class="pointer-events-none inline-block h-[1rem] w-[1rem] transform rounded-full bg-white shadow-lg ring-0 transition duration-200 ease-in-out translate-x-0.5"></span></button></div></div><div data-v-d8c082ee data-v-03f1a75d></div><div><h6 class="m-heading text-inherit m-h6 font-semibold pt-lg">Abstract</h6><div class="">To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR=0.45; P=0.002). At multivariable analysis, microvascular infiltration (HR=1.22; P<0.04) and a higher tumor grading (HR=1.27; P<0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR=0.56; P<0.001), a successful pre-transplant downstaging (HR=0.63; P=0.01) and use of everolimus (HR=0.46; P<0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (30 days; P<0.001), longer treatment duration (P<0.001), and higher drug exposure (5.9ng/mL; P<0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction of the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression.</div></div><div data-v-3ce94018><div class="pt-lg" data-v-3ce94018><span class="m-text text-body font-semibold" data-v-3ce94018>Keywords: </span><span class="m-text text-body pt-sm" data-v-3ce94018></span></div></div><div class="flex-1 pt-lg mr-lg lg:pt-0" data-v-da90062a><div class="pt-md" data-v-da90062a><div class="flex flex-wrap lg:flex-nowrap items-center" data-v-da90062a><span class="m-text text-body font-semibold" data-v-da90062a>Subject: </span><span class="m-text text-body" data-v-da90062a>Medicine and Pharmacology</span><span class="" data-v-da90062a> - </span><span class="m-text text-body" data-v-da90062a>Transplantation</span></div></div><div class="content-container" id="articleRef" data-v-da90062a><script type="text/x-mathjax-config"> MathJax.Hub.Config({ menuSettings: { CHTMLpreview: false }, "CHTML-preview":{ disabled: true }, "HTML-CSS": { scale: 90, availableFonts: [], preferredFont: null, preferredFonts: null, webFont:"Gyre-Pagella", imageFont:'TeX', undefinedFamily:"'Arial Unicode MS',serif", linebreaks: { automatic: false } }, "TeX": { extensions: ["noErrors.js"], noErrors: { inlineDelimiters: ["",""], multiLine: true, style: { "font-size": "90%", "text-align": "left", "color": "black", "padding": "1px 3px", "border": "1px solid" } } } }); </script><script type="text/javascript" async="" src="https://www.mdpi.com/bundles/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script> <section id="Introduction" type="intro"><h2 data-nested="1" id="preprints-h2-1"> Introduction</h2> <div class="html-p">Survival after liver transplantation (LT) in the long term is impacted by the complications of chronic immunosuppression (1). Nearly all long-term survivors show diverse co-morbidities, the most frequent being hypertension, chronic kidney dysfunction (CKD), de novo malignancies, diabetes mellitus (DM) and metabolic disease (2). Most of these complications are consequent to the use of calcineurin inhibitors (CNI) (cyclosporine (CyA) and tacrolimus (TAC)), although the impact of surgery, non-immunosuppressive co-medication, recipients’ aging, and native liver disease cannot be underestimated (1,2).</div> <div class="html-p">Introduced in clinical practice a decade ago (3-5), everolimus (EVR) is a member of the mammalian target of rapamycin (mTOR) inhibitors (mTORi) together with sirolimus (SRL) and has extensively been studied in pre-clinical studies (6), registration trials (3-5), and real-life clinical practice (7). Although approved for use in combination with tacrolimus (TAC) (3), numerous reports have investigated its administration as a single immunosuppressant. This is especially true for the treatment of CNI-associated nephrotoxicity or the prevention/treatment of post-transplant de novo or recurrent malignancies (8). Several pooled analyses and meta-analyses have shown that incorporating EVR into immunosuppression therapy can lead to an improvement in renal function (9-11). Additionally, it can reduce the risk of post-transplant malignancies and recurrence of hepatocellular carcinoma (HCC) (12). However, there is a large variability in reported outcomes across studies due to differences in patient selection, indications for EVR use, mode of administration and exposure, and study designs.</div> <div class="html-p">The antiproliferative profile of EVR makes it an ideal immunosuppressive agent for patients with HCC, especially for recipients with an advanced tumor stage or a higher risk of post-transplant recurrence (8). However, the impact of any immunosuppressive strategy on the risk of post-transplant tumor recurrence is dependent on a complex interplay of tumor-related (i.e., stage at transplantation, response to pre-transplant downstaging, biologic markers), condition-related (i.e., indication to transplantation, native liver disease, severity of liver dysfunction) and treatment-related correlates (i.e., time, mode, and duration of drug administration) (1). To elucidate these interactions in large populations and the long term, we carried out a retrospective analysis at our center on the post-transplant recurrence of HCC in adult LT recipients. </div></section><section id="MaterialsandMethods" type><h2 data-nested="1" id="preprints-h2-2"> Materials and Methods</h2> <section id="StudyDesign" type><h4 class="html-italic" data-nested="2"> Study Design </h4> <div class="html-p">This was a retrospective, single-center study at an Italian National Health System (NHS)-based liver transplant center. </div></section><section id="Population" type><h4 class="html-italic" data-nested="2"> Population</h4> <div class="html-p">We conducted a retrospective comparison of two groups of adult HCC patients who underwent primary, whole-size transplantation from deceased brain-dead donors (DCD) at our institution using a 2-tiered approach. Initially, we selected transplant recipients with HCC on explant histology, excluding those with macrovascular tumor portal infiltration and mixed cellular lineage (i.e. hepato-cholangio-hepatocellular carcinoma (CHC-HCC)). We then compared patients who received immunosuppression with EVR to those who received tacrolimus (TAC) with or without mycophenolate derivatives (MPA) between 2013 and 2021.</div></section><section id="PrimaryExposure" type><h4 class="html-italic" data-nested="2"> Primary Exposure</h4> <div class="html-p">Our primary exposure was the use of EVR alone or in combination with TAC versus TAC (±MPA) in the post-transplant immunosuppressive schedule. </div></section><section id="DataSource" type><h4 class="html-italic" data-nested="2"> Data Source</h4> <div class="html-p">For the current study, we used data from the regional transplant authority (CRT, <span class="html-italic">Centro Regionale Trapianti</span>) and the prospectively maintained recipient database of our institution. The CRT data system includes data on all donors, waitlisted candidates, and transplant recipients and provides regular oversight to the integrity, validity, and transparency of the database. The local ethics committee of the University of Pisa (Prot. 0036349/2020) approved all procedures. </div></section><section id="MeasureOutcomes" type><h4 class="html-italic" data-nested="2"> Measure Outcomes</h4> <div class="html-p">Our primary outcome was the cumulative incidence of post-transplant HCC recurrence in patients who received EVR versus TAC. The secondary outcome was overall survival (OS). All these measures were treated as time-to-event occurrences. Data were censored at the time of the event, the last follow-up visit, or December 31<sup>st</sup>, 2022, whichever came first. </div></section><section id="Immunosuppression" type><h4 class="html-italic" data-nested="2"> Immunosuppression</h4> <div class="html-p">In the study period, de novo immunosuppression consisted of a triple/quadruple regimen of anti-CD25 (basiliximab, Simulect®, Novartis, Origgio (VA), Italy), calcineurin inhibitors (CNI), CyA or TAC, steroids (S), and antimetabolites (azathioprine (AZA) or mycophenolic acid (MPA) derivatives) according to era, pre-transplant, intra-operative and post-transplant patient characteristics. </div> <div class="html-p">When used for prophylaxis of HCC recurrence or prevention of TAC-related adverse events, EVR (Certican®, Novartis, Origgio (VA), Italy) was introduced ≥1 month after transplant at a dosage of 1.0 mg bid with antimetabolites elimination and stepwise TAC dose reduction, unless otherwise clinically indicated. Prior to EVR introduction, patients were tested for liver function tests (LFT), hematocrit, lipid profile and creatinine/protein ratio. When used in combination schedules, EVR was adjusted to a trough level between 3 and 8 ng/mL and TAC between 3 and 5 ng/mL. When used alone, EVR trough level was between 6 and 10 ng/mL as clinically appropriate. When introduced for TAC-related complications, the time, mode, and dose of EVR were dependent on clinical indications. </div> <div class="html-p">Rejection episodes were histologically proved and graded according to the BANFF classification system (13). Treatment of rejection was with steroid boluses for non-HCV patients, while CNI and MMF dose increase/reintroduction were preferred for HCV-RNA positive recipients. In case of refractory rejection episodes, we tested patients for donor-specific and anti-HLA antibodies and used plasmapheresis, intravenous immunoglobulin, or rabbit anti-thymocyte immunoglobulin (rATG) as clinically appropriate. Anti-CMV prophylaxis was administered to recipients without acquired immunity (i.e., D+/R- and D-/R- combinations).</div></section><section id="DrugExposureAssay" type><h4 class="html-italic" data-nested="2"> Drug Exposure Assay</h4> <div class="html-p">EVR exposure was tested in whole blood with the QMS™ Everolimus Immunoassay, a homogeneous particle-enhanced turbidimetric immunoassay based on Quantitative Microparticle System (QMS®) technology. Mean EVR exposure was calculated based on samples obtained at our institution at follow-up visits. </div></section><section id="SpecialConsiderations" type><h4 class="html-italic" data-nested="2"> Special Considerations</h4> <div class="html-p">The transplant procedure, perioperative management, and immunosuppressive schedules changed during the study period according to technological advancements and scientific evidence. Celsior® (IGL, Lissieu, France) was utilized for graft perfusion until 2017 and replaced by Servator C® (SALF, Cenate Sotto (BG), Italy) thereafter. Bypass or the classical technique was standard until 2017. </div></section><section id="PreTransplantManagementofHCC" type><h4 class="html-italic" data-nested="2"> Pre-Transplant Management of HCC</h4> <div class="html-p">The diagnosis of HCC was according to the European Association for the Study of Liver Disease (EASL) guidelines (14). Patients within the Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate) were considered for transplantation (15). Pre-transplant downstaging/bridging was indicated for patients with >3 cm tumor mass, those with AFP levels >400 ng/mL, or with segmental portal infiltration. The down-staging technique was agreed upon during tumor board case evaluation and based on tumor size, location, and number of nodules. It consisted of trans-arterial chemoembolization (TACE), radiofrequency/microwave ablation, trans-arterial radioembolization (TARE), or surgery as appropriate. A successful downstaging procedure was associated with regression from beyond to within Milan criteria as per pre-transplant imaging or explant histology. </div></section><section id="CutOffsandDefinitions" type><h4 class="html-italic" data-nested="2"> Cut-Offs and Definitions</h4> <div class="html-p">Cold ischemia time (CIT) was defined as the time from cross-clamping until removal of the organ from the ice for implantation, and warm ischemia time (WIT) as a time of ischemia during graft implantation. EAD was defined according to Olthoff et al. (16) MELD scores at transplant were recalculated retrospectively based on available laboratory data. HCV recurrence was diagnosed by liver biopsy in the presence of HCV-RNA positivity. HBV infection recurrence was defined as HBsAg (± HBV DNA) reappearance in previously seroconverted patients irrespective of liver function. Renal function was evaluated as an estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD)-4 formula. Chronic kidney dysfunction (CKD) was defined as: a) estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m<sup>2</sup> for a post-LT period greater than three months according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria in patients with previous eGFR ≥60ml/min/1.73m<sup>2</sup> (17); b) evidence of intrinsic renal disease (proteinuria or kidney disease at ultrasound) (17); or c) presence of end-stage renal disease requiring renal replacement therapy (17). Acute kidney injury (AKI) was defined as doubling of baseline serum creatine (sCr) and/or a ≥50% reduction in eGFR within 14 days (17). Deteriorating renal function was defined as ≥one-grade downward shift in the kidney function category according to the KDIGO classification system (18). A post-transplant diabetes mellitus (PTDM) was defined using the comprehensive American Diabetes Association (ADA) 2018 criteria (19).</div> <div class="html-p">Arterial hypertension was defined as the need for medication or blood pressure 140/90 mmHg at two following visits. Dyslipidemia was defined as hypercholesterolemia >220 mg/dL and/or hypertriglyceridemia >200 mg/dL at two following visits. Biliary complications included symptomatic and treated biliary fistula, biliary stones, anastomotic biliary strictures, and posttransplant ischemic-type biliary lesion (ITBL). ITBL was defined as any non-anastomotic stenosis associated with symptoms or signs requiring an endoscopic or surgical procedure without vascular complications.</div></section><section id="StatisticalAnalyses" type><h4 class="html-italic" data-nested="2"> Statistical Analyses</h4> <div class="html-p">Initially, 2 groups of patients were extracted from the original population of HCC recipients transplanted at our center between 1996 and 2021 based on the mentioned inclusion criteria. The EVR group included patients who received the drug in their <span class="html-italic">de novo</span> immunosuppressive regimen for prophylaxis of post-transplant tumor recurrence or CNI -related complications other than HCC recurrence (i.e., renal function deterioration). The TAC group included patients who received TAC until complication (i.e., HCC recurrence, renal function deterioration) or the latest follow-up. </div> <div class="html-p">To address the non-randomized design of the study, the two groups were balanced using an inverse probability of treatment weighting (IPTW) approach. A propensity score for each patient in the original population was generated. The score was created using a multivariate logistic regression model considering post-transplant HCC recurrence (no/yes) as the dependent variable. Eighteen confounding factors that have clinical significance were chosen to serve as covariates for both DFS and OS: patient sex (20); age (21); HCV (22); diabetes mellitus at transplant (23); CKD at transplant (24); MELD score (25); donor sex (26); donor age (27); cerebrovascular accident (CVA) as donor cause of death (28); use of machine perfusion (MP) (29); CIT (30); pre-transplant tumor stage according to Milan criteria (31); pre-transplant alpha-fetoprotein (AFP) (32); efficacy of pre-transplant downstaging and defined as downstaging from beyond to within Milan criteria (33); tumor stage at histology according to Milan criteria (31-33); G3-G4 tumor grading (34); presence of microvascular infiltration (34), and mean TAC trough level within the first post-transplant month (≤10 ng/mL) (35).</div> <div class="html-p">With the intent to reduce the artificial modification of the sample size in the pseudo data, we used stabilized weights (SW) according to the formula: </div> <div class="html-p">SW = p/PS for the study group, and SW = (1-p)/(1-PS) for the control group</div> <div class="html-p">where p is the probability of etiology without considering covariates and PS is the propensity score. A stabilized approach was preferred not to inflate the sample populations versus the original ones.</div> <div class="html-p">Because p-values can be biased from population size, results from the comparisons between covariates subgroups were reported as effect size (Cohen's D value): values lower than |0.1| indicated very small differences between means, values between |0.1| and |0.3| indicated small differences, values between |0.3| and |0.5| indicated moderate differences, and values greater than |0.5| indicated considerable differences.</div> <div class="html-p">Multivariable Cox regression analyses were run after the stabilized IPTW to identify the risk factors for HCC recurrence and after LT. Hazard ratios (HR) and 95.0% confidence intervals (CI) were reported for significant variables. Survival analyses were performed using the Kaplan-Meier method, and the log-rank test was adopted to compare the obtained survivals. Variables with a p<0.05 were considered statistically significant. </div> <div class="html-p">Finally, after propensity matching, 3 further co-variates were used to explore the impact of EVR administration on the risk of HCC recurrence: (1) timing of EVR introduction; (2) duration of EVR treatment, and (3) EVR whole-blood concentration throughout the study period. Patients were dichotomized according to median values, and sensitivity analyses were performed between recurring and non-recurring patients. </div> <div class="html-p">According to their measure and level of distribution, variables were expressed by frequencies and percentages, medians, and interquartile ranges (IQR) or means and standard deviations (SD) as appropriate. Data errors and missingness were identified across the database and solved with specific queries. Missing data were handled with a single imputation method. In detail, a median of nearby points imputation was adopted. The median instead of the mean was adopted due to the skewed distribution of the managed variables. Recurrence-free survival (RFS) was defined as the time (months) from transplant to diagnosis of HCC recurrence. OS was defined as the time from transplantation to either death or last observation. </div> <div class="html-p">All statistical analyses and plots were run using the SPSS statistical package version 27.0 (SPSS Inc., Chicago, IL, USA). This study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee and was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.</div></section></section><section id="Results" type="results"><h2 data-nested="1" id="preprints-h2-3"> Results </h2> <section id="DemographicsandClinicalCharacteristicsoftheOriginalCohort" type><h4 class="html-italic" data-nested="2"> Demographics and Clinical Characteristics of the Original Cohort</h4> <div class="html-p">A total of 1,019 adult patients transplanted for HCC at our center between 1996 and 2021 were initially considered (<a href="#preprints-96239-t001" class="html-table">Table 1</a>). Among them, 463 (45.4%) received EVR for HCC recurrence prophylaxis or complications other than HCC recurrence, while 556 (54.6%) received CNI (either TAC or CyA) as the primary de novo immunosuppressant until CNI-related adverse events. At a median (IQR) follow-up of 8.7 (8.1) years, 384 (37.6%) patients died, 41 (4.0%) were retransplanted, and 635 (62.3%) were alive. The 1, 5, and 10-year Kaplan-Meier probability (95% CI) of survival was 91% (89-93%) and 90.2% (88-93%), 77% (74-80%), and 75.8% (72-79%), 67% (63-71%) and 65% (61%-70.2%) for patient and graft, respectively. </div> <div class="html-p"> <a href="#preprints-96239-t001" class="html-table">Table 1</a> shows the clinical features of the recipients and donors from 1996 to 2021 and before matching. CNI patients were more frequently transplanted before 2013 (66.0% versus 31.7%; P<0.0001), while EVR patients were more frequently beyond Milan criteria (32.8% versus 18.1%; P<0.0001), underwent more frequent pre-transplant downstaging procedures (59.6% versus 62.4%; P=0.01), and showed higher median (IQR) AFP levels before surgery (46.3 (28) versus 4.7 (19) ng/mL; P=0.002). Similarly, the proportion of G3-G4 grading (31.9% versus 25.1%; P=0.01) and microvascular infiltration (39.5% versus 32.7%; P=0.02) were higher in the EVR group.</div></section><section id="StabilizedIPTWEffect" type><h4 class="html-italic" data-nested="2"> Stabilized IPTW Effect </h4> <div class="html-p">To minimize the effect of selection biases caused by the non-randomized design of this retrospective study, the EVR and TAC pseudo-groups were balanced using a stabilized IPTW method. <a href="#preprints-96239-t002" class="html-table">Table 2</a> illustrates the results of the balancing procedure for the 18 potential confounders. Namely, 7 variables showed very small differences before balancing, 6 small, 4 moderate, and 1 considerable. After IPTW, 14 variables showed very small differences; 3 were small, and one was moderate. The IPTW yielded 2 pseudo-groups, i.e., 233 EVR patients versus 278 on TAC. </div></section><section id="ResultsintheBalancedGroups" type="results"><h4 class="html-italic" data-nested="2"> Results in the Balanced Groups</h4> <div class="html-p">After conducting IPTW balancing, <a href="#preprints-96239-t003" class="html-table">Table 3</a> presents the clinical characteristics of both groups. At a median follow-up of 4.4 (3.8) years after transplantation, the number of deaths, re-transplants, and HCC recurrences were 167 (32.7%), 20 (4.0%), and 65 (12.7%), respectively (<a href="#preprints-96239-t004" class="html-table">Table 4</a>). TAC patients showed higher death (37.8% versus 26.6%; RR=1.41; P=0.007) and HCC recurrence rates (16.9% versus 7.7%; RR=2.2; P=0.002). The main reasons for death in the TAC and EVR groups included HCC recurrence (15.1% versus 6.8%; RR=2.51; p=0.003), HCV recurrence (5.4% versus 6.9%; RR=0.8; P=0.48), infections/sepsis (5.7% versus 5.1%; RR=1.11; P=0.84), and <span class="html-italic">de novo</span> malignancies (3.9% versus 2.1%; RR=1.85; P=0.31) (<a href="#preprints-96239-t004" class="html-table">Table 4</a>). </div></section><section id="Retransplantation" type><h4 class="html-italic" data-nested="2"> Re-transplantation</h4> <div class="html-p">A total of 20 (3.9%) patients were retransplanted (<a href="#preprints-96239-t004" class="html-table">Table 4</a>). The main indication was primary non-function (PNF) of the liver graft, which accounted for 40% of such cases and was followed by ischemic cholangiopathy (30%) and hepatic artery thrombosis (HAT) (15.0%). No significant difference was found in the causes of re-transplantation between the two groups.</div></section><section id="HCCRecurrence" type><h4 class="html-italic" data-nested="2"> HCC Recurrence</h4> <div class="html-p">HCC recurred at a median (IQR) of 26.1 (48.7) months after transplantation and accounted for 15.1% of deaths in TAC versus 6.8% in EVR patients (RR=2.51; P=0.003). One-third of recurrences were in the liver only, while TAC patients showed more frequent multi-organ involvement (P=0.002) (<a href="#preprints-96239-t004" class="html-table">Table 4</a>).</div></section><section id="immunosuppression" type><h4 class="html-italic" data-nested="2"> immunosuppression</h4> <div class="html-p"> <a href="#preprints-96239-t005" class="html-table">Table 5</a> and <a href="#preprints-96239-t006" class="html-table">Table 6</a> illustrate the immunosuppressive regimen in the EVR group regarding indication, timing of introduction, duration of treatment, and median exposure. EVR was introduced at a median (IQR) interval post-transplantation of 30 (16) days for a median (IQR) of 46.6 (36.1) months. Median (IQR) EVR whole-blood exposure was 5.8 (1.7) ng/mL. </div> <div class="html-p">In the EVR group, patients with HCC recurrence showed later EVR introduction (median (IQR) = 52 (26.4) versus 30 (12) days; P<0.001), shorter duration of treatment (median (IQR) = 47.6 (57.0) versus 69.9 (24.8) months; P<0.001), and lower drug exposure (median (IQR) = 3.65 (0.55) versus 5.9 (1.4) ng/mL; P<0.001) (<a href="#preprints-96239-t006" class="html-table">Table 6</a>). </div></section><section id="RiskFactorsforRecurrenceFreeandOverallSurvival" type><h4 class="html-italic" data-nested="2"> Risk Factors for Recurrence-Free and Overall Survival </h4> <div class="html-p"> <a href="#preprints-96239-t007" class="html-table">Table 7</a> illustrates the results of the multivariable analysis of risk factors for OS and RFS in the entire post-IPTW population. A successful pre-transplant downstaging (HR=0.79; P=0.006), being within Milan criteria at transplant (HR=0.67; P<0.001) and at histology (HR=0.78; P=0.02) and use of EVR (HR=0.69; P=0.009) had a positive impact on survival.</div> <div class="html-p">As for HCC recurrence, the presence of vascular micro-infiltration (HR=1.22; P=0.04) and higher tumor grading (HR=1.27; P=0.044) had a negative impact on RFS, while a successful pre-transplant downstaging (HR=0.65; P=0.01), being within Milan criteria at transplant (HR=0.56; P=0.01) and at histology (HR=0.68; P=0.012) and use of EVR (HR=0.46; P<0.001) had a positive impact on the probability of tumor-free survival. </div> <div class="html-p"> <a href="#preprints-96239-f001" class="html-fig">Figure 1</a> illustrates the OS according to Milan criteria at transplant and type of immunosuppressant (EVR versus TAC). All strata comparisons were statistically significant except for EVR Milan-in versus TAC Milan-in patients (log-rank P =0.560). The 1-, 3- and 5-year actuarial OS (95% CI) for EVR patients within the Milan criteria were 98% (93-99%), 89% (82-90%), and 84% (79-88%) versus 98% (94-99%), 89% (83-90%), and 85% (80-87%) for EVR and TAC, respectively (log-rank p=0.506). For patients exceeding the Milan criteria, the OS (95% CI) was 94% (91-96%), 84% (81-86%), and 76% (72-79%) versus 92% (89-94%), 79% (73-80%), and 69% (66-70%) for EVR and TAC, respectively (log-rank p<0.001). </div> <div class="html-p"> <a href="#preprints-96239-f002" class="html-fig">Figure 2</a> illustrates the RFS according to Milan criteria at transplant and type of immunosuppressant (EVR versus TAC). All strata comparisons were statistically significant (log-rank P <0.001) except for EVR Milan-in versus TAC Milan-in patients (log-rank P=0.205). The actuarial (95% CI) RFS for patients within the Milan criteria was 96% (94-100%), 87% (84-89%) and 82% (77-89%) at 1, 3, and 5 years in the EVR group versus 96% (CI 88-99%), 87% (74-91%) and 80% (72-84%) in the TAC group, respectively (log-rank P=0.205). On the other hand, it was 90% (82-94%), 78% (64-81%), and 68% (57-71%) at 1, 2, and 3 years for EVR patients exceeding the Milan criteria versus 86% (72-90%), 75% (66-84%), and 65% (52-69%) for TAC patients beyond the Milan criteria. (log-rank p<0.001). </div></section></section><section id="Discussion" type="discussion"><h2 data-nested="1" id="preprints-h2-4"> Discussion</h2> <div class="html-p">To the best of our knowledge, this is one of the largest single-center series on the use of EVR in recipients of a liver graft for HCC, and with long-term follow-up data available in the international literature. Despite the expansion of the practice of LT for advanced HCC, information on the impact of EVR or SRL is derived mainly from systematic reviews and meta-analyses incorporating both drugs (11,36-40), with only a few multi-institutional research studies (9,41-43) and real-life clinical series (44-46). Although some authors dispute the advantage of mTORi for the reduction of post-transplant HCC recurrence (43), the overall evidence originating from these studies supports the use of mTORi for patients with HCC, suggesting earlier drug introduction and higher exposure levels to achieve greater antiproliferative activity (46). </div> <div class="html-p">Dysregulation of the mTOR pathway is frequently observed in HCC (47). However, transferring this evidence from the <span class="html-italic">in vitro</span> experimental setting to clinical practice is challenging because the overall impact of EVR on post-transplant HCC appears to be dependent on a complex interplay of molecular signaling, tumor cell viability, total tumor volume, plasma, and tumor drug concentration (48). In addition, pre-transplant tumor characteristics, response to adjuvant treatment, type of native liver disease, quality of liver graft, surgery, and immunosuppressive regimens all account for the variable outcomes reported in the literature. One strategy to overcome these limitations is to analyze real-life clinical practice and large data sets with the use of propensity-matching methodologies for the reduction of selection biases. For this reason, we opted for a retrospective comparison of 2 propensity-matched samples of HCC patients with the IPTW methodology. </div> <div class="html-p">The analysis revealed that the use of EVR could reduce the risk of HCC recurrence and increase RFS and OS in LT recipients. This was especially true for tumors beyond the Milan criteria and for patients with earlier drug introduction (≤30 days), longer time on treatment (about 5 years), and higher median EVR exposure level (≥5.9ng/mL). In such cases, a twofold reduction of the relative risk of HCC recurrence was observed alongside improved OS. In patients within Milan criteria, the oncological impact of EVR-based immunosuppression is weaker, but the overarching benefits of EVR on renal function deterioration and <span class="html-italic">de novo</span> malignancies suggest its use also in this category of patients. </div> <div class="html-p">Transferring these considerations to current clinical practice, however, is not simple. </div> <div class="html-p">Earlier EVR administration requires proper patient management due to a reported higher incidence of leukopenia, thrombocytopenia, dyslipidemia, and infections with the use of mTORi versus CNIs, as well as a higher discontinuation rate for patients on higher drug exposure (3,10). This is why the originally recommended exposure levels for EVR monotherapy (i.e., 6-10ng/mL) (3-5) are seldom implemented in clinical practice to avoid concentration-related adverse events. Furthermore, the current focus on immunosuppression minimization has expanded from CNI to include antimetabolites and mTORi alongside increased concerns about transplant recipients’ quality of life (49). </div> <div class="html-p">Despite its large number of patients and robust statistical methodology, our study has several limitations. First, its retrospective design does not always allow the granular information that real-practice clinical studies need to produce clinically transferable data. This is especially true for pre-transplant information on tumor clinical course and biology, and limited availability of drug exposure levels for patients with longer follow-ups. Additionally, it included the initial experience with EVR at our center and might inevitably be biased by a learning curve effect in terms of patient selection, drug discontinuation rates, and post-transplant therapeutic strategies for HCC recurrence. </div> <div class="html-p">Secondly, we excluded patients with unfavorable tumor characteristics from the current analysis, i.e., neoplastic portal thrombosis, due to its negative impact on RFS and OS and the limited number of cases at our center. Given the clinical expansion of Milan criteria and the introduction of novel neoadjuvant pre-transplant treatments (i.e., immunotherapy), it would be interesting to analyze the relative benefit of EVR-incorporating immunosuppression for this category of high-risk patients.</div> <div class="html-p">In conclusion, based on our results, EVR allows us to mitigate the risk of post-transplant HCC recurrence, especially for tumors beyond the Milan criteria and patients with earlier drug introduction, higher drug exposure, and longer time on treatment. These data advocate considering the use of mTORi for patients with HCC to reduce the attrition rate of chronic immunosuppression after LT. </div></section> <section class="html-notes"><h2 id="preprints-h2-5">Funding</h2> <div class="html-p">None.</div></section><section class="html-notes"><h2 id="preprints-h2-6">Conflicts of interest</h2> <div class="html-p">PDS has served as advisory board member for Novartis, Astellas, and Chiesi. The other authors have no interest to declare. </div></section><section class="html-notes"><h2 id="preprints-h2-7">Abbreviations:</h2> <div class="html-p">AFP, alpha-fetoprotein. </div> <div class="html-p">Anti-HBc, antibody to the hepatitis virus B core antigen.</div> <div class="html-p">Anti-HBs, antibody to the hepatitis B surface antigen. </div> <div class="html-p">BCLC, Barcelona Clinic Liver Cancer.</div> <div class="html-p">BMI, body mass index</div> <div class="html-p">CHC, cholangiocarcinoma; </div> <div class="html-p">CNI, calcineurin inhibitors. </div> <div class="html-p">CyA, cyclosporine.</div> <div class="html-p">EASL, European Association for the Study of Liver Disease</div> <div class="html-p">eGFR, estimated glomerular filtration rate.</div> <div class="html-p">EVR, everolimus.</div> <div class="html-p">HBc, hepatitis B core antigen.</div> <div class="html-p">HBs, hepatitis B surface antigen.</div> <div class="html-p">HBV, hepatitis B virus.</div> <div class="html-p">HCC, hepatocellular carcinoma. </div> <div class="html-p">HCV, hepatitis C virus. </div> <div class="html-p">HR, hazard ratio.</div> <div class="html-p">IQR, interquartile range.</div> <div class="html-p">LFT, liver function tests.</div> <div class="html-p">LT, liver transplantation. </div> <div class="html-p">MACE, major adverse cardiovascular events.</div> <div class="html-p">MDRD, modified diet and renal disease.</div> <div class="html-p">MELD, model for end-stage liver function. </div> <div class="html-p">MPA, mycophenolic acid derivatives. </div> <div class="html-p">mTOR, mammalian target of rapamycin.</div> <div class="html-p">mTORi, mammalian target of rapamycin inhibitors.</div> <div class="html-p">OS, overall survival.</div> <div class="html-p">PNF, primary non-function.</div> <div class="html-p">RFS, recurrence-free survival. </div> <div class="html-p">RR, relative risk.</div> <div class="html-p">S, steroids.</div> <div class="html-p">SD, standard deviation.</div> <div class="html-p">SRL, sirolimus.</div> <div class="html-p">TAC, tacrolimus.</div></section><section id="html-references_list"><h2 id="preprints-h2-8">References</h2> <ol class="html-xx"> <li id="B1-preprints-96239" class="html-x" data-content="1.">Di Maira, T.; Little, E.C.; Berenguer, M. Immunosuppression in liver transplant. <span class="html-italic">Best Pract Res Clin Gastroenterol</span> <b>2020</b>, <span class="html-italic">46-47</span>, 101681. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppression+in+liver+transplant&author=Di+Maira,+T.&author=Little,+E.C.&author=Berenguer,+M.&publication_year=2020&journal=Best+Pract+Res+Clin+Gastroenterol&volume=46-47&pages=101681&doi=10.1016/j.bpg.2020.101681&pmid=33158467" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.bpg.2020.101681" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/33158467" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B2-preprints-96239" class="html-x" data-content="2.">Noble, J.; Terrec, F.; Malvezzi, P.; Rostaing, L. Adverse effects of immunosuppression after liver transplantation. <span class="html-italic">Best Pract Res Clin Gastroenterol</span>, 2021; 54-55, 101762. [<a href="https://scholar.google.com/scholar_lookup?title=Adverse+effects+of+immunosuppression+after+liver+transplantation&author=Noble,+J.&author=Terrec,+F.&author=Malvezzi,+P.&author=Rostaing,+L.&publication_year=2021" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B3-preprints-96239" class="html-x" data-content="3.">De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; Saliba, F.; et al. Everolimus with Reduced Tacrolimus Improves Renal Function in <span class="html-italic">De Novo</span> Liver Transplant Recipients: A Randomized Controlled Trial. <span class="html-italic">Am J Transplant</span> <b>2012</b>, <span class="html-italic">12</span>, 3008–3020. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+with+Reduced+Tacrolimus+Improves+Renal+Function+in+De+Novo+Liver+Transplant+Recipients:+A+Randomized+Controlled+Trial&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=Saliba,+F.&author=et+al.&publication_year=2012&journal=Am+J+Transplant&volume=12&pages=3008%E2%80%933020&doi=10.1111/j.1600-6143.2012.04212.x&pmid=22882750" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1111/j.1600-6143.2012.04212.x" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22882750" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B4-preprints-96239" class="html-x" data-content="4.">Saliba, F.; De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. <span class="html-italic">Am J Transplant</span> <b>2013</b>, <span class="html-italic">13</span>, 1734–1745. [<a href="https://scholar.google.com/scholar_lookup?title=Renal+function+at+two+years+in+liver+transplant+patients+receiving+everolimus:+Results+of+a+randomized,+multicenter+study&author=Saliba,+F.&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=et+al.&publication_year=2013&journal=Am+J+Transplant&volume=13&pages=1734%E2%80%931745&doi=10.1111/ajt.12280&pmid=23714399" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1111/ajt.12280" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/23714399" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B5-preprints-96239" class="html-x" data-content="5.">Fischer, L.; Saliba, F.; Kaiser, G.M.; De Carlis, L.; Metselaar, H.J.; De Simone, P.; et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. <span class="html-italic">. Transplantation.</span> <b>2015</b>, <span class="html-italic">99</span>, 1455–1462. [<a href="https://scholar.google.com/scholar_lookup?title=Three-year+outcomes+in+de+novo+liver+transplant+patients+receiving+everolimus+with+reduced+tacrolimus:+Follow-up+results+from+a+randomized,+multicenter+study&author=Fischer,+L.&author=Saliba,+F.&author=Kaiser,+G.M.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=De+Simone,+P.&author=et+al.&publication_year=2015&journal=.+Transplantation.&volume=99&pages=1455%E2%80%931462&doi=10.1097/TP.0000000000000555&pmid=26151607" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000000555" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/26151607" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B6-preprints-96239" class="html-x" data-content="6.">Levy, G.; Schmidili, H.; Punch, J.; Tuttle-Newhall, E.; Mayer, D.; Neuhaus, P.; et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. <span class="html-italic">Liver Transpl</span> <b>2006</b>, <span class="html-italic">12</span>, 1640–1648. [<a href="https://scholar.google.com/scholar_lookup?title=Safety,+tolerability,+and+efficacy+of+everolimus+in+de+novo+liver+transplant+recipients:+12-+and+36-month+results&author=Levy,+G.&author=Schmidili,+H.&author=Punch,+J.&author=Tuttle-Newhall,+E.&author=Mayer,+D.&author=Neuhaus,+P.&author=et+al.&publication_year=2006&journal=Liver+Transpl&volume=12&pages=1640%E2%80%931648&doi=10.1002/lt.20707" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.20707" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B7-preprints-96239" class="html-x" data-content="7.">Saliba, F.; Dharancy, S.; Salamé, E.; Conti, F.; Eyraud, D.; Radenne, S.; et al. Time to conversion to an everolimus-based regimen: Renal outcomes in liver transplant recipients from the EVEROLIVER registry. <span class="html-italic">Liver Transpl</span> <b>2020</b>, <span class="html-italic">26</span>, 1465–1476. [<a href="https://scholar.google.com/scholar_lookup?title=Time+to+conversion+to+an+everolimus-based+regimen:+Renal+outcomes+in+liver+transplant+recipients+from+the+EVEROLIVER+registry&author=Saliba,+F.&author=Dharancy,+S.&author=Salam%C3%A9,+E.&author=Conti,+F.&author=Eyraud,+D.&author=Radenne,+S.&author=et+al.&publication_year=2020&journal=Liver+Transpl&volume=26&pages=1465%E2%80%931476&doi=10.1002/lt.25879&pmid=32869469" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.25879" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/32869469" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B8-preprints-96239" class="html-x" data-content="8.">De Simone, P.; Fagiuoli, S.; Cescon, M.; De Carlis, L.; Tisone, G.; Volpes, R.; Cillo, U. Use of everolimus in liver transplantation: Recommendations from a working group. <span class="html-italic">Transplantation</span> <b>2017</b>, <span class="html-italic">101</span>, 239–251. [<a href="https://scholar.google.com/scholar_lookup?title=Use+of+everolimus+in+liver+transplantation:+Recommendations+from+a+working+group&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Cescon,+M.&author=De+Carlis,+L.&author=Tisone,+G.&author=Volpes,+R.&author=Cillo,+U.&publication_year=2017&journal=Transplantation&volume=101&pages=239%E2%80%93251&doi=10.1097/TP.0000000000001438&pmid=27495768" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000001438" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27495768" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B9-preprints-96239" class="html-x" data-content="9.">Lee, S.G.; Jeng, L.B.; Saliba, F.; Singh Soin, A.; Lee, W.C.; De Simone, P.; et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. <span class="html-italic">Transplantation</span> <b>2021</b>, <span class="html-italic">105</span>, 1564–1575. [<a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+with+reduced+tacrolimus+in+liver+transplant+recipients:+24-month+results+from+the+pooled+analysis+of+2+randomized+controlled+trials&author=Lee,+S.G.&author=Jeng,+L.B.&author=Saliba,+F.&author=Singh+Soin,+A.&author=Lee,+W.C.&author=De+Simone,+P.&author=et+al.&publication_year=2021&journal=Transplantation&volume=105&pages=1564%E2%80%931575&doi=10.1097/TP.0000000000003394" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000003394" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B10-preprints-96239" class="html-xx" data-content="10.">Lin, M.; Mittal, S.; Sahebjam, F.; Rana, A.; Sood, G.K. Everolimus with early withdrawal or reduced dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. <span class="html-italic">Clin Transplant</span> <b>2017</b>, 31. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+with+early+withdrawal+or+reduced+dose+calcineurin+inhibitors+improves+renal+function+in+liver+transplant+recipients:+A+systematic+review+and+meta-analysis&author=Lin,+M.&author=Mittal,+S.&author=Sahebjam,+F.&author=Rana,+A.&author=Sood,+G.K.&publication_year=2017&journal=Clin+Transplant&pages=31&doi=10.1111/ctr.12872" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1111/ctr.12872" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B11-preprints-96239" class="html-xx" data-content="11.">Guan, T.W.; Lin, Y.J.; Ou, M.Y.; Chen, K.B. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. <span class="html-italic">Eur J Clin Invest</span> <b>2019</b>, <span class="html-italic">49</span>, e13179. [<a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+treatment+on+liver+transplant+recipients:+A+meta-analysis&author=Guan,+T.W.&author=Lin,+Y.J.&author=Ou,+M.Y.&author=Chen,+K.B.&publication_year=2019&journal=Eur+J+Clin+Invest&volume=49&pages=e13179&doi=10.1111/eci.13179" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1111/eci.13179" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B12-preprints-96239" class="html-xx" data-content="12.">Yan, X.; Huang, S.; Yang, Y.; Lu, Z.; Li, F.; Jiang, L.; et al. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis. <span class="html-italic">Liver Transpl</span> <b>2022</b>, <span class="html-italic">28</span>, 1063–1077. [<a href="https://scholar.google.com/scholar_lookup?title=Sirolimus+or+everolimus+improves+survival+after+liver+transplantation+for+hepatocellular+carcinoma:+A+systematic+review+and+meta-analysis&author=Yan,+X.&author=Huang,+S.&author=Yang,+Y.&author=Lu,+Z.&author=Li,+F.&author=Jiang,+L.&author=et+al.&publication_year=2022&journal=Liver+Transpl&volume=28&pages=1063%E2%80%931077&doi=10.1002/lt.26387" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.26387" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B13-preprints-96239" class="html-xx" data-content="13.">[No authors listed] Banff schema for grading liver allograft rejection: An international consensus document. <span class="html-italic">Hepatology</span> <b>1997</b>, <span class="html-italic">25</span>, 658–663. [<a href="https://doi.org/10.1002/hep.510250328" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B14-preprints-96239" class="html-xx" data-content="14.">EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. <span class="html-italic">J Hepatol</span> <b>2012</b>, <span class="html-italic">56</span>, 908–943. [<a href="https://doi.org/10.1016/j.jhep.2011.12.001" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22424438" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B15-preprints-96239" class="html-xx" data-content="15.">Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, A.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <span class="html-italic">J Hepatol</span> <b>2022</b>, <span class="html-italic">76</span>, 681–693. [<a href="https://scholar.google.com/scholar_lookup?title=BCLC+strategy+for+prognosis+prediction+and+treatment+recommendation:+The+2022+update&author=Reig,+M.&author=Forner,+A.&author=Rimola,+J.&author=Ferrer-F%C3%A0brega,+J.&author=Burrel,+M.&author=Garcia-Criado,+A.&author=et+al.&publication_year=2022&journal=J+Hepatol&volume=76&pages=681%E2%80%93693&doi=10.1016/j.jhep.2021.11.018" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2021.11.018" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B16-preprints-96239" class="html-xx" data-content="16.">Olthoff, K.M.; Kulik, L.; Samstein, B.; Kaminski, M.; Abecassis, M.; Emond, J.; Shaked, A.; Christie, J.D. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. <span class="html-italic">Liver Transpl</span> <b>2010</b>, <span class="html-italic">16</span>, 943–949. [<a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+current+definition+of+early+allograft+dysfunction+in+liver+transplant+recipients+and+analysis+of+risk+factors&author=Olthoff,+K.M.&author=Kulik,+L.&author=Samstein,+B.&author=Kaminski,+M.&author=Abecassis,+M.&author=Emond,+J.&author=Shaked,+A.&author=Christie,+J.D.&publication_year=2010&journal=Liver+Transpl&volume=16&pages=943%E2%80%93949&doi=10.1002/lt.22091&pmid=20677285" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.22091" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/20677285" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B17-preprints-96239" class="html-xx" data-content="17.">KDIGO Clinical Practice Guideline for Acute Kidney Injury. <span class="html-italic">Kidney International Supplements</span> <b>2012</b>, <span class="html-italic">2</span>, 1–141.</li> <li id="B18-preprints-96239" class="html-xx" data-content="18.">Tonon, M.; Rosi, S.; Gambino, C.G.; Piano, S.; Calvino, V.; Romano, A.; Martini, A.; Pontisso, P.; Angeli, P. Natural history of acute kidney disease in patients with cirrhosis. <span class="html-italic">J Hepatol</span> <b>2021</b>, <span class="html-italic">74</span>, 578–583. [<a href="https://scholar.google.com/scholar_lookup?title=Natural+history+of+acute+kidney+disease+in+patients+with+cirrhosis&author=Tonon,+M.&author=Rosi,+S.&author=Gambino,+C.G.&author=Piano,+S.&author=Calvino,+V.&author=Romano,+A.&author=Martini,+A.&author=Pontisso,+P.&author=Angeli,+P.&publication_year=2021&journal=J+Hepatol&volume=74&pages=578%E2%80%93583&doi=10.1016/j.jhep.2020.08.037" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2020.08.037" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B19-preprints-96239" class="html-xx" data-content="19.">Diabetes Standards of Care: ADA guidelines (2018). Available at: http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf. Accessed 1st September 2023.</li> <li id="B20-preprints-96239" class="html-xx" data-content="20.">Tejada, S.; Martinez-Revejo, R.; Nogueira, T.A.; Gòmez, A.; Pont, T.; Liao, X.; et al. The effect of sex inequality on solid organ transplantation: A systematic review and meta-analysis. <span class="html-italic">Eur J Int Med</span> <b>2023</b>, <span class="html-italic">109</span>, 58–67. [<a href="https://scholar.google.com/scholar_lookup?title=The+effect+of+sex+inequality+on+solid+organ+transplantation:+A+systematic+review+and+meta-analysis&author=Tejada,+S.&author=Martinez-Revejo,+R.&author=Nogueira,+T.A.&author=G%C3%B2mez,+A.&author=Pont,+T.&author=Liao,+X.&author=et+al.&publication_year=2023&journal=Eur+J+Int+Med&volume=109&pages=58%E2%80%9367&doi=10.1016/j.ejim.2022.12.009" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.ejim.2022.12.009" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B21-preprints-96239" class="html-xx" data-content="21.">Gil, E.; Kim, J.M.; Jeon, K.; Park, H.; Kang, D.; Cho, J.; Suh, G.Y.; Park, H. Recipient age and mortality after liver transplantation: A population-based cohort study. <span class="html-italic">Transplantation</span> <b>2018</b>, <span class="html-italic">102</span>, 2025–2032. [<a href="https://scholar.google.com/scholar_lookup?title=Recipient+age+and+mortality+after+liver+transplantation:+A+population-based+cohort+study&author=Gil,+E.&author=Kim,+J.M.&author=Jeon,+K.&author=Park,+H.&author=Kang,+D.&author=Cho,+J.&author=Suh,+G.Y.&author=Park,+H.&publication_year=2018&journal=Transplantation&volume=102&pages=2025%E2%80%932032&doi=10.1097/TP.0000000000002246" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000002246" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B22-preprints-96239" class="html-xx" data-content="22.">Bhamidimarri, K.R.; Satapathy, S.K.; Martin, P. Hepatitis C virus and liver transplantation. <span class="html-italic">Gastroenterol Hepatol (N Y)</span> <b>2017</b>, <span class="html-italic">13</span>, 214–220. [<a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+C+virus+and+liver+transplantation&author=Bhamidimarri,+K.R.&author=Satapathy,+S.K.&author=Martin,+P.&publication_year=2017&journal=Gastroenterol+Hepatol+(N+Y)&volume=13&pages=214%E2%80%93220" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B23-preprints-96239" class="html-xx" data-content="23.">Brodosi, L.; Petta, S.; Petroni, M.L.; Marchesini, G.; Morelli, M.C. Management of diabetes in candidates for liver transplantation and in transplant recipients. <span class="html-italic">Transplantation</span> <b>2022</b>, <span class="html-italic">106</span>, 462–478. [<a href="https://scholar.google.com/scholar_lookup?title=Management+of+diabetes+in+candidates+for+liver+transplantation+and+in+transplant+recipients&author=Brodosi,+L.&author=Petta,+S.&author=Petroni,+M.L.&author=Marchesini,+G.&author=Morelli,+M.C.&publication_year=2022&journal=Transplantation&volume=106&pages=462%E2%80%93478&doi=10.1097/TP.0000000000003867" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000003867" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B24-preprints-96239" class="html-xx" data-content="24.">Cullaro, G.; Verna, E.C.; Lee, B.P.; Lai, J.C. Chronic Kidney Disease in Liver Transplant Candidates: A rising burden impacting post-liver transplant outcomes. <span class="html-italic">Liver Transpl</span> <b>2020</b>, <span class="html-italic">26</span>, 498–506. [<a href="https://scholar.google.com/scholar_lookup?title=Chronic+Kidney+Disease+in+Liver+Transplant+Candidates:+A+rising+burden+impacting+post-liver+transplant+outcomes&author=Cullaro,+G.&author=Verna,+E.C.&author=Lee,+B.P.&author=Lai,+J.C.&publication_year=2020&journal=Liver+Transpl&volume=26&pages=498%E2%80%93506&doi=10.1002/lt.25694&pmid=31785069" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.25694" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31785069" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B25-preprints-96239" class="html-xx" data-content="25.">Avolio, A.W.; Franco, A.; Schlegel, A.; Lai, Q.; Meli, S.; Burra, P.; et al. Development and validation of a comprehensive model to estimate early allograft failure among patients requiring early liver retransplant. <span class="html-italic">JAMA Surg</span> <b>2020</b>, <span class="html-italic">155</span>, e204095. [<a href="https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+comprehensive+model+to+estimate+early+allograft+failure+among+patients+requiring+early+liver+retransplant&author=Avolio,+A.W.&author=Franco,+A.&author=Schlegel,+A.&author=Lai,+Q.&author=Meli,+S.&author=Burra,+P.&author=et+al.&publication_year=2020&journal=JAMA+Surg&volume=155&pages=e204095&doi=10.1001/jamasurg.2020.4095" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1001/jamasurg.2020.4095" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B26-preprints-96239" class="html-xx" data-content="26.">Sarkar, M.; Watt, K.D.; Terrault, N.; Berenguer, M. Outcomes in liver transplantation: Does sex matter? <span class="html-italic">J Hepatol</span> <b>2015</b>, <span class="html-italic">62</span>, 946–955. [<a href="https://scholar.google.com/scholar_lookup?title=Outcomes+in+liver+transplantation:+Does+sex+matter?&author=Sarkar,+M.&author=Watt,+K.D.&author=Terrault,+N.&author=Berenguer,+M.&publication_year=2015&journal=J+Hepatol&volume=62&pages=946%E2%80%93955&doi=10.1016/j.jhep.2014.11.023" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2014.11.023" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B27-preprints-96239" class="html-xx" data-content="27.">Kanneganti, M.; Olthoff, K.M.; Bittermann, T. Impact of older donor age on recipient and graft survival after LDLT: The US Experience. <span class="html-italic">Transplantation</span> <b>2023</b>, <span class="html-italic">107</span>, 162–171. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+older+donor+age+on+recipient+and+graft+survival+after+LDLT:+The+US+Experience&author=Kanneganti,+M.&author=Olthoff,+K.M.&author=Bittermann,+T.&publication_year=2023&journal=Transplantation&volume=107&pages=162%E2%80%93171&doi=10.1097/TP.0000000000004289" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000004289" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B28-preprints-96239" class="html-xx" data-content="28.">Singhal, A.K.; Sheng, X.; Drakos, S.G.; Stehlik, J. Impact of donor cause of death on transplant outcomes: UNOS registry analysis. <span class="html-italic">Transplant Proc</span> <b>2009</b>, <span class="html-italic">41</span>, 3539–3544. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+donor+cause+of+death+on+transplant+outcomes:+UNOS+registry+analysis&author=Singhal,+A.K.&author=Sheng,+X.&author=Drakos,+S.G.&author=Stehlik,+J.&publication_year=2009&journal=Transplant+Proc&volume=41&pages=3539%E2%80%933544&doi=10.1016/j.transproceed.2009.06.192" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2009.06.192" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B29-preprints-96239" class="html-xx" data-content="29.">Tingle, S.J.; Dobbins, J.J.; Thompson, E.R.; Figueiredo, R.S.; Mahendran, B.; Pandanaboyana, S.; Wilson, C. Machine perfusion in liver transplantation. Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No.: CD014685. [<a href="https://doi.org/10.1002/14651858.CD014685.pub2" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B30-preprints-96239" class="html-xx" data-content="30.">Figiel, W.; Smoter, P.; Krasnodębski, M.; Rykowski, P.; Morawski, M.; Grąt, M.; Patkowski, W.; Zieniewicz, K. Predictors of long-term outcomes after liver transplantation depending on the length of cold ischemia time. <span class="html-italic">Transpl Proc</span> <b>2022</b>, <span class="html-italic">54</span>, 1025–1028. [<a href="https://scholar.google.com/scholar_lookup?title=Predictors+of+long-term+outcomes+after+liver+transplantation+depending+on+the+length+of+cold+ischemia+time&author=Figiel,+W.&author=Smoter,+P.&author=Krasnod%C4%99bski,+M.&author=Rykowski,+P.&author=Morawski,+M.&author=Gr%C4%85t,+M.&author=Patkowski,+W.&author=Zieniewicz,+K.&publication_year=2022&journal=Transpl+Proc&volume=54&pages=1025%E2%80%931028&doi=10.1016/j.transproceed.2022.03.009" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2022.03.009" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B31-preprints-96239" class="html-xx" data-content="31.">Lingiah, V.A.; Niazi, M.; Olivo, R.; Paterno, F.; Guarrera, J.V.; Pyrsopoulos, N.T. Liver transplantation beyond Milan criteria. <span class="html-italic">J Clin Transl Hepatol</span> <b>2020</b>, <span class="html-italic">8</span>, 69–75. [<a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+beyond+Milan+criteria&author=Lingiah,+V.A.&author=Niazi,+M.&author=Olivo,+R.&author=Paterno,+F.&author=Guarrera,+J.V.&author=Pyrsopoulos,+N.T.&publication_year=2020&journal=J+Clin+Transl+Hepatol&volume=8&pages=69%E2%80%9375&doi=10.14218/JCTH.2019.00050" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.14218/JCTH.2019.00050" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B32-preprints-96239" class="html-xx" data-content="32.">Duvoux, C.; Roudot-Thoraval, F.; Decaens, T.; Pessione, F.; Badran, H.; Piardi, P.; et al. Liver transplantation for hepatocellular carcinoma: A model including α-fetoprotein improves the performance of Milan criteria. <span class="html-italic">Gastroenterology</span> <b>2012</b>, <span class="html-italic">143</span>, 986–994. [<a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+for+hepatocellular+carcinoma:+A+model+including+%CE%B1-fetoprotein+improves+the+performance+of+Milan+criteria&author=Duvoux,+C.&author=Roudot-Thoraval,+F.&author=Decaens,+T.&author=Pessione,+F.&author=Badran,+H.&author=Piardi,+P.&author=et+al.&publication_year=2012&journal=Gastroenterology&volume=143&pages=986%E2%80%93994&doi=10.1053/j.gastro.2012.05.052&pmid=22750200" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1053/j.gastro.2012.05.052" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22750200" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B33-preprints-96239" class="html-xx" data-content="33.">Mehta, N.; Guy, J.; Frenette, C.T.; Dodge, J.L.; Osorio, R.W.; Minteer, W.B.; Roberts, J.P.; Yao, F.Y. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: A multicenter study. <span class="html-italic">Clin Gastroenterol Hepatol</span> <b>2018</b>, <span class="html-italic">16</span>, 955–964. [<a href="https://scholar.google.com/scholar_lookup?title=Excellent+outcomes+of+liver+transplantation+following+down-staging+of+hepatocellular+carcinoma+to+within+Milan+criteria:+A+multicenter+study&author=Mehta,+N.&author=Guy,+J.&author=Frenette,+C.T.&author=Dodge,+J.L.&author=Osorio,+R.W.&author=Minteer,+W.B.&author=Roberts,+J.P.&author=Yao,+F.Y.&publication_year=2018&journal=Clin+Gastroenterol+Hepatol&volume=16&pages=955%E2%80%93964&doi=10.1016/j.cgh.2017.11.037" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.cgh.2017.11.037" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B34-preprints-96239" class="html-xx" data-content="34.">Jonas, S.; Bechstein, W.O.; Steinmueller, T.; Hermann, M.; Radke, C.; Berg, T.; Settmacher, U.; Neuhaus, P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. <span class="html-italic">Hepatology</span> <b>2001</b>, <span class="html-italic">33</span>, 1080–1086. [<a href="https://scholar.google.com/scholar_lookup?title=Vascular+invasion+and+histopathologic+grading+determine+outcome+after+liver+transplantation+for+hepatocellular+carcinoma+in+cirrhosis&author=Jonas,+S.&author=Bechstein,+W.O.&author=Steinmueller,+T.&author=Hermann,+M.&author=Radke,+C.&author=Berg,+T.&author=Settmacher,+U.&author=Neuhaus,+P.&publication_year=2001&journal=Hepatology&volume=33&pages=1080%E2%80%931086&doi=10.1053/jhep.2001.23561&pmid=11343235" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1053/jhep.2001.23561" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/11343235" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B35-preprints-96239" class="html-xx" data-content="35.">Rodríguez-Perálvarez, M.; Tsochatzis, E.; Naveas, M.C.; Pieri, G.; García-Caparrós, C.; O'Beirne, J.; et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. <span class="html-italic">J Hepatol</span> <b>2013</b>, <span class="html-italic">59</span>, 1193–1199. [<a href="https://scholar.google.com/scholar_lookup?title=Reduced+exposure+to+calcineurin+inhibitors+early+after+liver+transplantation+prevents+recurrence+of+hepatocellular+carcinoma&author=Rodr%C3%ADguez-Per%C3%A1lvarez,+M.&author=Tsochatzis,+E.&author=Naveas,+M.C.&author=Pieri,+G.&author=Garc%C3%ADa-Caparr%C3%B3s,+C.&author=O'Beirne,+J.&author=et+al.&publication_year=2013&journal=J+Hepatol&volume=59&pages=1193%E2%80%931199&doi=10.1016/j.jhep.2013.07.012&pmid=23867318" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2013.07.012" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/23867318" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B36-preprints-96239" class="html-xx" data-content="36.">Aloun, A.; Abu-Zeid, E.E.D.; Garzali, I.U. Does mTORi based immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? <span class="html-italic">Systematic review and meta-analysis of randomized controlled trials. Hepatol Forum</span> <b>2023</b>, <span class="html-italic">4</span>, 82–88. [<a href="https://scholar.google.com/scholar_lookup?title=Does+mTORi+based+immunosuppression+offer+survival+advantage+after+liver+transplantation+for+hepatocellular+carcinoma?&author=Aloun,+A.&author=Abu-Zeid,+E.E.D.&author=Garzali,+I.U.&publication_year=2023&journal=Systematic+review+and+meta-analysis+of+randomized+controlled+trials.+Hepatol+Forum&volume=4&pages=82%E2%80%9388&pmid=37250931" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/37250931" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B37-preprints-96239" class="html-xx" data-content="37.">Zhang, G.; Duan, B.; Li, G. mTORi-based immunosuppression reduces HCC recurrence at the expenses of increased adverse side effects: A systematic review and meta-analysis. <span class="html-italic">Clin Transplant</span> <b>2022</b>, <span class="html-italic">36</span>, e14823. [<a href="https://scholar.google.com/scholar_lookup?title=mTORi-based+immunosuppression+reduces+HCC+recurrence+at+the+expenses+of+increased+adverse+side+effects:+A+systematic+review+and+meta-analysis&author=Zhang,+G.&author=Duan,+B.&author=Li,+G.&publication_year=2022&journal=Clin+Transplant&volume=36&pages=e14823&doi=10.1111/ctr.14823&pmid=36124430" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1111/ctr.14823" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/36124430" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B38-preprints-96239" class="html-xx" data-content="38.">Grigg SE, Sarri GL, Gow PJ; Yeomans ND. <span class="html-italic">Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther</span> <b>2019</b>, <span class="html-italic">49</span>, 1260–1273.</li> <li id="B39-preprints-96239" class="html-xx" data-content="39.">Tarantino, G.; Magistri, P.; Ballarin, R.; Di Francia, R.; Berretta, M.; Di Benedetto, F. Oncological impact of mTOR inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: Review of the literature. <span class="html-italic">Front Pharmacol</span> <b>2016</b>, <span class="html-italic">7</span>, 387. [<a href="https://scholar.google.com/scholar_lookup?title=Oncological+impact+of+mTOR+inhibitor+immunosuppressive+therapy+after+liver+transplantation+for+hepatocellular+carcinoma:+Review+of+the+literature&author=Tarantino,+G.&author=Magistri,+P.&author=Ballarin,+R.&author=Di+Francia,+R.&author=Berretta,+M.&author=Di+Benedetto,+F.&publication_year=2016&journal=Front+Pharmacol&volume=7&pages=387&doi=10.3389/fphar.2016.00387&pmid=27818634" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.3389/fphar.2016.00387" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27818634" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B40-preprints-96239" class="html-xx" data-content="40.">Holdaas, H.; De Simone, P.; Zuckermann, A. Everolimus and malignancy after solid organ transplantation: A clinical update. <span class="html-italic">J Transplant</span> <b>2016</b>, <span class="html-italic">2016</span>, 4369574. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+and+malignancy+after+solid+organ+transplantation:+A+clinical+update&author=Holdaas,+H.&author=De+Simone,+P.&author=Zuckermann,+A.&publication_year=2016&journal=J+Transplant&volume=2016&pages=4369574&doi=10.1155/2016/4369574&pmid=27807479" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1155/2016/4369574" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27807479" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B41-preprints-96239" class="html-xx" data-content="41.">Geissler, E.K.; Schnitzbauer, A.A.; Zülke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label Phase 3 trial. <span class="html-italic">Transplantation</span> <b>2016</b>, <span class="html-italic">100</span>, 116–125. [<a href="https://scholar.google.com/scholar_lookup?title=Sirolimus+use+in+liver+transplant+recipients+with+hepatocellular+carcinoma:+A+randomized,+multicenter,+open-label+Phase+3+trial&author=Geissler,+E.K.&author=Schnitzbauer,+A.A.&author=Z%C3%BClke,+C.&author=Lamby,+P.E.&author=Proneth,+A.&author=Duvoux,+C.&author=et+al.&publication_year=2016&journal=Transplantation&volume=100&pages=116%E2%80%93125&doi=10.1097/TP.0000000000000965&pmid=26555945" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000000965" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/26555945" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B42-preprints-96239" class="html-xx" data-content="42.">Sapisochin, G.; Lee, W.C.; Joo Dj Joh, J.W.; Hata, K.; Soin, A.S.; et al. Long-term effects of everolimus-facilitated tacrolimus reduction in living donor liver transplant recipients with hepatocellular carcinoma. <span class="html-italic">Ann Transplant</span> <b>2022</b>, <span class="html-italic">27</span>, e937988. [<a href="https://scholar.google.com/scholar_lookup?title=Long-term+effects+of+everolimus-facilitated+tacrolimus+reduction+in+living+donor+liver+transplant+recipients+with+hepatocellular+carcinoma&author=Sapisochin,+G.&author=Lee,+W.C.&author=Joo+Dj+Joh,+J.W.&author=Hata,+K.&author=Soin,+A.S.&author=et+al.&publication_year=2022&journal=Ann+Transplant&volume=27&pages=e937988&doi=10.12659/AOT.937988" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.12659/AOT.937988" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B43-preprints-96239" class="html-xx" data-content="43.">Rodriguez-Peralvarez, M.; Guerrero, M.; Barrera, L.; Ferrin, G.; Alamo, J.M.; et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation. <span class="html-italic">Transplantation</span> <b>2018</b>, <span class="html-italic">102</span>, 2056–2064. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+early+initiated+everolimus+on+the+recurrence+of+hepatocellular+carcinoma+after+liver+transplantation&author=Rodriguez-Peralvarez,+M.&author=Guerrero,+M.&author=Barrera,+L.&author=Ferrin,+G.&author=Alamo,+J.M.&author=et+al.&publication_year=2018&journal=Transplantation&volume=102&pages=2056%E2%80%932064&doi=10.1097/TP.0000000000002270" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000002270" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B44-preprints-96239" class="html-xx" data-content="44.">Kang, I.; Lee, J.G.; Choi, S.H.; Kim, H.J.; Han, D.H.; Choi, G.H.; et al. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. <span class="html-italic">Clin Mol Hepatol</span> <b>2021</b>, <span class="html-italic">27</span>, 589–602. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+everolimus+on+survival+after+liver+transplantation+for+hepatocellular+carcinoma&author=Kang,+I.&author=Lee,+J.G.&author=Choi,+S.H.&author=Kim,+H.J.&author=Han,+D.H.&author=Choi,+G.H.&author=et+al.&publication_year=2021&journal=Clin+Mol+Hepatol&volume=27&pages=589%E2%80%93602&doi=10.3350/cmh.2021.0038&pmid=34293849" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.3350/cmh.2021.0038" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/34293849" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B45-preprints-96239" class="html-xx" data-content="45.">Wasilewicz, M.P.; Moczydlowska, D.; Janik, M.; Grat, M.; Zienewicz, K.; Raszeja-Wyszomirska, J. Immunosuppressive treatment with everolimus in patients after liver transplant: 4 years of single-center experience. <span class="html-italic">Pol Arch Intern Med</span> <b>2019</b>, <span class="html-italic">129</span>, 686–691. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppressive+treatment+with+everolimus+in+patients+after+liver+transplant:+4+years+of+single-center+experience&author=Wasilewicz,+M.P.&author=Moczydlowska,+D.&author=Janik,+M.&author=Grat,+M.&author=Zienewicz,+K.&author=Raszeja-Wyszomirska,+J.&publication_year=2019&journal=Pol+Arch+Intern+Med&volume=129&pages=686%E2%80%93691&pmid=31502586" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31502586" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B46-preprints-96239" class="html-xx" data-content="46.">Cholongitas, E.; Antoniadis, N.; Goulis, I.; Theocharidou, E.; Imvrios, G.; Giouleme, O.; et al. Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation. <span class="html-italic">Transplant Proc</span> <b>2019</b>, <span class="html-italic">51</span>, 450–453. [<a href="https://scholar.google.com/scholar_lookup?title=Trough+levels+of+everolimus+are+associated+with+recurrence+rates+of+hepatocellular+carcinoma+after+liver+transplantation&author=Cholongitas,+E.&author=Antoniadis,+N.&author=Goulis,+I.&author=Theocharidou,+E.&author=Imvrios,+G.&author=Giouleme,+O.&author=et+al.&publication_year=2019&journal=Transplant+Proc&volume=51&pages=450%E2%80%93453&doi=10.1016/j.transproceed.2019.01.069&pmid=30879564" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2019.01.069" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30879564" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B47-preprints-96239" class="html-xx" data-content="47.">Engl, T.; Rutz, J.; Maxeiner, S.; Juengel, E.; Roos, F.; Khoder, W.; et al. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma in vitro. <span class="html-italic">Mol Med Rep</span> <b>2017</b>, <span class="html-italic">16</span>, 7064–7071. [<a href="https://scholar.google.com/scholar_lookup?title=mTOR+inhibition+reduces+growth+and+adhesion+of+hepatocellular+carcinoma+in+vitro&author=Engl,+T.&author=Rutz,+J.&author=Maxeiner,+S.&author=Juengel,+E.&author=Roos,+F.&author=Khoder,+W.&author=et+al.&publication_year=2017&journal=Mol+Med+Rep&volume=16&pages=7064%E2%80%937071&doi=10.3892/mmr.2017.7401&pmid=28901501" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.3892/mmr.2017.7401" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/28901501" class="cross-ref pub_med" data-typ="pmid" target="_blank" rel="noopener noreferrer">PubMed</a>]</li> <li id="B48-preprints-96239" class="html-xx" data-content="48.">Ande, A.; Chaar, M.; Ait-Oudhia, S. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. <span class="html-italic">J Pharmacokinet Pharmacodyn</span> <b>2018</b>, <span class="html-italic">45</span>, 607–620. [<a href="https://scholar.google.com/scholar_lookup?title=Multiscale+systems+pharmacological+analysis+of+everolimus+action+in+hepatocellular+carcinoma&author=Ande,+A.&author=Chaar,+M.&author=Ait-Oudhia,+S.&publication_year=2018&journal=J+Pharmacokinet+Pharmacodyn&volume=45&pages=607%E2%80%93620&doi=10.1007/s10928-018-9590-0" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1007/s10928-018-9590-0" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> <li id="B49-preprints-96239" class="html-xx" data-content="49.">Cillo, U.; De Carlis, L.; Del Gaudio, M.; De Simone, P.; Fagiuoli, S.; Lupo, F.; Tisone, G.; Volpes, R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: Consensus recommendations from an Italian working group. <span class="html-italic">Liver Int</span> <b>2020</b>, <span class="html-italic">146</span>, 930–943. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppressive+regimens+for+adult+liver+transplant+recipients+in+real-life+practice:+Consensus+recommendations+from+an+Italian+working+group&author=Cillo,+U.&author=De+Carlis,+L.&author=Del+Gaudio,+M.&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Lupo,+F.&author=Tisone,+G.&author=Volpes,+R.&publication_year=2020&journal=Liver+Int&volume=146&pages=930%E2%80%93943&doi=10.1007/s12072-020-10091-5" class="google-scholar" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="https://doi.org/10.1007/s12072-020-10091-5" class="cross-ref" target="_blank" rel="noopener noreferrer">CrossRef</a>]</li> </ol></section><section id="FiguresandTables" type="display-objects"><div class="html-fig-wrap" id="preprints-96239-f001"> <div class="html-fig_img"> <div class="html-figpopup html-figpopup-link" href="#fig_body_display_preprints-96239-f001"> <img data-large="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png" data-original="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png" alt="Preprints 96239 g001" src="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png"> <a class="html-expand html-figpopup" href="#fig_body_display_preprints-96239-f001"></a> </div> </div> <div class="html-fig_description"> <b>Figure 1.</b> Kaplan-Meier probability of post-transplant overall patient survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.506).  </div> </div> <div class="html-fig_show mfp-hide" id="fig_body_display_preprints-96239-f001"> <div class="html-caption"> <b>Figure 1.</b> Kaplan-Meier probability of post-transplant overall patient survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.506).</div> <div class="html-img"><img data-large="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png" data-original="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png" alt="Preprints 96239 g001" src="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png"></div> </div> <div class="html-fig-wrap" id="preprints-96239-f002"> <div class="html-fig_img"> <div class="html-figpopup html-figpopup-link" href="#fig_body_display_preprints-96239-f002"> <img data-large="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png" data-original="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png" alt="Preprints 96239 g002" src="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png"> <a class="html-expand html-figpopup" href="#fig_body_display_preprints-96239-f002"></a> </div> </div> <div class="html-fig_description"> <b>Figure 2.</b> Kaplan-Meier probability of post-transplant recurrence-free survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.205).  </div> </div> <div class="html-fig_show mfp-hide" id="fig_body_display_preprints-96239-f002"> <div class="html-caption"> <b>Figure 2.</b> Kaplan-Meier probability of post-transplant recurrence-free survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.205).</div> <div class="html-img"><img data-large="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png" data-original="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png" alt="Preprints 96239 g002" src="https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png"></div> </div> <div class="html-table-wrap" id="preprints-96239-t001"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t001"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t001"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 1.</b> demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t001"> <div class="html-caption"> <b>Table 1.</b> demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center.</div> <table> <thead><tr> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Variable</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">EVR (#463)</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">CNI (#556)</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">P</th> </tr></thead> <tbody> <tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>RECIPIENT</b></td></tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Male sex, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">386 (83.4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">487 (87.6)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.55</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Age at transplant (median, IQR), years</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">56 (10)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">56 (10)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.28</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Indication to transplant, n (%)<br>HCV<br>HBV (±HDV)<br>HCV-HBV(±HDV)<br>Alcohol<br>NAFLD<br>Autoimmune/PSC</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br>237 (55.5)<br>123 (26.5)<br>17 (3.7)<br>54 (11.6)<br>20 (4.3)<br>12 (5.2)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br>294 (52.8)<br>153 (27.5)<br>20 (3.5)<br>59 (9.5)<br>24 (4.3)<br>6 (1.1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br>0.59<br>0.73<br>0.94<br>0.59<br>0.99<br>0.67</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Lab-MELD at transplant (median, IQR)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">7 (6)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">8 (7)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.45</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">DM at transplant, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">113 (24.4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">144 (25.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.58</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">CKD at transplant, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">27 (5.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">39 (7.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.44</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Hypertension at transplant, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">69 (14.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">76 (13.6)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.57</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><2013, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">147 (31.7)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">387 (66.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.0001</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">TAC, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">403 (86.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">313 (56.3)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.0001</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Mean TAC exposure >10 ng/mL within the first month post-transplantation</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">127 (27.4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">172 (31.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.22</td> </tr> <tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>DONOR</b></td></tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Male sex, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">241 (52.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">281 (50.5)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.63</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Age, median (IQR)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">69 (25)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">67 (26)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.78</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">ICU stay, median (IQR) days</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">3 (4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">3 (4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.67</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">CVA as cause of death, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">333 (71.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">411 (73.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.47</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Anti-HCV-positive, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">4 (0.86)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0 (0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.58</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Anti-HBc-positive, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">60 (12.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">77 (13.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.67</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Cardiac arrest episodes, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">43 (9.3)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">42 (7.5)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.31</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Use of inotropes, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">407 (87.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">483 (86.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.62</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>HCC</b></td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Tumor nodules*, median (IQR)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">2 (1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">2 (1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.78</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Largest nodule size*, median (IQR) (mm)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">28 (18)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">25 (15)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <b>0.04</b><br> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Total tumor size*, median (IQR) (mm)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">39.5 (25)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">36.5 (36)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <b>0.003</b><br> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Exceeding Milan criteria at transplant *, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">152 (32.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">101 (18.1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.0001</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Pre-transplant treatment, n (%)<br>None, n (%)<br>TACE, n (%)<br>RFA/MW, n (%)<br>PEI, n (%)<br>Resection, n (%)<br>TACE + RFA/MW, n (%)<br>TARE, n (%)<br><br>Successful downstage**, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br>141 (30.4) <br>229 (49.4)<br>33 (7.1) <br>6 (1.3) <br>6 (1.3) <br>42 (9.1) <br>6 (1.3) <br><br>75 (16.2)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br>209 (37.6) <br>307 (55.2)<br>22 (3.9) <br>12 (2.1) <br>4 (0.7) <br>2 (0.5)<br>0 (0)<br><br>45 (8.1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> <br><b>0.01</b><br>0.06<br><b>0.02</b><br>0.29<br>0.35<br><b><0.0001</b><br><b>0.008</b><br><br><b>0.0006</b> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">AFP at transplant, median (IQR) (ng/mL)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">46.3 (28)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">4.7 (19)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.002<br> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Milan-out at explant histology, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">120 (25.9)<br> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">167 (30.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.98</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">G3-4, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">148 (31.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">140 (25.1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>0.01</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Microvascular infiltration, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">88 (39.5)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">182 (32.7)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>0.02</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b>TRANSPLANTATION</b></td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"> </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">CIT, median (IQR) (min)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">424 (89)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">420 (101)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.09</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">MP, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">9 (1.9)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">7 (1.2)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.89</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Re-transplantation, n (%)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">18 (3.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">23 (4.1)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">0.45</td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: AFP, alpha-fetoprotein; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; IQR, interquartile range; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; MW, microwave ablation; MP, machine perfusion; PEI, percutaneous ethanol injection; PSC, primary sclerosing cholangitis; RFA, radiofrequency ablation; TAC, tacrolimus; TACE, trans-arterial chemoembolization; TARE, trans-arterial radioembolization. *Radiological; ** Radiological, as downstaged from outside to within Milan criteria.</span></div> <div style="clear:both;"></div> </div> </div> <div class="html-table-wrap" id="preprints-96239-t002"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t002"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t002"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 2.</b> Effect of stabilized IPTW in the population on the variables used for balancing the two groups. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t002"> <div class="html-caption"> <b>Table 2.</b> Effect of stabilized IPTW in the population on the variables used for balancing the two groups.</div> <table> <thead> <tr> <th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Variables</th> <th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Pre-IPTW </th> <th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Post-IPTW</th> </tr> <tr> <th align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">EVR (n=463)</th> <th align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">CNI (n=556)</th> <th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Cohen’s D-value</th> <th align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">EVR (n=233)</th> <th align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">TAC (n=278)</th> <th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Cohen’s D-value</th> </tr> <tr> <th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Mean (±SD)</th> <th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Mean (±SD)</th> </tr> </thead> <tbody> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Patient male sex</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.83±0.15</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.87±0.14</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.05</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.81±0.17</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.82±0.15</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.05</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Patient age, years</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.9±3.92</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">56.4±3.46</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.20</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.1±0.55</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.3±0.53</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.03</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>HCV</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.5±0.70</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.8±0.58</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.42</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">24.3±0.56</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">24.1±0.52</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Patient diabetes</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.24±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.26±0.45</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.12</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.24±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.00</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Patient CKD</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.05±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.07±0.42</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.42</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.05±0.01</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.05±0.01</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>MELD</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.07±0.26</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.11±0.33</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.15</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.38</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.07±0.37</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Donor male sex</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.52±0.38</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.50±0.41</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.08</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.51±0.28</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.50±0.28</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Donor age, years</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.69±0.65</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.67±0.64</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.68±0.38</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.67±0.37</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.03</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Donor cause of death (CVA)</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.71±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.73±0.40</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.13</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.71±0.46</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.72±0.45</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.02</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>MP</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.09±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.00</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>CIT, minutes</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">431.77±79.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">423.50±85.79</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.10</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.53±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.53±0.50</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Milan-out stage, radiologic</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">32.8±2.33</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">19±1.65</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.42</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">29.2±1.2</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">26.3±0.9</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.02</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Tumor downstaging</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.17±0.05</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.04</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.43</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.10±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.08±0.08</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.04</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>AFP at transplant</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.45±0.27</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.04±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.38</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23±0.04</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.19±0.06</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.14</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Milan-out stage, histology</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">26.1±1.5</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">29.1±2.3</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.16</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">24.0±2.3</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">22.0±2.8</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.12</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>G3-G4</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">32.0±2.4</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">25±1.8</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">29.0±2.3</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">28.2±2.0</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.21</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Microinfiltration</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">40.2±1.2</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">33.7±1.7</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.26</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">38.1±2.3</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">32.5±1.9</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.20</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>Mean TAC exposure >10 ng/mL within the first month</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.28±0.04</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.32±0.45</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.13</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.15±0.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.13±0.03</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.00</td> </tr> <tr><td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney disease; CVA, cerebro-vascular accident; G, grading; HCV, hepatitis C virus; IPTW, inverse probability therapy weighting; MP, machine perfusion; n, number; SD, standard deviation; TAC, tacrolimus. </td></tr> </tbody> </table> </div> <div class="html-table-wrap" id="preprints-96239-t003"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t003"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t003"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 3.</b> The characteristics of the 2 pseudo-groups after IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t003"> <div class="html-caption"> <b>Table 3.</b> The characteristics of the 2 pseudo-groups after IPTW matching.</div> <table> <thead><tr> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">Variable</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">EVR (#233)</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">TAC (#278)</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">P</th> </tr></thead> <tbody> <tr><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>RECIPIENT</b></td></tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Male sex, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">192 (82.4)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">228 (82.0)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.90</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Age at transplant (median, IQR), years</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.5 (9)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55.3 (10)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.89</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">HCV, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">58 (24.3)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">69 (24.8)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Lab-MELD at transplant (median, IQR) * </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">8 (6)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">7 (7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.78</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">DM at transplant, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">53 (22.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">66 (23.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.83</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">CKD at transplant, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">12 (5.1)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">14 (5.0)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Mean TAC exposure >10 ng/mL within the first month post-transplantation</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">35 (15.0)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">36 (12.9)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.52</td> </tr> <tr><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>DONOR</b></td></tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Male sex, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">118 (50.6)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">140 (50.3)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Age, median (IQR)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">68.0 (23)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">67 (26)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.89</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">CVA as cause of death, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">181 (77.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">200 (71.9)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.15</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>HCC</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Exceeding Milan criteria at transplant *, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">67 (28.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">72 (25.8)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.48</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Successful downstaging**, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">24 (10.3)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">23 (8.2)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.44</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">AFP at transplant, median (IQR) (ng/mL)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">23.3 (18)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">19 (11)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.56</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Milan-out at explant histology, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">55 (23.6)<br> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">62 (22.3)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.75</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">G3-4, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">67 (28.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">78 (28.1)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.92</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Microvascular infiltration, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">88 (37.8)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">91 (32.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.26</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>TRANSPLANTATION</b></td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> </td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">CIT, median (IQR) (min)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">432 (89)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">489 (101)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.06</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">MP, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">9 (1.9)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">7 (1.2)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.89</td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MELD, model for end-stage liver disease; MP, machine perfusion; TAC, tacrolimus. *Radiological; ** Radiological, as downstaged from outside to within Milan criteria.</span></div> <div style="clear:both;"></div> </div> </div> <div class="html-table-wrap" id="preprints-96239-t004"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t004"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t004"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 4.</b> Results in the study groups after stabilized IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t004"> <div class="html-caption"> <b>Table 4.</b> Results in the study groups after stabilized IPTW matching.</div> <table> <thead><tr> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">Variable</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">EVR (#233)</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">TAC (#278)</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">P</th> </tr></thead> <tbody> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Death, n (%)<br><br>HCC recurrence, n (%)<br>HCV recurrence, n (%)<br>Incomplete/delayed graft function, n (%)<br>MACE, n (%)<br>Intra/peri-operative, n (%)<br>Ischemic cholangiopathy, n (%)<br>Infection/sepsis, n (%)<br><span class="html-italic">De novo</span> malignancy, n (%)<br>Stroke, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">62 (26.6)<br><br>16 (6.8)<br>16 (6.9)<br>1 (0.4)<br>2 (0.8)<br>2 (0.8)<br>4 (1.7)<br>12 (5.1)<br>5 (2.1)<br>4 (1.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">105 (37.8)<br><br>42 (15.1)<br>15 (5.4)<br>2 (0.7)<br>6 (2.1)<br>3 (1.1)<br>7 (2.5)<br>16 (5.7)<br>11 (3.9)<br>3 (1.1)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> <b>0.007</b><br><br><b>0.003</b><br>0.48<br>0.22<br>0.30<br>1<br>0.76<br>0.84<br>0.31<br>0.70</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Re-transplantation, n (%)<br><br>Ischemic cholangiopathy, n (%)<br>PNF, n (%)<br>HAT, n %<br>Chronic rejection, n (%)<br>HCV recurrence, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">9 (3.9)<br><br>3 (1.3)<br>3 (1.3)<br>2 (0.8)<br>1 (0.4)<br>0 (0)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">11 (3.9)<br><br>3 (1.1)<br>5 (1.8)<br>1 (0.3)<br>1 (0.3)<br>1 (0.3)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1<br><br>1<br>0.73<br>0.59<br>1<br>0.99</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">HCC recurrence, n (%)<br><br>Liver only, n (%)<br>Liver and lung, n (%)<br>Liver and bone, n (%)<br>Lung only, n (%)<br>Bone only, n (%)<br>Lung and bone, n (%)<br>Nodes, n (%)<br>>2 organs, n (%)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">18 (7.7)<br><br>7 (3.0)<br>1 (0.4)<br>0 (0)<br>4 (1.7)<br>4 (1.7)<br>1 (0.4)<br>1 (0.4)<br>2 (0.8)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">47 (16.9)<br><br>15 (5.4)<br>8 (2.8)<br>4 (1.4)<br>9 (1.8)<br>1 (0.2)<br>4 (1.4)<br>6 (2.1)<br>16 (5.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.002<br><br>0.19<br>0.04<br>0.12<br>0.39<br>0.18<br>0.38<br>0.13<br>0.002</td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: EVR, everolimus; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MACE, major cardiovascular events; PNF, primary non-function; TAC, tacrolimus. .</span></div> <div style="clear:both;"></div> </div> </div> <div class="html-table-wrap" id="preprints-96239-t005"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t005"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t005"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 5.</b> Immunosuppression in the EVR study groups after stabilized IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t005"> <div class="html-caption"> <b>Table 5.</b> Immunosuppression in the EVR study groups after stabilized IPTW matching.</div> <table> <thead><tr> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">Variable</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">EVR (#233)</th> </tr></thead> <tbody> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Reason for EVR use, n (%)<br><br>HCC recurrence prophylaxis, n (%)<br>Deteriorating renal function *, n (%)<br>Neurologic complication *, n (%)<br>MACE *, n (%)<br> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"> <br><br>212 (91.0)<br>14 (6.0)<br>4 (1.7)<br>3 (1.2)</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Timing of EVR introduction, median (IQR) (days) * <br> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">30 (16) </td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Duration of EVR treatment, median (IQR) (months) *<br> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">46.6 (36.1)</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">EVR whole-blood exposure, median (IQR) (ng/mL) *<br> </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">5.8 (1.7)</td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: EVR, everolimus; HC, hepatocellular carcinoma; IPTW, inverse probability of treatment weigthing; IQR, interquartile range; MACE, major cardiovascular events.</span></div> <div style="clear:both;"></div> </div> </div> <div class="html-table-wrap" id="preprints-96239-t006"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t006"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t006"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 6.</b> EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t006"> <div class="html-caption"> <b>Table 6.</b> EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group.</div> <table> <thead><tr> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Variable</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Recurring HCC (#18)</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">Non-recurring HCC (#215)</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-center">P</th> </tr></thead> <tbody> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Timing of EVR introduction, median (IQR) (days) * </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">52 (26.4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">30 (12) </td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.001</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">Duration of EVR treatment, median (IQR) (months) *</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">46.5 (57.0)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">69.9 (24.8)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.001</b></td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">EVR whole-blood exposure, median (IQR) (ng/mL) *</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">3.65 (0.55)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center">5.9 (1.4)</td> <td align="center" valign="middle" style="border-bottom:solid thin" class="html-align-center"><b><0.001</b></td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: EVR, everolimus; HCC, hepatocellular carcinoma; IQR, interquartile range.</span></div> <div style="clear:both;"></div> </div> </div> <div class="html-table-wrap" id="preprints-96239-t007"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" href="#table_body_display_preprints-96239-t007"> <img src="https://pub.mdpi-res.com/img/table.png"> <a class="html-expand html-tablepopup" href="#table_body_display_preprints-96239-t007"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 7.</b> Results of the multivariable analysis of risk factors for both recurrence-free and overall survival. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_preprints-96239-t007"> <div class="html-caption"> <b>Table 7.</b> Results of the multivariable analysis of risk factors for both recurrence-free and overall survival.</div> <table> <thead><tr> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">Variable </th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">Coefficients (95%CI)<br> </th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">SE</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">z</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">HR</th> <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" class="html-align-left">p</th> </tr></thead> <tbody> <tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>OS</b></td></tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Successful pre-transplant downstaging</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.6 (0.15; 1.06)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.6</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.79</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.006</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Within Milan criteria at transplant</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-1.15 (-1.61;-0.7)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">5.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.67</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b><0.01</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Within Milan criteria at histology</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01 (0; 0.01)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.41</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.78</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.02</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Micro-infiltration</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.39 (-0.01; 0.78)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.2</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.91</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.13</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.056</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">G3-G4</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.25 (0.01; 0.5)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.12</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.02</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.18</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.077</td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">EVR</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.59 (-1.02; -0.16)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.22</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.7</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.69</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.009</b></td> </tr> <tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>RFS</b></td></tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Successful pre-transplant downstaging </td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.57 (0.12; 1.02)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.47</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.65</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.01</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Within Milan criteria at transplant</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-1.18 (-1.63;-0.72)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.23</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">5.11</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.56</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.01</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Within Milan criteria at histology</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.01 (0; 0.01)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.52</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.68</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.012</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">Micro-infiltration</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.42 (0.02; 0.81)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.2</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">2.06</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.22</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.04</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">G3-G4</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.22 (-0.02; 0.47)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.13</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.77</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">1.27</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b>0.04</b></td> </tr> <tr> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">EVR</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">-0.78 (1.2; -0.36)</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.21</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">3.66</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left">0.46</td> <td align="left" valign="middle" style="border-bottom:solid thin" class="html-align-left"><b><0.001</b></td> </tr> </tbody> </table> <div class="html-table_foot html-p"> <div class="html-p" style="text-indent:0em;"><span class="html-fn-content">NOTE: AFP, alpha-fetoprotein; EVR, everolimus; HCV, hepatitis C virus; OS, overall survival; RFS, recurrence-free survival.</span></div> <div style="clear:both;"></div> </div> </div> </section><section class="html-fn_group"><table><tr id> <td></td> <td><div class="html-p"> <b>Disclaimer/Publisher’s Note:</b> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</div></td> </tr></table></section> <section id="html-copyright"><br>© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a>).</section> </div><div class="pt-lg" data-v-da90062a><span class="m-text text-body font-semibold" data-v-da90062a>Copyright: </span><span class="m-text text-body" data-v-da90062a>This open access article is published under a <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" data-v-da90062a><span class="hover:underline cursor-pointer text-color-link-bold" data-v-da90062a>Creative Commons CC BY 4.0 license</span></a>, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.</span></div></div><div class="pt-md"><div class="swiper"><div class="swiper-wrapper"><div class="swiper-slide" data-swiper-slide-index="0"><a href="https://www.mdpi.com/authors/english?utm_source=preprintsweb&utm_medium=banner&utm_campaign=AS_High-quality" target="_blank"><img src="https://www.preprints.org/media/cache/resolve/webp/upload/banner/2024-10-30/c8ecd3b8b0ebf1abcd96d37f5ee4a609.jpeg" class="w-full h-auto"></a></div><div class="swiper-slide" data-swiper-slide-index="1"><a href="https://www.preprints.org/activity/award/announcement?utm_source=ArticlePage&utm_medium=Banner&utm_campaign=award" target="_blank"><img src="https://www.preprints.org/media/cache/resolve/webp/upload/banner/2024-10-30/58bbc3b8f7c90f2eab7ce32d00691421.jpeg" class="w-full h-auto"></a></div></div><div class="swiper-pagination"></div></div></div><div class="pt-md lg:pt-lg" data-v-694159ae><div class="m-accordion mx-auto flex w-full flex-col gap-3 rounded-2xl bg-white" data-v-694159ae><div class="m-accordion__item border-b border-color-default" data-v-694159ae><button id="accordion-button-expand-0" aria-controls="accordion-panel-0" class="relative mb-xs flex w-full cursor-pointer py-md text-sm outline-offset-2" aria-expanded="true"><span class="text-sm">Recommended Articles</span><div class="absolute right-0 top-1/2 -translate-y-1/2"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="keyboard_arrow_down" class="origin-center transition duration-150 rotate-180" style="" width="16" height="16" viewBox="0 0 16 16"></svg></div></button><div id="accordion-panel-0" aria-labelledby="accordion-button-expand-0" role="region" class="m-accordion__body overflow-hidden transition-height duration-150"><div class="break-words pb-md"><div class="w-full" data-v-694159ae><div class="mb-md"><a href="https://doi.org/10.20944/preprints202401.1027.v1" target="_blank"><div class="m-rich-text text-body font-semibold">Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation</div></a><div class="pt-xs flex"><div class="flex items-center pr-sm flex-wrap"><p class="m-text text-sm">Paolo De Simone</p><p class="m-text text-xs pl-xs">et al.</p><p class="m-text text-xs pl-xs italic">,</p><p class="m-text text-sm ml-xs font-semibold">2024</p></div></div></div><div class="mb-md"><a href="https://doi.org/10.20944/preprints202309.1286.v1" target="_blank"><div class="m-rich-text text-body font-semibold">Sequential Regorafenib or Nivolumab Therapy in Recurrent Hepatocellular Carcinoma with Sorafenib Failure in Liver Transplant Patients Does Not Improve Prognosis</div></a><div class="pt-xs flex"><div class="flex items-center pr-sm flex-wrap"><p class="m-text text-sm">Jieun Kwon</p><p class="m-text text-xs pl-xs">et al.</p><p class="m-text text-xs pl-xs italic">,</p><p class="m-text text-sm ml-xs font-semibold">2023</p></div></div></div><div class="mb-md"><a href="https://doi.org/10.20944/preprints202310.1682.v1" target="_blank"><div class="m-rich-text text-body font-semibold">Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer</div></a><div class="pt-xs flex"><div class="flex items-center pr-sm flex-wrap"><p class="m-text text-sm">Rie Sugimoto</p><p class="m-text text-xs pl-xs">et al.</p><p class="m-text text-xs pl-xs italic">,</p><p class="m-text text-sm ml-xs font-semibold">2023</p></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span></div><div class="border-t-[.0625rem] border-solid border-color-default"><div class="m-container mx-auto w-full flex-col-reverse py-section-mobile py-2xl lg:py-10xl bg-white" style="--container-ideal-width:92.5vw;"><div class="h-[auto]"><div class="flex flex-wrap"><div class="w-[100%] lg:w-[25%] xl:w-[25%] lg:px-[.9375rem] pb-lg"><div class="w-36 h-auto mb-lg cursor-pointer"><a href="/"><img src="/_nuxt/preprints.C_f_-Qxj.png" alt="Prerpints.org logo" class="w-36 h-auto"></a></div><p class="m-text text-sm mb-lg">Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.</p><div class="flex lg:items-center lg:block pb-0 items-start justify-between"><div class="flex lg:mb-lg"><a href="https://www.facebook.com/MDPIOpenAccessPublishing" target="_blank" rel="noopener noreferrer"><img src="/img/footerImg/facebook.svg" alt="facebook logo" class="w-6 h-6 mr-md"></a><a href="https://twitter.com/Preprints_org" target="_blank" rel="noopener noreferrer"><img src="/img/footerImg/twitter.svg" alt="twitter logo" class="w-6 h-6 mr-md"></a><a href="https://www.linkedin.com/showcase/preprints" target="_blank" rel="noopener noreferrer"><img src="/img/footerImg/linkedin.svg" alt="linkedin logo" class="w-6 h-6 mr-md"></a><div class="w-40"><div class="relative" data-headlessui-state><button id="headlessui-popover-button-mui-8235" type="button" aria-expanded="false" data-headlessui-state><img src="data:image/svg+xml,%3csvg%20width='22'%20height='19'%20viewBox='0%200%2022%2019'%20fill='none'%20xmlns='http://www.w3.org/2000/svg'%3e%3cg%20id='Group'%3e%3cpath%20id='Vector'%20d='M15.0641%206.7834C13.1271%206.8846%2011.4427%207.4718%2010.0751%208.79844C8.69347%2010.1388%208.06283%2011.7812%208.23515%2013.8172C7.47803%2013.7234%206.78843%2013.6202%206.09491%2013.5618C5.85539%2013.5416%205.57115%2013.5703%205.36827%2013.6848C4.69483%2014.0648%204.04931%2014.4938%203.28403%2014.9722C3.42443%2014.3372%203.51531%2013.781%203.67619%2013.2462C3.79451%2012.8531%203.73971%2012.6344%203.37755%2012.3782C1.05227%2010.7365%200.0721108%208.27972%200.805631%205.7502C1.48427%203.4102%203.15083%201.99108%205.41531%201.25132C8.50619%200.241717%2011.9797%201.27156%2013.8591%203.72548C14.5379%204.61188%2014.9541%205.60676%2015.0641%206.7834ZM6.14915%205.99524C6.16699%205.5326%205.76611%205.1158%205.28995%205.10188C4.80243%205.08756%204.40147%205.46012%204.38723%205.94052C4.37283%206.4274%204.74523%206.81756%205.23627%206.83004C5.72307%206.84236%206.13115%206.46932%206.14915%205.99524ZM10.8004%205.10156C10.3225%205.11036%209.91867%205.5174%209.92715%205.98188C9.93587%206.46332%2010.332%206.83996%2010.8235%206.83404C11.3162%206.82812%2011.6899%206.44748%2011.6852%205.95588C11.6811%205.47332%2011.2868%205.09268%2010.8004%205.10156Z'%20fill='white'/%3e%3cpath%20id='Vector_2'%20d='M19.4168%2018.8594C18.8034%2018.5863%2018.2408%2018.1765%2017.6417%2018.114C17.045%2018.0516%2016.4177%2018.3959%2015.7934%2018.4597C13.8917%2018.6543%2012.188%2018.1243%2010.7832%2016.8252C8.11148%2014.3539%208.49324%2010.5648%2011.5844%208.53972C14.3316%206.73988%2018.3607%207.33988%2020.2976%209.83724C21.988%2012.0164%2021.7893%2014.9092%2019.7258%2016.74C19.1287%2017.2698%2018.9139%2017.7058%2019.297%2018.4043C19.3676%2018.5332%2019.3757%2018.6965%2019.4168%2018.8594ZM12.4348%2012.0995C12.8253%2012.0999%2013.1468%2011.7943%2013.1616%2011.4086C13.1772%2011.0003%2012.8488%2010.6578%2012.44%2010.6561C12.0351%2010.6543%2011.696%2011.0016%2011.7101%2011.4038C11.7234%2011.7881%2012.0472%2012.099%2012.4348%2012.0995ZM16.9357%2010.6577C16.5569%2010.6551%2016.2349%2010.9652%2016.2195%2011.348C16.2031%2011.7574%2016.5212%2012.0936%2016.9264%2012.0946C17.3182%2012.096%2017.6279%2011.7996%2017.642%2011.4096C17.6572%2010.9993%2017.3389%2010.6605%2016.9357%2010.6577Z'%20fill='white'/%3e%3c/g%3e%3c/svg%3e" class="w-6 h-6 bg-black rounded cursor-pointer" alt="weChat logo"></button></div><div hidden style="position:fixed;top:1;left:1;width:1;height:0;padding:0;margin:-1;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border-width:0;display:none;"></div></div></div><div class="flex items-center flex-col w-min lg:gap-y-lg gap-y-md"><a class="inline-block" href="mailto:info@preprints.org"><button class="m-button m-button--md m-button--secondary rounded" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center">Contact Us</span></button></a><button class="m-button m-button--md m-button--secondary rounded !w-full" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="rss_feed" weight="400" style="" width="16" height="16" viewBox="0 0 16 16"></svg>RSS</span></button></div></div></div><div class="w-[100%] lg:w-[25%] xl:w-[25%] px-md pt-sm border-t border-color-black sm:pt-0 sm:border-0 sm:border-white"><div class="flex items-center justify-between lg:block"><h5 class="m-heading text-inherit m-h5 font-semibold pt-md lg:pt-0 pb-lg"> MDPI Initiatives </h5><div class="block lg:hidden"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="expand_more" weight="400" style="" width="24" height="24" viewBox="0 0 16 16"></svg></div></div><ul class="hidden lg:block"><li class="pb-lg"><a target="_blank" href="https://sciprofiles.com/" class="flex items-center"><p class="m-text text-sm">SciProfiles</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://sciforum.net/" class="flex items-center"><p class="m-text text-sm">Sciforum</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://encyclopedia.pub/" class="flex items-center"><p class="m-text text-sm">Encyclopedia</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://www.mdpi.com/books" class="flex items-center"><p class="m-text text-sm">MDPI Books</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://www.scilit.net/" class="flex items-center"><p class="m-text text-sm">Scilit</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://www.mdpi.com/about/proceedings" class="flex items-center"><p class="m-text text-sm">Proceedings</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li><li class="pb-lg"><a target="_blank" href="https://jams.pub/" class="flex items-center"><p class="m-text text-sm">JAMS</p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="open_in_new" class="align-middle ml-xs" style="" width="16" height="16" viewBox="0 0 16 16"></svg></a></li></ul></div><div class="w-[100%] lg:w-[25%] xl:w-[25%] px-[.9375rem] pt-[.625rem] border-t border-[#000] sm:pt-[.625rem] sm:border-t sm:border-[#000] lg:pt-0 lg:border-0 lg:border-white"><div class="flex items-center justify-between lg:block"><h5 class="m-heading text-inherit m-h5 font-semibold pt-md lg:pt-0 pb-lg"> Important Links </h5><div class="block lg:hidden"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="expand_more" weight="400" class="block lg:hidden" style="" width="24" height="24" viewBox="0 0 16 16"></svg></div></div><ul class="cursor-pointer hidden lg:block"><li class="pb-lg"><a href="/advisory-board" class=""><p class="m-text text-sm">Advisory Board</p></a></li><li class="pb-lg"><a href="/activity/award/announcement" class=""><p class="m-text text-sm">Award</p></a></li><li class="pb-lg"><a href="/collection" class=""><p class="m-text text-sm">Collections</p></a></li><li class="pb-lg"><a href="/friendly-journals" class=""><p class="m-text text-sm">Friendly Journals</p></a></li><li class="pb-lg"><a href="/about?scrollTo=works" class=""><p class="m-text text-sm">How It Works</p></a></li><li class="pb-lg"><a href="/topics" class=""><p class="m-text text-sm">MDPI Topics</p></a></li><li class="pb-lg"><a href="/statistics" class=""><p class="m-text text-sm">Statistics</p></a></li></ul></div><div class="w-[100%] lg:w-[25%] xl:w-[25%] px-[.9375rem] pt-[.625rem] border-t border-[#000] sm:pt-[.625rem] sm:border-t sm:border-[#000] lg:pt-0 lg:border-0 lg:border-white"><div class="flex items-center justify-between lg:block"><h5 class="m-heading text-inherit m-h5 font-semibold pt-md lg:pt-0 pb-lg"> Subscribe </h5><div class="block lg:hidden"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" data-testid="expand_more" weight="400" class="block lg:hidden" style="" width="24" height="24" viewBox="0 0 16 16"></svg></div></div><div class="hidden lg:block"><div class="pb-lg"><p class="m-text text-sm">Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.</p></div><a href="/user/notification/settings?scrollTo=subscribe" class=""><button class="m-button m-button--md m-button--tonal rounded !text-color-white !bg-black mr-5" type="button"><span class="inline-flex h-full w-full items-center gap-2 whitespace-nowrap justify-center">Subscribe</span></button></a></div></div></div></div></div><div class="bg-black"><div class="m-container mx-auto w-full flex-col-reverse py-section-mobile" style="--container-ideal-width:92.5vw;"><div class="text-color-white"><div class="flex justify-between items-center flex-wrap cursor-pointer"><p class="m-text text-sm py-lg hidden lg:block">© 2024 MDPI (Basel, Switzerland) unless otherwise stated</p><div class="lg:flex items-center py-xl"><div class="flex items-center pr-xl pb-md lg:pb-0"><p class="m-text text-sm pr-xs">Disclaimer</p><span></span></div><p class="m-text text-sm pr-xl pb-md lg:pb-0"><a href="/terms-of-use?scrollTo=term-use" class="">Terms of Use</a></p><p class="m-text text-sm"><a href="/terms-of-use?scrollTo=privacy-policy" class="">Privacy Policy</a></p></div><p class="m-text text-sm py-lg block lg:hidden">© 2024 MDPI (Basel, Switzerland) unless otherwise stated</p></div></div></div></div></div></div></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":721,"once":730,"_errors":731,"serverRendered":6,"path":733,"pinia":734},["ShallowReactive",3],{"blog-config":4,"strapi-config":39,"Ya7hZzqdE7":40,"mgOlEjP40X":120,"uI0nvcSvBJ":123,"JoG0wWOyMK":209,"Yq0Pll1P8W":220,"j4og9PLFeK":223},{"postsPerPage":5,"isInfinite":6,"cacheTime":7,"categories":8},9,true,1,[9,14,19,24,29,34],{"id":10,"title":11,"cacheKey":12,"href":13},288,"Learn about Preprints","288-posts","/blog/category/learn-about-preprints",{"id":15,"title":16,"cacheKey":17,"href":18},1383,"Platform Features","1383-posts","/blog/category/platform-features",{"id":20,"title":21,"cacheKey":22,"href":23},22,"Community Content","22-posts","/blog/category/community-content",{"id":25,"title":26,"cacheKey":27,"href":28},1351,"Featured Preprints","1351-posts","/blog/category/featured-preprints",{"id":30,"title":31,"cacheKey":32,"href":33},1380,"Preprints and Society","1380-posts","/blog/category/preprints-and-society",{"id":35,"title":36,"cacheKey":37,"href":38},1381,"News and Announcements","1381-posts","/blog/category/news-and-announcements",{"cacheTime":7},{"code":41,"msg":42,"data":43},0,"success",[44,51,58,65,72,79,85,92,99,106,113],{"id":7,"name":45,"name_system":46,"parent_id":47,"image_banner":48,"description":49,"converted_name_system":50},"Arts and Humanities","arts_and_humanities",null,"https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/bb621e164c1f8a2a8bfd78d6ac510e15.jpg","Immerse yourself in a world of creativity and critical thinking with our preprints in arts and humanities. Uncover the depths of human expression, history, and thought across disciplines like archaeology, literature, and philosophy. Explore diverse perspectives that enrich our understanding of cultural heritage and the human experience.","arts-and-humanities",{"id":52,"name":53,"name_system":54,"parent_id":47,"image_banner":55,"description":56,"converted_name_system":57},16,"Biology and Life Sciences","biology_and_life_sciences","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/8d795777f5834c04ac4b98f9c94c4c6b.jpg","Journey into the intricate world of living organisms with our preprints. From molecular mechanisms to ecosystem interactions, discover the wonders of life and the natural world through cutting-edge research. Dive into the forefront of biological discovery and explore the complexities of our living world.","biology-and-life-sciences",{"id":59,"name":60,"name_system":61,"parent_id":47,"image_banner":62,"description":63,"converted_name_system":64},41,"Business, Economics and Management","business_economics_and_management","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/ab197ef385773a30f4650e40ae8f03d5.jpg","Explore the dynamic world of business operations, economic theories, and organizational leadership with our preprints. Uncover insights in business, economics, and management that shape global commerce and innovation. Stay informed on the latest trends and research driving the landscape of business and economics.","business-economics-and-management",{"id":66,"name":67,"name_system":68,"parent_id":47,"image_banner":69,"description":70,"converted_name_system":71},50,"Chemistry and Materials Science","chemistry_and_materials_science","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/cc2a7d5d84540df918315b4feb38028a.jpg","Unravel the mysteries of matter and its transformations with our preprints. From atomic structures to novel material synthesis, stay informed on the latest research in this fascinating field. Explore the diverse properties and applications of chemistry and materials science that shape our world.","chemistry-and-materials-science",{"id":73,"name":74,"name_system":75,"parent_id":47,"image_banner":76,"description":77,"converted_name_system":78},71,"Computer Science and Mathematics","computer_science_and_mathematics","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/5b0a41a25a67d1112cb8833b497bf7be.jpg","Embark on a journey through the foundational principles of algorithms, artificial intelligence, and mathematical theories with our preprints. Explore cutting-edge research in computational mathematics and data analysis that drives innovation in the digital age. Dive into a world of innovation and discovery in this exciting field.","computer-science-and-mathematics",{"id":80,"name":81,"name_system":82,"parent_id":47,"image_banner":83,"description":84,"converted_name_system":82},94,"Engineering","engineering","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/908d2aac5be9f3be128d20cc98154c17.jpg","Explore the diverse realms of engineering with our preprints, where innovation meets expertise across various disciplines. From industrial processes to energy technologies, delve into the forefront of engineering advancements. Stay updated on the latest research shaping the dynamic and ever-evolving field of engineering.",{"id":86,"name":87,"name_system":88,"parent_id":47,"image_banner":89,"description":90,"converted_name_system":91},113,"Environmental and Earth Sciences","environmental_and_earth_sciences","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/427574c3272a512b9412d12b3bfb3f51.jpg","Investigate the dynamic processes shaping our planet with our preprints. From atmospheric phenomena to oceanography, explore the interconnected systems of our planet and the innovative solutions shaping its future. Stay informed on research that impacts our environment and sustainability.","environmental-and-earth-sciences",{"id":93,"name":94,"name_system":95,"parent_id":47,"image_banner":96,"description":97,"converted_name_system":98},130,"Medicine and Pharmacology","medicine_and_pharmacology","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/98c86d1fdf40abfda51ca959f75f3499.jpg","Embark on a journey through the vast world of medicine and pharmacology with our preprints. Explore breakthroughs in healthcare, from cardiology to neurology, which improve human health outcomes. Delve into the frontiers of medical research and pharmaceutical development that enhance quality of life.","medicine-and-pharmacology",{"id":100,"name":101,"name_system":102,"parent_id":47,"image_banner":103,"description":104,"converted_name_system":105},166,"Physical Sciences","physical_sciences","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/c2d6e400b105b8c3d32ec59f26ab969d.jpg","Explore the fundamental laws governing matter and energy in the universe with our preprints. From quantum mechanics to cosmology, stay abreast of research that advances our understanding of the natural world. Dive into a world of scientific discovery that pushes the boundaries of knowledge.","physical-sciences",{"id":107,"name":108,"name_system":109,"parent_id":47,"image_banner":110,"description":111,"converted_name_system":112},185,"Public Health and Healthcare","public_health_and_healthcare","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-11-07/ef7c6de55fa117659c3b6090edc7c4ff.jpg","Examine critical issues in public health policy, epidemiology, and healthcare systems with our preprints. Stay updated on research into health disparities, infectious disease control, and healthcare management, which informs public health interventions. Explore the latest trends in healthcare that impact population well-being and equity.","public-health-and-healthcare",{"id":114,"name":115,"name_system":116,"parent_id":47,"image_banner":117,"description":118,"converted_name_system":119},193,"Social Sciences","social_sciences","https://www.preprints.org/media/cache/resolve/webp/upload/subject/2024-09-12/910c960e3a6808861523728f0f26b2df.png","Gain insights into human behavior, societies, and cultures with our preprints. Explore disciplines like psychology, sociology, and political science, which shape our world and inform public policy. Stay engaged with research that explores social issues, cultural dynamics, and economic systems, enriching our understanding of human interactions.","social-sciences",{"code":41,"msg":42,"data":121},{"url":122},"https://www.preprints.org/rss",{"code":41,"msg":42,"data":124},{"temp_id":125,"version":7,"id":126,"hash_key":127,"doi":128,"article_abstract":129,"article_title":130,"keywords":131,"is_registering_doi":132,"mdpi_topic":47,"preprints_collections":133,"subject":134,"top_subject":137,"article_type":138,"submitted_at":141,"published_at":142,"last_edited_at":47,"authors":143,"ethical_approval":132,"ethical_approval_number":47,"ethical_approval_body":47,"ethical_approval_for_publication":132,"article_supplementary":47,"final_file":190,"graphic_abstract":194,"statistics":195,"is_peer_reviewed":6,"peer_reviewed_article_url":198,"almetric":199,"preserved_by_portico":6,"ms_xml":201,"versions":203,"citation":205,"peer_reviewed_citation":206,"version_changes":207,"updating_alert_registered":132,"preprints_process_url":47,"comments_count":41,"latest_version":7,"author_notes":208,"withdrawed_at":47,"is_withdrwan":132},96239,"202401.1027","48e42377516d025ac928e3e795502452","10.20944/preprints202401.1027.v1","To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR=0.45; P=0.002). At multivariable analysis, microvascular infiltration (HR=1.22; P<0.04) and a higher tumor grading (HR=1.27; P<0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR=0.56; P<0.001), a successful pre-transplant downstaging (HR=0.63; P=0.01) and use of everolimus (HR=0.46; P<0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (30 days; P<0.001), longer treatment duration (P<0.001), and higher drug exposure (5.9ng/mL; P<0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction of the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression.","Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation","liver transplantation; immunosuppression; everolimus; hepatocellular carcinoma; recurrence",false,[],{"id":135,"name":136},162,"Transplantation",{"id":93,"name":94},{"id":139,"name":140},15,"Article","2024-01-12 10:55:15","2024-01-15 10:26:22",[144,152,158,163,168,173,178,183],{"id":145,"name":146,"email":147,"is_corresponding":6,"orcid_link":148,"author_mark":149,"sp_link":150,"avatar":151},453388,"Paolo De Simone","paolo.desimone@unipi.it","https://orcid.org/0000-0001-6713-6170","*","https://sciprofiles.com/profile/3425892","/statics/img/design/default-user.png",{"id":153,"name":154,"email":155,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":157,"avatar":47},453389,"Arianna Precisi","a.precisi@ao-pisa.toscana.it","","https://sciprofiles.com/profile/author/ekVRV2NoVzg0amp3TGRGUkc4SVd4Zjl0dkM0U3JFclVZcDJKWFJkQkY1OD0=",{"id":159,"name":160,"email":161,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":162,"avatar":151},453390,"Quirino Lai","quirino.lai@uniroma1.it","https://sciprofiles.com/profile/974088",{"id":164,"name":165,"email":166,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":167,"avatar":151},453391,"Juri Ducci","j.ducci@ao-pisa.toscana.it","https://sciprofiles.com/profile/3407044",{"id":169,"name":170,"email":171,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":172,"avatar":151},453392,"Daniela Campani","daniela.campani@unipi.it","https://sciprofiles.com/profile/2123246",{"id":174,"name":175,"email":176,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":177,"avatar":151},453393,"Piero Marchetti","piero.marchetti@unipi.it","https://sciprofiles.com/profile/1944586",{"id":179,"name":180,"email":181,"is_corresponding":132,"orcid_link":47,"author_mark":156,"sp_link":182,"avatar":47},453394,"Stefano Gitto","s.gitto@unifi.it","https://sciprofiles.com/profile/author/VzBWRXlRbXpVZUxKNU1PYjBtY2dRSnJpbXRBektGVWFqb1VwdVNrR0Fhbz0=",{"id":184,"name":185,"email":186,"is_corresponding":132,"orcid_link":187,"author_mark":156,"sp_link":188,"avatar":189},453395,"Laura Crocetti","laura.crocetti@unipi.it","https://orcid.org/0000-0002-8160-0483","https://sciprofiles.com/profile/1658005","/img/user_image/1658005/laura_crocetti.png",{"filename":191,"url":192,"filesize":193},"final_file.pdf","/frontend/manuscript/48e42377516d025ac928e3e795502452/download_pub",634480,[],{"viewed":196,"downloaded":197},"46","107","https://www.mdpi.com/2072-6694/16/7/1243",{"score":7,"detail_url":200},"https://preprints.altmetric.com/details/doi/10.20944/preprints202401.1027.v1",{"html_content":202},"\u003Cscript type=\"text/x-mathjax-config\">\n MathJax.Hub.Config({\n menuSettings: {\n CHTMLpreview: false\n },\n \"CHTML-preview\":{\n disabled: true\n },\n \"HTML-CSS\": {\n scale: 90,\n availableFonts: [],\n preferredFont: null,\n preferredFonts: null,\n webFont:\"Gyre-Pagella\",\n imageFont:'TeX',\n undefinedFamily:\"'Arial Unicode MS',serif\",\n linebreaks: { automatic: false }\n },\n \"TeX\": {\n extensions: [\"noErrors.js\"],\n noErrors: {\n inlineDelimiters: [\"\",\"\"],\n multiLine: true,\n style: {\n \"font-size\": \"90%\",\n \"text-align\": \"left\",\n \"color\": \"black\",\n \"padding\": \"1px 3px\",\n \"border\": \"1px solid\"\n }\n }\n }\n });\n \u003C/script>\u003Cscript type=\"text/javascript\" async=\"\" src=\"https://www.mdpi.com/bundles/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML\">\u003C/script>\n \u003Csection id=\"Introduction\" type=\"intro\">\u003Ch2 data-nested=\"1\" id=\"preprints-h2-1\"> Introduction\u003C/h2>\n\u003Cdiv class=\"html-p\">Survival after liver transplantation (LT) in the long term is impacted by the complications of chronic immunosuppression (1). Nearly all long-term survivors show diverse co-morbidities, the most frequent being hypertension, chronic kidney dysfunction (CKD), de novo malignancies, diabetes mellitus (DM) and metabolic disease (2). Most of these complications are consequent to the use of calcineurin inhibitors (CNI) (cyclosporine (CyA) and tacrolimus (TAC)), although the impact of surgery, non-immunosuppressive co-medication, recipients’ aging, and native liver disease cannot be underestimated (1,2).\u003C/div>\n\u003Cdiv class=\"html-p\">Introduced in clinical practice a decade ago (3-5), everolimus (EVR) is a member of the mammalian target of rapamycin (mTOR) inhibitors (mTORi) together with sirolimus (SRL) and has extensively been studied in pre-clinical studies (6), registration trials (3-5), and real-life clinical practice (7). Although approved for use in combination with tacrolimus (TAC) (3), numerous reports have investigated its administration as a single immunosuppressant. This is especially true for the treatment of CNI-associated nephrotoxicity or the prevention/treatment of post-transplant de novo or recurrent malignancies (8). Several pooled analyses and meta-analyses have shown that incorporating EVR into immunosuppression therapy can lead to an improvement in renal function (9-11). Additionally, it can reduce the risk of post-transplant malignancies and recurrence of hepatocellular carcinoma (HCC) (12). However, there is a large variability in reported outcomes across studies due to differences in patient selection, indications for EVR use, mode of administration and exposure, and study designs.\u003C/div>\n\u003Cdiv class=\"html-p\">The antiproliferative profile of EVR makes it an ideal immunosuppressive agent for patients with HCC, especially for recipients with an advanced tumor stage or a higher risk of post-transplant recurrence (8). However, the impact of any immunosuppressive strategy on the risk of post-transplant tumor recurrence is dependent on a complex interplay of tumor-related (i.e., stage at transplantation, response to pre-transplant downstaging, biologic markers), condition-related (i.e., indication to transplantation, native liver disease, severity of liver dysfunction) and treatment-related correlates (i.e., time, mode, and duration of drug administration) (1). To elucidate these interactions in large populations and the long term, we carried out a retrospective analysis at our center on the post-transplant recurrence of HCC in adult LT recipients. \u003C/div>\u003C/section>\u003Csection id=\"MaterialsandMethods\" type>\u003Ch2 data-nested=\"1\" id=\"preprints-h2-2\"> Materials and Methods\u003C/h2>\n\u003Csection id=\"StudyDesign\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Study Design \u003C/h4>\n\u003Cdiv class=\"html-p\">This was a retrospective, single-center study at an Italian National Health System (NHS)-based liver transplant center. \u003C/div>\u003C/section>\u003Csection id=\"Population\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Population\u003C/h4>\n\u003Cdiv class=\"html-p\">We conducted a retrospective comparison of two groups of adult HCC patients who underwent primary, whole-size transplantation from deceased brain-dead donors (DCD) at our institution using a 2-tiered approach. Initially, we selected transplant recipients with HCC on explant histology, excluding those with macrovascular tumor portal infiltration and mixed cellular lineage (i.e. hepato-cholangio-hepatocellular carcinoma (CHC-HCC)). We then compared patients who received immunosuppression with EVR to those who received tacrolimus (TAC) with or without mycophenolate derivatives (MPA) between 2013 and 2021.\u003C/div>\u003C/section>\u003Csection id=\"PrimaryExposure\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Primary Exposure\u003C/h4>\n\u003Cdiv class=\"html-p\">Our primary exposure was the use of EVR alone or in combination with TAC versus TAC (±MPA) in the post-transplant immunosuppressive schedule. \u003C/div>\u003C/section>\u003Csection id=\"DataSource\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Data Source\u003C/h4>\n\u003Cdiv class=\"html-p\">For the current study, we used data from the regional transplant authority (CRT, \u003Cspan class=\"html-italic\">Centro Regionale Trapianti\u003C/span>) and the prospectively maintained recipient database of our institution. The CRT data system includes data on all donors, waitlisted candidates, and transplant recipients and provides regular oversight to the integrity, validity, and transparency of the database. The local ethics committee of the University of Pisa (Prot. 0036349/2020) approved all procedures. \u003C/div>\u003C/section>\u003Csection id=\"MeasureOutcomes\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Measure Outcomes\u003C/h4>\n\u003Cdiv class=\"html-p\">Our primary outcome was the cumulative incidence of post-transplant HCC recurrence in patients who received EVR versus TAC. The secondary outcome was overall survival (OS). All these measures were treated as time-to-event occurrences. Data were censored at the time of the event, the last follow-up visit, or December 31\u003Csup>st\u003C/sup>, 2022, whichever came first. \u003C/div>\u003C/section>\u003Csection id=\"Immunosuppression\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Immunosuppression\u003C/h4>\n\u003Cdiv class=\"html-p\">In the study period, de novo immunosuppression consisted of a triple/quadruple regimen of anti-CD25 (basiliximab, Simulect®, Novartis, Origgio (VA), Italy), calcineurin inhibitors (CNI), CyA or TAC, steroids (S), and antimetabolites (azathioprine (AZA) or mycophenolic acid (MPA) derivatives) according to era, pre-transplant, intra-operative and post-transplant patient characteristics. \u003C/div>\n\u003Cdiv class=\"html-p\">When used for prophylaxis of HCC recurrence or prevention of TAC-related adverse events, EVR (Certican®, Novartis, Origgio (VA), Italy) was introduced ≥1 month after transplant at a dosage of 1.0 mg bid with antimetabolites elimination and stepwise TAC dose reduction, unless otherwise clinically indicated. Prior to EVR introduction, patients were tested for liver function tests (LFT), hematocrit, lipid profile and creatinine/protein ratio. When used in combination schedules, EVR was adjusted to a trough level between 3 and 8 ng/mL and TAC between 3 and 5 ng/mL. When used alone, EVR trough level was between 6 and 10 ng/mL as clinically appropriate. When introduced for TAC-related complications, the time, mode, and dose of EVR were dependent on clinical indications. \u003C/div>\n\u003Cdiv class=\"html-p\">Rejection episodes were histologically proved and graded according to the BANFF classification system (13). Treatment of rejection was with steroid boluses for non-HCV patients, while CNI and MMF dose increase/reintroduction were preferred for HCV-RNA positive recipients. In case of refractory rejection episodes, we tested patients for donor-specific and anti-HLA antibodies and used plasmapheresis, intravenous immunoglobulin, or rabbit anti-thymocyte immunoglobulin (rATG) as clinically appropriate. Anti-CMV prophylaxis was administered to recipients without acquired immunity (i.e., D+/R- and D-/R- combinations).\u003C/div>\u003C/section>\u003Csection id=\"DrugExposureAssay\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Drug Exposure Assay\u003C/h4>\n\u003Cdiv class=\"html-p\">EVR exposure was tested in whole blood with the QMS™ Everolimus Immunoassay, a homogeneous particle-enhanced turbidimetric immunoassay based on Quantitative Microparticle System (QMS®) technology. Mean EVR exposure was calculated based on samples obtained at our institution at follow-up visits. \u003C/div>\u003C/section>\u003Csection id=\"SpecialConsiderations\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Special Considerations\u003C/h4>\n\u003Cdiv class=\"html-p\">The transplant procedure, perioperative management, and immunosuppressive schedules changed during the study period according to technological advancements and scientific evidence. Celsior® (IGL, Lissieu, France) was utilized for graft perfusion until 2017 and replaced by Servator C® (SALF, Cenate Sotto (BG), Italy) thereafter. Bypass or the classical technique was standard until 2017. \u003C/div>\u003C/section>\u003Csection id=\"PreTransplantManagementofHCC\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Pre-Transplant Management of HCC\u003C/h4>\n\u003Cdiv class=\"html-p\">The diagnosis of HCC was according to the European Association for the Study of Liver Disease (EASL) guidelines (14). Patients within the Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate) were considered for transplantation (15). Pre-transplant downstaging/bridging was indicated for patients with >3 cm tumor mass, those with AFP levels >400 ng/mL, or with segmental portal infiltration. The down-staging technique was agreed upon during tumor board case evaluation and based on tumor size, location, and number of nodules. It consisted of trans-arterial chemoembolization (TACE), radiofrequency/microwave ablation, trans-arterial radioembolization (TARE), or surgery as appropriate. A successful downstaging procedure was associated with regression from beyond to within Milan criteria as per pre-transplant imaging or explant histology. \u003C/div>\u003C/section>\u003Csection id=\"CutOffsandDefinitions\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Cut-Offs and Definitions\u003C/h4>\n\u003Cdiv class=\"html-p\">Cold ischemia time (CIT) was defined as the time from cross-clamping until removal of the organ from the ice for implantation, and warm ischemia time (WIT) as a time of ischemia during graft implantation. EAD was defined according to Olthoff et al. (16) MELD scores at transplant were recalculated retrospectively based on available laboratory data. HCV recurrence was diagnosed by liver biopsy in the presence of HCV-RNA positivity. HBV infection recurrence was defined as HBsAg (± HBV DNA) reappearance in previously seroconverted patients irrespective of liver function. Renal function was evaluated as an estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD)-4 formula. Chronic kidney dysfunction (CKD) was defined as: a) estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m\u003Csup>2\u003C/sup> for a post-LT period greater than three months according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria in patients with previous eGFR ≥60ml/min/1.73m\u003Csup>2\u003C/sup> (17); b) evidence of intrinsic renal disease (proteinuria or kidney disease at ultrasound) (17); or c) presence of end-stage renal disease requiring renal replacement therapy (17). Acute kidney injury (AKI) was defined as doubling of baseline serum creatine (sCr) and/or a ≥50% reduction in eGFR within 14 days (17). Deteriorating renal function was defined as ≥one-grade downward shift in the kidney function category according to the KDIGO classification system (18). A post-transplant diabetes mellitus (PTDM) was defined using the comprehensive American Diabetes Association (ADA) 2018 criteria (19).\u003C/div>\n\u003Cdiv class=\"html-p\">Arterial hypertension was defined as the need for medication or blood pressure 140/90 mmHg at two following visits. Dyslipidemia was defined as hypercholesterolemia >220 mg/dL and/or hypertriglyceridemia >200 mg/dL at two following visits. Biliary complications included symptomatic and treated biliary fistula, biliary stones, anastomotic biliary strictures, and posttransplant ischemic-type biliary lesion (ITBL). ITBL was defined as any non-anastomotic stenosis associated with symptoms or signs requiring an endoscopic or surgical procedure without vascular complications.\u003C/div>\u003C/section>\u003Csection id=\"StatisticalAnalyses\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Statistical Analyses\u003C/h4>\n\u003Cdiv class=\"html-p\">Initially, 2 groups of patients were extracted from the original population of HCC recipients transplanted at our center between 1996 and 2021 based on the mentioned inclusion criteria. The EVR group included patients who received the drug in their \u003Cspan class=\"html-italic\">de novo\u003C/span> immunosuppressive regimen for prophylaxis of post-transplant tumor recurrence or CNI -related complications other than HCC recurrence (i.e., renal function deterioration). The TAC group included patients who received TAC until complication (i.e., HCC recurrence, renal function deterioration) or the latest follow-up. \u003C/div>\n\u003Cdiv class=\"html-p\">To address the non-randomized design of the study, the two groups were balanced using an inverse probability of treatment weighting (IPTW) approach. A propensity score for each patient in the original population was generated. The score was created using a multivariate logistic regression model considering post-transplant HCC recurrence (no/yes) as the dependent variable. Eighteen confounding factors that have clinical significance were chosen to serve as covariates for both DFS and OS: patient sex (20); age (21); HCV (22); diabetes mellitus at transplant (23); CKD at transplant (24); MELD score (25); donor sex (26); donor age (27); cerebrovascular accident (CVA) as donor cause of death (28); use of machine perfusion (MP) (29); CIT (30); pre-transplant tumor stage according to Milan criteria (31); pre-transplant alpha-fetoprotein (AFP) (32); efficacy of pre-transplant downstaging and defined as downstaging from beyond to within Milan criteria (33); tumor stage at histology according to Milan criteria (31-33); G3-G4 tumor grading (34); presence of microvascular infiltration (34), and mean TAC trough level within the first post-transplant month (≤10 ng/mL) (35).\u003C/div>\n\u003Cdiv class=\"html-p\">With the intent to reduce the artificial modification of the sample size in the pseudo data, we used stabilized weights (SW) according to the formula: \u003C/div>\n\u003Cdiv class=\"html-p\">SW = p/PS for the study group, and SW = (1-p)/(1-PS) for the control group\u003C/div>\n\u003Cdiv class=\"html-p\">where p is the probability of etiology without considering covariates and PS is the propensity score. A stabilized approach was preferred not to inflate the sample populations versus the original ones.\u003C/div>\n\u003Cdiv class=\"html-p\">Because p-values can be biased from population size, results from the comparisons between covariates subgroups were reported as effect size (Cohen's D value): values lower than |0.1| indicated very small differences between means, values between |0.1| and |0.3| indicated small differences, values between |0.3| and |0.5| indicated moderate differences, and values greater than |0.5| indicated considerable differences.\u003C/div>\n\u003Cdiv class=\"html-p\">Multivariable Cox regression analyses were run after the stabilized IPTW to identify the risk factors for HCC recurrence and after LT. Hazard ratios (HR) and 95.0% confidence intervals (CI) were reported for significant variables. Survival analyses were performed using the Kaplan-Meier method, and the log-rank test was adopted to compare the obtained survivals. Variables with a p<0.05 were considered statistically significant. \u003C/div>\n\u003Cdiv class=\"html-p\">Finally, after propensity matching, 3 further co-variates were used to explore the impact of EVR administration on the risk of HCC recurrence: (1) timing of EVR introduction; (2) duration of EVR treatment, and (3) EVR whole-blood concentration throughout the study period. Patients were dichotomized according to median values, and sensitivity analyses were performed between recurring and non-recurring patients. \u003C/div>\n\u003Cdiv class=\"html-p\">According to their measure and level of distribution, variables were expressed by frequencies and percentages, medians, and interquartile ranges (IQR) or means and standard deviations (SD) as appropriate. Data errors and missingness were identified across the database and solved with specific queries. Missing data were handled with a single imputation method. In detail, a median of nearby points imputation was adopted. The median instead of the mean was adopted due to the skewed distribution of the managed variables. Recurrence-free survival (RFS) was defined as the time (months) from transplant to diagnosis of HCC recurrence. OS was defined as the time from transplantation to either death or last observation. \u003C/div>\n\u003Cdiv class=\"html-p\">All statistical analyses and plots were run using the SPSS statistical package version 27.0 (SPSS Inc., Chicago, IL, USA). This study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee and was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.\u003C/div>\u003C/section>\u003C/section>\u003Csection id=\"Results\" type=\"results\">\u003Ch2 data-nested=\"1\" id=\"preprints-h2-3\"> Results \u003C/h2>\n\u003Csection id=\"DemographicsandClinicalCharacteristicsoftheOriginalCohort\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Demographics and Clinical Characteristics of the Original Cohort\u003C/h4>\n\u003Cdiv class=\"html-p\">A total of 1,019 adult patients transplanted for HCC at our center between 1996 and 2021 were initially considered (\u003Ca href=\"#preprints-96239-t001\" class=\"html-table\">Table 1\u003C/a>). Among them, 463 (45.4%) received EVR for HCC recurrence prophylaxis or complications other than HCC recurrence, while 556 (54.6%) received CNI (either TAC or CyA) as the primary de novo immunosuppressant until CNI-related adverse events. At a median (IQR) follow-up of 8.7 (8.1) years, 384 (37.6%) patients died, 41 (4.0%) were retransplanted, and 635 (62.3%) were alive. The 1, 5, and 10-year Kaplan-Meier probability (95% CI) of survival was 91% (89-93%) and 90.2% (88-93%), 77% (74-80%), and 75.8% (72-79%), 67% (63-71%) and 65% (61%-70.2%) for patient and graft, respectively. \u003C/div>\n\u003Cdiv class=\"html-p\">\n\u003Ca href=\"#preprints-96239-t001\" class=\"html-table\">Table 1\u003C/a> shows the clinical features of the recipients and donors from 1996 to 2021 and before matching. CNI patients were more frequently transplanted before 2013 (66.0% versus 31.7%; P<0.0001), while EVR patients were more frequently beyond Milan criteria (32.8% versus 18.1%; P<0.0001), underwent more frequent pre-transplant downstaging procedures (59.6% versus 62.4%; P=0.01), and showed higher median (IQR) AFP levels before surgery (46.3 (28) versus 4.7 (19) ng/mL; P=0.002). Similarly, the proportion of G3-G4 grading (31.9% versus 25.1%; P=0.01) and microvascular infiltration (39.5% versus 32.7%; P=0.02) were higher in the EVR group.\u003C/div>\u003C/section>\u003Csection id=\"StabilizedIPTWEffect\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Stabilized IPTW Effect \u003C/h4>\n\u003Cdiv class=\"html-p\">To minimize the effect of selection biases caused by the non-randomized design of this retrospective study, the EVR and TAC pseudo-groups were balanced using a stabilized IPTW method. \u003Ca href=\"#preprints-96239-t002\" class=\"html-table\">Table 2\u003C/a> illustrates the results of the balancing procedure for the 18 potential confounders. Namely, 7 variables showed very small differences before balancing, 6 small, 4 moderate, and 1 considerable. After IPTW, 14 variables showed very small differences; 3 were small, and one was moderate. The IPTW yielded 2 pseudo-groups, i.e., 233 EVR patients versus 278 on TAC. \u003C/div>\u003C/section>\u003Csection id=\"ResultsintheBalancedGroups\" type=\"results\">\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Results in the Balanced Groups\u003C/h4>\n\u003Cdiv class=\"html-p\">After conducting IPTW balancing, \u003Ca href=\"#preprints-96239-t003\" class=\"html-table\">Table 3\u003C/a> presents the clinical characteristics of both groups. At a median follow-up of 4.4 (3.8) years after transplantation, the number of deaths, re-transplants, and HCC recurrences were 167 (32.7%), 20 (4.0%), and 65 (12.7%), respectively (\u003Ca href=\"#preprints-96239-t004\" class=\"html-table\">Table 4\u003C/a>). TAC patients showed higher death (37.8% versus 26.6%; RR=1.41; P=0.007) and HCC recurrence rates (16.9% versus 7.7%; RR=2.2; P=0.002). The main reasons for death in the TAC and EVR groups included HCC recurrence (15.1% versus 6.8%; RR=2.51; p=0.003), HCV recurrence (5.4% versus 6.9%; RR=0.8; P=0.48), infections/sepsis (5.7% versus 5.1%; RR=1.11; P=0.84), and \u003Cspan class=\"html-italic\">de novo\u003C/span> malignancies (3.9% versus 2.1%; RR=1.85; P=0.31) (\u003Ca href=\"#preprints-96239-t004\" class=\"html-table\">Table 4\u003C/a>). \u003C/div>\u003C/section>\u003Csection id=\"Retransplantation\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Re-transplantation\u003C/h4>\n\u003Cdiv class=\"html-p\">A total of 20 (3.9%) patients were retransplanted (\u003Ca href=\"#preprints-96239-t004\" class=\"html-table\">Table 4\u003C/a>). The main indication was primary non-function (PNF) of the liver graft, which accounted for 40% of such cases and was followed by ischemic cholangiopathy (30%) and hepatic artery thrombosis (HAT) (15.0%). No significant difference was found in the causes of re-transplantation between the two groups.\u003C/div>\u003C/section>\u003Csection id=\"HCCRecurrence\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> HCC Recurrence\u003C/h4>\n\u003Cdiv class=\"html-p\">HCC recurred at a median (IQR) of 26.1 (48.7) months after transplantation and accounted for 15.1% of deaths in TAC versus 6.8% in EVR patients (RR=2.51; P=0.003). One-third of recurrences were in the liver only, while TAC patients showed more frequent multi-organ involvement (P=0.002) (\u003Ca href=\"#preprints-96239-t004\" class=\"html-table\">Table 4\u003C/a>).\u003C/div>\u003C/section>\u003Csection id=\"immunosuppression\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> immunosuppression\u003C/h4>\n\u003Cdiv class=\"html-p\">\n\u003Ca href=\"#preprints-96239-t005\" class=\"html-table\">Table 5\u003C/a> and \u003Ca href=\"#preprints-96239-t006\" class=\"html-table\">Table 6\u003C/a> illustrate the immunosuppressive regimen in the EVR group regarding indication, timing of introduction, duration of treatment, and median exposure. EVR was introduced at a median (IQR) interval post-transplantation of 30 (16) days for a median (IQR) of 46.6 (36.1) months. Median (IQR) EVR whole-blood exposure was 5.8 (1.7) ng/mL. \u003C/div>\n\u003Cdiv class=\"html-p\">In the EVR group, patients with HCC recurrence showed later EVR introduction (median (IQR) = 52 (26.4) versus 30 (12) days; P<0.001), shorter duration of treatment (median (IQR) = 47.6 (57.0) versus 69.9 (24.8) months; P<0.001), and lower drug exposure (median (IQR) = 3.65 (0.55) versus 5.9 (1.4) ng/mL; P<0.001) (\u003Ca href=\"#preprints-96239-t006\" class=\"html-table\">Table 6\u003C/a>). \u003C/div>\u003C/section>\u003Csection id=\"RiskFactorsforRecurrenceFreeandOverallSurvival\" type>\u003Ch4 class=\"html-italic\" data-nested=\"2\"> Risk Factors for Recurrence-Free and Overall Survival \u003C/h4>\n\u003Cdiv class=\"html-p\">\n\u003Ca href=\"#preprints-96239-t007\" class=\"html-table\">Table 7\u003C/a> illustrates the results of the multivariable analysis of risk factors for OS and RFS in the entire post-IPTW population. A successful pre-transplant downstaging (HR=0.79; P=0.006), being within Milan criteria at transplant (HR=0.67; P<0.001) and at histology (HR=0.78; P=0.02) and use of EVR (HR=0.69; P=0.009) had a positive impact on survival.\u003C/div>\n\u003Cdiv class=\"html-p\">As for HCC recurrence, the presence of vascular micro-infiltration (HR=1.22; P=0.04) and higher tumor grading (HR=1.27; P=0.044) had a negative impact on RFS, while a successful pre-transplant downstaging (HR=0.65; P=0.01), being within Milan criteria at transplant (HR=0.56; P=0.01) and at histology (HR=0.68; P=0.012) and use of EVR (HR=0.46; P<0.001) had a positive impact on the probability of tumor-free survival. \u003C/div>\n\u003Cdiv class=\"html-p\">\n\u003Ca href=\"#preprints-96239-f001\" class=\"html-fig\">Figure 1\u003C/a> illustrates the OS according to Milan criteria at transplant and type of immunosuppressant (EVR versus TAC). All strata comparisons were statistically significant except for EVR Milan-in versus TAC Milan-in patients (log-rank P =0.560). The 1-, 3- and 5-year actuarial OS (95% CI) for EVR patients within the Milan criteria were 98% (93-99%), 89% (82-90%), and 84% (79-88%) versus 98% (94-99%), 89% (83-90%), and 85% (80-87%) for EVR and TAC, respectively (log-rank p=0.506). For patients exceeding the Milan criteria, the OS (95% CI) was 94% (91-96%), 84% (81-86%), and 76% (72-79%) versus 92% (89-94%), 79% (73-80%), and 69% (66-70%) for EVR and TAC, respectively (log-rank p<0.001). \u003C/div>\n\u003Cdiv class=\"html-p\">\n\u003Ca href=\"#preprints-96239-f002\" class=\"html-fig\">Figure 2\u003C/a> illustrates the RFS according to Milan criteria at transplant and type of immunosuppressant (EVR versus TAC). All strata comparisons were statistically significant (log-rank P <0.001) except for EVR Milan-in versus TAC Milan-in patients (log-rank P=0.205). The actuarial (95% CI) RFS for patients within the Milan criteria was 96% (94-100%), 87% (84-89%) and 82% (77-89%) at 1, 3, and 5 years in the EVR group versus 96% (CI 88-99%), 87% (74-91%) and 80% (72-84%) in the TAC group, respectively (log-rank P=0.205). On the other hand, it was 90% (82-94%), 78% (64-81%), and 68% (57-71%) at 1, 2, and 3 years for EVR patients exceeding the Milan criteria versus 86% (72-90%), 75% (66-84%), and 65% (52-69%) for TAC patients beyond the Milan criteria. (log-rank p<0.001). \u003C/div>\u003C/section>\u003C/section>\u003Csection id=\"Discussion\" type=\"discussion\">\u003Ch2 data-nested=\"1\" id=\"preprints-h2-4\"> Discussion\u003C/h2>\n\u003Cdiv class=\"html-p\">To the best of our knowledge, this is one of the largest single-center series on the use of EVR in recipients of a liver graft for HCC, and with long-term follow-up data available in the international literature. Despite the expansion of the practice of LT for advanced HCC, information on the impact of EVR or SRL is derived mainly from systematic reviews and meta-analyses incorporating both drugs (11,36-40), with only a few multi-institutional research studies (9,41-43) and real-life clinical series (44-46). Although some authors dispute the advantage of mTORi for the reduction of post-transplant HCC recurrence (43), the overall evidence originating from these studies supports the use of mTORi for patients with HCC, suggesting earlier drug introduction and higher exposure levels to achieve greater antiproliferative activity (46). \u003C/div>\n\u003Cdiv class=\"html-p\">Dysregulation of the mTOR pathway is frequently observed in HCC (47). However, transferring this evidence from the \u003Cspan class=\"html-italic\">in vitro\u003C/span> experimental setting to clinical practice is challenging because the overall impact of EVR on post-transplant HCC appears to be dependent on a complex interplay of molecular signaling, tumor cell viability, total tumor volume, plasma, and tumor drug concentration (48). In addition, pre-transplant tumor characteristics, response to adjuvant treatment, type of native liver disease, quality of liver graft, surgery, and immunosuppressive regimens all account for the variable outcomes reported in the literature. One strategy to overcome these limitations is to analyze real-life clinical practice and large data sets with the use of propensity-matching methodologies for the reduction of selection biases. For this reason, we opted for a retrospective comparison of 2 propensity-matched samples of HCC patients with the IPTW methodology. \u003C/div>\n\u003Cdiv class=\"html-p\">The analysis revealed that the use of EVR could reduce the risk of HCC recurrence and increase RFS and OS in LT recipients. This was especially true for tumors beyond the Milan criteria and for patients with earlier drug introduction (≤30 days), longer time on treatment (about 5 years), and higher median EVR exposure level (≥5.9ng/mL). In such cases, a twofold reduction of the relative risk of HCC recurrence was observed alongside improved OS. In patients within Milan criteria, the oncological impact of EVR-based immunosuppression is weaker, but the overarching benefits of EVR on renal function deterioration and \u003Cspan class=\"html-italic\">de novo\u003C/span> malignancies suggest its use also in this category of patients. \u003C/div>\n\u003Cdiv class=\"html-p\">Transferring these considerations to current clinical practice, however, is not simple. \u003C/div>\n\u003Cdiv class=\"html-p\">Earlier EVR administration requires proper patient management due to a reported higher incidence of leukopenia, thrombocytopenia, dyslipidemia, and infections with the use of mTORi versus CNIs, as well as a higher discontinuation rate for patients on higher drug exposure (3,10). This is why the originally recommended exposure levels for EVR monotherapy (i.e., 6-10ng/mL) (3-5) are seldom implemented in clinical practice to avoid concentration-related adverse events. Furthermore, the current focus on immunosuppression minimization has expanded from CNI to include antimetabolites and mTORi alongside increased concerns about transplant recipients’ quality of life (49). \u003C/div>\n\u003Cdiv class=\"html-p\">Despite its large number of patients and robust statistical methodology, our study has several limitations. First, its retrospective design does not always allow the granular information that real-practice clinical studies need to produce clinically transferable data. This is especially true for pre-transplant information on tumor clinical course and biology, and limited availability of drug exposure levels for patients with longer follow-ups. Additionally, it included the initial experience with EVR at our center and might inevitably be biased by a learning curve effect in terms of patient selection, drug discontinuation rates, and post-transplant therapeutic strategies for HCC recurrence. \u003C/div>\n\u003Cdiv class=\"html-p\">Secondly, we excluded patients with unfavorable tumor characteristics from the current analysis, i.e., neoplastic portal thrombosis, due to its negative impact on RFS and OS and the limited number of cases at our center. Given the clinical expansion of Milan criteria and the introduction of novel neoadjuvant pre-transplant treatments (i.e., immunotherapy), it would be interesting to analyze the relative benefit of EVR-incorporating immunosuppression for this category of high-risk patients.\u003C/div>\n\u003Cdiv class=\"html-p\">In conclusion, based on our results, EVR allows us to mitigate the risk of post-transplant HCC recurrence, especially for tumors beyond the Milan criteria and patients with earlier drug introduction, higher drug exposure, and longer time on treatment. These data advocate considering the use of mTORi for patients with HCC to reduce the attrition rate of chronic immunosuppression after LT. \u003C/div>\u003C/section>\n \n \u003Csection class=\"html-notes\">\u003Ch2 id=\"preprints-h2-5\">Funding\u003C/h2>\n\u003Cdiv class=\"html-p\">None.\u003C/div>\u003C/section>\u003Csection class=\"html-notes\">\u003Ch2 id=\"preprints-h2-6\">Conflicts of interest\u003C/h2>\n\u003Cdiv class=\"html-p\">PDS has served as advisory board member for Novartis, Astellas, and Chiesi. The other authors have no interest to declare. \u003C/div>\u003C/section>\u003Csection class=\"html-notes\">\u003Ch2 id=\"preprints-h2-7\">Abbreviations:\u003C/h2>\n\u003Cdiv class=\"html-p\">AFP, alpha-fetoprotein. \u003C/div>\n\u003Cdiv class=\"html-p\">Anti-HBc, antibody to the hepatitis virus B core antigen.\u003C/div>\n\u003Cdiv class=\"html-p\">Anti-HBs, antibody to the hepatitis B surface antigen. \u003C/div>\n\u003Cdiv class=\"html-p\">BCLC, Barcelona Clinic Liver Cancer.\u003C/div>\n\u003Cdiv class=\"html-p\">BMI, body mass index\u003C/div>\n\u003Cdiv class=\"html-p\">CHC, cholangiocarcinoma; \u003C/div>\n\u003Cdiv class=\"html-p\">CNI, calcineurin inhibitors. \u003C/div>\n\u003Cdiv class=\"html-p\">CyA, cyclosporine.\u003C/div>\n\u003Cdiv class=\"html-p\">EASL, European Association for the Study of Liver Disease\u003C/div>\n\u003Cdiv class=\"html-p\">eGFR, estimated glomerular filtration rate.\u003C/div>\n\u003Cdiv class=\"html-p\">EVR, everolimus.\u003C/div>\n\u003Cdiv class=\"html-p\">HBc, hepatitis B core antigen.\u003C/div>\n\u003Cdiv class=\"html-p\">HBs, hepatitis B surface antigen.\u003C/div>\n\u003Cdiv class=\"html-p\">HBV, hepatitis B virus.\u003C/div>\n\u003Cdiv class=\"html-p\">HCC, hepatocellular carcinoma. \u003C/div>\n\u003Cdiv class=\"html-p\">HCV, hepatitis C virus. \u003C/div>\n\u003Cdiv class=\"html-p\">HR, hazard ratio.\u003C/div>\n\u003Cdiv class=\"html-p\">IQR, interquartile range.\u003C/div>\n\u003Cdiv class=\"html-p\">LFT, liver function tests.\u003C/div>\n\u003Cdiv class=\"html-p\">LT, liver transplantation. \u003C/div>\n\u003Cdiv class=\"html-p\">MACE, major adverse cardiovascular events.\u003C/div>\n\u003Cdiv class=\"html-p\">MDRD, modified diet and renal disease.\u003C/div>\n\u003Cdiv class=\"html-p\">MELD, model for end-stage liver function. \u003C/div>\n\u003Cdiv class=\"html-p\">MPA, mycophenolic acid derivatives. \u003C/div>\n\u003Cdiv class=\"html-p\">mTOR, mammalian target of rapamycin.\u003C/div>\n\u003Cdiv class=\"html-p\">mTORi, mammalian target of rapamycin inhibitors.\u003C/div>\n\u003Cdiv class=\"html-p\">OS, overall survival.\u003C/div>\n\u003Cdiv class=\"html-p\">PNF, primary non-function.\u003C/div>\n\u003Cdiv class=\"html-p\">RFS, recurrence-free survival. \u003C/div>\n\u003Cdiv class=\"html-p\">RR, relative risk.\u003C/div>\n\u003Cdiv class=\"html-p\">S, steroids.\u003C/div>\n\u003Cdiv class=\"html-p\">SD, standard deviation.\u003C/div>\n\u003Cdiv class=\"html-p\">SRL, sirolimus.\u003C/div>\n\u003Cdiv class=\"html-p\">TAC, tacrolimus.\u003C/div>\u003C/section>\u003Csection id=\"html-references_list\">\u003Ch2 id=\"preprints-h2-8\">References\u003C/h2>\n\u003Col class=\"html-xx\">\n\u003Cli id=\"B1-preprints-96239\" class=\"html-x\" data-content=\"1.\">Di Maira, T.; Little, E.C.; Berenguer, M. Immunosuppression in liver transplant. \u003Cspan class=\"html-italic\">Best Pract Res Clin Gastroenterol\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">46-47\u003C/span>, 101681. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Immunosuppression+in+liver+transplant&author=Di+Maira,+T.&author=Little,+E.C.&author=Berenguer,+M.&publication_year=2020&journal=Best+Pract+Res+Clin+Gastroenterol&volume=46-47&pages=101681&doi=10.1016/j.bpg.2020.101681&pmid=33158467\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.bpg.2020.101681\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/33158467\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B2-preprints-96239\" class=\"html-x\" data-content=\"2.\">Noble, J.; Terrec, F.; Malvezzi, P.; Rostaing, L. Adverse effects of immunosuppression after liver transplantation. \u003Cspan class=\"html-italic\">Best Pract Res Clin Gastroenterol\u003C/span>, 2021; 54-55, 101762. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Adverse+effects+of+immunosuppression+after+liver+transplantation&author=Noble,+J.&author=Terrec,+F.&author=Malvezzi,+P.&author=Rostaing,+L.&publication_year=2021\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>]\u003C/li>\n\u003Cli id=\"B3-preprints-96239\" class=\"html-x\" data-content=\"3.\">De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; Saliba, F.; et al. Everolimus with Reduced Tacrolimus Improves Renal Function in \u003Cspan class=\"html-italic\">De Novo\u003C/span> Liver Transplant Recipients: A Randomized Controlled Trial. \u003Cspan class=\"html-italic\">Am J Transplant\u003C/span> \u003Cb>2012\u003C/b>, \u003Cspan class=\"html-italic\">12\u003C/span>, 3008–3020. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Everolimus+with+Reduced+Tacrolimus+Improves+Renal+Function+in+De+Novo+Liver+Transplant+Recipients:+A+Randomized+Controlled+Trial&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=Saliba,+F.&author=et+al.&publication_year=2012&journal=Am+J+Transplant&volume=12&pages=3008%E2%80%933020&doi=10.1111/j.1600-6143.2012.04212.x&pmid=22882750\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1111/j.1600-6143.2012.04212.x\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/22882750\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B4-preprints-96239\" class=\"html-x\" data-content=\"4.\">Saliba, F.; De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. \u003Cspan class=\"html-italic\">Am J Transplant\u003C/span> \u003Cb>2013\u003C/b>, \u003Cspan class=\"html-italic\">13\u003C/span>, 1734–1745. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Renal+function+at+two+years+in+liver+transplant+patients+receiving+everolimus:+Results+of+a+randomized,+multicenter+study&author=Saliba,+F.&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=et+al.&publication_year=2013&journal=Am+J+Transplant&volume=13&pages=1734%E2%80%931745&doi=10.1111/ajt.12280&pmid=23714399\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1111/ajt.12280\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/23714399\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B5-preprints-96239\" class=\"html-x\" data-content=\"5.\">Fischer, L.; Saliba, F.; Kaiser, G.M.; De Carlis, L.; Metselaar, H.J.; De Simone, P.; et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. \u003Cspan class=\"html-italic\">. Transplantation.\u003C/span> \u003Cb>2015\u003C/b>, \u003Cspan class=\"html-italic\">99\u003C/span>, 1455–1462. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Three-year+outcomes+in+de+novo+liver+transplant+patients+receiving+everolimus+with+reduced+tacrolimus:+Follow-up+results+from+a+randomized,+multicenter+study&author=Fischer,+L.&author=Saliba,+F.&author=Kaiser,+G.M.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=De+Simone,+P.&author=et+al.&publication_year=2015&journal=.+Transplantation.&volume=99&pages=1455%E2%80%931462&doi=10.1097/TP.0000000000000555&pmid=26151607\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000000555\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/26151607\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B6-preprints-96239\" class=\"html-x\" data-content=\"6.\">Levy, G.; Schmidili, H.; Punch, J.; Tuttle-Newhall, E.; Mayer, D.; Neuhaus, P.; et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. \u003Cspan class=\"html-italic\">Liver Transpl\u003C/span> \u003Cb>2006\u003C/b>, \u003Cspan class=\"html-italic\">12\u003C/span>, 1640–1648. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Safety,+tolerability,+and+efficacy+of+everolimus+in+de+novo+liver+transplant+recipients:+12-+and+36-month+results&author=Levy,+G.&author=Schmidili,+H.&author=Punch,+J.&author=Tuttle-Newhall,+E.&author=Mayer,+D.&author=Neuhaus,+P.&author=et+al.&publication_year=2006&journal=Liver+Transpl&volume=12&pages=1640%E2%80%931648&doi=10.1002/lt.20707\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1002/lt.20707\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B7-preprints-96239\" class=\"html-x\" data-content=\"7.\">Saliba, F.; Dharancy, S.; Salamé, E.; Conti, F.; Eyraud, D.; Radenne, S.; et al. Time to conversion to an everolimus-based regimen: Renal outcomes in liver transplant recipients from the EVEROLIVER registry. \u003Cspan class=\"html-italic\">Liver Transpl\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">26\u003C/span>, 1465–1476. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Time+to+conversion+to+an+everolimus-based+regimen:+Renal+outcomes+in+liver+transplant+recipients+from+the+EVEROLIVER+registry&author=Saliba,+F.&author=Dharancy,+S.&author=Salam%C3%A9,+E.&author=Conti,+F.&author=Eyraud,+D.&author=Radenne,+S.&author=et+al.&publication_year=2020&journal=Liver+Transpl&volume=26&pages=1465%E2%80%931476&doi=10.1002/lt.25879&pmid=32869469\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1002/lt.25879\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/32869469\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B8-preprints-96239\" class=\"html-x\" data-content=\"8.\">De Simone, P.; Fagiuoli, S.; Cescon, M.; De Carlis, L.; Tisone, G.; Volpes, R.; Cillo, U. Use of everolimus in liver transplantation: Recommendations from a working group. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2017\u003C/b>, \u003Cspan class=\"html-italic\">101\u003C/span>, 239–251. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Use+of+everolimus+in+liver+transplantation:+Recommendations+from+a+working+group&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Cescon,+M.&author=De+Carlis,+L.&author=Tisone,+G.&author=Volpes,+R.&author=Cillo,+U.&publication_year=2017&journal=Transplantation&volume=101&pages=239%E2%80%93251&doi=10.1097/TP.0000000000001438&pmid=27495768\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000001438\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/27495768\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B9-preprints-96239\" class=\"html-x\" data-content=\"9.\">Lee, S.G.; Jeng, L.B.; Saliba, F.; Singh Soin, A.; Lee, W.C.; De Simone, P.; et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2021\u003C/b>, \u003Cspan class=\"html-italic\">105\u003C/span>, 1564–1575. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+with+reduced+tacrolimus+in+liver+transplant+recipients:+24-month+results+from+the+pooled+analysis+of+2+randomized+controlled+trials&author=Lee,+S.G.&author=Jeng,+L.B.&author=Saliba,+F.&author=Singh+Soin,+A.&author=Lee,+W.C.&author=De+Simone,+P.&author=et+al.&publication_year=2021&journal=Transplantation&volume=105&pages=1564%E2%80%931575&doi=10.1097/TP.0000000000003394\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000003394\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B10-preprints-96239\" class=\"html-xx\" data-content=\"10.\">Lin, M.; Mittal, S.; Sahebjam, F.; Rana, A.; Sood, G.K. Everolimus with early withdrawal or reduced dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. \u003Cspan class=\"html-italic\">Clin Transplant\u003C/span> \u003Cb>2017\u003C/b>, 31. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Everolimus+with+early+withdrawal+or+reduced+dose+calcineurin+inhibitors+improves+renal+function+in+liver+transplant+recipients:+A+systematic+review+and+meta-analysis&author=Lin,+M.&author=Mittal,+S.&author=Sahebjam,+F.&author=Rana,+A.&author=Sood,+G.K.&publication_year=2017&journal=Clin+Transplant&pages=31&doi=10.1111/ctr.12872\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1111/ctr.12872\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B11-preprints-96239\" class=\"html-xx\" data-content=\"11.\">Guan, T.W.; Lin, Y.J.; Ou, M.Y.; Chen, K.B. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. \u003Cspan class=\"html-italic\">Eur J Clin Invest\u003C/span> \u003Cb>2019\u003C/b>, \u003Cspan class=\"html-italic\">49\u003C/span>, e13179. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+treatment+on+liver+transplant+recipients:+A+meta-analysis&author=Guan,+T.W.&author=Lin,+Y.J.&author=Ou,+M.Y.&author=Chen,+K.B.&publication_year=2019&journal=Eur+J+Clin+Invest&volume=49&pages=e13179&doi=10.1111/eci.13179\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1111/eci.13179\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B12-preprints-96239\" class=\"html-xx\" data-content=\"12.\">Yan, X.; Huang, S.; Yang, Y.; Lu, Z.; Li, F.; Jiang, L.; et al. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis. \u003Cspan class=\"html-italic\">Liver Transpl\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">28\u003C/span>, 1063–1077. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Sirolimus+or+everolimus+improves+survival+after+liver+transplantation+for+hepatocellular+carcinoma:+A+systematic+review+and+meta-analysis&author=Yan,+X.&author=Huang,+S.&author=Yang,+Y.&author=Lu,+Z.&author=Li,+F.&author=Jiang,+L.&author=et+al.&publication_year=2022&journal=Liver+Transpl&volume=28&pages=1063%E2%80%931077&doi=10.1002/lt.26387\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1002/lt.26387\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B13-preprints-96239\" class=\"html-xx\" data-content=\"13.\">[No authors listed] Banff schema for grading liver allograft rejection: An international consensus document. \u003Cspan class=\"html-italic\">Hepatology\u003C/span> \u003Cb>1997\u003C/b>, \u003Cspan class=\"html-italic\">25\u003C/span>, 658–663. [\u003Ca href=\"https://doi.org/10.1002/hep.510250328\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B14-preprints-96239\" class=\"html-xx\" data-content=\"14.\">EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. \u003Cspan class=\"html-italic\">J Hepatol\u003C/span> \u003Cb>2012\u003C/b>, \u003Cspan class=\"html-italic\">56\u003C/span>, 908–943. [\u003Ca href=\"https://doi.org/10.1016/j.jhep.2011.12.001\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/22424438\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B15-preprints-96239\" class=\"html-xx\" data-content=\"15.\">Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, A.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. \u003Cspan class=\"html-italic\">J Hepatol\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">76\u003C/span>, 681–693. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=BCLC+strategy+for+prognosis+prediction+and+treatment+recommendation:+The+2022+update&author=Reig,+M.&author=Forner,+A.&author=Rimola,+J.&author=Ferrer-F%C3%A0brega,+J.&author=Burrel,+M.&author=Garcia-Criado,+A.&author=et+al.&publication_year=2022&journal=J+Hepatol&volume=76&pages=681%E2%80%93693&doi=10.1016/j.jhep.2021.11.018\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.jhep.2021.11.018\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B16-preprints-96239\" class=\"html-xx\" data-content=\"16.\">Olthoff, K.M.; Kulik, L.; Samstein, B.; Kaminski, M.; Abecassis, M.; Emond, J.; Shaked, A.; Christie, J.D. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. \u003Cspan class=\"html-italic\">Liver Transpl\u003C/span> \u003Cb>2010\u003C/b>, \u003Cspan class=\"html-italic\">16\u003C/span>, 943–949. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Validation+of+a+current+definition+of+early+allograft+dysfunction+in+liver+transplant+recipients+and+analysis+of+risk+factors&author=Olthoff,+K.M.&author=Kulik,+L.&author=Samstein,+B.&author=Kaminski,+M.&author=Abecassis,+M.&author=Emond,+J.&author=Shaked,+A.&author=Christie,+J.D.&publication_year=2010&journal=Liver+Transpl&volume=16&pages=943%E2%80%93949&doi=10.1002/lt.22091&pmid=20677285\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1002/lt.22091\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/20677285\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B17-preprints-96239\" class=\"html-xx\" data-content=\"17.\">KDIGO Clinical Practice Guideline for Acute Kidney Injury. \u003Cspan class=\"html-italic\">Kidney International Supplements\u003C/span> \u003Cb>2012\u003C/b>, \u003Cspan class=\"html-italic\">2\u003C/span>, 1–141.\u003C/li>\n\u003Cli id=\"B18-preprints-96239\" class=\"html-xx\" data-content=\"18.\">Tonon, M.; Rosi, S.; Gambino, C.G.; Piano, S.; Calvino, V.; Romano, A.; Martini, A.; Pontisso, P.; Angeli, P. Natural history of acute kidney disease in patients with cirrhosis. \u003Cspan class=\"html-italic\">J Hepatol\u003C/span> \u003Cb>2021\u003C/b>, \u003Cspan class=\"html-italic\">74\u003C/span>, 578–583. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Natural+history+of+acute+kidney+disease+in+patients+with+cirrhosis&author=Tonon,+M.&author=Rosi,+S.&author=Gambino,+C.G.&author=Piano,+S.&author=Calvino,+V.&author=Romano,+A.&author=Martini,+A.&author=Pontisso,+P.&author=Angeli,+P.&publication_year=2021&journal=J+Hepatol&volume=74&pages=578%E2%80%93583&doi=10.1016/j.jhep.2020.08.037\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.jhep.2020.08.037\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B19-preprints-96239\" class=\"html-xx\" data-content=\"19.\">Diabetes Standards of Care: ADA guidelines (2018). Available at: http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf. Accessed 1st September 2023.\u003C/li>\n\u003Cli id=\"B20-preprints-96239\" class=\"html-xx\" data-content=\"20.\">Tejada, S.; Martinez-Revejo, R.; Nogueira, T.A.; Gòmez, A.; Pont, T.; Liao, X.; et al. The effect of sex inequality on solid organ transplantation: A systematic review and meta-analysis. \u003Cspan class=\"html-italic\">Eur J Int Med\u003C/span> \u003Cb>2023\u003C/b>, \u003Cspan class=\"html-italic\">109\u003C/span>, 58–67. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=The+effect+of+sex+inequality+on+solid+organ+transplantation:+A+systematic+review+and+meta-analysis&author=Tejada,+S.&author=Martinez-Revejo,+R.&author=Nogueira,+T.A.&author=G%C3%B2mez,+A.&author=Pont,+T.&author=Liao,+X.&author=et+al.&publication_year=2023&journal=Eur+J+Int+Med&volume=109&pages=58%E2%80%9367&doi=10.1016/j.ejim.2022.12.009\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.ejim.2022.12.009\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B21-preprints-96239\" class=\"html-xx\" data-content=\"21.\">Gil, E.; Kim, J.M.; Jeon, K.; Park, H.; Kang, D.; Cho, J.; Suh, G.Y.; Park, H. Recipient age and mortality after liver transplantation: A population-based cohort study. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2018\u003C/b>, \u003Cspan class=\"html-italic\">102\u003C/span>, 2025–2032. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Recipient+age+and+mortality+after+liver+transplantation:+A+population-based+cohort+study&author=Gil,+E.&author=Kim,+J.M.&author=Jeon,+K.&author=Park,+H.&author=Kang,+D.&author=Cho,+J.&author=Suh,+G.Y.&author=Park,+H.&publication_year=2018&journal=Transplantation&volume=102&pages=2025%E2%80%932032&doi=10.1097/TP.0000000000002246\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000002246\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B22-preprints-96239\" class=\"html-xx\" data-content=\"22.\">Bhamidimarri, K.R.; Satapathy, S.K.; Martin, P. Hepatitis C virus and liver transplantation. \u003Cspan class=\"html-italic\">Gastroenterol Hepatol (N Y)\u003C/span> \u003Cb>2017\u003C/b>, \u003Cspan class=\"html-italic\">13\u003C/span>, 214–220. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Hepatitis+C+virus+and+liver+transplantation&author=Bhamidimarri,+K.R.&author=Satapathy,+S.K.&author=Martin,+P.&publication_year=2017&journal=Gastroenterol+Hepatol+(N+Y)&volume=13&pages=214%E2%80%93220\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>]\u003C/li>\n\u003Cli id=\"B23-preprints-96239\" class=\"html-xx\" data-content=\"23.\">Brodosi, L.; Petta, S.; Petroni, M.L.; Marchesini, G.; Morelli, M.C. Management of diabetes in candidates for liver transplantation and in transplant recipients. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">106\u003C/span>, 462–478. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Management+of+diabetes+in+candidates+for+liver+transplantation+and+in+transplant+recipients&author=Brodosi,+L.&author=Petta,+S.&author=Petroni,+M.L.&author=Marchesini,+G.&author=Morelli,+M.C.&publication_year=2022&journal=Transplantation&volume=106&pages=462%E2%80%93478&doi=10.1097/TP.0000000000003867\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000003867\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B24-preprints-96239\" class=\"html-xx\" data-content=\"24.\">Cullaro, G.; Verna, E.C.; Lee, B.P.; Lai, J.C. Chronic Kidney Disease in Liver Transplant Candidates: A rising burden impacting post-liver transplant outcomes. \u003Cspan class=\"html-italic\">Liver Transpl\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">26\u003C/span>, 498–506. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Chronic+Kidney+Disease+in+Liver+Transplant+Candidates:+A+rising+burden+impacting+post-liver+transplant+outcomes&author=Cullaro,+G.&author=Verna,+E.C.&author=Lee,+B.P.&author=Lai,+J.C.&publication_year=2020&journal=Liver+Transpl&volume=26&pages=498%E2%80%93506&doi=10.1002/lt.25694&pmid=31785069\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1002/lt.25694\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/31785069\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B25-preprints-96239\" class=\"html-xx\" data-content=\"25.\">Avolio, A.W.; Franco, A.; Schlegel, A.; Lai, Q.; Meli, S.; Burra, P.; et al. Development and validation of a comprehensive model to estimate early allograft failure among patients requiring early liver retransplant. \u003Cspan class=\"html-italic\">JAMA Surg\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">155\u003C/span>, e204095. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+comprehensive+model+to+estimate+early+allograft+failure+among+patients+requiring+early+liver+retransplant&author=Avolio,+A.W.&author=Franco,+A.&author=Schlegel,+A.&author=Lai,+Q.&author=Meli,+S.&author=Burra,+P.&author=et+al.&publication_year=2020&journal=JAMA+Surg&volume=155&pages=e204095&doi=10.1001/jamasurg.2020.4095\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1001/jamasurg.2020.4095\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B26-preprints-96239\" class=\"html-xx\" data-content=\"26.\">Sarkar, M.; Watt, K.D.; Terrault, N.; Berenguer, M. Outcomes in liver transplantation: Does sex matter? \u003Cspan class=\"html-italic\">J Hepatol\u003C/span> \u003Cb>2015\u003C/b>, \u003Cspan class=\"html-italic\">62\u003C/span>, 946–955. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Outcomes+in+liver+transplantation:+Does+sex+matter?&author=Sarkar,+M.&author=Watt,+K.D.&author=Terrault,+N.&author=Berenguer,+M.&publication_year=2015&journal=J+Hepatol&volume=62&pages=946%E2%80%93955&doi=10.1016/j.jhep.2014.11.023\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.jhep.2014.11.023\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B27-preprints-96239\" class=\"html-xx\" data-content=\"27.\">Kanneganti, M.; Olthoff, K.M.; Bittermann, T. Impact of older donor age on recipient and graft survival after LDLT: The US Experience. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2023\u003C/b>, \u003Cspan class=\"html-italic\">107\u003C/span>, 162–171. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Impact+of+older+donor+age+on+recipient+and+graft+survival+after+LDLT:+The+US+Experience&author=Kanneganti,+M.&author=Olthoff,+K.M.&author=Bittermann,+T.&publication_year=2023&journal=Transplantation&volume=107&pages=162%E2%80%93171&doi=10.1097/TP.0000000000004289\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000004289\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B28-preprints-96239\" class=\"html-xx\" data-content=\"28.\">Singhal, A.K.; Sheng, X.; Drakos, S.G.; Stehlik, J. Impact of donor cause of death on transplant outcomes: UNOS registry analysis. \u003Cspan class=\"html-italic\">Transplant Proc\u003C/span> \u003Cb>2009\u003C/b>, \u003Cspan class=\"html-italic\">41\u003C/span>, 3539–3544. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Impact+of+donor+cause+of+death+on+transplant+outcomes:+UNOS+registry+analysis&author=Singhal,+A.K.&author=Sheng,+X.&author=Drakos,+S.G.&author=Stehlik,+J.&publication_year=2009&journal=Transplant+Proc&volume=41&pages=3539%E2%80%933544&doi=10.1016/j.transproceed.2009.06.192\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.transproceed.2009.06.192\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B29-preprints-96239\" class=\"html-xx\" data-content=\"29.\">Tingle, S.J.; Dobbins, J.J.; Thompson, E.R.; Figueiredo, R.S.; Mahendran, B.; Pandanaboyana, S.; Wilson, C. Machine perfusion in liver transplantation. Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No.: CD014685. [\u003Ca href=\"https://doi.org/10.1002/14651858.CD014685.pub2\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B30-preprints-96239\" class=\"html-xx\" data-content=\"30.\">Figiel, W.; Smoter, P.; Krasnodębski, M.; Rykowski, P.; Morawski, M.; Grąt, M.; Patkowski, W.; Zieniewicz, K. Predictors of long-term outcomes after liver transplantation depending on the length of cold ischemia time. \u003Cspan class=\"html-italic\">Transpl Proc\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">54\u003C/span>, 1025–1028. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Predictors+of+long-term+outcomes+after+liver+transplantation+depending+on+the+length+of+cold+ischemia+time&author=Figiel,+W.&author=Smoter,+P.&author=Krasnod%C4%99bski,+M.&author=Rykowski,+P.&author=Morawski,+M.&author=Gr%C4%85t,+M.&author=Patkowski,+W.&author=Zieniewicz,+K.&publication_year=2022&journal=Transpl+Proc&volume=54&pages=1025%E2%80%931028&doi=10.1016/j.transproceed.2022.03.009\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.transproceed.2022.03.009\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B31-preprints-96239\" class=\"html-xx\" data-content=\"31.\">Lingiah, V.A.; Niazi, M.; Olivo, R.; Paterno, F.; Guarrera, J.V.; Pyrsopoulos, N.T. Liver transplantation beyond Milan criteria. \u003Cspan class=\"html-italic\">J Clin Transl Hepatol\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">8\u003C/span>, 69–75. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Liver+transplantation+beyond+Milan+criteria&author=Lingiah,+V.A.&author=Niazi,+M.&author=Olivo,+R.&author=Paterno,+F.&author=Guarrera,+J.V.&author=Pyrsopoulos,+N.T.&publication_year=2020&journal=J+Clin+Transl+Hepatol&volume=8&pages=69%E2%80%9375&doi=10.14218/JCTH.2019.00050\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.14218/JCTH.2019.00050\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B32-preprints-96239\" class=\"html-xx\" data-content=\"32.\">Duvoux, C.; Roudot-Thoraval, F.; Decaens, T.; Pessione, F.; Badran, H.; Piardi, P.; et al. Liver transplantation for hepatocellular carcinoma: A model including α-fetoprotein improves the performance of Milan criteria. \u003Cspan class=\"html-italic\">Gastroenterology\u003C/span> \u003Cb>2012\u003C/b>, \u003Cspan class=\"html-italic\">143\u003C/span>, 986–994. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Liver+transplantation+for+hepatocellular+carcinoma:+A+model+including+%CE%B1-fetoprotein+improves+the+performance+of+Milan+criteria&author=Duvoux,+C.&author=Roudot-Thoraval,+F.&author=Decaens,+T.&author=Pessione,+F.&author=Badran,+H.&author=Piardi,+P.&author=et+al.&publication_year=2012&journal=Gastroenterology&volume=143&pages=986%E2%80%93994&doi=10.1053/j.gastro.2012.05.052&pmid=22750200\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1053/j.gastro.2012.05.052\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/22750200\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B33-preprints-96239\" class=\"html-xx\" data-content=\"33.\">Mehta, N.; Guy, J.; Frenette, C.T.; Dodge, J.L.; Osorio, R.W.; Minteer, W.B.; Roberts, J.P.; Yao, F.Y. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: A multicenter study. \u003Cspan class=\"html-italic\">Clin Gastroenterol Hepatol\u003C/span> \u003Cb>2018\u003C/b>, \u003Cspan class=\"html-italic\">16\u003C/span>, 955–964. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Excellent+outcomes+of+liver+transplantation+following+down-staging+of+hepatocellular+carcinoma+to+within+Milan+criteria:+A+multicenter+study&author=Mehta,+N.&author=Guy,+J.&author=Frenette,+C.T.&author=Dodge,+J.L.&author=Osorio,+R.W.&author=Minteer,+W.B.&author=Roberts,+J.P.&author=Yao,+F.Y.&publication_year=2018&journal=Clin+Gastroenterol+Hepatol&volume=16&pages=955%E2%80%93964&doi=10.1016/j.cgh.2017.11.037\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.cgh.2017.11.037\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B34-preprints-96239\" class=\"html-xx\" data-content=\"34.\">Jonas, S.; Bechstein, W.O.; Steinmueller, T.; Hermann, M.; Radke, C.; Berg, T.; Settmacher, U.; Neuhaus, P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. \u003Cspan class=\"html-italic\">Hepatology\u003C/span> \u003Cb>2001\u003C/b>, \u003Cspan class=\"html-italic\">33\u003C/span>, 1080–1086. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Vascular+invasion+and+histopathologic+grading+determine+outcome+after+liver+transplantation+for+hepatocellular+carcinoma+in+cirrhosis&author=Jonas,+S.&author=Bechstein,+W.O.&author=Steinmueller,+T.&author=Hermann,+M.&author=Radke,+C.&author=Berg,+T.&author=Settmacher,+U.&author=Neuhaus,+P.&publication_year=2001&journal=Hepatology&volume=33&pages=1080%E2%80%931086&doi=10.1053/jhep.2001.23561&pmid=11343235\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1053/jhep.2001.23561\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/11343235\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B35-preprints-96239\" class=\"html-xx\" data-content=\"35.\">Rodríguez-Perálvarez, M.; Tsochatzis, E.; Naveas, M.C.; Pieri, G.; García-Caparrós, C.; O'Beirne, J.; et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. \u003Cspan class=\"html-italic\">J Hepatol\u003C/span> \u003Cb>2013\u003C/b>, \u003Cspan class=\"html-italic\">59\u003C/span>, 1193–1199. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Reduced+exposure+to+calcineurin+inhibitors+early+after+liver+transplantation+prevents+recurrence+of+hepatocellular+carcinoma&author=Rodr%C3%ADguez-Per%C3%A1lvarez,+M.&author=Tsochatzis,+E.&author=Naveas,+M.C.&author=Pieri,+G.&author=Garc%C3%ADa-Caparr%C3%B3s,+C.&author=O'Beirne,+J.&author=et+al.&publication_year=2013&journal=J+Hepatol&volume=59&pages=1193%E2%80%931199&doi=10.1016/j.jhep.2013.07.012&pmid=23867318\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.jhep.2013.07.012\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/23867318\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B36-preprints-96239\" class=\"html-xx\" data-content=\"36.\">Aloun, A.; Abu-Zeid, E.E.D.; Garzali, I.U. Does mTORi based immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? \u003Cspan class=\"html-italic\">Systematic review and meta-analysis of randomized controlled trials. Hepatol Forum\u003C/span> \u003Cb>2023\u003C/b>, \u003Cspan class=\"html-italic\">4\u003C/span>, 82–88. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Does+mTORi+based+immunosuppression+offer+survival+advantage+after+liver+transplantation+for+hepatocellular+carcinoma?&author=Aloun,+A.&author=Abu-Zeid,+E.E.D.&author=Garzali,+I.U.&publication_year=2023&journal=Systematic+review+and+meta-analysis+of+randomized+controlled+trials.+Hepatol+Forum&volume=4&pages=82%E2%80%9388&pmid=37250931\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/37250931\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B37-preprints-96239\" class=\"html-xx\" data-content=\"37.\">Zhang, G.; Duan, B.; Li, G. mTORi-based immunosuppression reduces HCC recurrence at the expenses of increased adverse side effects: A systematic review and meta-analysis. \u003Cspan class=\"html-italic\">Clin Transplant\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">36\u003C/span>, e14823. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=mTORi-based+immunosuppression+reduces+HCC+recurrence+at+the+expenses+of+increased+adverse+side+effects:+A+systematic+review+and+meta-analysis&author=Zhang,+G.&author=Duan,+B.&author=Li,+G.&publication_year=2022&journal=Clin+Transplant&volume=36&pages=e14823&doi=10.1111/ctr.14823&pmid=36124430\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1111/ctr.14823\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/36124430\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B38-preprints-96239\" class=\"html-xx\" data-content=\"38.\">Grigg SE, Sarri GL, Gow PJ; Yeomans ND. \u003Cspan class=\"html-italic\">Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther\u003C/span> \u003Cb>2019\u003C/b>, \u003Cspan class=\"html-italic\">49\u003C/span>, 1260–1273.\u003C/li>\n\u003Cli id=\"B39-preprints-96239\" class=\"html-xx\" data-content=\"39.\">Tarantino, G.; Magistri, P.; Ballarin, R.; Di Francia, R.; Berretta, M.; Di Benedetto, F. Oncological impact of mTOR inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: Review of the literature. \u003Cspan class=\"html-italic\">Front Pharmacol\u003C/span> \u003Cb>2016\u003C/b>, \u003Cspan class=\"html-italic\">7\u003C/span>, 387. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Oncological+impact+of+mTOR+inhibitor+immunosuppressive+therapy+after+liver+transplantation+for+hepatocellular+carcinoma:+Review+of+the+literature&author=Tarantino,+G.&author=Magistri,+P.&author=Ballarin,+R.&author=Di+Francia,+R.&author=Berretta,+M.&author=Di+Benedetto,+F.&publication_year=2016&journal=Front+Pharmacol&volume=7&pages=387&doi=10.3389/fphar.2016.00387&pmid=27818634\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.3389/fphar.2016.00387\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/27818634\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B40-preprints-96239\" class=\"html-xx\" data-content=\"40.\">Holdaas, H.; De Simone, P.; Zuckermann, A. Everolimus and malignancy after solid organ transplantation: A clinical update. \u003Cspan class=\"html-italic\">J Transplant\u003C/span> \u003Cb>2016\u003C/b>, \u003Cspan class=\"html-italic\">2016\u003C/span>, 4369574. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Everolimus+and+malignancy+after+solid+organ+transplantation:+A+clinical+update&author=Holdaas,+H.&author=De+Simone,+P.&author=Zuckermann,+A.&publication_year=2016&journal=J+Transplant&volume=2016&pages=4369574&doi=10.1155/2016/4369574&pmid=27807479\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1155/2016/4369574\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/27807479\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B41-preprints-96239\" class=\"html-xx\" data-content=\"41.\">Geissler, E.K.; Schnitzbauer, A.A.; Zülke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label Phase 3 trial. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2016\u003C/b>, \u003Cspan class=\"html-italic\">100\u003C/span>, 116–125. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Sirolimus+use+in+liver+transplant+recipients+with+hepatocellular+carcinoma:+A+randomized,+multicenter,+open-label+Phase+3+trial&author=Geissler,+E.K.&author=Schnitzbauer,+A.A.&author=Z%C3%BClke,+C.&author=Lamby,+P.E.&author=Proneth,+A.&author=Duvoux,+C.&author=et+al.&publication_year=2016&journal=Transplantation&volume=100&pages=116%E2%80%93125&doi=10.1097/TP.0000000000000965&pmid=26555945\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000000965\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/26555945\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B42-preprints-96239\" class=\"html-xx\" data-content=\"42.\">Sapisochin, G.; Lee, W.C.; Joo Dj Joh, J.W.; Hata, K.; Soin, A.S.; et al. Long-term effects of everolimus-facilitated tacrolimus reduction in living donor liver transplant recipients with hepatocellular carcinoma. \u003Cspan class=\"html-italic\">Ann Transplant\u003C/span> \u003Cb>2022\u003C/b>, \u003Cspan class=\"html-italic\">27\u003C/span>, e937988. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Long-term+effects+of+everolimus-facilitated+tacrolimus+reduction+in+living+donor+liver+transplant+recipients+with+hepatocellular+carcinoma&author=Sapisochin,+G.&author=Lee,+W.C.&author=Joo+Dj+Joh,+J.W.&author=Hata,+K.&author=Soin,+A.S.&author=et+al.&publication_year=2022&journal=Ann+Transplant&volume=27&pages=e937988&doi=10.12659/AOT.937988\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.12659/AOT.937988\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B43-preprints-96239\" class=\"html-xx\" data-content=\"43.\">Rodriguez-Peralvarez, M.; Guerrero, M.; Barrera, L.; Ferrin, G.; Alamo, J.M.; et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation. \u003Cspan class=\"html-italic\">Transplantation\u003C/span> \u003Cb>2018\u003C/b>, \u003Cspan class=\"html-italic\">102\u003C/span>, 2056–2064. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Impact+of+early+initiated+everolimus+on+the+recurrence+of+hepatocellular+carcinoma+after+liver+transplantation&author=Rodriguez-Peralvarez,+M.&author=Guerrero,+M.&author=Barrera,+L.&author=Ferrin,+G.&author=Alamo,+J.M.&author=et+al.&publication_year=2018&journal=Transplantation&volume=102&pages=2056%E2%80%932064&doi=10.1097/TP.0000000000002270\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1097/TP.0000000000002270\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B44-preprints-96239\" class=\"html-xx\" data-content=\"44.\">Kang, I.; Lee, J.G.; Choi, S.H.; Kim, H.J.; Han, D.H.; Choi, G.H.; et al. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. \u003Cspan class=\"html-italic\">Clin Mol Hepatol\u003C/span> \u003Cb>2021\u003C/b>, \u003Cspan class=\"html-italic\">27\u003C/span>, 589–602. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Impact+of+everolimus+on+survival+after+liver+transplantation+for+hepatocellular+carcinoma&author=Kang,+I.&author=Lee,+J.G.&author=Choi,+S.H.&author=Kim,+H.J.&author=Han,+D.H.&author=Choi,+G.H.&author=et+al.&publication_year=2021&journal=Clin+Mol+Hepatol&volume=27&pages=589%E2%80%93602&doi=10.3350/cmh.2021.0038&pmid=34293849\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.3350/cmh.2021.0038\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/34293849\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B45-preprints-96239\" class=\"html-xx\" data-content=\"45.\">Wasilewicz, M.P.; Moczydlowska, D.; Janik, M.; Grat, M.; Zienewicz, K.; Raszeja-Wyszomirska, J. Immunosuppressive treatment with everolimus in patients after liver transplant: 4 years of single-center experience. \u003Cspan class=\"html-italic\">Pol Arch Intern Med\u003C/span> \u003Cb>2019\u003C/b>, \u003Cspan class=\"html-italic\">129\u003C/span>, 686–691. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Immunosuppressive+treatment+with+everolimus+in+patients+after+liver+transplant:+4+years+of+single-center+experience&author=Wasilewicz,+M.P.&author=Moczydlowska,+D.&author=Janik,+M.&author=Grat,+M.&author=Zienewicz,+K.&author=Raszeja-Wyszomirska,+J.&publication_year=2019&journal=Pol+Arch+Intern+Med&volume=129&pages=686%E2%80%93691&pmid=31502586\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/31502586\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B46-preprints-96239\" class=\"html-xx\" data-content=\"46.\">Cholongitas, E.; Antoniadis, N.; Goulis, I.; Theocharidou, E.; Imvrios, G.; Giouleme, O.; et al. Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation. \u003Cspan class=\"html-italic\">Transplant Proc\u003C/span> \u003Cb>2019\u003C/b>, \u003Cspan class=\"html-italic\">51\u003C/span>, 450–453. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Trough+levels+of+everolimus+are+associated+with+recurrence+rates+of+hepatocellular+carcinoma+after+liver+transplantation&author=Cholongitas,+E.&author=Antoniadis,+N.&author=Goulis,+I.&author=Theocharidou,+E.&author=Imvrios,+G.&author=Giouleme,+O.&author=et+al.&publication_year=2019&journal=Transplant+Proc&volume=51&pages=450%E2%80%93453&doi=10.1016/j.transproceed.2019.01.069&pmid=30879564\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1016/j.transproceed.2019.01.069\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/30879564\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B47-preprints-96239\" class=\"html-xx\" data-content=\"47.\">Engl, T.; Rutz, J.; Maxeiner, S.; Juengel, E.; Roos, F.; Khoder, W.; et al. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma in vitro. \u003Cspan class=\"html-italic\">Mol Med Rep\u003C/span> \u003Cb>2017\u003C/b>, \u003Cspan class=\"html-italic\">16\u003C/span>, 7064–7071. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=mTOR+inhibition+reduces+growth+and+adhesion+of+hepatocellular+carcinoma+in+vitro&author=Engl,+T.&author=Rutz,+J.&author=Maxeiner,+S.&author=Juengel,+E.&author=Roos,+F.&author=Khoder,+W.&author=et+al.&publication_year=2017&journal=Mol+Med+Rep&volume=16&pages=7064%E2%80%937071&doi=10.3892/mmr.2017.7401&pmid=28901501\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.3892/mmr.2017.7401\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>] [\u003Ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/28901501\" class=\"cross-ref pub_med\" data-typ=\"pmid\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed\u003C/a>]\u003C/li>\n\u003Cli id=\"B48-preprints-96239\" class=\"html-xx\" data-content=\"48.\">Ande, A.; Chaar, M.; Ait-Oudhia, S. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. \u003Cspan class=\"html-italic\">J Pharmacokinet Pharmacodyn\u003C/span> \u003Cb>2018\u003C/b>, \u003Cspan class=\"html-italic\">45\u003C/span>, 607–620. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Multiscale+systems+pharmacological+analysis+of+everolimus+action+in+hepatocellular+carcinoma&author=Ande,+A.&author=Chaar,+M.&author=Ait-Oudhia,+S.&publication_year=2018&journal=J+Pharmacokinet+Pharmacodyn&volume=45&pages=607%E2%80%93620&doi=10.1007/s10928-018-9590-0\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1007/s10928-018-9590-0\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003Cli id=\"B49-preprints-96239\" class=\"html-xx\" data-content=\"49.\">Cillo, U.; De Carlis, L.; Del Gaudio, M.; De Simone, P.; Fagiuoli, S.; Lupo, F.; Tisone, G.; Volpes, R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: Consensus recommendations from an Italian working group. \u003Cspan class=\"html-italic\">Liver Int\u003C/span> \u003Cb>2020\u003C/b>, \u003Cspan class=\"html-italic\">146\u003C/span>, 930–943. [\u003Ca href=\"https://scholar.google.com/scholar_lookup?title=Immunosuppressive+regimens+for+adult+liver+transplant+recipients+in+real-life+practice:+Consensus+recommendations+from+an+Italian+working+group&author=Cillo,+U.&author=De+Carlis,+L.&author=Del+Gaudio,+M.&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Lupo,+F.&author=Tisone,+G.&author=Volpes,+R.&publication_year=2020&journal=Liver+Int&volume=146&pages=930%E2%80%93943&doi=10.1007/s12072-020-10091-5\" class=\"google-scholar\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar\u003C/a>] [\u003Ca href=\"https://doi.org/10.1007/s12072-020-10091-5\" class=\"cross-ref\" target=\"_blank\" rel=\"noopener noreferrer\">CrossRef\u003C/a>]\u003C/li>\n\u003C/ol>\u003C/section>\u003Csection id=\"FiguresandTables\" type=\"display-objects\">\u003Cdiv class=\"html-fig-wrap\" id=\"preprints-96239-f001\">\n \u003Cdiv class=\"html-fig_img\">\n \u003Cdiv class=\"html-figpopup html-figpopup-link\" href=\"#fig_body_display_preprints-96239-f001\">\n \u003Cimg data-large=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\" data-original=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\" alt=\"Preprints 96239 g001\" src=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\">\n \u003Ca class=\"html-expand html-figpopup\" href=\"#fig_body_display_preprints-96239-f001\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-fig_description\">\n \u003Cb>Figure 1.\u003C/b>\n Kaplan-Meier probability of post-transplant overall patient survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.506).\n\u003C!-- \u003Cp>\u003Ca class=\"html-figpopup\" href=\"#fig_body_display_preprints-96239-f001\">\n Click here to enlarge figure\n \u003C/a>\u003C/p> -->\n\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-fig_show mfp-hide\" id=\"fig_body_display_preprints-96239-f001\">\n \u003Cdiv class=\"html-caption\"> \u003Cb>Figure 1.\u003C/b>\n Kaplan-Meier probability of post-transplant overall patient survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.506).\u003C/div>\n \u003Cdiv class=\"html-img\">\u003Cimg data-large=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\" data-original=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\" alt=\"Preprints 96239 g001\" src=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g001.png\">\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-fig-wrap\" id=\"preprints-96239-f002\">\n \u003Cdiv class=\"html-fig_img\">\n \u003Cdiv class=\"html-figpopup html-figpopup-link\" href=\"#fig_body_display_preprints-96239-f002\">\n \u003Cimg data-large=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\" data-original=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\" alt=\"Preprints 96239 g002\" src=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\">\n \u003Ca class=\"html-expand html-figpopup\" href=\"#fig_body_display_preprints-96239-f002\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-fig_description\">\n \u003Cb>Figure 2.\u003C/b>\n Kaplan-Meier probability of post-transplant recurrence-free survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.205).\n\u003C!-- \u003Cp>\u003Ca class=\"html-figpopup\" href=\"#fig_body_display_preprints-96239-f002\">\n Click here to enlarge figure\n \u003C/a>\u003C/p> -->\n\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-fig_show mfp-hide\" id=\"fig_body_display_preprints-96239-f002\">\n \u003Cdiv class=\"html-caption\"> \u003Cb>Figure 2.\u003C/b>\n Kaplan-Meier probability of post-transplant recurrence-free survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. All strata comparisons were statistically significant (log-rank p <0.001) except Milan-in on EVR versus Milan-in on TAC (log-rank P=0.205).\u003C/div>\n \u003Cdiv class=\"html-img\">\u003Cimg data-large=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\" data-original=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\" alt=\"Preprints 96239 g002\" src=\"https://www.preprints.org/frontend/picture/ms_xml/manuscript/48e42377516d025ac928e3e795502452/preprints-96239-g002.png\">\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t001\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t001\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t001\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 1.\u003C/b>\n demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t001\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 1.\u003C/b>\n demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Variable\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">EVR (#463)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">CNI (#556)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">P\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\u003Ctd colspan=\"4\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>RECIPIENT\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Male sex, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">386 (83.4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">487 (87.6)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.55\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Age at transplant (median, IQR), years\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">56 (10)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">56 (10)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.28\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Indication to transplant, n (%)\u003Cbr>HCV\u003Cbr>HBV (±HDV)\u003Cbr>HCV-HBV(±HDV)\u003Cbr>Alcohol\u003Cbr>NAFLD\u003Cbr>Autoimmune/PSC\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>237 (55.5)\u003Cbr>123 (26.5)\u003Cbr>17 (3.7)\u003Cbr>54 (11.6)\u003Cbr>20 (4.3)\u003Cbr>12 (5.2)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>294 (52.8)\u003Cbr>153 (27.5)\u003Cbr>20 (3.5)\u003Cbr>59 (9.5)\u003Cbr>24 (4.3)\u003Cbr>6 (1.1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>0.59\u003Cbr>0.73\u003Cbr>0.94\u003Cbr>0.59\u003Cbr>0.99\u003Cbr>0.67\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Lab-MELD at transplant (median, IQR)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">7 (6)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">8 (7)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.45\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">DM at transplant, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">113 (24.4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">144 (25.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.58\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">CKD at transplant, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">27 (5.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">39 (7.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.44\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Hypertension at transplant, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">69 (14.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">76 (13.6)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.57\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"><2013, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">147 (31.7)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">387 (66.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.0001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">TAC, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">403 (86.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">313 (56.3)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.0001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Mean TAC exposure >10 ng/mL within the first month post-transplantation\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">127 (27.4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">172 (31.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.22\u003C/td>\n\u003C/tr>\n\u003Ctr>\u003Ctd colspan=\"4\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>DONOR\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Male sex, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">241 (52.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">281 (50.5)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.63\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Age, median (IQR)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">69 (25)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">67 (26)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.78\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">ICU stay, median (IQR) days\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">3 (4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">3 (4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.67\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">CVA as cause of death, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">333 (71.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">411 (73.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.47\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Anti-HCV-positive, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">4 (0.86)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0 (0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.58\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Anti-HBc-positive, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">60 (12.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">77 (13.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.67\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Cardiac arrest episodes, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">43 (9.3)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">42 (7.5)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.31\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Use of inotropes, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">407 (87.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">483 (86.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.62\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>HCC\u003C/b>\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Tumor nodules*, median (IQR)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">2 (1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">2 (1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.78\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Largest nodule size*, median (IQR) (mm)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">28 (18)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">25 (15)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cb>0.04\u003C/b>\u003Cbr>\n\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Total tumor size*, median (IQR) (mm)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">39.5 (25)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">36.5 (36)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cb>0.003\u003C/b>\u003Cbr>\n\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Exceeding Milan criteria at transplant *, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">152 (32.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">101 (18.1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.0001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Pre-transplant treatment, n (%)\u003Cbr>None, n (%)\u003Cbr>TACE, n (%)\u003Cbr>RFA/MW, n (%)\u003Cbr>PEI, n (%)\u003Cbr>Resection, n (%)\u003Cbr>TACE + RFA/MW, n (%)\u003Cbr>TARE, n (%)\u003Cbr>\u003Cbr>Successful downstage**, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>141 (30.4) \u003Cbr>229 (49.4)\u003Cbr>33 (7.1) \u003Cbr>6 (1.3) \u003Cbr>6 (1.3) \u003Cbr>42 (9.1) \u003Cbr>6 (1.3) \u003Cbr>\u003Cbr>75 (16.2)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>209 (37.6) \u003Cbr>307 (55.2)\u003Cbr>22 (3.9) \u003Cbr>12 (2.1) \u003Cbr>4 (0.7) \u003Cbr>2 (0.5)\u003Cbr>0 (0)\u003Cbr>\u003Cbr>45 (8.1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\n\u003Cbr>\u003Cb>0.01\u003C/b>\u003Cbr>0.06\u003Cbr>\u003Cb>0.02\u003C/b>\u003Cbr>0.29\u003Cbr>0.35\u003Cbr>\u003Cb><0.0001\u003C/b>\u003Cbr>\u003Cb>0.008\u003C/b>\u003Cbr>\u003Cbr>\u003Cb>0.0006\u003C/b>\n\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">AFP at transplant, median (IQR) (ng/mL)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">46.3 (28)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">4.7 (19)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.002\u003Cbr>\n\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Milan-out at explant histology, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">120 (25.9)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">167 (30.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.98\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">G3-4, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">148 (31.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">140 (25.1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>0.01\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Microvascular infiltration, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">88 (39.5)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">182 (32.7)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>0.02\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb>TRANSPLANTATION\u003C/b>\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\"> \u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">CIT, median (IQR) (min)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">424 (89)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">420 (101)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.09\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">MP, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">9 (1.9)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">7 (1.2)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.89\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Re-transplantation, n (%)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">18 (3.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">23 (4.1)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">0.45\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: AFP, alpha-fetoprotein; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; IQR, interquartile range; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; MW, microwave ablation; MP, machine perfusion; PEI, percutaneous ethanol injection; PSC, primary sclerosing cholangitis; RFA, radiofrequency ablation; TAC, tacrolimus; TACE, trans-arterial chemoembolization; TARE, trans-arterial radioembolization. *Radiological; ** Radiological, as downstaged from outside to within Milan criteria.\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t002\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t002\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t002\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 2.\u003C/b>\n Effect of stabilized IPTW in the population on the variables used for balancing the two groups.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t002\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 2.\u003C/b>\n Effect of stabilized IPTW in the population on the variables used for balancing the two groups.\u003C/div>\n \u003Ctable>\n \u003Cthead>\n\u003Ctr>\n\u003Cth rowspan=\"3\" align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Variables\u003C/th>\n\u003Cth colspan=\"3\" align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Pre-IPTW \u003C/th>\n\u003Cth colspan=\"3\" align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Post-IPTW\u003C/th>\n\u003C/tr>\n\u003Ctr>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">EVR (n=463)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">CNI (n=556)\u003C/th>\n\u003Cth rowspan=\"2\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Cohen’s D-value\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">EVR (n=233)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">TAC (n=278)\u003C/th>\n\u003Cth rowspan=\"2\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Cohen’s D-value\u003C/th>\n\u003C/tr>\n\u003Ctr>\n\u003Cth colspan=\"2\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Mean (±SD)\u003C/th>\n\u003Cth colspan=\"2\" align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Mean (±SD)\u003C/th>\n\u003C/tr>\n\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Patient male sex\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.83±0.15\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.87±0.14\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.05\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.81±0.17\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.82±0.15\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.05\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Patient age, years\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.9±3.92\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">56.4±3.46\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.20\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.1±0.55\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.3±0.53\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.03\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>HCV\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.5±0.70\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.8±0.58\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.42\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">24.3±0.56\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">24.1±0.52\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Patient diabetes\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.24±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.26±0.45\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.12\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.24±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.00\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Patient CKD\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.05±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.07±0.42\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.42\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.05±0.01\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.05±0.01\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>MELD\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.07±0.26\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.11±0.33\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.15\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.38\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.07±0.37\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Donor male sex\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.52±0.38\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.50±0.41\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.08\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.51±0.28\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.50±0.28\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Donor age, years\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.69±0.65\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.67±0.64\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.68±0.38\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.67±0.37\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.03\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Donor cause of death (CVA)\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.71±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.73±0.40\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.13\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.71±0.46\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.72±0.45\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.02\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>MP\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.09±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.00\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>CIT, minutes\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">431.77±79.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">423.50±85.79\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.10\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.53±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.53±0.50\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Milan-out stage, radiologic\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">32.8±2.33\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">19±1.65\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.42\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">29.2±1.2\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">26.3±0.9\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.02\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Tumor downstaging\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.17±0.05\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.04\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.43\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.10±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.08±0.08\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.04\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>AFP at transplant\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.45±0.27\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.04±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.38\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23±0.04\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.19±0.06\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.14\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Milan-out stage, histology\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">26.1±1.5\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">29.1±2.3\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.16\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">24.0±2.3\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">22.0±2.8\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.12\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>G3-G4\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">32.0±2.4\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">25±1.8\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">29.0±2.3\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">28.2±2.0\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.21\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Microinfiltration\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">40.2±1.2\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">33.7±1.7\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.26\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">38.1±2.3\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">32.5±1.9\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.20\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>Mean TAC exposure >10 ng/mL within the first month\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.28±0.04\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.32±0.45\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.13\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.15±0.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.13±0.03\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.00\u003C/td>\n\u003C/tr>\n\u003Ctr>\u003Ctd colspan=\"7\" align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney disease; CVA, cerebro-vascular accident; G, grading; HCV, hepatitis C virus; IPTW, inverse probability therapy weighting; MP, machine perfusion; n, number; SD, standard deviation; TAC, tacrolimus. \u003C/td>\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t003\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t003\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t003\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 3.\u003C/b>\n The characteristics of the 2 pseudo-groups after IPTW matching.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t003\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 3.\u003C/b>\n The characteristics of the 2 pseudo-groups after IPTW matching.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">Variable\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">EVR (#233)\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">TAC (#278)\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">P\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\u003Ctd colspan=\"4\" align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>RECIPIENT\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Male sex, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">192 (82.4)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">228 (82.0)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.90\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Age at transplant (median, IQR), years\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.5 (9)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55.3 (10)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.89\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">HCV, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">58 (24.3)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">69 (24.8)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Lab-MELD at transplant (median, IQR) * \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">8 (6)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">7 (7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.78\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">DM at transplant, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">53 (22.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">66 (23.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.83\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">CKD at transplant, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">12 (5.1)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">14 (5.0)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Mean TAC exposure >10 ng/mL within the first month post-transplantation\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">35 (15.0)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">36 (12.9)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.52\u003C/td>\n\u003C/tr>\n\u003Ctr>\u003Ctd colspan=\"4\" align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>DONOR\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Male sex, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">118 (50.6)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">140 (50.3)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Age, median (IQR)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">68.0 (23)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">67 (26)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.89\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">CVA as cause of death, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">181 (77.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">200 (71.9)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.15\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>HCC\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Exceeding Milan criteria at transplant *, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">67 (28.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">72 (25.8)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.48\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Successful downstaging**, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">24 (10.3)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">23 (8.2)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.44\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">AFP at transplant, median (IQR) (ng/mL)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">23.3 (18)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">19 (11)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.56\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Milan-out at explant histology, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">55 (23.6)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">62 (22.3)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.75\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">G3-4, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">67 (28.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">78 (28.1)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.92\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Microvascular infiltration, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">88 (37.8)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">91 (32.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.26\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>TRANSPLANTATION\u003C/b>\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\"> \u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">CIT, median (IQR) (min)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">432 (89)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">489 (101)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.06\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">MP, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">9 (1.9)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">7 (1.2)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.89\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MELD, model for end-stage liver disease; MP, machine perfusion; TAC, tacrolimus. *Radiological; ** Radiological, as downstaged from outside to within Milan criteria.\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t004\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t004\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t004\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 4.\u003C/b>\n Results in the study groups after stabilized IPTW matching.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t004\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 4.\u003C/b>\n Results in the study groups after stabilized IPTW matching.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">Variable\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">EVR (#233)\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">TAC (#278)\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">P\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Death, n (%)\u003Cbr>\u003Cbr>HCC recurrence, n (%)\u003Cbr>HCV recurrence, n (%)\u003Cbr>Incomplete/delayed graft function, n (%)\u003Cbr>MACE, n (%)\u003Cbr>Intra/peri-operative, n (%)\u003Cbr>Ischemic cholangiopathy, n (%)\u003Cbr>Infection/sepsis, n (%)\u003Cbr>\u003Cspan class=\"html-italic\">De novo\u003C/span> malignancy, n (%)\u003Cbr>Stroke, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">62 (26.6)\u003Cbr>\u003Cbr>16 (6.8)\u003Cbr>16 (6.9)\u003Cbr>1 (0.4)\u003Cbr>2 (0.8)\u003Cbr>2 (0.8)\u003Cbr>4 (1.7)\u003Cbr>12 (5.1)\u003Cbr>5 (2.1)\u003Cbr>4 (1.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">105 (37.8)\u003Cbr>\u003Cbr>42 (15.1)\u003Cbr>15 (5.4)\u003Cbr>2 (0.7)\u003Cbr>6 (2.1)\u003Cbr>3 (1.1)\u003Cbr>7 (2.5)\u003Cbr>16 (5.7)\u003Cbr>11 (3.9)\u003Cbr>3 (1.1)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\n\u003Cb>0.007\u003C/b>\u003Cbr>\u003Cbr>\u003Cb>0.003\u003C/b>\u003Cbr>0.48\u003Cbr>0.22\u003Cbr>0.30\u003Cbr>1\u003Cbr>0.76\u003Cbr>0.84\u003Cbr>0.31\u003Cbr>0.70\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Re-transplantation, n (%)\u003Cbr>\u003Cbr>Ischemic cholangiopathy, n (%)\u003Cbr>PNF, n (%)\u003Cbr>HAT, n %\u003Cbr>Chronic rejection, n (%)\u003Cbr>HCV recurrence, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">9 (3.9)\u003Cbr>\u003Cbr>3 (1.3)\u003Cbr>3 (1.3)\u003Cbr>2 (0.8)\u003Cbr>1 (0.4)\u003Cbr>0 (0)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">11 (3.9)\u003Cbr>\u003Cbr>3 (1.1)\u003Cbr>5 (1.8)\u003Cbr>1 (0.3)\u003Cbr>1 (0.3)\u003Cbr>1 (0.3)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1\u003Cbr>\u003Cbr>1\u003Cbr>0.73\u003Cbr>0.59\u003Cbr>1\u003Cbr>0.99\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">HCC recurrence, n (%)\u003Cbr>\u003Cbr>Liver only, n (%)\u003Cbr>Liver and lung, n (%)\u003Cbr>Liver and bone, n (%)\u003Cbr>Lung only, n (%)\u003Cbr>Bone only, n (%)\u003Cbr>Lung and bone, n (%)\u003Cbr>Nodes, n (%)\u003Cbr>>2 organs, n (%)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">18 (7.7)\u003Cbr>\u003Cbr>7 (3.0)\u003Cbr>1 (0.4)\u003Cbr>0 (0)\u003Cbr>4 (1.7)\u003Cbr>4 (1.7)\u003Cbr>1 (0.4)\u003Cbr>1 (0.4)\u003Cbr>2 (0.8)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">47 (16.9)\u003Cbr>\u003Cbr>15 (5.4)\u003Cbr>8 (2.8)\u003Cbr>4 (1.4)\u003Cbr>9 (1.8)\u003Cbr>1 (0.2)\u003Cbr>4 (1.4)\u003Cbr>6 (2.1)\u003Cbr>16 (5.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.002\u003Cbr>\u003Cbr>0.19\u003Cbr>0.04\u003Cbr>0.12\u003Cbr>0.39\u003Cbr>0.18\u003Cbr>0.38\u003Cbr>0.13\u003Cbr>0.002\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: EVR, everolimus; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MACE, major cardiovascular events; PNF, primary non-function; TAC, tacrolimus. .\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t005\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t005\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t005\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 5.\u003C/b>\n Immunosuppression in the EVR study groups after stabilized IPTW matching.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t005\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 5.\u003C/b>\n Immunosuppression in the EVR study groups after stabilized IPTW matching.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">Variable\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">EVR (#233)\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Reason for EVR use, n (%)\u003Cbr>\u003Cbr>HCC recurrence prophylaxis, n (%)\u003Cbr>Deteriorating renal function *, n (%)\u003Cbr>Neurologic complication *, n (%)\u003Cbr>MACE *, n (%)\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\n\u003Cbr>\u003Cbr>212 (91.0)\u003Cbr>14 (6.0)\u003Cbr>4 (1.7)\u003Cbr>3 (1.2)\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Timing of EVR introduction, median (IQR) (days) * \u003Cbr>\n\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">30 (16) \u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Duration of EVR treatment, median (IQR) (months) *\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">46.6 (36.1)\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">EVR whole-blood exposure, median (IQR) (ng/mL) *\u003Cbr>\n\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">5.8 (1.7)\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: EVR, everolimus; HC, hepatocellular carcinoma; IPTW, inverse probability of treatment weigthing; IQR, interquartile range; MACE, major cardiovascular events.\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t006\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t006\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t006\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 6.\u003C/b>\n EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t006\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 6.\u003C/b>\n EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Variable\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Recurring HCC (#18)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">Non-recurring HCC (#215)\u003C/th>\n\u003Cth align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-center\">P\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Timing of EVR introduction, median (IQR) (days) * \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">52 (26.4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">30 (12) \u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">Duration of EVR treatment, median (IQR) (months) *\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">46.5 (57.0)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">69.9 (24.8)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">EVR whole-blood exposure, median (IQR) (ng/mL) *\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">3.65 (0.55)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">5.9 (1.4)\u003C/td>\n\u003Ctd align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-center\">\u003Cb><0.001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: EVR, everolimus; HCC, hepatocellular carcinoma; IQR, interquartile range.\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003Cdiv class=\"html-table-wrap\" id=\"preprints-96239-t007\">\n \u003Cdiv class=\"html-table_wrap_td\">\n \u003Cdiv class=\"html-tablepopup html-tablepopup-link\" href=\"#table_body_display_preprints-96239-t007\">\n \u003Cimg src=\"https://pub.mdpi-res.com/img/table.png\">\n \u003Ca class=\"html-expand html-tablepopup\" href=\"#table_body_display_preprints-96239-t007\">\u003C/a>\n \u003C/div>\n\n \u003C/div>\n \u003Cdiv class=\"html-table_wrap_discription\">\n \u003Cb>Table 7.\u003C/b>\n Results of the multivariable analysis of risk factors for both recurrence-free and overall survival.\n \u003C/div>\n\u003C/div>\n\u003Cdiv class=\"html-table_show mfp-hide \" id=\"table_body_display_preprints-96239-t007\">\n \n\n \u003Cdiv class=\"html-caption\">\n\u003Cb>Table 7.\u003C/b>\n Results of the multivariable analysis of risk factors for both recurrence-free and overall survival.\u003C/div>\n \u003Ctable>\n \u003Cthead>\u003Ctr>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">Variable \u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">Coefficients (95%CI)\u003Cbr>\n\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">SE\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">z\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">HR\u003C/th>\n\u003Cth align=\"left\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" class=\"html-align-left\">p\u003C/th>\n\u003C/tr>\u003C/thead>\n\u003Ctbody>\n\u003Ctr>\u003Ctd colspan=\"6\" align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>OS\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Successful pre-transplant downstaging\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.6 (0.15; 1.06)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.6\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.79\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.006\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Within Milan criteria at transplant\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-1.15 (-1.61;-0.7)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">5.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.67\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb><0.01\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Within Milan criteria at histology\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01 (0; 0.01)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.41\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.78\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.02\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Micro-infiltration\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.39 (-0.01; 0.78)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.2\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.91\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.13\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.056\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">G3-G4\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.25 (0.01; 0.5)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.12\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.02\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.18\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.077\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">EVR\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.59 (-1.02; -0.16)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.22\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.7\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.69\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.009\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\u003Ctd colspan=\"6\" align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>RFS\u003C/b>\u003C/td>\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Successful pre-transplant downstaging \u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.57 (0.12; 1.02)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.47\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.65\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.01\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Within Milan criteria at transplant\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-1.18 (-1.63;-0.72)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.23\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">5.11\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.56\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.01\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Within Milan criteria at histology\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.01 (0; 0.01)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.52\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.68\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.012\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">Micro-infiltration\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.42 (0.02; 0.81)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.2\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">2.06\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.22\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.04\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">G3-G4\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.22 (-0.02; 0.47)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.13\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.77\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">1.27\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb>0.04\u003C/b>\u003C/td>\n\u003C/tr>\n\u003Ctr>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">EVR\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">-0.78 (1.2; -0.36)\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.21\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">3.66\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">0.46\u003C/td>\n\u003Ctd align=\"left\" valign=\"middle\" style=\"border-bottom:solid thin\" class=\"html-align-left\">\u003Cb><0.001\u003C/b>\u003C/td>\n\u003C/tr>\n\u003C/tbody>\n \u003C/table>\n\n\u003Cdiv class=\"html-table_foot html-p\">\n\u003Cdiv class=\"html-p\" style=\"text-indent:0em;\">\u003Cspan class=\"html-fn-content\">NOTE: AFP, alpha-fetoprotein; EVR, everolimus; HCV, hepatitis C virus; OS, overall survival; RFS, recurrence-free survival.\u003C/span>\u003C/div>\n\u003Cdiv style=\"clear:both;\">\u003C/div>\n\u003C/div>\n\n\u003C/div>\n\u003C/section>\u003Csection class=\"html-fn_group\">\u003Ctable>\u003Ctr id>\n\u003Ctd>\u003C/td>\n\u003Ctd>\u003Cdiv class=\"html-p\">\n\u003Cb>Disclaimer/Publisher’s Note:\u003C/b> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.\u003C/div>\u003C/td>\n\u003C/tr>\u003C/table>\u003C/section>\n \u003Csection id=\"html-copyright\">\u003Cbr>© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (\u003Ca href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">http://creativecommons.org/licenses/by/4.0/\u003C/a>).\u003C/section>\n ",[204],{"version":7,"hash_key":127,"id":126,"change":47},"De Simone, P.; Precisi, A.; Lai, Q.; Ducci, J.; Campani, D.; Marchetti, P.; Gitto, S.; Crocetti, L. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. \u003Cem>Preprints\u003C/em> \u003Cb>2024\u003C/b>, 2024011027. https://doi.org/10.20944/preprints202401.1027.v1","De Simone, P.; Precisi, A.; Lai, Q.; Ducci, J.; Campani, D.; Marchetti, P.; Gitto, S. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. \u003Cem>Cancers\u003C/em> \u003Cb>2024\u003C/b>, \u003Cem>16\u003C/em>, 1243.",[],[],{"code":41,"msg":42,"data":210},[211,215],{"id":7,"name":212,"image":213,"url":214,"statistic_type":7},"Author Services","https://www.preprints.org/media/cache/resolve/webp/upload/banner/2024-10-30/c8ecd3b8b0ebf1abcd96d37f5ee4a609.jpeg","https://www.mdpi.com/authors/english?utm_source=preprintsweb&utm_medium=banner&utm_campaign=AS_High-quality",{"id":216,"name":217,"image":218,"url":219,"statistic_type":47},3,"award","https://www.preprints.org/media/cache/resolve/webp/upload/banner/2024-10-30/58bbc3b8f7c90f2eab7ce32d00691421.jpeg","https://www.preprints.org/activity/award/announcement?utm_source=ArticlePage&utm_medium=Banner&utm_campaign=award",{"code":41,"msg":42,"data":221},{"rows":222,"total":41},[],{"code":41,"msg":42,"data":224},[225,238,272,363,430,488,531,575,612,691],{"doi":128,"title":130,"url":226,"authors":227,"published_at":236,"journal_name":47,"click_trigger_url_hash":237},"https://doi.org/10.20944/preprints202401.1027.v1",[228,229,230,231,232,233,234,235],{"name":146,"email":147},{"name":154,"email":155},{"name":160,"email":161},{"name":165,"email":166},{"name":170,"email":171},{"name":175,"email":176},{"name":180,"email":181},{"name":185,"email":186},"2024-01-15","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfjFkzoykk79i4vp0gCgpZGnjO0tCoksvXGxC7p-88jhuk-nXP4dOL2P_Wyz_zfsVQg",{"doi":239,"title":240,"url":241,"authors":242,"published_at":270,"journal_name":47,"click_trigger_url_hash":271},"10.20944/preprints202309.1286.v1","Sequential Regorafenib or Nivolumab Therapy in Recurrent Hepatocellular Carcinoma with Sorafenib Failure in Liver Transplant Patients Does Not Improve Prognosis","https://doi.org/10.20944/preprints202309.1286.v1",[243,246,249,252,255,258,261,264,267],{"name":244,"email":245},"Jieun Kwon","jieun_gs.kwon@samsung.com",{"name":247,"email":248},"Jongman Kim","jongman94.kim@samsung.com",{"name":250,"email":251},"Sang Oh Yun","sangoh.yun@samsung.com",{"name":253,"email":254},"Sunghae Park","sunghae89.park@samsung.com",{"name":256,"email":257},"Manuel Lim","manuel.lim@samsung.com",{"name":259,"email":260},"Jaehun Yang","jaehun.yang@samsung.com",{"name":262,"email":263},"Jinsoo Rhu","jinsoo.rhu@samsung.com",{"name":265,"email":266},"Gyu-Seong Choi","gyuseong.choi@samsung.com",{"name":268,"email":269},"Jae-Won Joh","jw.joh@samsung.com","2023-09-19","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfhNiBATGAwpt5qPYM40hKaGv-qRJABikdUty-0TMlobbuuE49vbIH8Vl6GW8GU0xEw",{"doi":273,"title":274,"url":275,"authors":276,"published_at":361,"journal_name":47,"click_trigger_url_hash":362},"10.20944/preprints202310.1682.v1","Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer","https://doi.org/10.20944/preprints202310.1682.v1",[277,280,283,286,289,292,295,298,301,304,307,310,313,316,319,322,325,328,331,334,337,340,343,346,349,352,355,358],{"name":278,"email":279},"Rie Sugimoto","sugirie5@yahoo.co.jp",{"name":281,"email":282},"Kenta Motomura","kmotomurah2@aih-net.com",{"name":284,"email":285},"Takeaki Satoh","sato.takeaki.ky@mail.hosp.go.jp",{"name":287,"email":288},"Yuki Tanaka","horikawa724@yahoo.co.jp",{"name":290,"email":291},"Shinsaku Yamashita","yamashita.shinsaku.kp@mail.hosp.go.jp",{"name":293,"email":294},"Nobito Higuchi","nobi-kyu@umin.ac.jp",{"name":296,"email":297},"Toshimasa Koyanagi","tosiyosi1001@yahoo.co.jp",{"name":299,"email":300},"Tsukasa Nakamura","nakanaka3237@yahoo.co.jp",{"name":302,"email":303},"Masatake Tanaka","tanaka.masatake.656@m.kyushu-u.ac.jp",{"name":305,"email":306},"Yuuki Azuma","azumayuki11200896@icloud.com",{"name":308,"email":309},"Takeshi Goya","goya.takeshi.120@m.kyushu-u.ac.jp",{"name":311,"email":312},"Akifumi Kuwano","akuwanoh1@aih-net.com",{"name":314,"email":315},"Aritsune Ooho","ooho.a@ns.yawata-mhp.or.jp",{"name":317,"email":318},"Mari Ooe","marikotohe@gmail.com",{"name":320,"email":321},"Taiji Mutsuki","oh-----@hotmail.co.jp",{"name":323,"email":324},"Masami Kuniyoshi","kuniyoshi.masami.gn@mail.hosp.go.jp",{"name":326,"email":327},"Kazuki Kurosaka","kurosaka.kazuki.954@m.kyushu-u.ac.jp",{"name":329,"email":330},"Yusuke Morita","yusuke1781@yahoo.co.jp",{"name":332,"email":333},"Seiya Tada","tada.seiya.yw@mail.hosp.go.jp",{"name":335,"email":336},"Yoshifusa Aratake","aratake.yoshifusa.jh@mail.hosp.go.jp",{"name":338,"email":339},"Tsuyoshi Yoshimoto","yoshimotchy@gmail.com",{"name":341,"email":342},"Takeshi Senju","tsenju1213@gmail.com",{"name":344,"email":345},"Tomoyuki Kurashige","tomoyuki_fate@yahoo.co.jp",{"name":347,"email":348},"Shigeru Harada","shigeru622@outlook.jp",{"name":350,"email":351},"Akihiro Ueda","aued00@gmail.com",{"name":353,"email":354},"Masayuki Miyazaki","zakizaki0802@gmail.com",{"name":356,"email":357},"Makoto Nakamuta","nakamuta.makoto.ya@mail.hosp.go.jp",{"name":359,"email":360},"Motoyuki Kohjima","kojima.motoyuki.gh@mail.hosp.go.jp","2023-10-26","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfhjxqkjAbmmChdXh3PULtSGesutQaNLBo1y8N_Hlh-6ZTUq9MnvvW5SHBJqTeJ5veQ",{"doi":364,"title":365,"url":366,"authors":367,"published_at":428,"journal_name":47,"click_trigger_url_hash":429},"10.20944/preprints201906.0285.v1","Lenvatinib as an Initial Treatment in Patients with Intermediate-stage Hepatocellular Carcinoma Beyond up-to-seven Criteria and Child-Pugh A Liver Function: A Proof-of-Concept Study","https://doi.org/10.20944/preprints201906.0285.v1",[368,371,374,377,380,383,386,389,392,395,398,401,404,407,410,413,416,419,422,425],{"name":369,"email":370},"Masatoshi Kudo","m-kudo@med.kindai.ac.jp",{"name":372,"email":373},"Kazuomi Ueshima","kaz-ues@jb3.so-net.ne.jp",{"name":375,"email":376},"Stephan Chan","l_chan@clo.cuhk.edu.hk",{"name":378,"email":379},"Tomohiro Minami","tekatyuu@yahoo.co.jp",{"name":381,"email":382},"Hirokazu Chishina","chocolatecake3candy@yahoo.co.jp",{"name":384,"email":385},"Tomoko Aoki","t.aoki1918@gmail.com",{"name":387,"email":388},"Masahiro Takita","masahirot2797@yahoo.co.jp",{"name":390,"email":391},"Satoru Hagiwara","hagi-318@hotmail.co.jp",{"name":393,"email":394},"Yasunori Minami","minkun@med.kindai.ac.jp",{"name":396,"email":397},"Hiroshi Ida","hidakuhp@gmail.com",{"name":399,"email":400},"Mamoru Takenaka","matakenaka@med.kindai.ac.jp",{"name":402,"email":403},"Toshiharu Sakurai","sakurai@med.kindai.ac.jp",{"name":405,"email":406},"Tomohiro Watanabe","tomohiro@med.kindai.ac.jp",{"name":408,"email":409},"Masahiro Morita","s0750081@kuhp.kyoto-u.ac.jp",{"name":411,"email":412},"Chikara Ogawa","chikara.ogawa.19721202@gmail.com",{"name":414,"email":415},"Yoshiyuki Wada","yoshi_wada1227@yahoo.co.jp",{"name":417,"email":418},"Masafumi Ikeda","masikeda@east.ncc.go.jp",{"name":420,"email":421},"Hiroshi Ishii","hirishii@chiba-cc.jp",{"name":423,"email":424},"Namiki Izumi","izumi012@musashino.jrc.or.jp",{"name":426,"email":427},"Naoshi Nishida","naoshi@med.kindai.ac.jp","2019-06-27","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfn8HSAlaSehMh2TM5EjTd3JdkXzYYDS6tdv7tLw7Iui5hRxBbhF3ilxoSwj7RJNWrQ",{"doi":431,"title":432,"url":433,"authors":434,"published_at":486,"journal_name":47,"click_trigger_url_hash":487},"10.20944/preprints202307.1474.v1","Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study","https://doi.org/10.20944/preprints202307.1474.v1",[435,438,441,444,447,450,453,456,459,462,465,468,471,474,477,480,483],{"name":436,"email":437},"Ji Hoon Kim","jihoon23@gmail.com",{"name":439,"email":440},"Hee-Chul Nam","hcnam128@catholic.ac.kr",{"name":442,"email":443},"Chang Wook Kim","cwkim@catholic.ac.kr",{"name":445,"email":446},"Hee Sun Cho","jhs-cho@hanmail.net",{"name":448,"email":449},"Jae-Sung Yoo","imjsyoo@gmail.com",{"name":451,"email":452},"Ji Won Han","tmznjf@catholic.ac.kr",{"name":454,"email":455},"Jeong Won Jang","garden@catholic.ac.kr",{"name":457,"email":458},"Jong Young Choi","jychoi@catholic.ac.kr",{"name":460,"email":461},"Seung Kew Yoon","yoonsk@catholic.ac.kr",{"name":463,"email":464},"Hyun Yang","oneggu@naver.com",{"name":466,"email":467},"Si Hyun Bae","baesh@catholic.ac.kr",{"name":469,"email":470},"Suho Kim","lucidnature@naver.com",{"name":472,"email":473},"Jung-Suk Oh","oj-cumc@hanmail.net",{"name":475,"email":476},"Ho Jong Chun","chunray@catholic.ac.kr",{"name":478,"email":479},"Chang Ho Chun","changho.jeon@gmail.com",{"name":481,"email":482},"Jaegyoon Ahn","jgahn@inu.ac.kr",{"name":484,"email":485},"Pil Soo Sung","pssung@catholic.ac.kr","2023-07-21","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfoERmdJ8bnTKbYJHWujbEWBUmjgwjwniW2BCrjEAWnsisLO69vBb66KLuAR4jUjXjw",{"doi":489,"title":490,"url":491,"authors":492,"published_at":529,"journal_name":47,"click_trigger_url_hash":530},"10.20944/preprints202311.1972.v1","Generating Patient-Derived HCC Cell Lines Suitable for Predictive In-Vitro and In-Vivo Drug Screening by Orthotopic Transplantation","https://doi.org/10.20944/preprints202311.1972.v1",[493,496,499,502,505,508,511,514,517,520,523,526],{"name":494,"email":495},"Lisa Staffeldt","l.staffeldt@uke.de",{"name":497,"email":498},"Gregor Mattert","gregor.mattert@mhb-fontane.de",{"name":500,"email":501},"Kristoffer Riecken","k.riecken@uke.uni-hamburg.de",{"name":503,"email":504},"Götz Rövenstrunk","goetz.roevenstrunk@mhb-fontane.de",{"name":506,"email":507},"Anika Volkmar","anika-volkmar@gmx.de",{"name":509,"email":510},"Mohamed Moustafa","mo.moustafa@uke.de",{"name":512,"email":513},"Asmus Heumann","a.heumann@uke.de",{"name":515,"email":516},"Manfred Jücker","juecker@uke.de",{"name":518,"email":519},"Boris Fehse","fehse@uke.de",{"name":521,"email":522},"Udo Schumacher","uschumacher@uke.de",{"name":524,"email":525},"Stefan Lüth","s.lueth@uk-brandenburg.de",{"name":527,"email":528},"Janine Kah","j.kah@uk-brandenburg.de","2023-11-30","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfpfkFpGijcHb8FFLZYTy_a81OHTrjvjU_ohj6v9P-GbPKXAVDCLXmzCSmlTLobQpow",{"doi":532,"title":533,"url":534,"authors":535,"published_at":573,"journal_name":47,"click_trigger_url_hash":574},"10.20944/preprints202107.0559.v1","Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study","https://doi.org/10.20944/preprints202107.0559.v1",[536,539,540,541,544,545,547,550,553,556,559,562,563,564,567,569,570,571,572],{"name":537,"email":538},"Jaejun Lee","pwln0516@gmail.com",{"name":451,"email":452},{"name":484,"email":485},{"name":542,"email":543},"Soon Kyu Lee","blackiqq@gmail.com",{"name":463,"email":464},{"name":546,"email":440},"Hee Chul Nam",{"name":548,"email":549},"Sun Hong Yoo","calla0108@naver.com",{"name":551,"email":552},"Hae Lim Lee","atom069@naver.com",{"name":554,"email":555},"Hee Yeon Kim","hee82@catholic.ac.kr",{"name":557,"email":558},"Sung Won Lee","zambrotta@catholic.ac.kr",{"name":560,"email":561},"Jung Hyun Kwon","doctorkwon@catholic.ac.kr",{"name":454,"email":455},{"name":442,"email":443},{"name":565,"email":566},"Soon Woo Nam","drswnam@hanmail.net",{"name":568,"email":473},"Jung Suk Oh",{"name":475,"email":476},{"name":466,"email":467},{"name":457,"email":458},{"name":460,"email":461},"2021-07-26","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfkb_A_77TXClFAuHMVhQjxIDcdioPWRhuaotcf1XA8Ee1vRf8KrbGqBgAYxkpQc8lw",{"doi":576,"title":577,"url":578,"authors":579,"published_at":610,"journal_name":47,"click_trigger_url_hash":611},"10.20944/preprints201906.0045.v1","Response Relating Factors of Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in Patients with Alcoholic Cirrhosis","https://doi.org/10.20944/preprints201906.0045.v1",[580,583,586,589,592,595,598,601,604,607],{"name":581,"email":582},"Haripriya Gupta","phr.haripriya13@gmail.com",{"name":584,"email":585},"Gi Soo Youn","gisu0428@gmail.com",{"name":587,"email":588},"Sang Hak Han","drhsh74@hallym.or.kr",{"name":590,"email":591},"Min Jea Shin","wehome3@hallym.ac.kr",{"name":593,"email":594},"Sang Jun Yoon","ysjtlhuman@gmail.com",{"name":596,"email":597},"Dae Hee Han","eogmlgks@gmail.com",{"name":599,"email":600},"Na Young Lee","na0lee0218@gmail.com",{"name":602,"email":603},"Dong Joon Kim","djkim@hallym.ac.kr",{"name":605,"email":606},"Soon Koo Baik","baiksk@yonsei.ac.kr",{"name":608,"email":609},"Ki Tae Suk","ktsuk@hallym.ac.kr","2019-06-05","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfv9ClbXNuftePjRyLN4nW5KRPPGseq57YVs_l44mou2vt3QFmEe5cypeI5nEom-_8Q",{"doi":613,"title":614,"url":615,"authors":616,"published_at":689,"journal_name":47,"click_trigger_url_hash":690},"10.20944/preprints202310.0836.v1","Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma","https://doi.org/10.20944/preprints202310.0836.v1",[617,620,623,626,629,632,635,638,641,644,647,650,653,656,659,662,665,668,671,674,677,680,683,686],{"name":618,"email":619},"Shigeki Yano","yano0319@hiroshima-u.ac.jp",{"name":621,"email":622},"Tomokazu Kawaoka","kawaokatomo@hiroshima-u.ac.jp",{"name":624,"email":625},"Shintaro Yamasaki","syamasaki@hiroshima-u.ac.jp",{"name":627,"email":628},"Yusuke Johira","jyusuke9@hiroshima-u.ac.jp",{"name":630,"email":631},"Masanari Kosaka","m0607k@hiroshima-u.ac.jp",{"name":633,"email":634},"Yuki Shirane","yuki0415@hiroshima-u.ac.jp",{"name":636,"email":637},"Ryoichi Miura","ryoichim@hiroshima-u.ac.jp",{"name":639,"email":640},"Kei Amioka","amioka@hiroshima-u.ac.jp",{"name":642,"email":643},"Kensuke Naruto","uzumaki1@hiroshima-u.ac.jp",{"name":645,"email":646},"Kenji Yamaoka","yamaokak@hiroshima-u.ac.jp",{"name":648,"email":649},"Yasutoshi Fujii","fujiiyasu@hiroshima-u.ac.jp",{"name":651,"email":652},"Shinsuke Uchikawa","shinuchi@hiroshima-u.ac.jp",{"name":654,"email":655},"Hatsue Fujino","fujino920@hiroshima-u.ac.jp",{"name":657,"email":658},"Atsushi Ono","atsushi-o@hiroshima-u.ac.jp",{"name":660,"email":661},"Takashi Nakahara","nakahara@hiroshima-u.ac.jp",{"name":663,"email":664},"Eisuke Murakami","emusuke@hiroshima-u.ac.jp",{"name":666,"email":667},"Daiki Miki","daikimiki@hiroshima-u.ac.jp",{"name":669,"email":670},"Masataka Tsuge","tsuge@hiroshima-u.ac.jp",{"name":672,"email":673},"Yuji Teraoka","teraoka.yuji.ed@mail.hosp.go.jp",{"name":675,"email":676},"Hirotaka Kouno","kouno.hirotaka.pz@mail.hosp.go.jp",{"name":678,"email":679},"Shintaro Takaki","takakishiroshima@gmail.com",{"name":681,"email":682},"Nami Mori","nami7373@star.ocn.ne.jp",{"name":684,"email":685},"Keiji Tsuji","k_tsuji_@yahoo.co.jp",{"name":687,"email":688},"Shiro Oka","oka4683@hiroshima-u.ac.jp","2023-10-12","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfoZCOaSmo-5FXTRsIUOtJLv1kdqObWzF3xrX_6iBHE-WrLFrQV-rYc4cfDpsaUv8Ug",{"doi":692,"title":693,"url":694,"authors":695,"published_at":361,"journal_name":47,"click_trigger_url_hash":720},"10.20944/preprints202310.1656.v1","Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology","https://doi.org/10.20944/preprints202310.1656.v1",[696,699,702,705,708,711,714,717],{"name":697,"email":698},"Shinichiro Nakamura","s-nakamura@himeji.jrc.or.jp",{"name":700,"email":701},"Toshifumi Tada","tadat0627@gmail.com",{"name":703,"email":704},"Masahiko Sue","yqxrw014@gmail.com",{"name":706,"email":707},"Yu Matsuo","1781c6@gmail.com",{"name":709,"email":710},"Shiho Murakami","poem_walk_star@yahoo.co.jp",{"name":712,"email":713},"Toshiro Muramatsu","tossshirom@gmail.com",{"name":715,"email":716},"Kazuhiko Morii","moriikazuhiko@gmail.com",{"name":718,"email":719},"Hiroyuki Okada","h-okada@himeji.jrc.or.jp","6NDYF0rWYbBywNc0fWBhIR_LM-Lo0aEBMAFDd6KOeJaQX28ooemMJIsFhCW0_w0QDBAOPogDoZkeVmCoY2uPfr5PP0nDSqgE0HbGlLb3ABFacA3ASrIwIyYslC1P8WdLws1HgAxhHz4mleVexvjwAg",["Reactive",722],{"$scookieConsent":723,"$stoast-ui":724,"$ssite-config":726},{"necessary":6,"functional":132,"statistic":132,"marketing":132,"unclassified":132},{"showToast":132,"toastMessage":156,"toastVariant":725},"neutral",{"env":727,"name":728,"url":729},"production","nuxt-app","http://frontend.preprints.org/",["Set"],["ShallowReactive",732],{"uI0nvcSvBJ":47,"mgOlEjP40X":47,"Ya7hZzqdE7":47,"Yq0Pll1P8W":47,"JoG0wWOyMK":47,"j4og9PLFeK":47},"/manuscript/202401.1027/v1",["Reactive",735],{"auth":736,"share-modal":738,"useHeader":739},{"userInfo":737,"isLogin":132},{},{"isShareModalOpen":132,"item":47},{"height":41}]</script> <script>window.__NUXT__={};window.__NUXT__.config={public:{turnstile:{siteKey:"0x4AAAAAAAeRafIKjAzYS6R5"},strapiUrl:"",blog:"https://preprintsblog.wordpress.sciforum.net",envData:{USER:"www-data",SSH_CLIENT:"10.10.0.129 56114 22",npm_config_user_agent:"npm/8.19.2 node/v18.10.0 linux x64 workspaces/false",npm_node_execpath:"/usr/local/node/bin/node",CURRENT_USER:"weijun.yu@mdpi.com",SHLVL:"2",npm_config_noproxy:"",MOTD_SHOWN:"pam",HOME:"/home/www",OLDPWD:"/home/www",npm_package_json:"/var/www/sciprints.net-frontend/package.json",npm_config_userconfig:"/home/www/.npmrc",npm_config_local_prefix:"/var/www/sciprints.net-frontend",COLOR:"0",npm_config_metrics_registry:"https://registry.npmjs.org/",LOGNAME:"www-data",_:"/usr/bin/npm",npm_config_prefix:"/usr/local/node",npm_config_cache:"/home/www/.npm",npm_config_node_gyp:"/usr/local/node/lib/node_modules/npm/node_modules/node-gyp/bin/node-gyp.js",PATH:"/var/www/sciprints.net-frontend/node_modules/.bin:/var/www/node_modules/.bin:/var/node_modules/.bin:/node_modules/.bin:/usr/local/node/lib/node_modules/npm/node_modules/@npmcli/run-script/lib/node-gyp-bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin:/usr/games:/usr/local/games:/snap/bin",NODE:"/usr/local/node/bin/node",npm_package_name:"nuxt-app",LANG:"en_US.UTF-8",PACFILE:".pac/config-prod.sh",npm_lifecycle_script:"nuxt build --logLevel=silent",SHELL:"/bin/bash",npm_lifecycle_event:"build",npm_config_globalconfig:"/usr/local/node/etc/npmrc",npm_config_init_module:"/home/www/.npm-init.js",PWD:"/var/www/sciprints.net-frontend",npm_execpath:"/usr/local/node/lib/node_modules/npm/bin/npm-cli.js",SSH_CONNECTION:"10.10.0.129 56114 10.1.0.124 22",npm_config_global_prefix:"/usr/local/node",npm_command:"run-script",INIT_CWD:"/var/www/sciprints.net-frontend",EDITOR:"vi",NODE_ENV:"production",NUXT_USING_SSR:"true",NUXT_APP_URL:"https://www.preprints.org",NUXT_LOGIN_URL:"/login",NUXT_IDP_URL:"https://login.mdpi.com",NUXT_FIREBASE_API_KEY:"AIzaSyAyKu1mWkkTnfv7HtCQcptOymDZ1w4Jzy0",NUXT_FIREBASE_AUTH_DOMAIN:"preprints-b6f4b.firebaseapp.com",NUXT_FIREBASE_PROJECT_ID:"preprints-b6f4b",NUXT_FIREBASE_STORAGE_BUCKET:"preprints-b6f4b.appspot.com",NUXT_FIREBASE_MESSAGING_SENDER_ID:"369406057228",NUXT_FIREBASE_APP_ID:"1:369406057228:web:4be3e02b94bc45be260729",NUXT_PUBLIC_TURNSTILE_SITE_KEY:"0x4AAAAAAAeRafIKjAzYS6R5",NUXT_PUBLIC_BLOG:"https://preprintsblog.wordpress.sciforum.net",NUXT_BLOG_USER:"lloyd.shu@mdpi.com",NUXT_BLOG_TOKEN:"B0K6 kfJs bPsY gVWZ ELn2 J6yw",NUXT_PUBLIC_SENTRY_DSN:"https://4594052328229da018023f50bcd17eb8@o4506621248798720.ingest.us.sentry.io/4508131538960384",NUXT_PUBLIC_SENTRY_ENVIRONMENT:"production"},gtm:{devtools:true,id:"GTM-NX2CT4D"},sentry:{dsn:"https://4594052328229da018023f50bcd17eb8@o4506621248798720.ingest.us.sentry.io/4508131538960384",environment:"production"},nuxtHighcharts:{pluginOptions:{},hcMods:["accessibility","annotations-advanced","annotations","arc-diagram","arrow-symbols","boost-canvas","boost","broken-axis","bullet","coloraxis","current-date-indicator","cylinder","data-tools","data","datagrouping","debugger","dependency-wheel","dotplot","drag-panes","draggable-points","drilldown","dumbbell","export-data","exporting","flowmap","full-screen","funnel","funnel3d","gantt","geoheatmap","grid-axis","heatmap","heikinashi","histogram-bellcurve","hollowcandlestick","item-series","lollipop","map","marker-clusters","mouse-wheel-zoom","navigator","networkgraph","no-data-to-display","offline-exporting","organization","overlapping-datalabels","parallel-coordinates","pareto","pathfinder","pattern-fill","pictorial","price-indicator","pyramid3d","sankey","series-label","series-on-point","solid-gauge","sonification","static-scale","stock-tools","stock","streamgraph","sunburst","tiledwebmap","tilemap","timeline","treegraph","treegrid","treemap","variable-pie","variwide","vector","venn","windbarb","wordcloud","xrange"]},cookieConsent:{consentMode:true,consentModeDefaults:true,provider:"cookiebot",init:true,dev:false,scripts:{necessary:[],functional:[],statistic:[],marketing:[],unclassified:[]},cbid:"6b5b25c6-89f0-4619-834a-8af9d1157dc1"},strapi:{url:"http://localhost:1337",prefix:"/api",admin:"/admin",version:"v4",cookie:{},auth:{},cookieName:"strapi_jwt",devtools:false}},app:{baseURL:"/",buildId:"665f035c-6c69-41d6-996d-1cf3ec9234e7",buildAssetsDir:"/_nuxt/",cdnURL:""}}</script></body></html>